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ABSTRACT
The failure of the vasculature to deliver blood to the body as a result of vascular disease, 
accounts for the highest rates of morbidity in western societies. Small diameter (<6 mm) 
vascular reconstructions have proven to be considerably more problematic than large 
diameter vessel reconstruction, where reduced diameter and low flow rates compounded by 
high resistance result in poor performance. In terms of small diameter replacement vessels, 
autologous arteries are considered the “gold standard” for graft success with patency rates 
of ~90% at five years. By comparison patency rates as low as 30% over 5 years are 
obtained when synthetic alternatives. In approximately 30% of all small diameter vascular 
reconstructions, autologous vessels are unavailable for bypass grafting necessitating the use 
of synthetic grafting materials. Due to the limited supply of autologous vessels a number of 
alternative approaches have been developed. The approach favoured in this thesis is a 
relatively new methodology termed ‘tissue engineering’. The essential elements using the 
principles of tissue engineering are, specific human cell lineages, a scaffolding that supports 
3-diamenional cell growth and a bioreactor/perfusion system to apply stresses that mimic in 
vivo haemodynamics. This project has focused on the development of a novel biomaterial 
with arterial-like mechanical characteristics and the design and implementation of a novel 
bioreactor that emulates the in vivo arterial environment in vitro, replicating arterial 
conditions, which are critical in maintaining correct cellular phenotype.
Porcine carotid arteries, harvested from 6-8 month old Great White pigs, were processed to 
generate a matrix consisting of mostly collagen and elastin, whilst retaining components of 
the internal elastic laminar and basement membrane. Matrix processing was aimed at 
removing the nonstructural components of the native vessel to reduce the potentially 
immunogenic bioburden, without compromising structural stability. Processing entailed 
solvent extraction of lipids by multiple washes in ethanol over a 24 hour period, followed 
by proteolytic digestion with trypsin over 24 hours and washing to remove cellular and 
nonstructural extracellular matrix debris from the matrix. The matrix was then stabilized 
against enzymatic degradation (which further reduces the potential for immune rejection) by 
cross-linking matrix proteins using a photo-oxidative reaction with methylene green as the 
photoactive agent. The reaction ran for 24 hours at 0°C in a 4M NaCl solution with 0.1% 
(w/v) methylene green at pH 7.4, using approximately 30000 Lux of visible light as the 
energy source. Results using reverse phase high pressure liquid chromatography (RP- 
HPLC) have shown the matrix to be approximately 3 times more resistant to enzymatic 
digestion than unprocessed tissue. Cell culture under static conditions has shown the matrix 
to be biocompatible when human umbilical endothelial cells (HUVEC) and human vascular 
smooth muscle cells (hVSMC) were seeded at 90 cells/mm2 onto the lumenal surface and 
333 cell/mm2 on the ablumenal surface respectively. After preconditioning the matrix, 
HUVEC displayed as high as 1082% seeding and proliferative efficiency after 9 days 
culture. hVSMC displayed a degree of migration into the matrix (-150-200 pm), but this 
was speculated to be from the cut edge of the matrix, not by transmural ingrowth.
The development of a novel bioreactor and process flow system allowed analysis of seeding 
and culture of HUVEC and hVSMC monocultures under pulsed perfusion conditions 
peaking at 80 beats per minute (bpm) (165.5 ml/min). Lumenal HUVEC densities of 632 
cells/mm2 were achieved with hVSMC producing a layer of cells surrounding the ablumenal 
surface. Perfusion cultures of hVSMC of ~ 600 cell/mm2 were shown to maintain the 
phenotypic marker, a-actin, after 5 weeks culture. Confirmation of matrix remodelling and 
hVSMC migration was assessed by immunohistochemical localisation of MMP-2 and 9 and 
Cathepsin-L and histological staining.
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r.t. Room Temperature
SEM Scanning Electron Microscopy
SIS Small Intestine Submucosa
SMC Smooth Muscle Cells
TE Tissue engineered
TLC Thin Layer Chromatography
Tween 80 Polyoxyethylenesorbitsan monolaurate
UC Umbilical cords
VSMC Vascular Smooth Muscle Cells
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CHAPTER ONE: BACKGROUND TO ARTIFICIAL BLOOD 
V E S S E L S
1 .1  In t r o d u c t io n
Vascular disease is a major health concern in western society, where the progressive 
occlusion of blood vessels results initially in symptoms of hypoxia leading to gross 
organ damage and death. Considerable success has been attained with large diameter 
synthetic conduits, where higher flow rates compared to peripheral vessels contribute to 
acceptable patency rates. Bypass surgery of blood vessels less than -  6 mm in diameter 
using traditional prosthetics such as Dacron or ePTFE results in rapid occlusion of the 
graft yielding unacceptable low patency rates (Ratcliffe, 2000). The grafting material of 
choice is autologous artery e.g. the mammary artery with patency rates approaching 
90% at 5 years, however these vessels are often reserved for heart bypass. It is generally 
accepted that autologous vein is the next best replacement vessel, unfortunately, for 
-30% of patients requiring bypass surgery, autologous vessels (arterial or vein) are 
either unavailable or inappropriate for use due to prior extraction or inherent vascular 
disease. In these cases synthetic replacement vessels are used with patency rates as low 
as 30% over 5 years. It must be noted however that the position and physical 
dimensions of the replacement vessel have a profound effect on graft patency. With 
larger diameter vessels exposed to higher flow rates achieving improved patency rates.
The failure of small diameter arteries due to atherosclerotic disease is the leading cause 
of mortality in the United States, with other western cultures facing similar statistics 
(Niklason et al., 1999). Mean costs per patient for primary revascularisation operations 
with autologous vein are approximately £7 512. Limb amputations cost approximately 
£10 863 with recurring annual costs up to £21 000 per patient per annum for long-term 
institutional care. With higher reintervention rates for synthetic grafts (PTFE) 
compared to autologous grafts, the cost is only marginally (6%) cheaper than 
amputation, though without the additional long-term care (Cheshire et al., 1992). From 
both a patient care and economic standpoint there is, without doubt, an urgent need for 
viable small diameter grafts. The ultimate goal of reconstructive vascular research is a 
procedure that artificially induces a patient's own body to regenerate/grow replacement
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vessels in situ, as required. This may well be possible in the future; however the current 
status of vascular reconstruction is limited to by-passing or excision of the diseased 
tissue, and replacement with one of several options e.g. internal mammary artery, 
saphenous vein, or a synthetic substitute.
The primary aim of this project is to develop a functional small diameter artery (< 6 
mm) for use as a prosthetic graft. An essential requirement is the establishment of a 
microenvironment that mimics in vivo conditions. A key step in this project is the 
development of a bioreactor that is designed to apply physiological conditions and allow 
delivery and removal of gases, nutrients, waste etc. Identification of the physical 
conditions required is based on the premise that the pressure wave, pulse and flow rates 
have generic properties that can be modelled or replicated over a variety of internal 
diameters. The importance of local environmental conditions on cell behaviour has 
been well documented; for example, changes between endothelial cell/substrate contacts 
(Olivier et al., 1999) and the transition from random to aligned cell focal contacts when 
exposed to laminar flow (Nerem and Seliktar, 2001).
Essential requirements for functional arterial grafts:
Immunological acceptance by patient 
Availability i.e. time to produce
Durability i.e. ability to withstand haemodynamic stresses  
Positive handling characteristics i.e. suturability and simplicity of handling 
Resistance to thrombosis and graft infection 
Post implantation healing c.f. scar tissue formation
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T h e s is  o v e r ie w
In this thesis the progress made towards solving the problem of poor vascular graft 
patency has been described. As discussed previously, this thesis is directly applicable to 
small diameter (<6 mm) vascular reconstructions as larger vessel replacements such as 
the abdominal aorta, achieve acceptable patency rates using current technology. This is 
not to preclude the technology discussed in this thesis for use in larger grafts, 
particularly in growing children, where a graft must be able to ‘grow and remodel’ as 
the child develops. Only the said technology is directed at an area where demand far 
exceeds supply.
An important issue in vascular reconstructive surgery is the time required to produce a 
viable graft due to patient morbidity; for this reason emphasis has been placed on 
increasing the efficiency of process and design. Each of the results chapters begins with 
a brief introduction to that specific aspect of the thesis, followed by a literature review, 
unless the topic has been previously covered, that aims to summarize the current state of 
the art in direct relation to that specific chapter. Here, comprehensive reviews obtained 
from the literature may be summarised in order to complement literature and 
experimental procedures described in later chapters. After detailing results, the 
discussion with conclusions follows in each chapter.
Chapter 1 has begun with a general introduction and brief historical overview of the 
current technology to introduce the reader to the extent of the clinical problem. This is 
followed by a gross description of the human vascular system, which later details 
components of the arterial wall such as collagen, elastin, glycoproteins, proteoglycans 
etc. As the research to develop successful small diameter vascular grafts is a field 
where the problem is engaged from several angles, the various strategies to accomplish 
this are discussed. The chapter finishes by reviewing the current state-of-the-art with 
direct relation to tissue engineering of small diameter vascular grafts. The remainder of 
this introduction gives a brief overview of the content and aims of this thesis on a 
chapter-by-chapter basis.
Chapter 2: Materials and Methods, contains general materials and experimental
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methods. Primary adult human vascular smooth muscle cells (hVSMC) and human 
umbilical vein endothelial cells (HUVEC) have been used throughout this thesis. Adult 
human cell growth is considerably slower and more problematic than either neonatal or 
non-human cells, it would have been preferable to use all adult human cells due to the 
works clinical relevance, unfortunately only adult hVSMC were available, requiring the 
use of neonatal EC.
The chapter concludes with all analytical methods used throughout this thesis. Each of 
the results chapters contains a materials and methods section describing only materials 
and experimental methods specific or discrete to that chapter.
Chapter 3: Static cell culture on porcine type I collagen, describes the analysis of a 
porcine derived dermal type I collagen matrix. The primary aim was to assess the 
matrix for its potential as a scaffold for applications in tissue engineering of small 
diameter vascular grafts. Primary human vascular smooth muscle cells (hVSMC) and 
human umbilical vein endothelial cells (HUVEC) were seeded and cultured on the 
matrix to assess cell adhesion, proliferation and maintenance over time. This was 
followed by exploring various methodologies to enhance cell compatibility and growth 
dynamics by modifying the material to improve its potential as a matrix for vascular 
tissue engineering.
Chapter 4: Development of a scaffold for tissue engineering blood vessels using porcine 
carotid arteries, was based on knowledge and experience gained in Chapter 3 to develop 
a specific, tailor-made material, for vascular tissue engineering. To this extent the 
progressive development of a unique porcine derived arterial matrix is described. The 
chapter is introduced with a literature review of methodologies currently used to 
generate acellular biomaterials. Methodologies are examined to efficiently strip porcine 
cells and non-structural components of the artery and stabilise against enzymatic 
degradation to yield a theoretically immunologically inert, or near inert acellular 
biomaterial that maintains an acceptable degree of native biomechanical characteristics.
Chapter 5: Static cell cultures on a porcine derived arterial matrix, has focused on 
assessing the developed biomaterial in terms of cell biocompatibility. Specifically, 
adhesion and maintenance of HUVEC on the lumenal surface and hVSMC on the
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ablumenal surface of the matrix. These analyses were conducted under static culturing 
conditions to reduce variables. Methods have been explored to improve cell adhesion 
and proliferation as a prelude to culturing specific human cells under pulsed flow 
conditions. Cell migration into and remodelling of the matrix by seeded cells, 
specifically hVSMC, is of critical importance to graft development. A variety of 
enzymes have been assessed immunohistochemically with antibody probes for MMP-2 
and 9 and cathepsin L.
Chapter 6: Development of a vascular perfusion culture system, is introduced with an 
overview of the effects mechanical forces have on the two main cell types of the 
vasculature, endothelial cells (EC) and VSMC. The chapter then details the progressive 
development of a novel bioreactor and process flow support system. The bioreactor 
development has aimed to focus attention on the matrix supported between the lumenal 
inlet and outlet of the reactor, where conditions such as pressure, pulsed wave form, 
flow, gas content, glucose and pH have been assessed to emulate physiological arterial 
conditions. It is believed that an accurate representation of in vivo conditions is the key 
to cell phenotype stability and thus graft success.
Chapter 7: Perfusion bioreactor studies of human vascular cells on porcine derived 
vascular matrix, describe the natural progression from Chapter 5 and 6 to deliver 
chemical, gas and mechanical forces to both hVSMC and HUVEC seeded and cultured 
on the matrix that is representative of the in vivo conditions described in Chapter 6. 
Similarly to Chapter 5, the ability of the matrix to support cell adhesion and 
proliferation are key to the success of this project. Given the perfusion conditions under 
which cells are cultivated, particularly the high shear in the lumen (compared to static 
culture) a number of seeding methodologies have been explored to increase the 
efficiency of both HUVEC and hVSMC adhesion on their appropriate surfaces. In line 
with the data gathered in Chapter 5, static cultures on the arterial derived biomaterial, 
hVSMC have been immunohistochemically assessed under defined flow conditions for 
expression of MMP-2 and 9 and cathepsin L, and their ability to migrate within the 
matrix as a comparative analysis to static cultures.
Chapter 8, the final chapter, gives final conclusions to each of the experimental chapters 
and a description of future work. Appendices brings the thesis to a close.
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1 .2  D e v e l o p m e n t  o f  th e  c u r r e n t  clinical  t e c h n o l o g y
Vascular diseases such as arteriosclerosis (e.g. atherosclerosis, arteriolosclerosis and 
Monckebergs's calcific medial sclerosis) are major health concerns within western 
society. The natural development of these diseases is the progressive occlusion of blood 
vessels where the initial symptoms are manifested as hypoxia, ultimately leading to 
gross organ damage and death unless treated. Methodologies to halt or repair diseased 
blood vessels include: diet modifications, stent installation, angioplasty and complete 
vessel replacement. Although autogenous artery is considered to be the best vessel 
replacement, such as the intemal-thoracic-artery (ITA) or internal mammary artery, they 
are seldom used due to limited availability. Previous studies (Loop et al., 1986), (Zeff 
et al., 1988) have shown the ITA graft to be a superior conduit and (Cameron et al., 
1996) evaluated ITA versus saphenous vein when used as coronary-artery bypass. Due 
to the higher performance of the ITA graft, it is usually reserved for heart bypass 
operations. The American Registry of the Coronary Artery Surgery Study (24958 
patients) over a 15-year period, found that the ITA graft conferred a distinct survival 
advantage, regardless of age, sex or disease state over other procedures.
The saphenous vein is understood to be the next best option (site specific) and 
considered superior to current synthetic replacements. The saphenous vein, like other 
veins including; cephalic or basilic vein, cryopreserved saphenous vein allografts, 
umbilical vein grafts and the superficial femoral vein, is susceptible to late 
complications. These include aneurysmal degeneration, intimal fibrosis, intimal 
hyperplasia and accelerated atherosclerosis. By comparison autogeneous arteries, 
specifically the ITA grafts have been shown, in post-mortem examinations, to have little 
if  any evidence of atherosclerosis (Cameron et al., 1996). Unfortunately, 30-40% of 
femoropopliteal reconstructions (Charlesworth et al., 1985) or in general, 15-30% of 
cases the veins, like arteries, are found to be unsuitable for use due to “gross 
abnormalities” or their prior use has precluded them (Esquivel and Blaisdell, 1986).
These findings are significant in the choice of matrix material used to develop a tissue 
engineered graft, where the preferred option for vessel replacement is autogeneous 
biological artery, displaying fewer disease symptoms long-term, compared with vein 
grafts. Importantly the most successful graft materials are firstly biological and
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secondly those which are structurally and mechanically similar to the original vessel 
being replaced. As an alternative to autogenous material, synthetic conduits are used in 
vascular reconstructive surgery. Voorhees et al (1952) pioneered this work by 
proposing the use of Vinyon ‘N ’ cloth to bridge arterial defects (Voorhees et al., 1952). 
Later Blakemore and Voorhees, (1954) continued this work with limited success in 
clinical trials (Blakemore and Voorhees, 1954).
Since these early trials, research has concentrated on improving graft biocompatibility. 
This has lead to the widespread use synthetic materials such as Dacron (polyethylene 
terephthalate or PET), polyurethane and Teflon (expanded polytetrafluoroethylene or 
ePTFE) as graft material. Vascular reconstructive surgery has had considerable success 
with the use of large diameter synthetic conduits (> 6 mm) as replacement vessels. By 
contrast, small diameter synthetic conduits occlude rapidly resulting in very low patency 
rates. This is particularly so in the peripheral vasculature where high resistance is 
compounded by low flow rates cumulating in graft thrombosis (Callow, 1982). 
Prosthetic materials are typically found to be inferior to autologous saphenous vein as 
replacement vessels, where thrombosis and graft infection reduce patency rates of 
synthetic materials (Thomas et al., 1999). Larger diameter synthetic replacements have 
proved more reliable than small diameter grafts and with long term use of 
anticoagulants and platelet inhibitors, grafts attain patency rates in excess of 10 years 
(Antiplatelet Trialist’s Collaboration , 1994). Principally the development of neointimal 
hyperplasia and the absence of a fully biocompatible lumenal surface, compounded by 
low flow rates and high resistance are the main causes of graft occlusion and failure. 
This is particularly so in smaller diameter vessels of the peripheral vasculature. One of 
the synthetic materials available for use in reconstructive surgery, ePTFE is commonly 
used for femoropopliteal bypasses (Bos et al., 1998). Surgical assessments of ePTFE 
have found cumulative patency rates at 6-years to be 20-30% in comparison to 
autologous vein with cumulative patency rates at 5-years of 70% and 60% at 10-years, 
when used in femoropopliteal bypasses. Charlesworth et al (1985) proposed that when 
autologous material was unavailable for use it “may be wiser to elect non-operative 
management than perform reconstructions of limited durability” (Charlesworth et al., 
1985). These results have been further iterated in later studies reviewed by Jeschke et al 
(1999) where “long-term” (in this case 2-years) patency rates of -30% for ePTFE grafts 
were achieved (Jeschke et al., 1999). Thus, an alternative replacement prostheses to
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native vessels in which patency rates are deemed acceptable is of the highest priority 
and is a task that tissue engineers and others have set to solve.
1 .3  A n o v e r v ie w  o f  th e  v a sc u l a t u r e
To recognize the prerequisites for development of a successful conduit, an overview of 
basic structure and function of the vasculature is provided.
1.3.1 B l o o d  v e s s e l  c l a s s i f i c a t i o n  a n d  s t r u c t u r e
Within the circulatory system, blood vessel function has been classified into four groups 
based on their role within the vasculature. Firstly, the conductance vessels, with 
internal diameters ranging from 4-25mm and wall thicknesses of 2mm, these have a low 
resistance to fluid flow and are designed for rapid fluid transport. Vessels in this 
category are the elastic and muscular arteries, which deliver blood to distal vessels. 
Secondly, resistance vessels, with internal diameters ranging from 30pm -  4mm and 
wall thicknesses from 30pm -  1mm, which are the terminal arteries and arterioles, these 
act to control local blood flow. Through contraction or dilation of the smooth muscle 
fibres of the vessel wall, (controlled predominantly through the sympathetic nervous 
system and the adrenal medullary hormones) blood flow to downstream capillary beds 
is controlled (Wheater et al., 1979). Thirdly, exchange vessels, with internal diameters 
approximately 8pm and wall thicknesses of 1pm, which are the capillaries themselves. 
These characteristically have a single layer of flattened endothelial cells that form a 
continuous epithelium that optimises mass transfer between blood and tissues. Finally 
capacitance vessels, the veins and venules of the vasculature. These vessels are thin- 
walled and offer low resistance to blood flow. With the exception of venous 
components of the microcirculation, capacitance vessels function as a low-pressure 
collection system and a variable capacity blood reservoir (containing approximately 
65% of the bodies blood volume), which ultimately returns blood to the heart.
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S tructure of ‘normal’ arteries
Blood vessel structure, whether arterial or venous, basically consist of three main layers 
or tunicae. Tunica intima, the innermost layer, comprises an inner layer of flattened 
epithelial cells, termed the endothelium, which lines the lumen. Outside the 
endothelium is a zone of connective tissue, a basement membrane of type IV collagen. 
This supports the endothelium that is encased by the internal elastic lamina, a ‘sleeve’ 
of elastic tissue that limits the distension of the blood vessel (Hampton, 1983). The 
tunica media, an intermediate muscular layer, forms a tube around the internal elastic 
lamina. In the larger arteries, elastin is entwined within the collagen fibres whereas in 
the aorta, elastin is the dominant structural protein. At the boundary between the tunica 
media and adventitia lies the external elastic lamina, less defined than the internal 
lamina and absent from some arteries e.g. the cerebral arteries. The tunica adventitia is 
an outer layer of loose connective tissue that merges with adjacent structures, containing 
lymphatic vessels, autonomic nerves and vasa vasorum. The increased wall thickness of 
the larger vessels and diffusion implications of wastes, nutrients and gases within the 
vessels predicts the requirement for a network of small arteries, vasa vasorum, within 
the vessels themselves to supply nutrients and gases. Vasa vasorum are predominantly 
within the tunica adventitia though some capillary beds are found to extend into the 
tunica media (Sunthareswaran, 1998), see Figure 1.01. Although the basic structure of 
the vasculature remains constant throughout the circulatory system, there is 
considerable variation between tunica from one type of vessel to another. The major 
histological difference is the density of smooth muscle cells and the structural protein 
elastin. The function of the arterial system is to deliver blood from the heart to capillary 
beds throughout the body, thus supplying the necessary gasses and nutrients for tissue 
maintenance. Delivery is via the cyclic pumping of the heart, forcing blood into the 
arterial network in a pulsatile flow. The effect of this flow regime cumulates in 
distension of the arterial wall and its subsequent recoil as the pressure wave passes. 
Vessel structure (e.g. muscular arteries, veins) display physical characteristics pertinent 
to their function. Arteries for example have increased demands from a pressure 
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Figure 1.01: Gross structural components of blood vessels, Sunthareswaran, (1998).
1 .3 .2  T he ex tra c ellu la r  matrix
ECM components are o f fundamental importance to the efficient functioning of the 
vasculature and are therefore a significant aspect o f vascular research. In this section, 
an overview o f the structure and function o f these vascular components is presented. 
The ECM consists o f four major classes o f macromolecules: collagen, proteoglycans, 
structural glycoproteins and elastin, each of which are discussed in the following 
sections.
C o l l a g e n
Collagen can be described as a multifunctional family o f  structural proteins where one 
or more domains have the conformation o f a triple helix (Van der Rest and Garrone, 
1991). It is the most abundant protein in the animal kingdom, accounting for 30 - 40% 
of the protein in the human body and is found in all multicellular organisms. Table 1.01 
shows the diversity o f the collagen molecule, with 18 genetically distinct collagen types. 
The predominant collagen types within the vasculature are types I and III in the arterial 
wall and type IV as the major constituents o f the basement membrane. By providing a 
scaffold with inherent mechanical properties, collagen allows for cell attachment and 
motility thus empowering specific tissues to perform their function. From ligaments to 
blood vessels, collagen is the main structural component within connective tissue which
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holds, binds and strengthens individual tissues. In most living systems structure and 
function have a close relationship that results in efficient design; collagen is no 
exception. The importance of the extra-cellular matrix in tissue engineering cannot be 
understated. The matrix composition provides various cell types with ‘local’
information, from topological arrangement to dynamic interactions with its 
surroundings or environment. For example, the pulsatile nature of blood flow on the 
blood vessel wall, as a mechanical effect, is one of the determinants in maintaining 
vascular smooth muscle cell (VSMC) phenotype. VSMC in traditional culture will 
ultimately revert to a non-specialised fibroblast-like state and subsequent loss of 
function, for example, it has been shown that vascular smooth cells not only increase 
expression of h-caldesmon, a marker for the differentiated SMC state when exposed to 
cyclic strain but are also induced to proliferate (Birukov et al., 1995).
Table 1.01: Genetically distinct collagen types (Ramshaw et al., 1995). The predominant 
collagen types in blood vesse ls have been highlighted.
Group Structure Type/s
1 Collagen forming long fibrils 1, II, III, V, XI
2 Fibril-associated collagen with interrupted triple helices IX, XII, XIV
3 Fibril-associated collagen forming beaded filaments VI
4 Collagen that form sheets IV, VIII, X
5 Collagen that form anchoring fibrils VII
6 Others XVII
7 Unknown functions XIII, XV, XVI, XVIII
E lastin
The second most abundant structural protein in blood vessels is elastin, the main 
component of elastic fibres. Where collagen confers strength to tissues, elastin gives 
tissues resilience in order to recoil after each stretching action. Collagen fibres are 
interwoven with the elastic fibres in order to delimit extension and prevent tearing of the 
tissue. Elastin is of particular importance in blood vessels as it confers elasticity thus 
allowing the blood vessels to recoil as the pressure pulse wave propagates through the 
arterial vasculature, Figure 1.02 (Alberts et al., 1994).
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Figure 1.02: Elastin content of small diameter arteries. This LT-SEM micrograph shows the 
network of elastic fibres as dense and longitudinal aligned, all other components have been 
digested away with enzymes and formic acid (Alberts et al., 1994).
Like collagen, elastin is rich in proline and glycine but differs dramatically in that it is 
not glycosylated, contains few hydroxylated proline residues, no hydroxylysine and is 
encoded by a single gene product, tropoelastin (Haralson and Hassell, 1995). Once 
secreted by the cell, elastin becomes highly cross-linked, in a manner similar to collagen 
covalent cross-linking, between lysine residues forming substantial lattice o f fibres and 
sheets. Alanine and lysine rich, a-helical, hydrophobic segments alternating along the 
polypeptide chain o f elastin form cross-links between adjacent molecules, each o f these 
a-helical segments is coded by separate DNA exons. Although the molecular structure 
and the action o f elastin is well documented, the exact mechanism by which its elastic 
properties are conferred is still debated. Theoretically elastin molecules form a ‘random 
coil’ when relaxed. When stretched, fibres extend until straightened while adjacent 
cross-links hold the fibre intact, until the strain is released and the fibre can recoil, much 
like a rubber band (Alberts et al., 1994).
P r o t e o g l y c a n s
The basic structure o f proteoglycans (PG) consists o f a protein core to which one or 
more carbohydrate components, glycosaminoglycan side chains (GAGs) are covalently 
bound via a serine residue. Potentially 18 genetically different core proteins have been 
elucidated, which have 1 or more domains that can interact with other ECM components
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and cell surface proteoglycans. Proteoglycan gene families associated with cells and the 
ECM are shown in Table 1.02. An important member of the orphans, is perlecan, 
located in basement membranes and associated with cell attachment (Haralson and 
Hassell, 1995). The basic structural feature of GAG chains is the alteration of two 
monosaccharide units. GAGs can be subdivided into three major groups: 
chondroitin/dermatan sulphate, heparin and heparan sulphate and keratan sulphate 
(Haralson and Hassell, 1995). The biological properties and functions of proteoglycans 
are diverse. These functions range from stabilising the ECM mechanically to effects on 
cell adhesion and migration to influences on cell differentiation and morphogenesis. 
The functionality of PG is not limited to the core protein but its activity is often related 
to the GAG side chain component or the two components working in concert.
Table 1.02: Selected proteoglycan families, modified from (Haralson and Hassell, 1995)
Family_______________ Source________ Examples____________ Proposed Function (examples)
Binds matrix constituents and
Syndecan Cell surface Syndecan l-IV growth factors via GAG side 
chains
Orphans (a) Cell surface CD44 Binds collagen IV
Leucine-rich ECM Fibromodulin Associates with fibrillar collagens
Hyaluronate binding ECM Aggrecan Cartilage, resists compression
Collagenous ECM Collagens IX and XII Cartilage, resists compression
Orphans (b) ECM Perlecan Basement membrane, filtration and cell attachment
S tr u c t u r a l  g l y c o p r o t e in s
Structural glycoproteins of the ECM exhibit several common features in that their 
primary structure is both structural and functional, have independent binding sites for 
matrix and cell ligands and commonly have multiple protein subunits. Examples of 
these ECM components in terms of location and function are outlined in Table 1.03.
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Table 1.03: Selected structural glycoproteins of the ECM, modified from (Haralson and Hassell, 
1995).
Glycoprotein Location (examples) Function (examples)
Fibronectin
Cellular fibronectin (produced by 
fibroblasts, epithelial, EC and 
chondrocytes)
Cell adhesion; Thrombosis and wound repair 
Binds heparin collagens 1 and III, and fibrin
Interaction with collagen IV, entactin and
Laminin Basement membranes heparin sulphate; cell binding to ECM; cell differentiation; wound healing and 
angiogenises
Entactin Basement membranes Binds laminin, type IV collagen and fibronectin; RGD sequence and EGF-like domains
Thrombospondin Produced by EC SMC bone cells and fibroblasts
Cell attachment; platelet adhesion, proliferation 
and migration of SMC; binding sites for 
fibrinogen, fibronecin, laminin and plasminogen
SPARC/ Basement membranes; tissue Binds collagen 1, II and IV, calcium and cells;
Osteonectin undergoing remodelling influences cell migration
Vitronectin Liver, platelets, plasma and RGD mediated attachment of fibroblasts andmacrophages EC; associated with elastin; binds heparin
Fibrillin Aorta, skin, lung, muscle Constituent of elastic fibres
1 .4  D e v e l o p m e n t  o f  sm a ll  diam eter  v a s c u l a r  g r a f t s
Techniques to create/generate small diameter replacement vessels with acceptable 
patency rates vary greatly. Generally these methodologies can be grouped into three 
distinct strategies which have been previously reviewed (Bos et al., 1998). The 
differences within each strategy group represent the choice of matrix or support 
structure used to support cell growth; these generally fall into three categories: synthetic 
(e.g. ePTFE), biologically derived (e.g. collagen), or a combination of both (see Table 
1.04).
27
Table 1.04: Alternative strategies to develop vascular prostheses, (Bos et al., 1998) including 
additions and omissions.
Strategies for small diameter vascular graft development_____________________
1 Development of biocompatible synthetic materials
1a. Modification to the materials gross physical structure
1 b. Introduction of functional groups
1c. Incorporation of biologically active substances
2 Development of biopoiymer biomateriais
3 Tissue engineering: ‘living grafts’
3a. Endothelial cell seeding onto vascular prostheses
3b. Biopolymer-based materials
3c. Self-assembly model
3d. Polymer-based synthetic materials
3e. Decellularised tissues
The first strategy is often the reapplication of an existing material from either non­
medical applications or a material that has proven biocompatibility characteristics and 
modified to suit a specific need. Advantages of the reapplication of a material 
previously accepted for human implantation is that most of the regulatory steps have 
already been approved, and materials with previous surgical success are more likely to 
be accepted by the procuring surgeon.
1.4.1 S t r a t e g y  1 : D e v e lo p m e n t  o f  b io c o m p a t ib le  s y n t h e t i c  m a t e r ia l s
Gore-Tex (PTFE), like other synthetic materials has been modified to offer a variety of 
characteristics such as internal diameter variation, wall thickness variation, ringed, 
ringed thin walled, tapered, bifurcated and patches. Thus, Gore-Tex is not one product 
that fits all, but one that has been modified over time to improve characteristics and 
offer a larger, more diverse product range. Table 1.05 illustrates some of the many 
methodologies that have been used to alter the physical or chemical structure of existing 
synthetics.
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Table 1.05: Techniques used to modify the gross physical structure and surface morphology of 
existing synthetic vascular grafts, (Bos et al., 1998) including additions and omissions.
Strategy 1a. Modification to the materials gross physical structure
Modification Method Effect Reference/s
Gross structure Alternative knitting 
procedures e.g. woven
Increases in structural 
stability
(Mary etal., 1997)





Mild hydrolisation Allows attachment of 
biomolecules
(Phaneuf et al., 1995)
Gamma-radiation Improved cell growth 
on modified matrix
(Kirkpatrick et al., 1991)
Radio frequency glow 
discharge e.g. conversion 




(Kiaei et al., 1992)
Polyurethane (PU), was initially used in the form of intravenous catheters where it 
displayed excellent blood compatibility and cellular adhesion properties. In the mid­
eighties PU became a popular ‘potential’ material for vascular conduits due to its 
durability, elasticity and compliance. However, some of the past successes have not 
been reproducible, with continued structural failures (Jeschke et al., 1999), thrombosis 
and embolism (Bos et al., 1998a) resulting in PU being perceived as a less promising 
option. PU has recently seen a revival of interest. As with other synthetic materials, 
modification of either the chemical structure, addition of other polymers, or variations 
in manufacturing processes aim to enhance the material characteristics. Recently a 
modified PU has been produced with ‘improved’ hydrolytic and oxidative stability. 
Assessment of the material in terms of biocompatibility compared to ePTFE was carried 
out in a small animal study (Jeschke et al., 1999). Of the parameters studied, PU 
displayed faster lumenal endothelisation, less chronic neointimal proliferation and a 
thinner neointima compared to ePTFE grafts. These advantages in biocompatibility 
were not realised in terms of patency rates, as no significant differences between PU 
(82% at 6-months) and ePTFE (81% at 6-months) were observed. Like previous work 
comparing patency rates between ePTFE and autologous vein, initial patency of ePTFE 
grafts is comparable, though lower, to autologous vein patency, where as long-term 
implantation (2-years and over) saphenous vein patency is considerably better 
(Charlesworth et al., 1985; Jeschke et al., 1999). The authors also acknowledged
29
limitations of the study in that although the study is comparative between ePTFE and 
PU in a rat model, no conclusions can be drawn relating to the effectiveness of PU as a 
prosthetic graft in humans. Both of these factors are important to the long-term patency 
of any prosthetic vascular material. They conclude with a positive outlook on PU as a 
grafting material due to increased biocompatibility compared with ePTFE. Importantly, 
the choice of animal model and the site of graft implantation are critical in determining 
graft outcome. For example, grafts placed in the rat abdominal aorta, a small diameter 
vessel with high blood flow  and low resistance, are quite unlike diseased tissues of the 
peripheral human vasculature which show low blood flow  and high resistance may lead 
to false positives. In many animal models spontaneous endothelisation occurs, whereas 
in humans only small regions of the prosthetic graft may gain endothelial cell coverage 
immediately adjacent to the anastomosis, termed transanastomotic endothelialisation 
(Davids et al., 1999).
The development of synthetic materials is an important area of research for vascular 
replacement technology. Particularly when a surgical procedure is urgent, the material 
maybe taken directly from bulk storage, without requiring cell culture such as tissue 
engineering methodologies. In addition synthetic materials have a significant advantage 
over competing technologies in that they are likely to be less expensive, considerably 
less complicated and less problematic than methodologies requiring a cell culture phase 
prior to implantation. For these reasons a synthetic material displaying extended 
patency may ultimately be the prosthetic of choice; this is however not in the 
foreseeable future.
Reapplication of an existing material facilitates the process of regulatory acceptance, 
while the use of a previously accepted graft further simplifies this process. Within this 
overall strategy, a huge variety of research has been conducted that encompasses direct 
surface modification of the graft material, application of biologically inert and 
biologically active substances. Each of these ‘general’ methodologies is to a large 
extent interrelated and boundaries between groups are often not clear. Strategies are 
discussed in the three groups mentioned above. Table 1.06 summarises the methods 
that introduce functional groups to enhance performance of vascular grafts in vivo. 
Based on Bos et al (1998a), with omissions and additions (Bos et al., 1998)
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Table 1.06: Introduction of functional groups and/or the incorporation of biologically active 
substances to existing synthetic vascular grafts (Bos et al., 1998) including additions and 
omissions.
Strategy 1b. Introduction of functional groups
Modification Method Effect Reference/s
Chemical Treatment with ammonia or Improved cell adhesion (Sipehia et al., 1993)
treatment alkylamine plasma to to matrix (Tran and Walt, 1989)
covalently biomolecules
Binding specific Chemical modification and Seals graft pores (Guidoin etal., 1989)
biomolecules addition of e.g. collagen, negating the (Guidoin etal., 1987)
gelatin requirement for pre­ (Weadock and Goggins,
clotting 1993)
(Marois et al., 1995)
e.g. albumin Biocompatibility (Kottke-Marchant et al.,
Healing 1989)
(Marois et al., 1996)
Cross-linking Glutaraldehyde etc to bind Reduces risk of, (Schmidt et al., 1998)
biomolecules Aneurysm (Werkmeister et al., 1995)
Thrombosis
Hyperplasia
Variation of glutaraldehyde vs. Differential effects on (Slimane et al., 1988)
cross-linking carbodiimide cell cytotoxicity
agents Calcification of matrix
The aim of modifying existing vascular prostheses is to enhance in vivo characteristics 
whereby cell adhesion, reduced thrombogenicity and post-implantation healing 
processes maybe optimised. Surface or structural modifications vary from relatively 
simple changes in the method of production, where fibres of the material maybe woven, 
knitted, of variable thickness, tapered etc. to chemical modification. A further study has 
reported on four different types of tubing used in bypass surgery and evaluated under 
static in vitro conditions. Silicon elastomer tube with a platinum cured catalyst, silicon 
elastomer tube cured with a peroxide initiator, Polyvinylchloride (PVC) and PVC 
coated with heparin using ionic bonding. Each of the four materials where monitored 
for biomarkers of the complement system, coagulation, and fibrinolytic cascades using 
both direct contact (cells seeded directly on the material) and extracts of the materials 
(conditioned media) to Balb/3T3/A31 cells. Variations in pH of liquid extracts of each 
material range from 7.82 to 8.50, extracts of liquid heparin-coated-PVC resulted in a 
decrease in cell densities of 24% (P < 0.01), whereas other materials showed no 
statistical difference in cell densities. Both PVCs displayed no significant cytotoxic 
effects when in direct cell contact, whereas the heparin-bonded material displayed a
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38% reduction in cell density (Harmand and Briquet, 1999). The authors suggest that 
this is likely to be due a component of the heparin binding process as heparin itself is 
well characterised and considered to have no cytotoxic potential. None of the materials 
exhibited any significant haemolytic effects or platelet activation. Where the heparin- 
bonded material displayed negative results in some of the cytotoxic evaluations, it 
contrasted the other materials with a lower thrombogenicity. Although this paper has 
only characterised a few of the important cell/material interactions, it highlights the 
subtleties of graft/cell behaviour. Table 1.07 summarises the methods that modify or 
add compounds/molecules to enhance performance of vascular grafts in vivo. Based on 
(Bos et al., 1998), with omissions and additions.
Table 1.07: The incorporation of biologically active substances to existing synthetic vascular 
grafts, (Bos et al., 1998) including additions and omissions.
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formation (or not) 
Prevention of platelet 
adhesion by inhibition 
of complement 
cascade
Promote cell growth 
proliferation 
Differentiation of 
specific cells (EC) 
Prevention of graft 
infection (Dacron, PU)
Reference/s 
(Gemmell et al., 1998) 
(Kodama, 1990) 
(Laemmel et al., 1998) 
(Wilson etal., 1993)
(Ito and Lo Gerfo, 1990) 
(Phaneuf et al., 1997)
(Gemmell et al., 1998)
(DeBlois et al., 1994) 
(Gray et al., 1994)
(Doi and Matsuda, 1997)
(Gahtan et al., 1995) 
(Galdbart et al., 1996)
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1.4.2 S t r a t e g y  2: A c e l l u l a r  b io m a te r ia ls
Similar to the development of synthetic materials, acellular ‘biomaterials’ aim to 
develop a successful material that is immunologically inert and structurally sound that 
can be supplied immediately to patients in critical care in sufficient quantities, and 
implanted into the patient without the requirement of a pre-implantation culture phase. 
The development of acellular biological prosthetic substitutes stemmed from the 
positive aspects of synthetic grafts when biological molecules were bonded or cross- 
linked to the synthetic matrix. Table 1.08 displays a selection of biologically derived 
matrix materials used as acellular implants. Similar to many synthetic grafts, these 
materials are designed to be implanted directly into the patient.
Table 1.08: Selected biological materials used as direct implants.
Strategy 2. Acellular biomaterials
Matrix Type Research Cells seeded Reference/s
Small Intestine Matrix characterisation 3T3, 3T3/J2 fibroblasts (Badylak et al.,
Submucosa human fibroblasts, keratinocytes 1998)
and microvascular EC
Mechanical properties - (Hiles et al., 1995)
SIS in situ - (Robotin-Johnson et
development al., 1998)
Umbilical vein Vessel replacement - (Dardik et al., 1988)
Bovine carotid Vessel replacement . (Rosenburg et al.,
artery 1976)
Porcine carotid Vessel replacement - (Tamura et al.,
artery 1999)
A biological material receiving considerable attention in recent years is the porcine 
derived small-intestine submucosa (SIS). The initial material is harvested by removing 
the superficial layers of the mucosa and the external muscle layers from the porcine 
small intestine. The 80 pm thick sheet is then disinfected, sterilised and all cellular 
components removed with the final structure retaining its native 3-D structure and 
composition (Badylak et al., 1998). Hiles et al (1995), have shown after 1 month of 
implantation that the SIS (when used as an arterial graft) induces a post implantation 
healing response, whereby the graft is remodelled to form an artery-like vessel that is 
both structurally and functionally similar to natural vessels (Hiles et al., 1995). Further
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studies were carried out by Robotin-Johnson et al (1998), where autologous SIS was 
implanted into 11 piglets (superior vena cava) and assessed by the grafts ability to 
develop or remodel as the piglets matured. Of the nine surviving piglets (2 died of non­
related causes) the mean weight gain from 10.3 ± 2.0 kg before the operation to 59.2 ± 
16.7 kg, compared favourably with controls at 58.5 ± 6.6 kg (Robotin-Johnson et al.,
1998). This study illustrates the potential of SIS as a grafting material; nevertheless 
long-term implantation studies must be carried out to determine ultimate patency rates. 
An issue with all biological material used with the intention of applying for certification 
for human implantation is that of consistency or uniformity of the final product. Our 
own experience has shown the extensive variation in porcine carotid arteries, within 
animals of the same breed, age and sex. It is this variation that may undermine the 
feasibility of scaling-up these processes.
1.4.3 Str a teg y  3: T issue  Engineering  ‘living  g r a fts ’
As the search for replacement blood vessels with prolonged patency rates continues, a 
new strategy ‘Tissue Engineering’, has become an important player in the field of 
vascular research. Tissue engineering aims to circumvent the dire shortage of donor 
organs by ‘growing’ de novo replacement organs, neo-organs. From skin to livers, 
tissue engineers aim to replicate the body's natural processes of development to create 
“off-the-shelf’ whole organs thereby alleviating this shortage. Although the creation of 
a complete biological neo-liver is unlikely to occur in the near future, due to the organ’s 
shear complexity, major inroads to neo-liver (as well as other organs) development are 
underway. Notably, the first tissue engineered product to achieve American FDA 
approval was “Transcyte”, produced by Advanced Tissue Sciences in 1997, as a non­
living wound covering. This construct was developed by culturing human foreskin 
fibroblasts on a synthetic polymer, which could then be frozen for later use (Naughton,
1999). Since then, other living tissues have been developed for skin replacements and 
being marketed internationally. Complex organs such as blood vessels (L'Heureux et al., 
1998; Weinberg and Bell, 1986); (Niklason et al., 1999) and heart valves (Shinoka et 
al., 1997) are being intensively studied with the same eventual aim of developing 
efficient grafts.
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The question, “what does tissue engineering offer, or potentially offer, that traditional 
synthetic substitutes do not”, is important as it lays down the foundation for this 
research. The fundamental difference between a discrete synthetic substitute and a 
tissue engineered vessel is that the tissue engineered replacement tissue is 'grown' using 
either the patients own cells or another cell source that maybe recognised as ‘self, in 
the laboratory or a clinical environment prior to surgical implantation. Once implanted 
the organ remains a fully functional and an interactive 'device' (Bos et al., 1998). In 
addition the graft maybe exposed to mechanical forces that mimic the in vivo 
environment, providing the necessary cues for correct development. All cells within 
any individual, with the exception of n germ cells and non-specific mutations, have 
exactly the same genetic content or genotype. In order for a cell to perform a specific 
function it must first differentiate e.g. a neurone, osteoblast or muscle cell. In vivo cells 
are maintained within a dynamic perfusion system, where cells interact with chemical 
signals, such as growth factors, signals associated with the ECM, such as adhesion 
molecules and mechanical stimuli, e.g. shear stress and cyclic strain. It is this dynamic 
physical environment that allows cells to firstly differentiate and secondly maintain 
their specific function or phenotype. Without external queues a cell is likely to 
dedifferentiate back to a non-specialised state, for example vascular smooth muscles 
cells revert to a non-specialised fibroblast state, with resulting loss of function. 
Mechanical influences on cellular growth, proliferation and differentiation have become 
an increasingly important factor in the biocompatibility and healing processes involved 
in graft acceptance. The incorporation of fundamental engineering principles into 
experimental design has become a major factor in mimicking the in vivo environment 
within an in vitro experimental setting of tissue engineering applications. Effects on 
cell phenotype resulting from the application of mechanical forces is further discussed 
in Chapters 6 and 7, where the development of a perfusion bioreactor has enabled the 
application of mechanical forces on the construct developed in this thesis.
Current research relating to tissue engineering vascular grafts can be broadly 
categorised into five generic approaches utilising different matrix types or 
methodologies: 1. EC seeded synthetic graphs, 2. reconstituted biological
macromolecules e.g. reconstituted collagens, 3. self-assembled vessels 4. polymer 
based synthetics e.g. ePTFE, and 5. decellularised tissue, see Table 1.04. The primary 
constituents of a tissue engineered vascular graft are vascular cells, which may include:
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EC, SMC and fibroblasts in concert with an extracellular matrix (ECM) to provide the 
framework by which the development of the 3D organ is guided. The following section 
highlights the critical observations reported previously and the current knowledge that 
relates to this project. To introduce the reader to the developmental process preceding 
this project, selected articles have been reviewed that represent landmarks or critical 
observations that have been made in tissue engineering of small diameter vascular 
grafts.
S tr a te g y  3a. E n d o th e lia l c e l l  seeding o f  v a s c u la r  p ro s th e s e s
A replacement prosthesis that could be removed from sterile packaging in the operating 
theatre ready for immediate use, with high patency rates would be the simplest and most 
cost effective option for reconstructive surgery. While manufactures of synthetic 
replacements work towards this goal, methodologies to enhance both existing and 
prototype graft patencies are actively researched. The first application of surgically 
implanting Tiving-grafts’ was the concept of seeding endothelial cell lined synthetic 
matrices (Schmidt and Bowlin, 1999). This process aims to enhance graft patency by 
providing optimal biocompatibility at the blood/matrix interface. Unlike the first two 
strategies (1 and 2), endothelial cell seeding adds a new level of complexity and cost to 
production. Firstly, cells must be isolated from patient tissue (until immunologically 
inert cells such as stem cells or genetically modified cells are available for use, (Nerem 
and Seliktar, 2001) and seeded onto the graft material prior to graft implantation.
Much of the current tissue engineering research utilised either HUVEC or other animal 
EC, which are relatively simple to isolate, however the relevance of these investigations 
has been questioned because of the origin and nature of these terminally differentiated 
cells. Isolation of autologous vascular EC in adequate quantities is a more difficult and 
expensive task. Not only is the isolation method more technically challenging but also 
cells isolated from adult tissue behave very differently from HUVEC used for 
preliminary research. Zilla et al (1994) and others have shown the human EC isolated 
from the jugular vein were unlikely to proliferate if autologous serum with elevated 
levels of lipoprotein A was used in cultures (Zilla et al., 1994). An important issue with 
the use of 'living' grafts is the increased costs associated with graft production and 
maintenance prior to clinical use. A promising method to obtain vascular endothelial
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cells is to isolate them from adipose tissue associated with the omentum, containing 
adipocytes and microvascular EC (Williams et al., 1989). Williams et al (1994) 
confirmed that EC derived from adipose tissue are indeed EC and not mesothelial in 
origin (Williams et al., 1994). Purification of EC from contaminating fibroblasts (and 
others) had been a problem associated with this procedure, however by repetitive 
positive selection with Ulex Europaeus Agglutinin /-coated paramagnetic beads to EC, 
contaminating cells maybe removed from culture (Jackson et al., 1990).
Early studies concluded no significant advantage in graft patency with the use of EC 
seeded grafts (Fasol et al., 1987; Herring et al., 1987; Walker et al., 1987), and also 
reported an increase in platelet activation, of both seeded and unseeded grafts compared 
to saphenous vein grafts (Fasol et al., 1989). Variation in clinical procedure including, 
graft placement, diameter, material, EC type, cell seeding method and use of 
anticoagulants, has made interpretation of results difficult (Bos et al., 1998). The 
adhesion of endothelial cells is an important issue in tissue engineering blood vessels. 
To reduce the thrombogenicity of the graft surface, the stage or state of endothelisation 
prior to the grafts clinical use is critical to the success of the graft. Meinhart et al (1997) 
reported low patency rates when the growth and proliferation of EC had not reached 
confluence prior to implantation. Allowing the EC layer to reach confluence and 
mature for a period (12 ± 3  days) of incubation prior to implantation, has proven a 
significant advantage in graft patency compared to unseeded grafts at three-years 
(Meinhart et al., 1997). Zilla et al (1994) with a patient group of 49 with a mean age of
65.2 ± 9 .8  years, reported on combined above and below knee reconstructive surgery. 
Autologous EC were harvested from a section of the right external jugular vein, cultured 
to a final density of 16 x 106 cells and seeded onto 6 mm ePTFE grafts ‘preclotted’ with 
a fibrinolytically inhibited fibrin glue. Prior to implantation EC confluence was shown 
to be 88.9%, with 77.8% grafts confluent and 14.8% grafts subconfluent. The clinical 
follow-up after 32 months implantation showed patency rates for controls at 55.4% and 
EC seeded grafts at 84.71% (Zilla et al., 1994). Although these studies have shown an 
improvement in graft patency, the added complication of a two stage process has proven 
a significant hurdle to the wide spread uptake of this technology.
Further techniques and studies in endothelial cell seeding and growth are tabulated 
below, Table 1.09. Methodologies to enhance cell seeding onto bioprotheses are
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discussed in context with the cell seeding studies carried out in this thesis Chapter 7.4.
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(Herring et al., 1979) 
(Schmidt et al., 1991) 
(Belden et al., 1982) 
(Stanley et al., 1982) 
(Szilagyi et al., 1991) 
(Graham et al., 1980) 
(Schmidt et al., 1991) 
(Schmidt et al., 1991) 
(Watkins et al., 1984) 
(Meinhart et al (1997) 
(Jackson et al., 1990) 
(Hubble et al., 1991) 
(Hynes, 1992)
(Boyd et al., 1988)
(Bull et al., 1995)
(Ottand Ballermann, 1995) 
(Shayani et al., 1994)______
S t r a t e g y  3 b . B io p o ly m e r -based  b io m a teria ls
The concept of allowing an entire graft to develop in vitro using tissue engineering 
principles was first conducted by Weinberg and Bell (1986), where an entirely 
biological, multi-layered structure with the gross physical appearance of an artery was 
developed. Earlier trials using this methodology failed under physiological pressures, 
later constructs supported by a Dacron mesh were able to withstand higher pressures. 
The development of the tissue engineered construct was modelled around a three- 
layered tissue using bovine derived EC, SMC and fibroblasts and animal collagen. The 
intima had an endothelial cell lining; the media had SMC and de novo matrix materials. 
The vascular media was made by casting a gel forming collagen with SMC within an 
annular mould and left to gel (37°C), for a period of several days to allow the gel to 
contracted to form a tubular lattice around a central mandrel. The Dacron mesh was 
then slipped over the lattice. The adventitial layer was constructed with fibroblasts and 
matrix materials that was supported by a Dacron mesh to provide structural integrity
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and was cast around the first layer. When the outer layer (adventitia) was fully 
contracted the mandrel was removed and an EC suspension was seeded into the lumen. 
The matrix was rotated at 1 Hz for 1 week to allow cells to adhere evenly on the 
matrices lumenal surface. Histological analysis showed SMC displayed bipolar 
differentiation with bundles of filaments, dense bodies and secreted collagen. EC 
formed a near complete monolayer (92.1%) with intercellular junctions acting as a 
permeability barrier to large molecules such as albumin. The EC also released 
prostacyclin, a potent inhibitor of platelet aggregation and produced von Willebrand 
factor an established marker for the EC phenotype. The authors attributed the vessel’s 
structural integrity to: the Dacron mesh, collagen contraction, initial seeding density 
and time lapsed for casting. Unfortunately this model did not display the required 
mechanical strength, even when reinforced with Dacron. Burst pressures without 
Dacron mesh were < 1 0  mmHg, and with one mesh layer 40-70 mmHg and two mesh 
supports 120 -180 mmHg. Although 180 mmHg is at the top end of normal blood 
pressure, there is zero tolerance. Maximal burst strength was attained between 3-6 
weeks post casting with the structural integrity declining after 6 weeks. This was 
attributed to collagenase activity. This model displays important features of a natural 
graft but was limited by reduced mechanical strength, lack of elastin, SMC orientation 
and the longitudinal alignment of collagen fibres unlike that in vivo with LH and RH 
alternating spirals. Finally SMC density was 1/8 to a 1/4 of in vivo densities (Weinberg 
and Bell, 1986). An important point with this earlier work was that once the graft had 
been developed it was not exposed, or cultivated under pulsed pressure conditions. Had 
it been so, the ability of the graft to withstand higher pressures may have improved 
significantly.
Further to this work L'Heureux et al (1993) using a similar methodology to Weinberg et 
al, (1986) and human vascular cells, developed a Tissue Engineered blood vessel. Again 
problems with low burst pressures have shown this technique in its current form to be 
limited (L'Heureux et al., 1993). Hirai and Matsuda (1996), again with a similar 
methodology using canine jugular cells, poured a cold mix of VSMC (5 x 105 cell/ml) 
and type I collagen (1.5 mg/ml) into a glass mould and incubated with the inner mandrel 
at 37°C for 10 d. The inner 8 mm mandrel was then removed and a smaller support 
consisting of 6 stainless steels wires was inserted, a 2 ml solution of EC (1 x 106 
cell/ml) was then inoculated into the lumen. After incubation at 37°C for 20 minutes
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the vessel was rotated 90° and a further 2 ml solution of EC (1 x 106 cell/ml) was 
inoculated to improved EC density. This process was repeated four times. The 3 cm 
long grafts were implanted into the posterior vena cava position of 14 dogs. All grafts 
utilised autologous canine tissue. A Dacron mesh was used to support the graft and the 
two anastomoses as cases of severe bleeding were noted due to the graft tearing. 
Importantly, neither anti-platelet nor anti-coagulant treatment was used throughout the 
implantation period (up to 24 weeks) other than intraopperative heparin. Results 
showed an overall patency of 64% (9 out of 14), with confluent EC (from 1 week), 
circumferential orientation of VSMC, fibroblast in growth, vessel wall contraction and 
the appearance of fibrous collagen, giving the appearance of near complete remodelling 
over the 24 week implantation period (Hirai and Matsuda, 1996). From the same 
group, Kobashi and Matsuda (1999) using a similar process have uniquely developed a 
branched prosthesis reinforced with a Dacron sleeve. In an attempt to improve the 
graft’s structural integrity, twice the concentration of type I collagen (3mg/ml) and six 
fold increase in VSMC density (to 3 x 106 cell/ml) was employed. After a total of three 
weeks in culture EC were seeded (several times) at 3 x 106 cell/ml until confluence was 
reached. After EC seeding the graft was exposed to pulsatile pressure of 1 Hz, between 
30 and 60 mmHg for 24 h. Without the Dacron mesh support the graft ruptured at 40 
mmHg. With Dacron the graft remained viable at 250 mmHg (Kobashi and Matsuda,
1999). Advantages with this technique are clear, high densities of VSMC can be 
directly incorporated into the developing medial layer of the vessel, subsequent seeding 
of EC immediately positions cells in their native ‘setting’ within effective 
communication distances (Francis and Palsson, 1997). Although the orientation of the 
VSMC is not circumferential and EC do not align with the direction of flow, the applied 
haemodynamic stresses will encourage cell alignment, and subsequent improvements in 
phenotypic expression of cellular constituents over time. While the 24 h period in this 
article is likely to be too short for full development of cellular orientation and density, 
an extended culture period under progressive pulsed flow will improve strength through 
increased collagen deposition and VSMC density. Like all current methods using cells 
seeded within a collagen gel, the inherent floor is the weakness of the initial gel. The 
very fact that a permanent synthetic sleeve is used to reinforce the matrix limits the 
ultimate remodelling potential of the graft by preventing the potential vasotone, which 
may eventually result in intimal hyperplasia (Nerem and Seliktar, 2001).
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S tr a t e g y  3 c . S elf-a s s e m b ly  m odel
Described as the self-assembly model this technique was pioneered by L'Heureux et al
(1998) who created a tissue engineered blood vessel based exclusively on cultured 
human cells without exogenous biological materials. This is the first model to show 
sufficient structural integrity to withstand physiological conditions. Key to this result 
was culturing cell types in ascorbic acid to induce increased production of ECM, 
resulting in cohesive cellular sheets. Graft development was a four-step process: 1. 
Production of an acellular inner membrane (IM) using a dehydrated fibroblast sheet 
formed into a tube, 2. The IM is slipped around a tubular, perforated PTFE mandrel 
(OD 3.0 mm) and a sheet of SMC is rolled around the IM, creating the vascular media. 
This was placed in a bioreactor, providing lumenal flow and support for one week, 3. A 
sheet of fibroblasts was rolled around the smooth muscle cell layer, creating the 
adventitial layer; this was incubated in a bioreactor for a further 8 weeks when the 
PTFE mandrel was removed. Finally, step 4, the inner PTFE mandrel was removed and 
either used for EC seeding or mechanical testing (L'Heureux et al., 1998). The total 
culture time necessary for the graft developed by L'Heureux et al (1998) was 12 weeks, 
excluding cell expansion and IM production. The final structure was 'artery-like’ in 
appearance; displayed differentiated tissues, intima, media and adventitia; SMC did not 
penetrate the inner membrane (8 weeks) and the EC layer reached 99.2% confluence. 
SMC density was lower than in vivo tissue, but was considered high by the authors for 
an in vitro model. Collagens type I, IE and IV were present, and burst pressures up to 
2594 mmHg were achieved at 8 weeks. Animal studies carried out in a canine model 
implanted with the graft, less the human endothelial cell lining to prevent chronic 
rejection, results show the graft to be thrombogenic. The authors suggest this is due to 
the lack of an EC cell layer. They conclude that the graft is “clearly” more compliant 
than ePTFE grafts, but less than human saphenous vein (HSV) grafts. Any foreign 
material implanted into either an animal model or human is subjected to the host 
immune system, clearly some materials are potentially more thrombogenic or immune- 
reactive than others. With the exception of grafts grown within the recipients own body 
(Campbell et al., 1999) all other tissue engineering applications employ a foreign matrix 
and are thus subjected to the host immune system. Therein lies the major advantage 
with this particular method, minimal, if any immune response. Although the results 
presented by the authors show a poor performance of the graft, the use of autologous
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cells (both EC and VSMC) would without a doubt show a vast improvement (L'Heureux 
et al., 1998). Present applications for this type of graft are limited by the time scales 
required to generate the complete graft. This obstacle may become less of an issue as 
improved methods are explored to speed up initial cell densities, such as application of 
growth factors, larger biopsy material or the use of stem cells.
S tr a t e g y  3 d . P o ly m e r - based  s y n th e tic  m a ter ia ls
Early designers of synthetic grafts concentrated on developing immunologically inert 
materials. In recent years there has been a drive to develop materials that interact with 
the biological environment in which they are implanted. Examples of the introduction 
of functional groups and/or incorporation of biologically active substances to synthetic 
materials are shown in Table 1.07. Variation of cellular response to different synthetic 
materials is not only dependent on the material but also the manner in which it is 
presented, for example the weave pattern and porosity of the same synthetic material 
(Greisler et al., 1996).
Shinoka et al (1998), used a synthetic biodegradable matrix (polyglactin woven mesh, 
sealed with a polyglycolic acid nonwoven mesh) 20 mm x 15 mm (L x W), designed to 
degrade over a 6-8 week time course. Mixed autologous ovine vascular cell populations 
(2-3% EC, with the remaining being VSMC and Fb) were seeded at 1 x 107 cells onto 
the matrix and cultured for 6-9 weeks prior to surgical implantation of a 2 cm section 
into the pulmonary artery (PA). The aim of this work was to develop a living graft that 
would ‘grow* with the animal, as a preliminary study for pediatric vascular 
reconstruction. Results showed all grafts remained patent after 12 weeks (n=7) with no 
evidence of thrombus formation or calcium deposition. By two weeks the graft material 
had almost entirely disappeared, with a reduction in wall thickness compared to native 
PA. Immunohistochemical staining showed EC presence on the graft lumen, with the 
hydroxyproline analysis of the graft material displaying about 70% natural collagen 
(Shinoka et al., 1998). This model has shown it has potential to remodel and grow over 
the 12-week implantation period, with the graft remaining viable after the degradation 
of the synthetic matrix.
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The use of a complete or near complete matrix prior to cell seeding is a method to 
reduce development times. To achieve this Niklason et al (1999) have used a synthetic 
polymer, a non-cross-linked PGA scaffold sewn into a tubular form. Bovine aortic 
SMC were seeded onto the PGA vessel and cultured for 8 weeks under pulsatile 
conditions using a bioreactor in a parallel flow system. A compliance chamber was 
used to reduce high frequency vibrations (300ml) and the pulsatile radial stress set at 
165 beats/min (Niklason et al., 1999). SMC migrated into matrix creating a smooth 
lumenal surface onto which the EC were seeded followed by 3 days of continuous 
perfusion culture. The resulting vessel displayed burst pressures well in excess of 
physiological conditions (8 weeks 2150 ± 709 mm Hg), compared to native saphenous 
vein 1680 ± 307 mm Hg. Advantages with the use of pulsatile pressure were an 
increase in collagen deposition, though SMC density was unaffected by pulsatile 
pressure conditions. SMC densities were higher than systems using collagen gels. The 
authors speculated that this is due to space being occupied by matrix (15% of total after 
5 weeks). Vessel contraction in response to various hormones was considered to be 
evidence of retained phenotype; often lost in standard culture. The EC lining the 
lumenal surface inhibited SMC proliferation. Implantation studies conducted with 6- 
month old pigs, grafts were implanted into the right saphenous artery and monitored up 
to 4 weeks before explantation. Results from these studies are promising with all grafts 
remaining patent for 2 weeks postoperatively. The pulsed (prior to implantation) 
xenograft remained patent for 24 days with no evidence of stenosis or dilation. The 
pulsed autologous vessel was patent at 4 weeks with a reduced flow rate, non-pulsed 
autologous vessel occluded at 3 weeks. Histological analysis of the explanted vessels 
displayed a highly organised structure with minimal inflammation. Importantly the 
effects of pulsatile culturing conditions have produced positive effects on the viability 
of engineered vessels. Long-term implantation studies are required to fully test the 
effectiveness of this methodology. Again, the choice of model is critical. Kim et al
(1999) have shown the addition of 10% serum increases VSMC proliferation of rat 
aortic cells grown on both PGA and collagen type I scaffolds. The application of 
pulsatile pressure on seeded grafts prior to implantation and the resulting benefits seen 
through the maintenance of cell phenotype and the up regulation of both elastin and 
collagen genes has lead to a significant increase in tensile strength of the engineered 
tissues (Kim and Mooney, 1998). These distinct effects will bring the graft closer to its 
in vivo phenotype and potentially improve graft success through the first three critical
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months after vascular reconstruction.
In a more recent publication Niklason et al (2001), have expanded on their earlier 
studies, where neovessels are created in vitro (Niklason et al., 2001). Again using 
bovine cells seeded onto a biodegradable PGA scaffold, the group has focused on a 
variety of culture parameters to understand the mechanisms affecting graft 
development. The effects of the degradation or presence of PGA scaffold residues on 
SMC phenotype has been previously noted (Greisler et al., 1993), where SMC 
dedifferentiated to a fibroblast-like state resulting in a hyperplastic response. In this 
model, cultures at 5-8 weeks showed similar histology and burst strength, however the 
lack of elastin expression prevented native mechanical behaviour and the contractility of 
the graft was a fraction of native vessels. The group is currently exploring ways to 
induce elastin expression in order to extend mechanical compatibility (Niklason et al., 
2001). Interestingly the model Kim et al (1999) used, confirmed elastin expression with 
murine cells. This effect can be attributed either to the increased mechanical stresses 
used or different cells types and their differential reactions to the in vitro environment. 
Both groups used PGA scaffolds, which weakens the argument that PGA residues 
dedifferentiate SMC under these conditions. These positive results will need to be 
introduced into a more stringent model where graft diameters are reduced, implanted in 
lower flow rate systems and adult primary human cells used to determine the 
effectiveness of this method. As discussed in Chapter 4, a fine balance must be 
acquired with the use of biodegradable matrices, reduced growth rates and culture times 
associated with primary humans.
S tr a t e g y  3 e . D e c e llu la r ised  biolog ical  t is s u e s
To reiterate several of the prescription details for a matrix for use in vascular tissue 
engineering it is clear that the matrix must have sufficient porosity to allow rapid cell 
invasion to populate all aspects of the graft, maintain haemostasis, be immunologically 
inert to reduce thrombotic effects at the blood interface and tolerance at the ablumenal 
surface, non-cytotoxic, must degrade progressively to allow complete remodelling, have 
matched compliance to the replaced vessel, mechanical strength to cope with 
haemodynamic stresses and have adequate handling characteristics for surgical 
implantation. As described in Table 1.01 graft designers have taken several
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approaches to encompass as many of the listed items as possible, including full 
synthetic matrices, biological polymers and combinations of each. Most of these 
materials do not provide biomechanical properties that mimic the natural artery, such 
that the compliance mismatch between grafted matrix and patient artery is excessive, 
which may lead to early graft failure by intimal hyperplasia (Schmidt and Baier, 2000; 
Seifalian et al., 1999). No other replacement material has the same biomechanical 
properties as the bodies own arteries due to the complex relationship between collagen, 
elastin and associated ECM molecules. A method employed to provide improved 
mechanical properties and cell adhesion properties more akin to a natural artery is the 
use of decellularised xeno or allograft tissue. Much of the earlier work has focused on 
bioprosthetic devices such as heart valves that have preferential properties, e.g. reduced 
noise, improved haemodynamics and immunological tolerance by the patient immune 
system over mechanical valves. Unfortunately biologically derived valves tend to have 
a shorter lifespan (7-10 years) compared to mechanical man-made valves (>25 years) in 
which the patient is required to maintain lifelong immune suppression. In order to 
minimise host immune response and prevent rapid degradation once implanted, 
biomaterials are cross-linked to stabilise the material ensuring the maintenance of 
structural integrity. The failure of biological materials, in particular glutaraldehyde fixed 
prostheses has been associated with cytotoxicity, mechanical failure and calcification 
(Schmidt and Baier, 2000). Alternatives to glutaraldehyde have been pursued that 
minimise these negative responses and are further discussed in Chapters 3 and 4.
The extraction of cellular components aims primarily to reduce the immunological 
response to the implanted tissue and thus improve graft patency by removing as many of 
the foreign epitopes from the tissue as possible. Chapter 4 reviews the main
methodologies used and their effects on the tissue. Most tissue decellularised for 
arterial replacement has been used as a direct grafting material, (Badylak et al., 1998; 
Dardik et al., 1988; Rosenburg et al., 1976; Tamura et al., 1999). Karim et al (1999) 
used enzyme treatments to extract porcine cells from aortic specimens. The treatment 
was shown to remove cytoskeleton components, integrins, collagen IV and fibronectin 
leaving fibrillar collagen and elastin of the aortic wall. After seeding and culture with 
human myofibroblasts production of ECM components such as human pro-collagen I, 
fibronectin and laminin was shown as an evidence of matrix remodelling in vitro 
(Karim et al., 1999). Teebken et al (2000) applied a decellularisation process on
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thoracic aortas of adult large German pigs using enzymatic extraction of protein, DNA 
and RNA, no cross-linking step was reported as described in Section 4.1.2. After the 
extraction process, human saphenous vein myofibroblasts and EC were seeded onto the 
lumenal surface of the matrix and assessed under both static and pulsed conditions. 
After 4 days in perfusion culture, (flow rates 120-190 ml/min. pressure 70-140 mmHg) 
EC density increased from initial numbers to produce a near confluent endothelial cell 
layer. Myofibroblasts generally formed monolayers on the grafts lumenal surface, 
though one sample displayed cells in multiple layers (Teebken et al., 2000). Like 
synthetic polymers used in tissue engineering, biological matrices are designed to either 
remain intact, i.e. be stable against host degradation, or to remodel over time. Teebken 
et al (2000) have chosen not to cross-link the prepared matrix. Advantages of this 
method are seen as enhanced tissue remodelling processes by seeded cells, which would 
otherwise be prevented by cross-linking. Cross-linking procedures certainly reduce, the 
ability of seeded cells to remodel the tissue by proteolytic means such as MMP. 
Further, by not introducing toxic chemicals and the negative effects cross-linking often 
has on the mechanical properties of biological tissues (Schoen and Levy, 1999), seeded 
cells are likely to have improved performance over treated tissues in the remodelling 
process. Importantly with this method, like bioresorbable synthetics is the relationship 
between host remodelling and graft structural integrity. Excessive host degradation of 
the matrix prior to autologous cells laying down newly synthesised structural proteins 
may result in graft dilatation and failure.
Another approach has seen the use of only the elastin component of the arterial wall as a 
matrix for tissue engineering purposes. Gregory et al., (2000) have prepared an elastin 
matrix from processed porcine carotid arteries and have seeded porcine aortic 
endothelial cells. Using a bioreactor (not described) endothelial cells (EC) were 
exposed to a progressive flow regime up to 90 ml/min. SEM and histological analysis 
have shown EC to form a confluent endothelium serving as a barrier between the 
internal elastic membrane and the lumen of the vessel. Similarly Berglund et al., 
(2002), have produced an elastin matrix by exposing porcine carotid arteries to 
treatments to remove all other extracellular matrix (ECM) components to leave only the 
elastin component of the artery. Cells (either human dermal fibroblasts of rat aortic 
SMC) were seeded to the ablumenal surface suspended within a collagen gel. After 8 
and 23 days of culture, construct had shown improved mechanical properties over the
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initial elastin matrix which approach those of native arteries. It is important to note that 
in both these cases the cell types used limit the applicability to aged patients where 
autologous cells must be used.
The use of natural ECM components in the native structure is seen as positive step 
forward in attaining mechanical properties similar to native arteries, critical to the 
success of a small diameter vascular graft. An issue surrounding the use of grafts 
without polymeric reinforcement, may face problems with regulatory acceptance and 
the surgeons approval, which may delay the wide spread use of this type of replacement 
vessel (Bos et al., 1998).
Sceptics of the tissue engineering approach have foreseen cell availability, graft length, 
development time and difficulties transferring laboratory base technology into a clinical 
situation as areas that will prevent this technology being successful in the clinical arena. 
A clinical application of tissue engineering principles has recently been described by 
Shin’oka et al., (2002), where a 4 year old girl with a total occlusion of the right 
intermediate pulmonary artery was treated by inserting a tissue engineered ‘living’ graft. 
Using a copolymer of PCL-PLA (50:50) reinforced with PGA (10 mm diameter, 20 mm 
long by 1 mm thick) designed to degrade by 8 weeks, autologous venous cells were 
taken by biopsy and bulked up to approximately 1.2 xlO7 cells at 8 weeks. These cells 
were seeded onto the matrix, which was cultured for 10 days before surgical 
implantation. At 7 months post implantation the graft remains patent with no signs of 
occlusion or aneurysm. Although this graft is not placed in a more stringent ‘model’, 
such as an aged person in an area of restricted blood flow an of a smaller diameter, it 
give a glimpse of the potential this field has to offer. New developments discussed 
above using the methodology of tissue engineering will ensure a promising outlook for 
improved grafts with extended patency rates.
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C o n c l u s io n s
The problems that require solving in order to provide for the continued health and 
longevity of persons with progressive vascular disease are numerous. In short the 
current technology provides a poor substitute for the bodies natural vasculature. The 
first choice the vascular surgeon has, given the current technology, is to excise and 
relocate arteries or veins to repair diseased sections of the vasculature. As these vessels 
may be diseased or previously used, options are limited to synthetic replacement 
vessels. Current prosthetic grafts are manufactured from synthetic polymers, which are 
maintained as permanent structures within the body. By their very nature they lack the 
ability to remodel, preventing integration into the patient as ‘self tissue’ and as such 
elicit varying degrees of immune rejection. Critical to graft success is the initial period 
of implantation where graft thrombosis or neointimal hyperplasia restricts and 
eventually blocks blood flow in a majority of synthetic grafts. Table 1.10 summarises 
various important aspects of different approaches to small diameter graft development.
Table 1.10: Advantages and disadvantages of graft developmental approaches, where












synthetics + + + + + +
----- - - - ----- ----- +
Modified
synthetics + + + + +
----- ----- ----- ----- +
Biological
biomaterials + + + +
----- + + + + + +
E C seeding - + + ----- + + ----- +
T.E. degradable 
synthetics
----- ----- + + + + + + + + + + + + +
T.E. biological 
biomaterials
----- ----- + + + + + + + + + + + + +
Of the essential requirements necessary for a replacement vessel, listed in Section 1.1, 
areas that synthetic grafts excel in are availability, durability, handling characteristics
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and acceptable costs. Where they fail is in immunological tolerance, resistance to 
thrombosis and infection; these are the primary reasons for early graft failure, coupled 
to the production of a neointima at the graft-native vessel anastomosis, which may block 
the graft. Two primary reasons (theorised) for early failure of traditional synthetic 
grafts is the lack of compliance matching, or matched mechanical properties, and the 
fact the graft is inert. Early biomaterials focused on achieving the highest degree of 
‘inertness’ so that the body essentially ignores the materials presence. In recent years 
the complex communication between cell types associated within the arterial wall have 
been shown to modulate cell behaviour, in particular the hyperplastic response of 
VSMC at the graft anastomoses. Of the options available to generate a neoartery only 
the tissue engineering approach has the potential to deliver into the patient a developed 
artery that has a reduced lag time to fully integrate once implanted, it is this time that 
most other grafts fail as the body attempts to heal the ‘damaged’ area.
Given the current literature, novel aspects of this thesis are:
• Characterisation, modification and utilisation of a porcine dermal biomaterial to guide cell 
growth and proliferation to develop a small diameter vascular graft.
•  Development of a novel processing methodology that strips cellular and non-structural 
components from porcine carotid arteries, whilst maintaining the matrices native mechanical 
properties in addition to the potential reduction in calcification and host immune response 
with the novel use of multiple treatment regimes.
Assessed by: TLC, RP-HPLC, burst pressure and stress strain analysis
• Design and application of a novel bioreactor and process flow system that allow has allowed 
long term culture of the ‘living’ tissue engineered graft, under conditions that mimics human 
peripheral arterial conditions. Where human primary cells (HUVEC and hVSMC) and 
culture under defined haemodynamic-like conditions, followed by assessment of expressed 
hVSMC matrix remodelling enzymes.
In this thesis the principles of tissue engineering have been applied to produce a ‘living’ 
graft that has aimed to fore fill all the essential requirements of the ideal vascular graft. 
By culturing a biomaterial that contains many of the native arteries extracellular matrix 
(ECM) cell signalling systems, with the patients own cells in a bioreactor that mimics 
the gas, chemical and physical environment of a native artery, a ‘living’ graft may be 
generated in which cell phenotype has been retained. With an intact endothelium and 
VSMC within communicative distance of the endothelium ‘growing’ within the graft, it 
is hoped that early graft failure be minimised due to functional neovessel and long-term 
implantation may equal if  not exceed the patency rates of autologous arteries.
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CHAPTER TWO: MATERIALS AND METHODS
This chapter details the general materials and methods used in this thesis. Any further 
specific experimental methods are described in the appropriate chapters.
2 .1  Ma t e r ia l s
2.1.1 Prim ary  cells
During the course of this work a variety of different human cell lineages were isolated 
and grown in culture. Human vascular smooth muscle cells (hVSMC) and endothelial 
cells (EC) have been used for experimental purposes in this thesis. All human tissue 
was obtained and used with appropriate ethical consent.
The hVSMC were sourced from either adult human saphenous vein or human umbilical 
cord veins, described as human vascular smooth muscle cells (hVSMC) for the adult 
cells and neonatal hVSMC from umbilical cords. Saphenous vein segments were 
refrigerated at +5°C until processing (<12 hours post operatively) for cell isolation. 
Umbilical cords were stored at +5°C until processing for isolation of neonatal hVSMC 
(between 2 hours and 3 days of child delivery). Refer section 2.2.1.2/3 for isolation 
protocols
EC were sourced from human umbilical cord veins (sourced and processed as above). 
Refer section 2.2.1.1 for isolation protocols.
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2.1.2 C ollagen  matrices
The acellular matrix utilised in Chapter 3 was derived from porcine dermal tissue 
processed to generate a matrix material substantially free of cellular components 
(Permacol, Tissue Science Laboratories, Aldershot, UK). The matrix was received in a 
sterile condition as flat sheets measuring 50 x 50mm (L x W) in two thicknesses, 0.75 or 
1.5mm (see Section 3.1).
Porcine vascular tissue was also used to develop a tubular scaffold. Porcine carotid 
arteries were extracted from 6-8 month old Great White pigs at the Bath Abattoir 
(Cheltenham Street, Bath). Briefly, the porcine carotid arteries were removed from the 
heart, liver, lung and throat section that had been removed (1-3 minutes previously) 
from the animal’s carcass during the slaughtering process. Extraction required washing 
excess blood from the organs and isolating any intact arteries, (as the slaughtering 
process aims to cut one or both of the animals carotids, to ‘bleed’ the animal) running 
from the heart up and along the remnants of the animals’ oesophagus. Once isolated a 
butchers knife was used to gently remove connective tissue around artery and the ends 
were severed to free the artery. The arteries were then placed in a sterile container (for 
not more than 2 hours prior to storage at 5°C). All tissue processing was complete 
within 48 hours of extraction.
Initial tissue processing involved removal of loose connective tissue surrounding the 
vessel with forceps and scalpel, (Chapter 4.2.1). The overall process described in 
Chapter 4, utilises several steps to extract arterial lipid, remove non-structural proteins 
and stabilise the vessel by cross-linking proteins within the ECM.
2 .1 .3  CELL CULTURE MEDIA
Two fundamentally different cell culture medias were used for HUVEC and hVSMC 
culture, firstly the DMEM and M l99 based medias with 10-20% foetal calf serum. For 
two reasons the media was changed to a lower serum containing media. Firstly due to 
lower serums ability to maintain physiological pH in the bioreactor and secondly the
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lower pH media is preferential from an FDA approval perspective, where defined 
medias are required for all human implantation studies. The reduced serum medias will 
allow the use of minimal quantities of autologus serum for patient trials.
2.1.3.1  G r o w t h  m e d ia  fo r  hum an  va s c u la r  s m o o th  m u s c le  c ells
Two growth media were used for the culture of human vascular smooth muscle cells 
(hVSMC), DMEM and low serum media, as follows.
DMEM based VSMC media: Experiments using the porcine dermal collagen matrix 
utilised Dulbecco’s Modified Eagle Medium (DMEM) with Na, Pyruvate, L-glutamine 
(Cat. No 31885-023, Gibco Life technologies, Paisley, Scotland). 500 ml aliquots were 
supplemented with 75 ml (100%) Foetal calf serum (heat inactivated), (Cat. 10108-165, 
Gibco Life technologies, Paisley, Scotland), 86 U/ml penicillin and 86 pg/ml 
streptomycin, (Cat. No 15149-114, Gibco Life Technologies, Paisley, Scotland). Media 
were stored at 4°C.
Low serum VSMC media: Later work (Chapters 5 and 8) used a low serum media, 
Human vascular smooth muscle cell Growth Media (C-22062 PromoCell, Heidelberg, 
Germany) with SupplementMix (C-39267, PromoCell, Heidelberg, Germany). The 
SupplementMix once mixed with the base media resulted in final ingredient 
concentrations within the media of: 5% (v/v) Foetal Calf Serum, 0.5 ng/ml Epidermal 
Growth Factor, 2 ng/ml basic Fibroblast Factor, Insulin 5 pg/ml, 50 ng/ml Amphotericin 
B, 50 pg/ml Gentamicin. Media was stored at 4°C.
2 .1 .3 .2  G r o w t h  m e d iu m  fo r  h um an  um bilical  v e in  e n d o th e l ia l  cells
Two growth media were used for the culture of human endothelial cells (EC), Ml 99 and 
a low serum media, as follows.
M199 based EC media: Experiments in Chapter 3, utilised the M199 based media 
(500 ml) with Modified Earls Salts (Cat. 31153-026, Gibco Life technologies, Paisley, 
Scotland). Media was supplemented with 100 ml (100%) Foetal calf serum (heat 
inactivated), (Cat. 10108-165, Gibco Life Technologies, Paisley, Scotland), 83 U/ml
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penicillin and 83 pg/ml streptomycin, (Cat. No 15149-114, Gibco Life Technologies, 
Paisley, Scotland). 15 mg Endothelial cell growth supplement (from bovine neural 
tissue) (Cat. No E-2759, Sigma, Poole, Dorset), Heparin 5000 IU (monoparin, CP 
Pharmaceuticals, UK). All quantities are final concentrations. Media was stored at 4°C.
Low serum EC media: Experiments in Chapters (5 and 7) utilised Endothelial Cell 
Growth Media (C-22010) with the SupplementMix (C-39215), (PromoCell, Heidelberg, 
Germany). Final media (media mixed with SupplementMix pack) contained 0.4% 
Heparin, 2% Foetal Calf Serum, 0.1 ng/ml Epidermal Growth Factor, 1 pg/ml 
Hydrocortison, 1 ng/ml basic Fibroblast Factor, 50 ng/ml Amphotericin B, 50 pg/ml 
Gentamicin. All quantities are final concentrations 500ml.
2.1.4 C hem icals
Table 2.01: Materials and suppliers
Material Cat. No. Supplier Address
Accutase AT104 TCS CellWorks Bucks, UK
Acetone 1 0 3 8 6 6 x BDH, UK Ltd. Poole, UK.
Acetonitrile 10477 4P BDH, UK Ltd. Poole, UK.
Acrylaminde (40%) 20-2400-05 Anachem Luton, UK
Alpha-Actin M 0851 DAKO Ely, UK
Amino acid standards (HPLC) A-9531 Sigma Chemical Co. Gillingham, UK
Ammonium hydroxide A-6899 Sigma Chemical Co. Gillingham, UK
Ammonium Bicarbonate A-6141 Sigma Chemical Co. Gillingham, UK
Ammonium persulphate (AMPS) A-9164 Sigma Chemical Co. Gillingham, UK
Anti freeze (universal) T-216-6652 Silkoilene Lubricants Henley, UK
Aquamount slide adhesive (aqueauos) 36226 2H BDH, UK Ltd. Poole, UK.
Arginine A-4881 Sigma Chemical Co. Gillingham, UK
Boric acid B-0252 Sigma Chemical Co. Gillingham, UK
Bovine albumin serum A-8667 Sigma Chemical Co. Gillingham, UK
Bromophenol blue H5011 Promega Southampton, UK
1-Butanol 34867 Riedel-de Haen Gillingham, UK
Calcium Chloride C-3881 Sigma Chemical Co. Gillingham, UK
CD 31 EC antibody M0823 DAKO Ely, UK
Chloroform 277105X BDH, UK Ltd. Poole, UK.
Citric acid C-0759 Sigma Chemical Co. Gillingham, UK
Collagenase (bovine) C-9891 Sigma Chemical Co. Gillingham, UK
DAPI D-9542 Molecular Probes London, UK
Sigma-Fast DAB D-4293 Sigma Chemical Co. Gillingham, UK
di-Sodium hydrogen orthophosphate 102494C BDH, UK Ltd. Poole, UK.
DL-Dithiothreitol (DTT) V3151 Promega Southampton, UK
DNase 1 (Deoxyribonuclease 1) DN-25 Sigma Chemical Co. Gillingham, UK
Dodeca-Molybdophosphoric acid 101613k BDH, UK Ltd. Poole, UK.
DPX slide adhesive (non-aqueous) 36029 2F BDH, UK Ltd. Poole, UK.
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Eosin 35084 41K BDH, UK Ltd. Poole, UK.
Ethanol 10107EP BDH, UK Ltd. Poole, UK.
9-fluorenylmethyl chloroformate F-0378 Sigma Chemical Co. Gillingham, UK
9 fluoroenylmethyl F-0378 Sigma Chemical Co. Gillingham, UK.
Formaldhyde (37%) 20910-328 BDH, UK Ltd. Poole, UK.
Formal saline 36136 7L BDH, UK Ltd. Poole, UK.
Fungizone -  Squibb 16-723-46 Flow Lab UK
Glutaraldehyde R1312 TAAB UK
Glycerol G-7893 Sigma Chemical Co. Gillingham, UK
Harris Haematoxylin 35194 5S BDH, UK Ltd. Poole, UK.
Hanks Balanced Salt Solution (HBSS) TH2513 Sigma Chemical Co. Gillingham, UK
Horse Radish Peroxidase P 6782 Sigma Chemical Co. Gillingham, UK
Hydrochloric acid (concentrated) 28507BF BDH, UK Ltd. Poole, UK.
Hydroxyproline (standards) H-7279 Sigma Chemical Co. Gillingham, UK
Industrial methylated spirits (IMS) 35194 4R BDH, UK Ltd. Poole, UK
Methanol 15250 6X BDH, UK Ltd. Poole, UK.
Methylene Green M-7766 Sigma Chemical Co. Gillingham, UK
Molecular weight marker (rainbow) Amersham Bucks, UK
TEMED V3161 Promega Southampton, UK
N-A-Benzoyl-L-Arginine Ethyl Ester B-4500 Sigma Chemical Co. Gillingham, UK
Osmium tetroxide EM (2% w/v) 15 TAAB UK
Nunc chamber slides 154461 GibcoBRL Lifetech Paisley, Scotland
nystatin 15340-045 GibcoBRL Lifetech Paisley, Scotland
Oxalic acid 0-0376 Sigma Chemical Co. Gillingham, UK
Penicillin-Streptomycin 30339316 GibcoBRL Lifetech Paisley, Scotland
Pentane 15334 6U BDH, UK Ltd. Poole, UK.
Pepsin P-6887 Sigma Chemical Co. Gillingham, UK
Peracetic acid Solution 77240 Fluka Gillingham, UK
Poly (2-hydroxyethyl methacrylate) P-3932 Sigma Chemical Co. Gillingham, UK
potassium permanganate 29644 BDH, UK Ltd. Poole, UK.
RNase 11-A (ribonuclease A) R-50000 Sigma Chemical Co. Gillingham, UK
Silica gel 60 TLC plates (20 x 20 cm) 155552J MERCK UK Ltd. Poole, UK.
Slide cover slips 406/0188/34 BDH, UK Ltd. Poole, UK.
Slides (histology) 406/0179/00 BDH, UK Ltd. Poole, UK.
Smooth muscle growth medium 2 C-22062 PromoCell Heidelberg Germany
SMC growth medium supplement mix C-39267 PromoCell Heidelberg Germany
Sodium acetate S-7670 Sigma Chemical Co. Gillingham, UK
Sodium azide S-8032 Sigma Chemical Co. Gillingham, UK
Sodium chloride 102415 BDH, UK Ltd. Poole, UK.
Sodium dihydrogen orthophosphate 102454R BDH Poole, UK.
Sodium dodecyl sulphate (SDS) L-4509 Sigma Chemical Co. Gillingham, UK
Sodium Hydroxide S-5881 Sigma Chemical Co. Gillingham, UK
Sucrose S-7903 Sigma Chemical Co. Gillingham, UK
Tetramethylammonium chloride 15309 2R BDH, UK Ltd. Poole, UK.
Tris/base H5131 Promega Southampton, UK
Trizma Hydrochloride T-3253 Sigma Chemical Co. Gillingham, UK
Trypan Blue T-8154 Sigma Chemical Co. Gillingham, UK
Trypsin-EDTA solution (1X) 25300-054 Life Technologies, Paisley, Scotland
Trypsin-EDTA solution (10X) 35400-027 Life Technologies, Paisley, Scotland
Triton-X100 T9284 Sigma Chemical Co. Gillingham, UK
Tween 80 560234H BDH, UK Ltd. Poole, UK.
van Gieson (elastin stain) 351154S BDH, UK Ltd. Poole, UK.
von Willebrand factor antibody M 0616 DAKO Ely, UK
Weigerts Resorcin Fuchsin AS021 R.A. Lamb Eastbourn, UK
Xylene 305756G BDH, UK Ltd. Poole, UK.
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2 .2  E x pe r im e n t a l  M e t h o d s
Experimental methodologies used throughout this thesis, have been divided into two 
groups, firstly, those methods having been used in more than one section of work, such 
as cell culture protocols, are described in this chapter, Chapter 2. Secondly, methods 
specific or unique to any one of the experimental chapters (Chapters 3-7) are described 
separately in the appropriate chapter.
2.2.1 C ell  iso latio n  protocols
2.2.1.1  Is o la tio n  o f  H um an  U m bilical V ein  E n d o th e lia l  C ells
The method of HUVEC isolation was a modification of the method first described by 
Jaffe et al (1973). Sheets of gauze were laid out on a suitable sterile plate, measuring at 
least 250 x 250mm (to prevent spillage of blood) and soaked with IMS to collect excess 
blood and minimise the possibility of infection. Umbilical cords (UC) were then laid 
onto the plate and wiped clean using additional gauze soaked in IMS. UC were then 
checked for perforations resulting from injection or clamping. A suitable cord was 
selected and a plastic luer adapter was inserted into one end of the vein. Plastic zip ties 
(Cat. No 221/0371/01, BDH, Poole, UK) were then used to secure the UC to the leur 
adapters. Using a new 40ml syringe, sufficient sterile PBS was run through the cord to 
remove all traces of visible blood. The open end was then tied off with another zip tie, 
thus forming a chamber. Bovine collagenase (1 mg/ml) was made in sufficient volumes 
for the number of cords to be processed, approximately 20 ml per cord, in PBS, mixed, 
filter sterilised and preheated to 37°C prior injecting into the UC via a syringe and 
attachment. The collagenase was repeatedly injected into and drawn out of the UC to 
displaced air within the vein. The collagenase solution was then fully injected into the 
vein and incubated at 37°C for 35 minutes. After incubation the adapter furthermost 
from syringe was cut off and the collagenase was drained into a sterile 50 ml Falcon 
tube. The cord was then flushed with a further 20 ml of sterile PBS into the same 
Falcon tube to remove any remaining cells. 10 ml of DMEM-based HUVEC media was 
then pipetted into the Falcon tube to inactivate the collagenase. The solution was then
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centrifuged (ACL PK130, Jencons, London, UK) for 5 minutes at 1100 rpm (164 mm 
rotor radius) to pellet cells. The resulting supernatant was discarded. The cell pellet 
was then resuspended in 5 ml of HUVEC media and transferred into a T25 flask for 
culture (Jaffe et al., 1973).
2 .2 .1 .2  I s o la t io n  o f  a d u l t  Human v a s c u l a r  s m o o t h  m u s c le  c e l l s :  e x p la n t
METHOD
Diseased saphenous veins were collected and stored overnight in HBSS at 5°C, as 
described in section 2.1.1. The protocol used to isolate hVSMC from explanted tissue is 
a modification of the method described by (Kirschenlohr, et al. 1996). The samples 
were then placed in a sterile Petri dish containing 10 ml of sterile HBSS. Sections of 
vein that were devoid of, (or had reduced diseased) symptoms were isolated and the 
remaining tissue discarded. The selected tissue was then sliced/cut longitudinally and 
laid lumenal surface uppermost in a Petri dish. The lumenal surface was then scraped 
with a sterile scalpel to remove the endothelial cell lining and rinsed with HBSS to 
remove free endothelial cells. A pair of forceps was used to ‘pinch’ the medial layer 
and pull away from the adventitial layer in strips. The strips of medial tissue 
(essentially the basement membrane of the internal elastic lamina and surrounding cells) 
containing hVSMC were then placed individually into the well of a 24 well culture plate 
and covered with 0.5 ml of either low or high serum SMC media, as described in 
materials Section 2.1.3. and incubated at 37°C in a 5% CCVair atmosphere. Tissue was 
left for 3 days to allow adhesion to the plastic, after which normal feeding protocols 
were followed, see Section 2.2.2. After approximately 10-14 days hVSMC began to 
migrate from the tissue explant. Media was replenished three times a week until the 
cells reached sufficient density for either passaging or experimental use. (Kirschenlohr, 
et al. 1996).
2 .2 .1 .3  I s o la t io n  o f  n e o n a t a l  v a s c u l a r  s m o o th  m u s c le  c e l l s :  en zy m e
DISPERSION
The isolation of venous derived hVSMC was carried out as part of the isolation of 
HUVEC process (Section 2.2.1.1) and was a modification of the method described by
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(Kirschenlohr, et al. 1996). Once the EC had been extracted, a fresh solution 
(approximately 25 ml for a 300 mm long cord) of filter sterilised collagenase (1 mg/ml) 
in PBS was prepared and preheated to 37°C. The distal end of the cord was tied closed 
and the collagenase solution injected into the vein using the same methodology as 
described in Section 2.2.1.1 and incubated for a further 30 minutes at 37°C. After 
incubation the adapter furthermost from the syringe was cut off and the collagenase/cell 
suspension was drained into a sterile 50 ml Falcon tube. The UC was then flushed with 
20 ml of sterile PBS to flush out any remaining cells into the tube. 10 ml of medium 
was then pipetted into the solution to inactivate the collagenase. The solution was then 
centrifuged for 5 minutes at 1100 rpm, (conditions as in Section 2.2.1.1) to pellet cells 
with the resulting supernatant being discarded. The cell pellet was then resuspended in 
5 ml of SMC media and transferred into a T25 flask for cell culture, (Kirschenlohr, et al. 
1996).
2.2.2 C ell culture
All cell populations were maintained in a routine manner, incubated at 37°C in an 
atmosphere of air supplemented with 5% CO2 . Cell cultures requiring passaging were 
dissociated from the plastic culture dish by exposure to a solution of sterile 1 x trypsin- 
EDTA (trypsin 2.5 mg/ml and 1 mg/ml EDTA in PBS) for 5-10 minutes (used in 
Chapter 3) or a 100% solution of Accutase (used in Chapters 5 and 6) within the 37°C 
incubator. Once cells had dissociated from the plastic culture plate and were free in 
solution an equal volume of the appropriate media was added to inactivate the enzyme 
solution. The cell suspension was then centrifuged for 5 minutes at 1100 rpm as before. 
The resulting supernatant was then removed leaving a pellet of cells which were 
resuspended in 5 ml of the appropriate media. Initial density determination was carried 
out visually by standard low power light microscopy. Cell counts were routinely carried 
out to determine appropriate seeding densities for replating cells into fresh culture 
flasks. Cell cultures were then incubated at 37°C with 5% CO2 as described above 
(Kirschenlohr, et al. 1996; Morgan 1996).
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2.2.2.1  E n d o th e lia l  cell  c u ltu r e
Media replacement for all ‘static’ HUVEC cultures was three times a week, in 
accordance with guidelines from (Morgan 1996) for M199-based media. Protocols for 
the use of media supplied by PromoCell for endothelial cell cultivation (PromoCell, 
Heidelberg, Germany) were carried out as per the manufactured instructions where the 
media was changed three times a week. After initial cell isolation cultures were allowed 
to reach near confluence (2-4 days) then passaged, as described above. All further 
passages were carried out at ~80-90% confluence to maintain cell proliferation (Morgan 
1996).
2 .2 .2 .2  Hum an v a s c u l a r  s m o o th  m u s c le  c e l l  c u l t u r e
Media replacement for DMEM based media in ‘static* hVSMC cultures was twice a 
week, in accordance with guidelines from (Kirschenlohr, Metcalfe et al. 1996). Cell 
cultured with the PromoCell media, (PromoCell, Heidelberg, Germany) had the media 
changed three times a week in accordance with the manufacturers protocols for human 
vascular smooth muscle cell growth media. hVSMC were allowed to reach full 
confluence before passaging, as before.
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2 .3  A nalytical  M e t h o d s
Unless specified otherwise all images throughout this thesis are representative of the 
sections (either cut sections or surface microscopy) viewed.
2.3.1 C ell c o u ntin g
Cells were removed from the plastic culture flasks using the standard protocol with 
trypsin EDTA or Accutase, as described previously in Section 2.2.2. The cell 
suspension was spun down (lOOOrpm for 5 minutes, as before) and resuspended in the 
cell specific media to an appropriate volume for counting purposes (i.e. if cells from 
T25 flasks are being harvested, 5 ml media is used to resuspended cells, if cultured on 
T75 flasks, 20 ml of media is added). Samples were then loaded into an improved 
Neubauer haemocytometer (Cat. No. 403/0024/00, BDH, Poole, UK) and counted as per 
manufactures instructions giving a total of ten individual counts per sample lot.
2.3.1 .1  C ell c o u n tin g  on  p o r c in e  d e r iv e d  d er m a l  c o lla g en
This method was used exclusively in Chapter 3. In this chapter collagen was cut into 16 
mm diameter discs, with a surface area of 201 mm2. The microscope, (Mod. 68040 
phase contrast microscope, Carl Zeiss, UK), was calibrated using a stage micrometer 
(Cat. No. 316/1212/26, BDH, Poole, UK), and an eyepiece graticule, (Cat. No. 
316/1212/20, BDH, Poole, UK) with a grid formation 10 x 10 squares, such that the 
total grad area was calculated to be 750 x 750 pm, resulting in a surface area of 0.56 
mm2. Semi-random counting areas were assigned by moving the microscope stage to a 
new area (according to a prescribed plan, see Figure 3.01), without looking through the 
eyepiece. In this way it was possible to objectively select the area (random) without the 
subjectivity of actually viewing cell density until the area had been preselected. A total 
of 12 counts were taken on each disk (see Figure 3.01) with a total of 36 counts over the 
triplicate data set. Representing approximately 10% of one disks surface area (20.16 
mm2) which was deemed an adequate representation of the entire disc. Counts were 
taken using a prescribed pattern as far as possible to ensure each of the 12 counts per 
disc were representative of the entire disc area.
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Figure 3.01: Counting pattern on dermal collagen discs: semi-random
2.3.1.2 C e l l  c o u n t in g  o n  a r t e r ia l  b a s e d  m a t r ix  a f t e r  s t a t ic  c e l l  c u lt u r e
This method was used exclusively in Chapter 5, with a Carl Zeiss Axioskop2 
fluorescent microscope described in Section 2.3.7. Primary human cells were cultured 
on sections o f  the arterial based matrix under static conditions. On completion o f the 
culture duration, tissue sections (approximately 5 x 5  mm) with cells seeded onto either 
the lumenal or ablumenal surface were removed from culture, fixed, then stained with 
DAPI as described in Section 2.3.5.10 Image analysis equipment was set up with an 
image size o f  762 x 480 pixels, which when calibrated equalled approximately 625 x 
400 pm (250000 pm2 or 0.25 mm2) using the 10 x objective. Five semi-random sites 
were selected (total o f 1.25 mm2) per tissue section (duplicate) and cells counted 
resulting in the number o f cells per mm2.
2.3.1.3 C e ll  c o u n t in g  o n  a r t e r ia l  b a s e d  m a t r ix  a f t e r  p e r f u s io n  c e ll
CULTURE
This method was used exclusively in Chapter 7, perfusion cultures. Counting HUVEC 
on the lumenal surface o f the matrix was conducted in a similar fashion to static cultures 
(Section 2.3.1.2). After each experiment, where two reactors were run in series, matrix 
sections were removed from the reactor and fixed in the normal manner for DAPI 
staining (see Section 2.4.2.3). Each matrix had a total length o f 100 mm, o f which 30 
mm from the proximal and 20 mm from the distal ends were discarded to reduce error 
from end effects. The remaining 50 mm sample was sectioned in half (2 x 25 mm) and 
then cut longitudinally to produce a total o f 4 x 25 mm sections with the lumen exposed. 
These sections were stained with DAPI in the normal manner. Five counts were taken
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from each section, (total o f 20 per vessel) evenly spaced along the entire length in a 
zigzag fashion, see Figure 2.02. In the same manner as Section 2.3.1.2 the image 
analysis equipment was calibrated to view matrix sections 625 x 400 pm (250000 pm2 
or 0.25 mm2) and results expressed as cells/mm2. Cells were counted in each semi­
random section from the two matrices (run in series) and pooled to yield the final data 
set for each run.
a  n 1___1*  AT ' B
m □ □
Figure 2.02: A diagrammatic representation of the cell counting pattern used for assessing cell 
density on/in matrix samples cultured in the perfusion bioreactor. A, the matrix and B counting 
zones.
2.3.1.4 C e ll  v ia b il it y
Determination o f cell viability with Trypan Blue (0.4%). Trypan Blue is used as a dye 
exclusion assay for cell viability procedures. This is method is based on the principle 
that live (viable) cells will not take up the dye, whereas dead cells (non-viable) will. 
Total solution volumes equal 1.0 ml, comprising 0.5 ml o f 0.4% Trypan Blue, 0.3 ml 
HBSS and 0.2 ml o f cell suspension (dilution factor = 5). The suspension is mixed 
thoroughly and allowed to stand for 5-15 minutes. Cells that stained dark blue after the 
incubation period are deemed non-viable.
2.3 .2  L ip id  a n a ly s i s
Ascending one-dimensional thin layer chromatography (TLC) was used to evaluate, 
qualitatively, the extent o f lipid extraction using dodeca-molybdophosphoric acid as the 
detection reagent. The protocol used was a modification o f methods described by 
(Sherma 1986; Stevens, et al. 1988).
The experimental methodology followed prior to lipid analysis is described in Chapter 
4.2.2.3. At each prescribed time point samples were collected, cut and weighed to
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approximately 0.4 ± 0.03 g, 5 mm sections were removed and discarded from the 
exposed end to reduce end effects on total lipid extraction. Samples were then diced 
using a sterile scalpel and liquidized in a glass homogeniser with 1 ml of butanol. Prior 
to spotting the sample onto the TLC plate, plates were ‘activated’ by immersion in the 
mobile phase, consisting of 100% solutions of chloroform, methanol and distilled water 
in ratio 30:10:1.2, for 2-3 minutes. The plates were then air dried and activated by 
heating at 120°C for 15 minutes. The homogenate was then spun down with one pulse 
for 5 s (Techne Genofuge Cat. 193-980, Jencons PLS, London, UK) to remove 
suspended particulates remaining the supernatant. The supernatant was collected in a 
500 pi Epindorf tube and subsequently spotted in aliquots of 1 pi onto the silica gel 60 
TLC plates. Once the spots had air dried the plates were run in the mobile phase 
(enough volume to immerse the bottom 5 mm of the TLC plate) for 15-18 minutes, 
resulting in a migration distance of approximately 85 mm. The chromatogram was 
then air dried and washed in a suitably sized glass container with the detection reagent, 
(250 mg dodeca-molybdophosphoric acid, dissolved in 50 ml ethanol with 4 ml of 
concentrated HC1 per 100 ml of reagent solution) for a further 2 minutes. The TLC 
plates were air dried then heated to 150°C in a vented lab oven for 15 minutes. Lipid 
appeared as dark blue zones on a yellow background. Exposure of the TLC to the 
gaseous vapour from a 25% ammonia solution (gas) for 3-5 minutes bleached the 
yellow background white.
The delipidised tissue was tested for stability by immersion in a 1 x solution of trypsin 
at 20°C. Tissue degradation was observed qualitatively over time.
2 .3 .3  P r o t e i n  a n a l y s i s
2.3.3.1  T r y p s in  sta b il ity  a ss a y  ‘w h o le  t is s u e ’
This analytical technique was a modification of Sigma quality control test procedure 
(‘Enzymatic Assay of Trypsin’ Sigma, Dorset, UK). Continuous spectrophotometric 
rate determination was attained using a Hitachi U-2010 spectrophotometer, Jencons- 
PLS, London, with UV-Solutions software at A253 nm. The substrate, Na-Benzyol-L- 
Arginine Ethyl Ester (BAEE), is hydrolysed to form Na-Benzyol-L-Arginine and
62
ethanol. The result was a linear relationship between absorbance (Abs) and time. The 
gradient was calculated, yielding the enzyme’s activity in absorbance units/min.
Four analyses were completed which included two controls. Arterial sections digested 
in trypsin, trypsin alone, and controls 1. enzyme solution heated to 75°C for 30 minutes 
and 2. buffer less BAEE substrate. For tissue digestion analysis, porcine carotid artery 
sections weighing 0.5 g, post lipid extraction, were aseptically transferred to 15 ml 
Falcon tubes and trypsin solution (filter sterilized) was added in a ratio of 1 g tissue to 
15 ml trypsin solution (1 x). Samples were placed on a rock/roll table at room 
temperature 19 ± 2°C for the duration of the experiment. At prescribed time intervals 
samples were collected for analysis as shown in results, Section 4.3.2, protein digestion. 
A 67 mM di-sodium hydrogen orthophosphate (anhydrous), (BDH, Dorset, UK) buffer 
was prepared, adjusted to pH 7.6 with 1 M NaOH to a total volume of 50 ml. BAEE 
was made up to a final concentration of 0.25 mM in the buffer solution. All Trypsin- 
EDTA solutions were diluted from 10 times concentration to 1 times concentration in 
PBS (10 x trypsin concentration: 5.0 g/L porcine trypsin and 2.0 g/L EDTA in 0.9% 
sodium chloride). 67 pi of sample solution was added to the buffer/BAEE solution and 
the reaction recorded as an absorbance change over time (as above) at 25°C.
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2.3.3.2 T r y p s in  d ig e st io n -S D S  PAGE
Preparation o f sample protein
Tissue samples with a mean weight of 0.3 ± 0.02 g were immersed in a 1 x trypsin 
solution (15:1 as described previously). Samples were placed on a rock/roll table at 
room temperature 19 ± 2°C for the duration of the experiment. Due to the insolubility 
of the ECM proteins a more comprehensive method to solubilise whole tissue was 
followed. Tissue was firstly weighed and dried with blotting paper then diced as small 
as possible with a scalpel. Tissue samples were then placed in a ceramic mortar and 
pestle and approximately 50 ml of liquid nitrogen was added. Liquid nitrogen was 
applied until tissue had frozen. When the liquid nitrogen had evaporated the sample 
was ground until a fine powder was produced. Finally the sample was homogenising in 
the glass mortar and pestle in 1 ml H2O with 20% w/v SDS. The homogenate was then 
spun down with one pulse for 5 s (Techne Genofuge Cat. 193-980, Jencons PLS, 
London, UK) to remove particulates remaining the supernatant.
Bradford’s Assay: protein concentration
Samples were prepared as above for SDS PAGE protocol above. Calibrations of bovine 
serum albumen (BSA) standards were prepared by serial half dilution. 35 /d of BSA 
(20 mg/ml) was made up to 160 fil in distilled H2 O, 80 /d of which was pipetted into the 
first well of a 96 well microplate (NUNC, UK). A further 80 /d of distilled water was 
added and mixed thoroughly to the same well bring the total volume to 160 /d. Into 
each of the remaining 6 wells adjacent to the first well 80/d of distilled water was 
added. Then 80 /d from the 160 /d in the first well was removed and added to the 
second well, this was mixed thoroughly. The process was repeated to each of the 
remaining wells, removing 80 /d from the previous well and adding to the next, so that 
each well was left with a final volume of 80 /d. Well number 6 was the last well that 
had the protein standard, well 7 was distilled water only. Into a separate well 80 pi of 
neat protein sample was added. 20 pi Coomassie Brilliant Blue was added to each well 
bring the total volume to lOOpl and mixed thoroughly. After 5 minutes the optical 
densities of the samples is read at 595 nm using a microplate reader (Mod. 448-127 
MRX microplate reader, Jencons PLS, London UK). A calibration was completed with 
each protein analysis, where BSA standards were read against wave length, from which 
the total protein content was read.
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Preparation of the loading buffer
10 pi of sample protein was added to 10 pi of sample buffer, although this was not an 
absolute ratio due to variation in the samples total protein content (determined by the 
Bradfords assay, (above), up to 16 pi of sample and 4ml buffer was deemed to be 
acceptable. The sample/buffer was mixed and denatured by heating at 100°C for 1 hour. 
This solution was then spun down. 10 pi of sample buffer was added to 6 pi of 
Rainbow Marker as an indicator of sample molecular weights on the gels. The samples 
were then loaded, lid fitted, power reconnected and the power pack set to run for 2 
hours at 100V. Once finished the power supply was disconnected and the gels removed 
from the tank. Gels were removed from the glass plates and placed in the staining 
solution for two hours. Gels were then washed and destained until a majority of the 
background staining was removed. Gels were then scanned for reference.
SDS PAGE gels utilized an 8 % acrylamide resolving gel and 4% stacking gel 
(Laemmli 1970), loaded with 5-10 pi of sample in 10 pi loading buffer (as above) 
which had been mixed and denatured by heating at 99°C for 5-10 minutes. Gels were 
run at 80 volts until migration was complete, stained using Coomassie blue for 4 hours 
and destained in 5% methanol, 7.5% acetic acid. Further details of the SDS-PADE 
methodology are provided in Appendix A3
2.3.4  M edia  analysis
Analysis of media parameters: pH, PCO2 , PO2 and HCO3 was conducted with the use of 
an integrated AVL blood gas analyser, model OMNI, Stone, UK. Glucose testing 
utilized a hand held glucose monitor ‘Accu-Chek, Advantage, Boots, pharmacy, UK, 
used for diabetic analysis of blood glucose concentration. At prescribed time intervals 
the sample (5 pi) from the media solution was removed under sterile conditions and 
stored on ice for periods not more than 15 minutes before analysis with either the AVL 
blood gas analyser or the Accu-Chek glucose monitor mentioned above.
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2 .3 .5  C r o s s - l in k in g  a n a ly s i s  u s in g  r e v e r s e  p h a s e -h ig h  p e r f o r m a n c e  liq u id
CHROMATOGRAPHY
The procedure for the assaying for hydroxyproline (Hyp) was derived from a method 
described by (Bank, et al. 1996). The procedure uses RP-HPLC to separate the amino 
acids. In order to detect the separated amino acids, they are derivatized using 9- 
fluorenylmethyl chloroformate (FMOC-C1), a fluorescing agent, before the separation 
step. Due to the sample volume required by the auto-sampler, the sample volume for 
the derivatisation step was increased, the volumes of all other reagents used were 
increased proportionately to maintain the ratios used in the original method. After early 
runs the number of extraction steps used to remove excess FMOC-C1 and its hydrolysis 
product FMOC-OH was increased to improve background ‘noise’ in the chromatogram. 
The method described below is the result of the refinements made to the Bank et al
(1996) protocol to suit the C l8 RP-HPLC column used.
A Gilson 715 HPLC system (Gilson, UK) was used, consisting of Gilson model 305 and 
306 pumps, 811C mixer and a 231 auto-sampler. A Perkin Elmer LC240 fluorescence 
detector was used to detect derivatized amino acids. The C l8 reverse phase HPLC 
column (4.6 x 250 mm; Kromasil KR100-5C18-4498, BDH, UK) was maintained at 
40°C in a water bath with a Grant temperature controller.
2.3.5.1  S o l u t io n  P r ep a r a tio n
Borate buffer was prepared from boric acid (0.1M) adjusted to pH 8.0 with 5N sodium 
hydroxide. Amino acid standards were prepared by adding 120pl of the stock solution 
to 100ml 0.1M borate buffer. Hydroxyproline standards were prepared by adding 120pl 
of the concentrated Hyp stock (20mg Hyp/10ml water) to 100ml 0.1M borate buffer 
resulting in a Hyp concentration of 15.25 pmol/ml. To achieve lower concentrations for 
generating calibration plots, this stock solution was mixed in the appropriate ratios with 
0.1M borate buffer to produce the desired Hyp concentrations. For the enzyme digested 
tissue samples, the remaining intact tissue was removed, and the solution was filtered 
with a 0.2 pm filter to remove solid particles.
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2.3.5.2 T issue  D ig e s ts
Both control and cross-linked matrix materials were exposed to increasing 
concentrations o f pepsin (results from 1000 and 5000 activity units/ml shown) to yield 
quantitative data o f the Hyp and total free amino acids in solution. Unless otherwise 
stated the following procedure was used. Enzyme solutions were made up in ultra pure 
water and adjusted to pH 4.2 with HC1. All sample weights were recorded, 0.102 + 
0.0 lg. To each tissue sample a 3ml aliquot o f enzyme solution was added and placed in 
a water bath maintained at 37°C for the appropriate time.
Repeatability and accuracy o f the assay was tested, running 15.25 pmol/ml o f Hyp 
standard, recording the retention time and Hyp peak area. Figure 2.03 shows a 
chromatogram o f the Hyp standard for initial repeatability tests. A mean retention time 
o f 13.479 ± 0.19 minutes was determined with a mean peak area o f 47300 ± 2580 units.
1 00 .00-1 Hyp
9 0 .0 0 -
80 . 0 0 -
70 .0 0 -
60 .0 0 -
% peak
5 0 .0 0 -
40 . 0 0 -
30 . 0 0 -
20 .0 0 -
1 0 .0 0 -
0 .0 0  -
0.00 5.00 10.00 15.00 20.00 25.00 30.00 35.00
Time
Figure 2.03: Chromatogram of hydroxyproline standards
2.3.5.3 D e r iv a t is a t io n
The reactant solution consisted o f FMOC-C1 dissolved in acetone (1.5 mg/ml, 6 mM). 2 
ml o f FMOC-C1 solution was added to 2 ml o f sample solution mixed immediately and 
allowed to stand at room temperature for 10 minutes. Termination o f the reaction and 
removal o f excess reagent (FMOC-C1), and its hydrolysis product FMOC-OH, and 
acetone were performed by extraction with 6ml o f pentane. After mixing and a short
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period (~1 minute) to allow phase separation, the upper layer was discarded. After 4 
additional extractions, 4 ml of 25% (v/v) acetonitrile in 0.1 M borate buffer was added. 
20 pi aliquots of this diluted sample were injected into the HPLC.
2 .3 .5 .4  C h r o m a to g r a p h y
Derivatized amino acids were separated using the ternary gradient system described 
below, see Table 2.02 for a summary of gradient conditions (Bank, et al. 1996). All 
solvents were filtered through a 0.2 micron filter and degassed with helium for a 
minimum of 30 minutes
Eluent A: was 20 mM citric acid containing 5 mM tetramethylammonium chloride and 
0.015 (w/v) sodium azide, adjusted to pH 2.85 with 20 mM sodium acetate containing 5 
mM tetramethylammonium chloride and 0.01% (w/v) sodium azide.
Eluent B: 80% (v/v) of 20 mM sodium acetate solution containing 5 mM 
tetramethylammonium chloride and 0.01% (w/v) sodium azide (adjusted to pH 4.5 with 
concentrated phosphoric acid) plus 20% (v/v) methanol.
Eluent C: Acetonitrile.
For elution the gradient was as given in the table below. The flow rate was maintained 
at 1.4 ml/min throughout the analysis. The separation was performed at a column 
temperature of 40°C and fluorescence was monitored at 254 and 630 nm (excitation and 
emission wavelengths respectively).
Table 2.02: Gradient conditions for the elution of derivatized amino acids (Bank, et al. 1996)
Time (min) Eluent A (%) Eluent B (%) Eluent C (%)
0 75 - 25
11.5 60 - 40
13 60 - 40
13.1 - 64 36
18 - 62 38
25 - 30 70
30 - 25 75
32 - 25 75
32.1 75 - 25
40 75 - 25
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2 .3 .5 .5  Hyd r o x y p r o lin e  c alibr atio n
Calibration o f Hyp to chart peak area was carried out to determine the concentration of  
Hyp in free solution, see Figure 2.04. Hyp standard solutions were made up to the 






0 3 6 9 12 15
Hyp concentration (umol/ml)
Figure 2.04: Calibration plot to determine experimental Hyp concentration, n = 3, ± 1 sd.
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2.3.6 M a t r i x  m e c h a n i c a l  p r o p e r t i e s
2.3.6.1 P r e s s u r e  t e s t in g
A stainless steel reservoir was filled with distilled H2O and air pressurized to deliver a 
regulated pressure increase to the arterial section (pressure control valve, Swagelok, 
UK). Pressure increments were monitored with a 7 bar pressure transducer connected to 
a data acquisition system (Model PCL 818L Bede Technology Ltd, Tyne and Wear, 
UK). Genie Builder Version 3.0, Advantech™ (Bede Technology Ltd, Tyne and Wear, 
UK), running Windows 3.1, was used to record the data at a sample rate o f 5 per second 
into the computer-based format, Figure 2.05.
Tissue samples were attached to tapered glass adapters directly into the 3.2 mm ED PVC 
tubing (275/0100/06, BDH, Poole, UK) circuit and tensioned to remove slack. Wall 
thickness and internal diameter were measured at each end o f the arterial section to 
obtain an average dimension. The control valve was progressively opened, pressurising 
the arterial section until vessel failure. From the computerised data, the observed 
maximum pressure (mmHg), at which bursting occurred, was collected.
Air supply
.Control valve
I » r = ® =
Reservoir
Test sample Pressure transducer
Glass tubes
Computer
Figure 2.05: Diagrammatic representation of the apparatus used for the pressure testing tests.
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2 .3 .6 .2  L o a d - ex ten sio n  tests
Arterial sections greater than 2 mm in length were cut o ff each end to eliminate end 
effects caused by damage during explantation (Courtman, et al. 1994). The artery was 
then cut into 5 mm long circular ringlets. Hiles et al (1995) used 3-5 mm length 
sections, and Courtman et al (1995) used 4 mm sections in similar procedures 
(Courtman, et al. 1994; Hiles, et al. 1995). 5 mm sections were chosen, as these were 
similar in size and using a larger size would reduce the effect o f error for stress 
calculations, where the cross-sectional area is required. The average wall thickness and 
internal diameter were measured for each ringlet. The wall was considered to be the 
bulk tissue o f  the medial layer, which was distinguishable from the loose, adventitial 
tissue. A stress/strain analysis rig (Instron 1122 test rig, Instron, UK) was used to 
obtain load-extension data, where individual ringlets where attached to stainless steel 
hooks and extension data was acquired until matrix/ringlet rupture, see Figure 2.06. 
The equipment was calibrated and zeroed; chart drive speed was set to 50 mm/min. The 
maximum deflection on the chart was set to 5000 g. The cross-head control was set to 5 
mm/min. Similar tests by Courtman et al (1995) and Hiles et al (1995) worked with 
strain rates from 10 to 25 mm/min. A lower value o f 5 mm/min was used to decrease 
the strain rate to improve graphical results. Results were expressed as a stress strain 
trace on a chart recorder, as illustrated in Appendix A4.
Direction of strain
.instron test ng
Stainless steol hooks 2
.Test section
Chart recorder
Figure 2.06: A representation of the Instron 1122 test rig, used for obtaining load-extension 
data. Arterial ringlets were attached to the stainless steel hooks and pulled apart till rupture. A 
chart recorder records the increase in load required for the constant increase in extension.
71
2.3.7 H i s t o l o g y
2.3.7.1  T ISSUE SECTIONING, PARAFFIN EMBEDDING TISSUE AND DEWAXING
Tissue used in histological analysis was first processed in an automated system 
(HistoCentrel, Shandon Inc., Pittsburgh, USA) to fix and prepare the tissue for paraffin 
embedding. After processing the tissue was paraffin embedded (HistoCentre2, Shandon 
Inc., Pittsburgh, USA) into an appropriately sized carrier block. After the wax blocks 
had cooled the metal blocks were removed and excess wax was trimmed, sections of 5 
pm thickness were cut on a standard sledge microtome (Wetzler sledge microtome, 
Leitz, UK). Sectioned tissue was floated in H2 O (45°C) to flatten, then mounted on 
glass slides. Slides were then heated at 65°C overnight and then stored for later use. 
When required, slides were dewaxed in xylene for 2 x 2 minutes followed by 2 x 1 
minutes in IMS then rehydrated in slow running tap water for 5 minutes.
2 .3 .7 .2  H a e m a to x y lin  a n d  e o s in  s ta in in g  t i s s u e  s e c t i o n s
Following dewaxing (xylene for 2x 2 minutes followed by IMS for 2x 1 minutes) 
sections were immersed in Harris’s haematoxylin for 5 minutes followed by washing in 
tap water for 5 minutes. Samples were then differentiated acid alcohol (1% (v/v) HC1 
[conc.] / IMS) for 30 seconds with gentle shaking followed by washing in tap water for 
5 minutes. If staining of the cells cytoplasm was required an additional step of Eosin 
for 30 seconds followed by a further 5 minutes wash in tap water was required. Finally 
slides where dehydrated by immersion in IMS for 2x 1 minute followed by xylene for 
2x 2 minutes. Slides were mounted with DPX, see Section 2.3.3.4.
2 .3 .7 .3  V an  G ie s o n  s t a in  f o r  e l a s t i n  f ib r e s
Following dewaxing, sections were immersed in acidified potassium permanganate for 
2 minutes then rinsed in tap water for 5 minutes. This was followed by immersion in 
1% Oxalic acid 30 seconds and again rinsing in tap water for 5 minutes. Samples were 
then washed in 70% alcohol for 1 minute then stained in Weigerts Resorcin Fuchsin, at
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room temperature for 20 minutes followed by washing for 10 minutes. Samples were 
then differentiated in acid alcohol for 30 seconds, see Section 2.3.3.2, washed in tap 
water for a further 5 minutes then stained in van Gieson for 5 minutes. Finally samples 
where washed in tap water for 5 minutes prior to clearing and mounted in DPX.
2 .3 .7 .4  M o u n tin g  s e c t i o n s  in D PX
After dehydrating the sections through graded alcohols and xylene an appropriately 
sized coverslip was selected and placed on a sheet of fibre-free paper. A drop of DPX 
was applied to the coverslip and using forceps slides were removed from the holding 
rack, excess xylene was drained away and the cover slips were then gently lowered onto 
the slides containing the section, such that the section is sandwiched between its slide 
and the coverslip. The slides were then turned over allowing the DPX to spread 
between the slide and coverslip. Excess DPX was removed with the fibre free tissue 
and the slides were left to dry overnight.
2 .3 .7 .5  C e l l  p h e n o ty p in g
All phenotypic characterisation (including cells on tissue culture plastic as well those 
seeded onto the biomatrix) was carried out using the R.T.U. VectorStain (code PK- 
7800, Vector Labs, UK), universal quick kits containing reagents in ready-to-use form, 
including: prediluted normal horse serum, prediluted biotinylated secondary antibody 
and a preformed streptavidin/peroxidase complex solution. Two primary antibodies 
were used for the immunocytochemical phenotype characterisation of HUVEC, both of 
which were monoclonal mouse antibodies, Monoclonal Mouse-Anti-human Von 
Willebrand Factor (vWF), Clone F8/86 (500:1 dilution) (code No. M0616 Lot 039 
DAKO ltd. Ely, UK) and Monoclonal Mouse -  Anti-human endothelial cell, CD31: 
clone JC/70A (50:1 dilution) (code No. M0823, Lot 028 DAKO, Ely, UK). The 
antibody used for hVSMC identification was Monoclonal Mouse -  Anti-human smooth 
muscle actin: clone 1A4 (40:1 dilution) (code No. M0851 lot 028 DAKO ltd. Ely, UK). 
See Appendix Al-2 for results of cell phenotyping.
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Following dewaxing (above) sections were rinsed in tap water for 5 minutes. Slides 
were incubated with prediluted blocking serum for 10 minutes, followed by incubation 
with the primary antibody for 1 hour at room temperature. Slides were then washed in 
PBS for 5 minutes (x3), followed by incubation with the prediluted biotinylated 
secondary antibody then washed in PBS for 5 minutes (x3). Slides were then incubated 
in the preformed streptavidin/peroxidase complex reagent for 5 minutes, followed by 
washing in PBS for 5 minutes (x3). Slides were then incubated in the peroxidase 
substrate solution (VectorLabs, No. SK-4600) until the desired staining intensity was 
achieved. Finally slides were rinsed in tap water for 5 minutes and counterstained (if 
required) before clearing in graded alcohols and mounting with DPX.
2 .3 .7 .6  IMMUNOFLUORESCENT STAINING ANTIBODIES
Prim ary Antibodies: Goat anti-cathepsin L (S-20) polyclonal antibody (Santa Cruz 
Biotechnology Inc. Cat No. SC-6500) used at 1:100 dilution, MMP-2 mouse anti- 
human-MMP-2 monoclonal antibody (Cat. MAB3308 Chemicon, UK) and MMP-9 
mouse anti-human-MMP-9 monoclonal antibody (Cat. MAB3309 Chemicon, UK). 
Secondary Antibodies: Mouse anti-goat rhodamine conjugated secondary antibody 
(100:1 dilution) (Cat, AP300R Chemicon UK) MMP-2 and MMP-9 used a horse-anti- 
mouse-FITC conjugate in a 1:100 dilution (Cat, 5024 Chemicon UK).
2 .3 .7 .7  Im m u n o f l u o r e s c e n t  S ta in in g  P r o to c o l
Slides were dewaxed in xylene 2 x 2mins followed by IMS 2 x lmin then washed in 
PBS 2 x 5mins. Slides were then incubated in blocking solution (0.5 mg bovine serum 
albumin, 333 pi FCS, 10 ml PBS) for 20 minutes at room temperature. The blocking 
solution was removed and the primary antibody (made up in blocking solution) applied, 
then incubated at 4°C overnight. Slides were washed in PBS ( 2 x 5  minutes), followed 
by incubation in the appropriate fluorescently tagged secondary antibody made up in 
blocking solution for 30 minutes at room temperature; slides were protected from light. 
Finally the slides were washed 2 x 5  minutes in PBS and mounted using DAKO 
fluorescent mounting medium (DAKO, Cat No. S3023 Ely, UK).
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2.3.7.8 B r o m o d e o x y u r i d i n e  i n c o r p o r a t i o n  a s  p r o l i f e r a t i o n  m a r k e r
Assessment of cell proliferation used the incorporation of pyrimidine 
bromodeoxyuridine (BrdUrd), an analogue of the nucleotide uracil during DNA 
replication. Mitotic cells are identified by immunocytochemistry as those with nuclear 
DNA stained dark brown. BrdUrd is prepared to a final concentration of 10 pM in the 
growth media, which is added to the cell culture. This is then incubated for 24 hours in 
standard cell culture conditions. After 24 hours the growth media was aspirated off 
leaving the cell/matrix, which was then fixed with 70% ethanol in PBS/0.5% Tween 80 
for 30 minutes at room temperature. The fixative was then diluted in equal volumes 4M 
HC1 for a further 30 minutes. After washing twice ( 2 x 1 0  minutes) with PBS/0.5% 
Tween 80, mouse anti-BrdUrd (DAKO, Ely, UK) in PBS/1 % Bovine Serum Albumin 
(BSA) added at a dilution of 1:50, and incubated over night at 4°C. After a further two 
washes (2 x lOminutes) with PBS/0.5% (v/v) Tween 80, the secondary antibody, Horse 
radish Peroxidase (HRP) conjugated rabbit anti-mouse IgG (DAKO, Ely, UK) in PBS, 
1% (v/v) BSA, was added to a dilution of 1:200 and incubated for 30 minutes at room 
temperature. After further washings (2 x 10 minutes) with PBS/0.5% (v/v) Tween 80, 
the chromogen DAB was added. Its development was monitored using the light 
microscope and arrested at completion (approximately 5-10 minutes) by rinsing with tap 
water thus identifying nonmitotic cells. Cell proliferation was assessed by microscopic 
visualisation of dark brown stained cells (BrdUrd nuclear stain).
2.3.7.9 Labelling  fixed  c el ls  u sin g  DAPI
From a stock solution of DAPI (m.w. 350) at 10 mg/ml made up in distilled H2 O, a 
5000-fold dilution in PBS was prepared for labelling cells. Cell media was aspirated 
and the samples rinsed in PBS for 5 minutes (x3). Samples were then fixed in a freshly 
made up 3.7% formaldehyde solution for 10 minutes followed by permeabilization of 
the cells by immersion in 0.2% Triton X-100 for 5 minutes. This solution was then 
aspirated and samples rinsed in PBS for 5 minutes (x3). Samples were then incubated 
in the prepared DAPI labelling solution for 1-5 minutes at room temperature. Samples 
were then rinsed in PBS for 5 minutes (x3) and mounted. Observation of DAPI labelled 
DNA was carried out with a Zeiss Florescent microscope and image analysis with
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software from Image Associates, UK. The excitation wavelength maximum is near 359 
nm and the emission wavelength maximum is approximately 461 nm when bound to 
DNA. It is believed that DAPI associates with the minor groove of double-stranded 
DNA with a preference for the-AT clusters. Fluorescence increases approximately 20- 
fold when DAPI is bound to double-stranded DNA.
2.3.8 M ic r o s c o p y
2.3.8.1  Lo w -t e m p e r a t u r e  sc a n n in g  ele c tr o n  m ic r o s c o p y
Prior to examination with the low temperature SEM specimens are washed (gently) with 
PBS (3x) to remove any protein residues left from the media. Then specimens were 
fixed with 1% (v/v) glutaraldehyde being added per well for two hours prior to viewing. 
Both low temperature scanning electron microscopy and standard vacuum SEM, used 
the JEOL JSM-6310 SEM (Jeol Tokyo, Japan).
The cold stage and anticontaminator were cooled with nitrogen gas at a pressure of 0.5 
kg/cm (7psi) for 1-2 minutes. The dewar was then filled with liquid nitrogen (the inlet 
was checked to ensure it was not restricted. The dewar was topped up and gas flow 
adjusted as was necessary as the temperature on the control monitor dropped to 
approximately -180°C as the system cooled. Likewise the cryo-preparation chamber 
dewar was filled with liquid nitrogen, until the temperature fell below -160°C. Both 
dewar were topped up as necessary throughout the session to maintain temperature. The 
specimens were fixed to the rod/holder with glue (Tissue tek, OTC compound plus 
carbon, EM Supplies, UK) and plunged into nitrogen slush for several minutes to allow 
the specimen plus holder to fully cool. The specimen was then transferred from the 
nitrogen slush into the vacuum transfer device. The chamber was then flushed with N2 
gas. Once completed the specimen and holder were located onto the cold stage of 
preparation chamber.
The temperature was set on the controller to -85 to -95°C to allow sublimation at a 
controllable rate. The heater was then activated whilst observing the specimen at a
76
low KV monitoring the sublimation. When completed the specimen was transferred 
back to the cryo-preparation stage. The stage temperature was maintained at -170°C or 
colder and the vacuum set to 0.1 torr. The splutter was then activated and volts set to 
maximum (30 seconds). The argon valve was slowly opened until the current rose and 
stabilised at approximately 1-2 milliamps. The timer was reset to 2-3 minutes and 
specimen was positioned directly beneath the splutter head. The timer is activated to 
commence coating. When complete the argon valve was closed and volts set to zero. 
The specimen holder (plus specimen) was transferred from the cryo-preparation stage to 
the SEM cold stage and viewed in the normal way at 10-15 KV.
2 .3 .8 .2  S t a n d a r d  s c a n n in g  ele c tr o n  m ic r o s c o p y
Specimens were fixed in two stages firstly as in section 2.4.2.1. secondly with osmium 
tetroxide to stabile cellular lipids. Fixation was carried out by preparing a 25% (v/v) 
solution of osmium tetroxide in which tissue sections were immersed. Fixation required 
1 hour with specimens held in a slow revolving mixer. After fixation specimens were 
dehydrated in graded acetone treatments (50, 60, 70, 80, 90, 95 and 100% dry acetone). 
Samples were then critical point dried (Polaron 3000, Agar Scientific, Stanstead, UK), 
by draining acetone and replacing with liquid CO2 in the critical point dryer. The 
temperature was then gradually raised above 31°C at a pressure of 1150 p.s.i. (critical 
point) to 35°C, at which the liquid CO2 behaves as a gas and is bled away. Samples 
were coated in gold in a similar fashion to the LT-SEM method described above. 
Samples were viewed under vacuum with the JEOL JSM-6310. Both LT-SEM and 
standard SEM images were saved as TIFF files.
2 .3 .8 .3  P h a s e -c o n t r a s t  lig h t  m ic r o s c o p y
Specimens of both tissue and collagen are fixed in the same manner as for standard 
histological analysis with formal saline (room temperature) for a minimum of two hours 
prior to staining. Once fixed, specimens stained as appropriate and visualised 
electronically. All digital images other than SEM derived images were obtained using a 
Carl Zeiss Axioskop2 phase-contrast microscope utilising a JVC 3-CCD KY-F55B 
colour video camera with a KS 300 Imaging System (Imaging Associates Ltd, Thames,
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UK). All light microscopy images (including florescent) were saved as JPEG files.
2 .3 .8 .4  FLUORESCENT MICROSCOPY
All florescent image analysis was carried out using a Carl Zeiss Axioskop2 florescent 
microscope at wave lengths described in section 2.2.5.
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CHAPTER THREE: STATIC CELL CULTURE ON 
PO R C IN E TYPE I COLLAGEN
3 .1  In t r o d u c t io n
Considerable efforts have been made to produce non-toxic, stable and non- 
immunogenic biomaterials that retain natural mechanical characteristics. Cross-linking 
methodologies, which include glutaraldehyde, carbodiimides, hexamethylene 
diisocynate (HMDI) and a variety of other fixation methods, often proved problematic 
due to issues of toxicity. This is of particular significance to this chapter as the process 
used to stabilize, or cross-link this particular collagen matrix utilises HMDI as the cross- 
linking agent. HMDI is proposed to degrade to hexamethylene diamine and is cited to 
be minimally cytotoxic (Chvapil, 1992 and Khor, 1997). Further evidence of its 
cytotoxic nature has been reported e.g. (van Luyn et al., 1992a), in particular 
Bellincampi and Dunn, (1997), declared that the compound in their hands was 
“impractical for use in a tissue engineering device”. Using a methylcellulose 
cytotoxicity cell culture test (van Luyn et al., (1991) reported that HMDI elicited both 
primary and secondary cytotoxicity; the primary toxicity being the direct diffusion of 
the residual compound and the secondary cytotoxicity by enzymatic actions, and 
aqueous hydrolysis. Although the bulk of the toxic compounds were released by 6 days, 
glutaraldehyde, by contrast was shown to elicit a secondary response for as long as 42 
days (van Luyn et al., 1992b). van Luyn et al (1992b) concluded the residual secondary 
response would not “seriously influence biocompatibility over time”. Bellincampi et al
(1997) compared several methods of cross-linking collagen fibres, including ultraviolet 
radiation, dehydrothermal treatment and HMDI, and found that fibroblast attachment, 
proliferation and morphology on HMDI cross-linked collagen was significantly lower 
than other methods of cross-linking. The primary cytotoxic response to both 
glutaraldehyde and HMDI is reduced after the application of controlled washing 
regimes. Repeated exposure of human fibroblasts to HMDI cross-linked materials 
eliminated all cytotoxic substances by day 18 (Bellincampi and Dunn, 1997). Published 
methodologies for the preparation of biological tissues for biomaterial development and 
components of the extracellular matrix (ECM) are further discussed in Chapter 4.11 
(ECM components) and 4.1.2 (processing biological tissues).
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This chapter describes the gross morphology of the type I dermal collagen matrix used 
in this thesis, where preliminary growth studies to characterise (qualitatively) the ability 
of cells (HUVEC and hVSMC) to adhere, grow and proliferate under static conditions 
followed by modifications to the matrix to improve cellular compatibility have been 
conducted.
3 .2  Ma t e r ia l s  a n d  M e t h o d s
3.2.1 M a t e r ia l s
General materials and methods are described in Chapter 2, including protocols for the 
isolation and culture of primary HUVEC and hVSMC, SEM sample preparation, 
processing, histology, immunohistochemistry and image analysis. Discrete protocols, 
unique to this chapter are described within Section 3.2.2.
3.2.2  E x p e r im e n ta l  m e th o d s
3.2.2.1 T y p e  I d e r m a l c o l l a g e n  p r e p a r a t io n
The initial stages of this project assumed that, since this matrix had been cleared for 
human implantation there would be negligible, if  any, cytotoxic effects. The first step 
in preparation therefore was to simply cut uniform sections of equal surface area that 
allows an accurate assessment of cell numbers per unit area. To this extent a simple set 
of protocols were developed to cut and wash the collagen matrix whilst maintaining 
sterility. The material were cut manually under sterile conditions with a scalpel into 10 
x 10mm (100mm ) sections immediately prior to experimental use. Later cutting 
methods utilized a circular (16 mm diameter, 2 cm2) leather punch. The protocol was 
altered to ensure the collagen surface area remained consistent, as manually cutting 
squares proved inconsistent. Also circular disks would fit directly into the wells of 
standard culture plates without any exposed plastic. The benefit of this is that no 
compensation is required for seeding volume to actual seeded density. An added benefit 
is that the collagen is handled less thus reducing the risk of contamination.
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Washing potentially contaminating toxic compounds from the matrix
In order to achieve increased cell adhesion, growth and continued proliferation, a 
protocol of washing the collagen was developed to ensure removal of non-bound cross- 
linking agent (HMDI) and any other potentially toxic compounds, including acetone. 
Other than using the matrix material directly from its sterile packaging, two other 
methods were used to remove potentially contaminating compounds:
Method one: A preliminary washing protocol was used to establish the effectiveness of 
washing the matrix prior to cell seeding. The matrix (no more than 9 disks/50ml) was 
washed for two weeks in 100 ml HBSS containing Penicillin, Streptomycin (250pl) and 
Fungizone (50j l x 1) to guard against potential bacterial contamination, with the solution 
being changed twice over the two week period.
Method two: The second method was designed to maximise the washing process, as 
follows. Square cut sections 10x10x1.5 mm (LxWxD), or disks (1.5x16 mm diameter) 
were cut to size and placed in 25 ml Sterilin tubes, eight separate washes (no less than 3 
hours each) in sterile PBS were applied followed by two washes in the appropriate 
media for the cell type to be cultured. The final solution (media) included 100 pi 
Fungizone per 20ml media in addition to the standard lOOU/ml penicillin and lOOpg/ml 
streptomycin to guard against potential bacterial and fungal contamination.
3 .2 .2.2 ADHESION AND PROLIFERATION ON STANDARD AND MODIFIED DERMAL 
COLLAGEN MATRIX
HUVEC and hVSMC were seeded onto the sterile matrix directly from its packaging, 
for culture periods of 20, 96 and 168 hours prior to assessment by LT-SEM. Studies of 
cell growth and cytotoxicity where conducted with VSMC and HUVEC (PII-PV), at 
densities ranging from 1.4 x 104 and 4.5 x 105 cells/ml. Removal of cells from plastic 
and matrix material was achieved with the use of the proteolytic enzyme trypsin to 
digest adhesion molecules binding the cells to Permacol, thus releasing it into solution, 
see Section 2.2.2 for details on cell passaging and general culture. Viability as 
determined with Sigma's standard protocol, see Section 2.3.2.9. Prior to counting 
sample wells where washed gently with PBS to remove cells in free solution. Standard 
tissue culture techniques were carried out, were media was changed every three days.
Cell viability
A quantitative assessment of cell and viability on type I collagen was assessed with 
(0.4%) Trypan Blue, Sigma 192 protocol. HUVEC (PHI) were seeded at density of 6.5 
x 104 cell/ml (3.25 x 104 cell/cm2) onto 10x10x0.75 mm (LxWxD) type I collagen. The 
matrix was prepared as per protocol 1, Section 3.2.2. The Matrix was removed directly 
from the packet i.e. not washed prior to cell seeding. Samples were cultured in 4 well 
tissue culture plates with a total surface area of 2 cm2. Each culture plate (4 wells) 
contained 2 controls and 2 matrix samples. The cell suspensions were pipetted evenly 
over the entire surface area of both controls and matrix samples. Removal of cells from 
both plastic and Permacol was achieved with the use of the proteolytic enzyme trypsin. 
Prior to counting sample wells where washed gently with PBS to remove cells in free 
solution. For details on cell passaging and general culture, see Section 2.2.2. 
Procedure: Total solution volumes equal 1.0 ml, comprising 0.5 ml of 0.4% Trypan 
Blue, 0.3 ml HBSS and 0.2 ml of cell suspension (dilution factor = 5). The suspension is 
mixed thoroughly and allowed to stand for 5-15 minutes. Cells that stain dark blue after 
the incubation period are deemed non-viable.
3 .2 .2 .3  In v e s t ig a t io n  o f  p r e -s e e d in g  c o n d it io n s  t o  e n h a n c e  cell  a d h e s io n
AND PROLIFERATION 
Bromodeoxyuridine Proliferation Assay
The BrdUrd protocol has been described previously in Section 2.3.3.8. Cell types used: 
hVSMC and HUVEC. Seeding densities for hVSMC (PIV) and HUVEC (PIV) were 4 
x 104 and 9 x 104 cell/well respectively. A preliminary washing protocol was used to 
establish the effectiveness of washing the matrix prior to cell seeding. The matrix was 
washed for two weeks in 100 ml HBSS containing Penicillin, Streptomycin (250pl) and 
Fungizone (50pl) with the solution being changed twice. Comparisons between washed 
and non-washed matrix in terms of cell proliferation were conducted with both HUVEC 
and VSMC. Primary cell cultures were cultured as per standard protocols and seeded 
onto 16 mm diameter matrix disks (see section 3.2.2.1). Cells were seeded at 1.08 x 105 
(HUVEC) and 1.21 x 105 cell/well (VSMC), [to convert to cell/mm2 divide total cell 
number by matrix disk area 201 mm , 537 and 600 cell/mm respectively]. Cells were 
seeded either directly onto non-washed matrix, straight from packaging, or washed 
matrix. A standard washing protocol was adopted. A total of nine, 16 mm disked could
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be cut from each 5 x 5  matrix sheet. These 9 disks were washed in 50 ml of sterile PBS 
followed by two washes in the appropriate media for the cell type to be cultured on a 
standard bottle roller. Washes were no less than 2 hours between each wash. The final 
solution (media) included lOOU/ml penicillin, 100 pg/ml streptomycin with 100 
pl/20ml Fungizone (final concentrations) to minimize any potential contamination. Cell 
counts were conducted as described in Section 2.3.1.1.
Chemical modification with sodium hydroxide
Matrix disks were immersed in a 0.2 M solution of NaOH for 4 minutes (matrix begins 
to turn opaque) at room temperature (16 ± 3°C). Disks were then washed (2x rapidly) 
plus 3 further washes with a minimum of 1 hour between each. Disks were stored at 
4°C in the final wash (media as above) until required.
Matrix modification by heparin
Matrix disks were immersed in 5 ml Heparin (Heparin 5000 U/ml'1 monoparin, CP 
Pharmaceuticals, UK) plus 20 ml PBS for 48 hours on the rock/roll table. Solution is 
then drained and replaced with high serum SMC media containing additional 250 U/ml 
penicillin and 250 pg/ml streptomycin and 100 U/ml of nystatin (final concentration), 
stored at 5°C until required. At prescribed days, samples were removed from culture, 
and fixed for analysis. Controls were seeded onto culture plates, without collagen disks.
3.2.3 A n a l y t i c a l  m e th o d s




3.3.1 Morphology of the dermal collagen matrix
The aim o f this section was to characterise the matrix in terms o f it morphological 
microstructure, whereby transverse sections o f matrix samples were cut and prepared 
for histological analysis as described in Section 2.3.3.1 and viewed by either phase 
contrast microscopy or LT-SEM. Cross-sections o f the dermal collagen display large 
interwoven collagen fibres characteristic of type I collagen, Figure 3.01. The surface 
of the matrix exhibited open areas that lead into the matrix, where areas o f free space 
are visible between the large collagen fibrils. Spaces or gaps in the fibrous structure are 
important for cell migration into the matrix.
Figure 3.01: A transverse section of the porcine derived type I dermal collagen matrix. The 
matrix (0.75 mm thick) displays the interwoven nature of the predominantly type I collagen, H & 
E stained.
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The surface morphology o f the collagen matrix was assessed using low-temperature 
scanning electron microscopy (LT-SEM). These images detail this matrix surface 
structure, as predominately flatted or compressed areas confirming the phase contrast 
microscopy results that show a nonuniform matrix surface see Figures 3.02. Figure 
3.03, a higher magnification o f the fibrous matrix surface shows pores in the matrix 
fibres as up to 15 pm. Figure 3.04, like Figure 3.03, shows a higher magnification 
detailing the flattened or compressed collagen fibres that are unlikely to allow cell 
migration via passive motility.
Figure 3.02: Low magnification LT-SEM displaying the variable surface morphology of the type 
I dermal collagen matrix. In addition to the flat or compressed sections a more open porous 
structure is noted with ‘pores’ up to 30 x 15 pm.
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Figure 3.03: Higher magnification LT-SEM detailing the fibrous structure of the collagen matrix. 
Pores ranging from 1-10 pm are evident.
Figure 3.04: High magnification LT-SEM of the flattened or compressed surface fibres of the 
type I dermal collagen matrix. Compared to pores in the fibrous regions this compressed 
morphology has pores less than 1pm (qualitative assessment).
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3.3.2 A sse ssm en t o f  c e l l  adhesion  and  p ro l i f e r a t io n  on th e  d e rm al
COLLAGEN MATRIX
HVSMC GROWTH ANALYSIS
A growth analysis was conducted with SMC resulting in a typical growth curve, Figure 
3.05. Cells were enzymatically removed from the surface o f the plastic culture plate. 
Results were expressed as the mean number o f cells/mm . Although this growth 
analysis indicates a ‘typical’ growth curve it was noted that large variations occur in cell 
doubling times between different individuals (patients) with differing stages o f disease. 
A standard growth analysis o f hVSMC was conducted to use as a base or reference 
point for hVSMC culture directly on the type I dermal collagen matrix. Results show an 
expected increase in cell density o f approximately 114 cells/mm2 until proliferation 










- -  <>  






Figure 3.05: Standard growth profile of primary hVSMC on tissue culture plastic, error is shown 
as from triplicate samples from one tissue/cell isolation.
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HUVEC AND hVSMC a d h e s i o n  o n  P e r m a c o l
These experiments were designed to assess the ability of human cell lineages (HUVEC 
and hVSMC) to adhere, maintain adhesion, grow and proliferate in static growth 
conditions on the type I dermal collagen matrix. Cells were seeded onto the dermal 
collagen matrix and cultured using techniques described in Section 2.2.2. At prescribed 
time points (approximately 1, 4 and 7 days) samples were removed from culture rinsed 
in PBS and fixed in glutaraldehyde in preparation for LT-SEM, as described in Section 
2.4.2.1.
HUVEC seeded at 1 x 105 and 2 x 105 cells/ml and cultured for approximately 1 day 
have adhered to the matrix with pseudopodia-like structures extending into the matrix, 
cell-cell contacts have formed indicating a maturation of adhesion post initial contact. 
Cells appear both singularly (see Figure 3.07) and in clusters (see Figure 3.06) 
randomly dispersed over the entire matrix surface. As a qualitative assessment, 
densities are an order of magnitude less than plastic controls. Visual assessment of 
HUVEC seeded onto the matrix displayed little difference in cell density when seeded 
at twice the density 1 x 105 and 2 x 105 cells/ml. Both HUVEC and hVSMC were 
found in higher concentrations randomly dispersed over the matrix surface, with other 
areas completely void of all cells. Figure 3.07 a LT-SEM of HUVEC after 1 day static 
culture showing a single cell with a pseudopodia-like protrusion (A) extending into the 
matrix pores. Further details of cell-cell contacts are shown in Figure 3.08. Similar 
results were found with hVSMC, Figure 3.09.
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Figure 3.06: HUVEC (A) cultured for 1 day on the dermal collagen matrix. Cells were seeded 
onto the matrix at 1 x 105 cell/ml.
Figure 3.07: A HUVEC cell displaying pseudopodia-like structures (A) extending into the matrix
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Figure 3.08: Cell-cell (B) and cell-matrix (C) interactions of HUVEC (A) after 20 hours static 
culture. At higher magnifications these interactions are clearly visible; HUVEC were seeded at 
2 x 105 cells/ml
l O O p m
Figure 3.09: 20 hour static cultures of hVSMC (A) seeded on the dermal collagen matrix. 
hVSMC seeded at 1 x 105 cell/ml displayed similar densities to HUVEC cultures, where both 
high and low densities of cells were present. In this image hVSMC appear longitudinally 
orientated.
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After 4 d culture periods, LT-SEM analyses o f HUVEC show cells remain adhered to 
the matrix and display similar morphologies and densities to 20 hour cultures. Figure 
3.10 shows HUVEC seeded at 1 x 105 cell/ml onto the type I collagen matrix (non- 
washed), again regions o f higher densities were observed randomly over the matrix 
surface. The only distinct difference noted between the two time points was the 
appearance o f  more advanced cell-cell contact, Figure 3.11. Little difference, if  any, is 
noted between seeding densities o f 1 x 105 cell/ml and 2 x 105 cell/ml (qualitative 
assessment). hVSMC cultured over the 4 d period, like HUVEC, had adhered to the 
matrix displaying similar densities to HUVEC cultures seeded at the same density. 
Again cells appear both singularly on the matrix and in clusters, see Figure 3.12 where 
hVSMC morphology was difficult to interpret in this series o f images. Compared to 
confluent cell layers on flat-bottomed T25 culture flasks (controls) cell densities are 
considerably lower (qualitatively).
Figure 3.10: 96 hour culture of HUVEC on the dermal collagen matrix. HUVEC were seeded 
at 1 x 105 cell/ml onto the type I collagen matrix and cultured under static conditions.
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Figure 3.11: LT-SEM of HUVEC after 4 days static culture on the dermal collagen matrix. 
Cells display signs of more established cell-cell contact (A).
Figure 3.12: hVSMC cultured for 96 hours (1x105 cell/ml) under static conditions on the dermal 
collagen matrix, cell morphologies were more difficult to interpret.
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Few cells remain adhered to the matrix after 7 days culture. Both HUVEC and hVSMC 
appear stressed (rounded and globular) compared with cells cultured for 1 and 4 days, 
Figures 3.13 and 3.14. Both cell types are morphologically similar, displaying a 
contracted globular nature as cells loose adhesion to the surface o f the collagen matrix 
followed by detachment, cumulating at 7 day culture period.
Figure 3.13: HUVEC reduction in cell density after 7 days static culture on the dermal collagen 
matrix. HUVEC seeded at 2x105 cell/ml, on non-washed dermal collagen
Figure 3.14: Loss of viability and cell adhesion of hVSMC after 7 days static culture, as noted 
by the qualitative reduction in total cell density over the experimental time course.
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Expanding zone of cell necrosis
This experiment was designed to assess (qualitatively) if any cytotoxic compounds were 
leaching from the matrix resulting in a loss in cell viability. Previous observations 
noted an expanding zone (over time) of cell exclusion emanating from the collagen 
matrix, where controls display normal cell growth and morphology. Square sections, 
10x10x1.5 mm (LxWxD) of the dermal collagen were placed into larger (35 mm OD), 
circular culture plates (6-well Nunc. UK), where an area of plastic void of collagen 
remained for cells to adhere and monitor cell morphology over time. SMC (Pin) and 
HUVEC (PV) were seeded at a density of 4.5 x 105 cell/ml and 2.5 x 105 cell/ml 
respectively onto the matrix and surrounding plastic of the culture well. Cultures were 
observed with an inverted phase-contrast microscope, observational evidence only.
From the initial seeding through to day-3 cells (both HUVEC and hVSMC) display 
‘normal’ morphology surrounding the matrix. After 5 days cells adhered immediately 
adjacent to the matrix and were showing gross changes in morphology compared to 
controls. By day-7 both hVSMC and HUVEC in the zone immediately around the 
matrix appear to have lysed, with cells of typical morphology present only at the 
extreme edge of the culture wells, again controls normal. Day-10 results where as day- 
7. After 10 days an increase in cell density was observed at the periphery of the culture 
well. Controls displayed normal cell morphologies and typical confluent densities.
Cell viability on Permacol
Cell viability was assessed with trypan blue, used as a dye exclusion assay for cell 
viability procedures, see section 2.3.7.9. Post seeding there is an initial decline in cell 
density, considered normal when seeding primary human cells onto any surface. 
Control data show a consistently higher cell density compared with cells seeded on 
Permacol. Cells seeded onto the dermal collagen matrix follow a similar pattern of 
decline to control samples immediately post seeding, though cell numbers did not 
recover and remained low compared to controls. Non-viable cell numbers were also 
lower compared to controls, which indicates a lower total cell number.
The general trend indicates a low percentage cell adhesion and little if any cell growth 
and/or proliferation. Results displayed in Figure 3.15 show HUVEC adhesion and 
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Figure 3.15: HUVEC viability on collagen matrix and plastic controls: ♦control-viable, ®control- 
nonviable, x collagen-nonviable, A collagen viable.
3.3.3 E n h a n c em en t  of cell  a dhesio n  a nd  pr o life r a tio n  on  th e  d erm al
COLLAGEN MATRIX
A critical issue in tissue engineering is the lead-time from the isolation of (autologous) 
cells, the bulking-up phase through to the mature Tissue Engineered construct within 
the bioreactor. Particularly so with replacement organs such as the heart, vascular 
tissue, liver etc., where extended culture periods may impact directly o f patient 
mortality. The rate at which a population o f cells reach an optimal density is critical; an 
important step to optimise. With the aim to further enhance initial cell adhesion and 
subsequent proliferation rates, methodologies were assessed to determine if  modifying 
the surface o f the dermal collagen matrix would affect cell adhesion/growth. In this 
series o f experiments cell proliferation was assessed after the dermal collagen matrix 
had been washed. The effect o f further washing the matrix was then assessed in terms 
of cell density over time. In order to further improve adhesion and growth dynamics, 
the matrix surface was modified by exposure to heparin and NaOH, with comparative 
analysis. NaOH modifies the surface structure o f the collagen matrix by attacking 
acidic residues, were as heparin has been shown to improve cell adhesion (Bos et al.,
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1998), enhance vascularisation (Doi and Matsuda, 1997) and reduce the incidence of  
intimal hyperplasia (Laemmel et al., 1998).
C e ll  p r o l if e r a t io n
The presence o f  an unknown cytotoxic compound (possibly residues from the HMDI 
cross-linking process, known to be cytotoxic) diffusing from the collagen matrix was 
clearly affecting cell viability. To determine whether or not a simple washing step may 
reduce or eliminate this compounds effect, HUVEC PIV (9 x 104 cells/well) and 
hVSMC PIV (4 x 104 cell/well) were seeded onto a pre-washed matrix (matrix 
preparation see method 1, Section 3.2.2.1) with the aim o f confirming cellular 
proliferation as opposed to adhesion and growth during the early stages o f cell culture. 
Cell proliferation was assessed by assaying for the primidine bromodeoxyuridine 
(BrdUrd), a nucleotide analogue and its incorporation into DNA during DNA 
replication. Figure 3.16 displays BrdUrd positive cells with nuclear regions stained 
brown. The time point o f day 5 was chosen being immediately after the last day of 
confirmed cell adhesion (day 4) and was prior to the loss o f cell adhesion by day 7. 
Clearly cells are proliferating at day 5, indicating the washing step had improved 




Figure 3.16: Conformation of HUVEC proliferation by positive staining by BrdUrd. After a 
preliminary matrix washing step and 5 days in static culture, mitotic (or post mitotic) cells 
(proliferating cells) were identified by dark stained nuclear DNA (BrdUrd assay).
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Matrix washing
In order to maximise the washing process collagen sections were cut to size and a more 
comprehensive washing protocol applied, method 2, as described in Section 3.2.2.1. 
This experiment emphasised the need to wash thoroughly the collagen matrix, where a 
near eight-fold increase in cell density o f hVSMC and HUVEC over 30 days to non- 
washed collagen is observed, Figures 3.17-19. At day 16 cells (both hVSMC and 
HUVEC) on the washed matrix displays a four-fold increase in cell density from day 16 
through day 30, Figure 3.17. In contrast densities o f cells seeded directly onto matrix
(non-washed) continue to decline until day 22 where densities begin to rise from a low
2 2 o f 27 cell/mm back to 65 cell/mm approximately equivalent densities at day 16 (66
cell/mm2). See Figures 3.18 and 3.19 for comparative smooth muscle cell growth at 30
days.
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Figure 3.17: Comparative analysis of HUVEC and hVSMC cell density on washed and non- 
washed matrix. (A )  HUVEC and (o) hVSMC on washed matrix, compared to (□) non-washed 
matrix. Cell density shown as the mean number of cell/mm2, ± 1 standard deviation.
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Figure 3.18: Cell density of hVSMC cultured on the non-washed type I dermal collagen matrix 
at day 30.
50 fim




Prior to matrix modification the matrix was washed with the more comprehensive 
washing protocol, method 2, as described in section 3.2.2.1. Sample pre-treatments are 
described in section 3.2.2.3. In addition to the washing procedure, NaOH treated disks 
were washed 2x rapidly plus 3 further washes with a minimum o f 1 hour between each 
in PBS to neutralise the alkaline pH. Results from these data suggest that NaOH treated 
dermal collagen offers a better environment for cell adhesion and subsequent growth. 
Results from heparin treated collagen displayed higher densities over days 3 and 7, 
however between day 7 and 11 cell density declines rapidly, Figure 3.20. hVSMC 
cultured days 21 on heparin treated collagen, displayed large ‘sheets’ o f what appeared 
to be the heparin layer loosing adhesion from the collagen matrix, Figure 3.21 . In 
contrast hVSMC cultured on NaOH treated collagen at 21 days, remained adhered to the 
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Figure 3.20: Comparative matrix treatments of heparin and NaOH in terms of hVSMC density 
over time. Analysis of hVSMC density over time between heparin (x), NaOH (□) treated 
matrices and plastic controls tissue culture plates (A).
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Figure 3.21: hVSMC cultures at day 21 on heparin treated collagen, large ‘sheets’ of what 
appears to be the heparin layer have detached collagen matrix.
50 pm
Figure 3.22: hVSMC cultured on NaOH treated collagen at 21 days, remained adhered to the 
matrix.
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3 .4  D is c u s s io n
This chapter describes the use of a modified porcine dermal collagen as a scaffold for 
three-dimensional cell growth and proliferation. The matrix consists primarily of 
collagen and elastin and has been treated to remove cells, cell debris, cross-linked to 
increase immune tolerance and stabilise against host degradation. The aim was to 
determine the suitability of this material for use as a matrix for tissue engineering 
vascular prostheses. Supplied by Tissue Science Laboratories, London, Permacol has 
been described in the patent WO 85/05274 invented by Roy Oliver and Roy Grant as; 
“A collagenous fibrous tissue preparation of human or animal origin which is suitable 
for homo- or hetero transplantation as a permanent implant. The fibrous tissue 
preparation is preferably in sheet form and is prepared by a process which results in the 
tissue being substantially free of non-fibrous tissue proteins, glycoproteins, cellular 
elements, lipids and lipid residues. This process involves the treatment of the fibrous 
tissue with a polyisocyanate which unlike earlier processes using, for example, 
dialdehyde treatment agents, provides a fibrous tissue preparation which is non- 
cytotoxic and is stable to endogenous proteolytic enzymes” (Oliver and Grant, 1985). 
Two important aspects of Permacol with regard to its use as a matrix in tissue 
engineering vascular prostheses are, that Permacol is derived from dermal collagen 
which is primarily type I collagen with lesser amounts of type HI collagen, whereas the 
predominant collagen type in native blood vessels is type IH, with a small amount of 
type IV collagen associated with the basement membrane. However, the molecular 
formulas of type I, [al(I)]2a2(I) and type ID, [al(ffl)]3 , both contain similar a l  
polypeptides and polymerise to form fibrils. Secondly, the content elastin within 
Permacol estimated between 2 and 4% by the patent holders, is considerably lower than 
in native blood vessels (depending on the vessel type and location) (Sunthareswaran,
1998). The impact of these discrepancies is discussed in relation to cell adhesion, 
growth and proliferation. It has not been the aim of this project to comprehensively 
characterise the type I dermal collagen matrix (Permacol). Studies have been limited to 
understanding fundamental aspects describing the matrices gross morphology and 
ability to confer cell adhesion, growth and proliferation under in vitro conditions with 
the aim to develop a small diameter vascular graft.
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3 .4 .1  M o r p h o l o g y  o f  t h e  d e r m a l  c o l l a g e n  m a t r ix
Initial observations of transverse sections of the dermal collagen matrix analysed by 
phase contrast microscopy show clearly the fibrous nature of the dermal matrix with 
open spaces of sufficient size that may allow cellular penetration (non-proteolytic 
migration) into the matrix. Given appropriate stimuli, cells seeded onto the matrix 
surface v/ill migrate into the matrix ultimately conferring a cell dense biomaterial. LT- 
SEM characterisation of matrix surface structure iterates the transverse sections, 
showing both fibrous and compressed areas. The fibrous areas are seen to be critical to 
allow cell migration into the collagen matrix, particularly so if cellular mechanisms to 
digest the matrix are unable to digest the collagen fibres due to excessive cross-linking.
A porous structure will improve mass transfer of nutrients/waste products into and out 
of the matrix essential if high densities of cells are to develop within the matrix wall. 
Of the samples studied with the LT-SEM a qualitative assessment that approximately 
50-65% of the matrix surface is in the form of compressed fibres that are unlikely to 
allow passive migration of cells into the matrix.
3.4.2 A s se ssm e n t  of cell  adhesion  and  pro liferatio n  on the  dermal
COLLAGEN MATRIX
Cell proliferation rates will vary dramatically depending on the patients age and the 
disease state of the tissue from which the cells were originally isolated. This can be 
explained by the nature and origin of the cell types used, not least variation between 
species. hVSMC used in this report are primary cell lineages, isolated from diseased 
venous tissue, having variable growth characteristics from one individual to the next. In 
addition hVSMC are isolated from tissue in various stages of vascular disease and 
origin, which again results in variability of growth characteristics. This is in direct 
contrast to cell lines (e.g. Hela cells), which can potentially maintain consistent growth 
and proliferation rates, indefinitely. A standard growth analysis was conducted using 
hVSMC as the ‘gold standard’ by culturing on tissue culture plastic. hVSMC have the 
slowest replication rates of the cells cultured in this project and are likely to be the time 
limiting step in generating the tissue engineered blood vessel. Throughout this
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thesis primary human cells, with regard to the hVSMC sourced predominantly from or 
near diseased tissue (e.g. saphenous veins), the rational behind this was that any product 
or protocol generated by this project would use patient cells, as discussed in the 
literature review. In order to better understand limitations in terms of diseased cell 
growth and proliferation it was preferential to use the patient group as a source of cells. 
Results from the growth analysis were therefore limited as each individual cell lineage 
exhibits differing growth and proliferation properties. Similar growth rates will be 
achieved from other tissue samples, however there is considerable variation in primary 
cell growth rates between individuals.
As explained above, the results have provided limited information about hVSMC 
growth as an independent lineage of cells was used that have been grown in vitro on an 
unnatural substrate. Furthermore this culture is 2-dimentional, where migration into a 
tissue is not possible with the effects of contact inhibition preventing continued cell 
proliferation. It is hoped that 3D culture will allow cells to migrate into a matrix to 
reach densities approaching physiological levels, where EC form an endothelium and 
hVSMC have a sufficient density to confer vascular tone, whereby VSMC contraction 
within the matrix wall will confer physiological control over blood flow.
An interesting issue is the phenotypic state of hVSMC in relation to their proliferative 
activity and the method cells are isolated for in vitro cultivation. hVSMC isolated by 
the ‘explant method’ (used in this thesis) have a higher proliferation rate and lower 
expression of a-actin than cell isolated by the ‘enzymatic method’ (Kirschenlohr, et al. 
1996). It has been postulated that the later method is less phenotypically damaging to 
cell populations, hence they are likely to retain the phenotypical gene expression pattern 
of in vivo cells. As cells proliferate increased resources, such as a-actin expression, are 
potentially compromised thus the reduced immunocytochemical staining for this protein 
(Kirschenlohr, et al. 1996). The substrate cells are grown on dramatically influences 
their phenotype. It is possible that the higher proliferative rate of hVSMC gained from 
the explant method and grown on tissue culture plastic revert back to a more 
phenotypically correct state with reduced proliferation, when cultivated on a 3D 
collagen matrix, more akin to the in vivo environment. Experimentation was not 
conducted to confirm this, however these results are valuable as an indirect comparison 
for later cell culture on the collagen matrix.
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Cell adhesion studies on the type I dermal collagen matrix was confirmed with the LT- 
SEM, 1 day after cell seeding. HUVEC had adhered to the matrix displaying 
pseudopodia-like structures extending into the matrix, Figure 3.07. Further evidence of 
more mature adhesion was the establishment of cell-cell contacts was noted in Figure 
3.08. Although this initial study was qualitative, it could be clearly seen that 
comparative densities to cells cultured on plastic tissue culture flasks, cell densities on 
the collagen matrix where considerably lower. Cells appeared both singularly and in 
clusters of higher densities that are randomly dispersed over the entire matrix surface, 
which did not change after 4 days culture. HUVEC and hVSMC adhered to the matrix 
and displayed similar morphologies and densities to 1 day cultures, though possibly 
more advanced, Figure 3.11. These observations appeared consistent across all samples, 
where seeding density ranged from 1 x 105 cell/ml to 2 x 105 cell/ml. By 7 days very 
few cells (hVSMC and HUVEC) are adhered to the matrix. Remaining cells appear 
stressed (rounded and globular) compared with cells cultured over shorter periods (see 
Figures 3.13 & 3.14)
As this matrix had been granted a rating for human implantation, it was expected, based 
on the literature provided by the company that human cells would adhere grow and 
proliferate on the matrix (Oliver and Grant, 1985). The first set of experiments was 
designed to characterise (qualitatively) the ability of HUVEC and hVSMC to adhere to 
the matrix under static growth conditions (1, 4 and 7 day culture periods). No 
preparation of the matrix was performed prior to cell seeding, the matrix was simply 
removed from its packaging, cut to size and the cell suspension seeded directly on top. 
After seeding cells onto the collagen matrix and through the period of culture, cells that 
were initially confluent around the matrix material (adhered to the plastic culture dish) 
either lost adhesion or became necrotic. It was observed that over time the zone of cell 
disruption expanded from the matrix towards the periphery of the culture plate. With 
evidence from the SEM adhesion studies, where a reduction in cell density was noted 
and the additional evidence in the literature concerning cytotoxic residues the presence 
of a cytotoxic compound was speculated e.g. (van Luyn et al., 1992a) and (Bellincampi 
and Dunn, 1997). To assess (qualitatively) this observation, small sections of Permacol 
were seeded with cells, such that the surrounding tissue culture plastic was also covered 
with cells. The samples where monitored over time to indirectly observe if any 
potentially cytotoxic compound was leaching from the matrix resulting in cell necrosis.
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The observed results indicated a toxic compound was leaching from the matrix being 
diluted over time with normal tissue culture practices. This allowed the remaining cells 
(that survived the initial toxic shock) to recover and begin proliferating approximately 
15 days post seeding. The experimental design did not take into account the possibility 
that matrix movement (during culture maintenance) could be the cause of the observable 
effect, however, care was taken to minimise this effect and the expanding zone extended 
well past any potential area the matrix may have inadvertently moved, i.e. no more than 
3-4 mm.
To quantify changes in cell density over time and assess cell viability, an assay using 
‘Trypan Blue’ was utilised. Results have shown an initial decline in cell numbers post 
seeding, which is consistent with cell adhesion/densities on plastic controls, although 
the reduction in cell density is much less on plastic controls. This decline in cell density 
is amplified in the collagen matrix samples to the point where viable cell numbers fall 
below statistically significant levels. Non-viable cells on the matrix are lower (80
9  9cell/mm ) than plastic non-viable cells (150 cell/mm ), this is possibly due to the 
presence of cytotoxic compounds stressing cells on the matrix prior to the development 
of mature adhesion where the production of secondary matrix proteins aids the binding 
of cells, thus non-viable cells maybe washed away during standard cultivation. It is also 
possible that the trypsin treatment did not remove all of the cells from the collagen 
surface, resulting in lower counts, however this is not consistent with the LT-SEM 
micrographs.
Previous results had been based on empirical (LT-SEM) or data taken from cell counts, 
where cells had been removed from the matrix by trypsin digestion. Although the LT- 
SEM is an effective method to observe cells adhered on the surface of a matrix material, 
it is neither cost nor time efficient to use on a daily basis. The later method relied on the 
ability of trypsin to effectively remove all cells from the collagen matrix. Personal 
communication with Dr. Philip Chan (Sheffield General Hospital, UK.) expressed 
concern that not all hVSMC would be removed from the collagen substrata by 
enzymatic digestion, particularly if cells were cultured for extended durations. hVSMC 
secrete collagen producing a secondary matrix around cells, in addition cells may 
migrate into the matrix further complicating the removal process. In order to reduce the 
subjectivity and improve accuracy of data collection and analysis a more cost effective,
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quantitative method was required to determine specific cell densities. Standard 
methodologies, such as H & E, excessively stained the opaque matrix to the point where 
cells were not discemable from the background collagen. The first stage required the 
development of a cell staining protocol, where cells adhered to the matrix could be 
visualized with a phase-contrast microscope. In order to visualise cells on the surface of 
the collagen matrix a modification of the standard H & E histological technique was 
developed where only Haematoxylin was used, see Section 2.3.7.2. The combination 
of maximum illumination and a reduced H & E protocol with no eosin step, resulted in 
cells being observable on the surface of the collagen matrix with the phase-contrast 
microscope, from which counts where made. Although cells, particularly hVSMC, may 
migrate into the matrix and distort results, the protocol was reliable when the principal 
question was whether or not the material was capable of supporting cell adhesion, 
growth and proliferation.
3.4.3 E nhancem ent  of cell adhesion  and  pro liferatio n  on the  dermal
COLLAGEN MATRIX
The application of a preliminary washing protocol was used to establish the 
effectiveness of washing the matrix prior to cell seeding as a method to reduce or 
eliminate the toxicity effect. Previous studies had shown that by day 5 virtually all cells 
had detached from the matrix. The aim of this experiment was to firstly confirm the 
presence of cells and a brief analysis of the proliferative state using the BrdUrd assay. 
Results from this experiment confirmed cells (at 5 days) have both adhered and 
proliferated on the matrix. Although a qualitative assessment, these results are 
encouraging in that previous experiments with non-washed collagen have shown a near 
complete loss in cell numbers/density over the same time period. Here, where the 
matrix has been through a rudimentary washing protocol cells have adhered and more 
importantly, are proliferating Figure 3.16. Control samples (collagen matrix without 
cells) displayed minimal non-specific antibody binding. The experiment was not 
repeated to give a more quantitative result, as the aim was to determine cell 
proliferation, to this extent the results were positive. Washing the matrix in terms of 
cell proliferation was evaluated further in the next section.
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A specific requirement in tissue engineering to obtain tissue that approximates the 
native organ is to firstly attain an appropriate cell density within the matrix material and 
secondly to do so as rapidly as possible. With particular reference to a vascular 
prosthesis, the ability of cells to adhere, grow and proliferate is vital, particularly so if 
the patients condition is in a life threatening, where the delay whilst waiting for the graft 
to ‘grow’ in vitro may decrease patient mortality, and secondly to provide a sound 
economic basis for graft production. Initial experiments with the LT-SEM (visual 
conformation) and enzymatic removal of hVSMC off collagen (actual counts) indicate 
percentage cell adhesion is very low. To further reduce the cytotoxic potential of the 
unwashed matrix and hence improve biocompatibility, a more comprehensive washing 
protocol was applied followed by two washes in the appropriate media for the cell type. 
This experiment was conducted to determine the effect of washing and pre-soaking in 
media prior to cell seeding comparative to non-washed collagen (controls) determining 
the effects on cell adhesion, growth and proliferation on this type I collagen matrix.
Heparin sulphate and NaOH have been used to potentially increase the performance 
(both in terms of cell adhesion and in vivo biocompatibility), where hVSMC growth 
was compared on heparin and NaOH pre-treated matrix, Figure 3.20. These data suggest 
that the NaOH treated matrix offers a better environment for cell adhesion and growth, 
however, cells adhered heparin treated Permacol at higher densities over days 3 and 7. 
Between day 7 and 11 heparin cell density declines rapidly as a result of the heparin 
‘layer’ formed upon the matrix surface disengaging from the matrix resulting in loss of 
the cell layer, see Figure 3.21. NaOH treated samples continue to increase in density 
through day 21. This experiment used plastic culture plates as a control matrix material, 
which, since having determined the effectiveness of washing the collagen matrix and 
soaking it in media prior to its use should ideally have been used in conjunction with the 
plastic culture plates.
Previous use of heparin (Gemmell et al., 1998), (Laemmel et al., 1998) and (Bos et al.,
1999) has successfully been used to increase the grafts performance, in terms of cell 
adhesion and in vivo biocompatibility. The basic structure of the heparin and heparan 
sulphate GAG chains, which are covalently bound to a protein core, is the alteration of 
two monosaccharide units, polymers of alternating glucosamine and glucronic/iduronic 
acid units (Haralson and Hassell, 1995). Although not a native product of the arterial
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wall the main advantage seen with heparin, which in vivo is stored in mast cells found 
in connective tissues, as an anticoagulant that blocks the conversion of prothrombin to 
thrombin (enzymes in the blood clotting cascade that converts fibrinogen to fibrin).
The loss of heparin/cell adhesion between day 7 and 11 is almost certainly due to the 
inability of heparin to bind the collagen matrix securely. Although there is no direct 
evidence that the heparin substrate attached to the matrix in the first place, the formation 
and subsequent loss of an entire ceil layer would indicate this possibility. Secondly 
heparin is known in some cases to be a direct inhibitor of hVSMC proliferation 
(Laemmel et al., 1998), methods to improve heparin binding are cited in the literature 
(Chanda et al., 1999) and (Laemmel et al., 1998). A previous study by Greisler et al 
(1996) had shown that lower concentrations of heparin (5 and 50 U/ml'1) significantly 
increased SMC proliferation, whereas concentrations as high as 500 U/ml'1 significantly 
decreased proliferation (Greisler et al., 1996). Soaking the dermal collagen matrix in 
25000 U '1 heparin does not provide the necessary information as to the final 
concentration of the heparin additive once the matrix was rinsed in media and cells 
seeded. It does appear that hVSMC recovered in a similar fashion to NaOH treated 
samples up to day 7 prior to declining in cell density.
NaOH was used to modify the surface of the collagen matrix by attacking the acidic 
residues of the collagen molecule, resulting in a semi controlled degradation of the 
material. The explanation for improved cell adhesion and subsequent growth is not 
fully understood. Speculatively, as the matrix degrades with the NaOH treatment, noted 
by the material turning opaque, the ability of cells to enter and populate deeper into the 
matrix increases.
The effective distance with which communication is possible has been theoretically 
estimated at approximately 250 pm, (Francis and Palsson, 1997). For this to occur 
between SMC seeded onto the grafts ablumenal surface and EC seeded to the lumenal 
surface, cells will need to migrate up to 500 pm on material 0.75 mm thick to be within 
this theoretical distance. If the initial adhered population is higher than control tissues, 
even if in mono-culture, proliferation rates are likely to be higher due to the proximity 
of neighbouring cells, where proliferation is density dependent.
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This type I collagen matrix ‘Permacol’, as described previously, is delivered as flat 
sheets of porcine derived collagen (initially with thickness of either 0.75 and 1.5 mm in 
a variety of pre-cut lengths and widths). Several advantages are noted for its use as 
tissue engineering matrix for a vascular graft. A proven durability (Oliver and Grant, 
1985) that is ‘likely’ to be more than capable of withstanding local haemodynamic 
stresses. Previous surgical experiences have shown the material to have positive 
handling characteristics i.e. suturability and simplicity of handling, is relatively 
immunologically inert (as an implanted dermal graft), and is available at a relatively low 
cost.
Based on these positive attributes the question must therefore be asked “Is this collagen 
matrix suitable as a biomaterial for small diameter vascular grafts?” For this reason, the 
less attractive aspects of Permacol for use as a potential vascular biomaterial for tissue 
engineering purposes have been evaluated. As such, the experimental design has 
focused on compatibility issues of this matrix to culture in vitro of human primary cells. 
It is a specific requirement that primary cells can adhere, grow and proliferate to attain 
significant densities and secondly to do so as rapidly as possible. With particular 
reference to a vascular prosthesis, the ability of cells to adhere with high efficiency then 
proliferate to the required density in vitro is critical. The patient may well be in a life 
threatening condition throughout the graft preparation time, thus any reduction in terms 
of the grafts ‘lead time’ is advantageous. In addition extended in vitro culture periods 
would lead to potentially unfeasible economics of graft production. Although product 
optimisation is a critical step, it is a secondary issue in this project.
Flat sheets of dermal collagen are in principle relatively simple to process into tubular 
form, it is however considered second rate to a pre-formed tube specifically designed 
(artificially or naturally) elastic material that may be adaptable as a vascular prosthesis. 
Several considerations were taken into account when deciding to develop a specific or 
novel matrix rather than modify the existing dermal collagen matrix (Permacol). 1. 
Initial experimental studies with washed matrix have displayed time lags in excess of 30 
days before cell densities begin to approach initial seeding densities, see Figure 3.17. In 
order to create a ‘tube’ from Permacol it is necessary to roll the material, resulting in a 
large lumenal ridge (when wetted approximately 1 mm) running longitudinally along 
the matrix. Although this effect has not been quantified, it is considered an inferior
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attribute compared to existing or alternative materials. 3. Although this material has a 
proven durability when implanted subcutaneously, no data is available with regard to 
haemodynamic stresses, only assessments based on the materials mechanical properties. 
4. The matrix has been shown to elicit a “mild immune response” (Oliver and Grant, 
1985) which maybe acceptable when used as a subcutaneous graft, however the 
increased sensitivity of small diameter grafts to thrombosis from even “mild” reactions 
is likely to render the prosthesis invalid. 5. In respect to an active or functional arterial 
graft, EC must form an endothelium and hVSMC, ideally, need to approach in vivo 
densities to confer vascular tone. The heavily cross-linked nature of this material 
appears to inhibit or indeed prevent cellular migration into the matrix by one of the 
primary methods of cell migration, proteolytic digestion, for example matrix 
metalloproteinase , matrix remodelling enzymes. The dermal collagen matrix, as stated 
previously, is specifically cross-linked with HMDI, a strong mechanism to stabilise 
collagen molecules. In addition to this specific cross-linking step the material is 
exposed to both acetone (lipid extraction) and gamma radiation (matrix sterilisation) 
both of which add to the materials ability to withstand in vitro and in vivo degradation. 
Although the porous structure characteristic of type I collagen has been essentially 
maintained, it is evident from the low temperature scanning electron micrographs that 
sections of the matrix surface are as compressed collagen fibres which form a non- 
porous structure, approximately 50-65% Section, 3.3.1. The two distinct surface 
morphologies of this dermal collagen are likely to be an artefact, resulting from the 
processing methods used during manufacture. The open, more fibrous, areas of the 
collagen matrix are closer in nature to the unprocessed fibrous networks of type I 
collagen. From the Figure 3.03, it is possible to hypothesise that the compressed 
sections are areas that have contracted either during the HMDI or a-radiation processes 
resulting in the exposure of the underlying fibrous collagen and compression or 
compaction of the surface collagen. It is however speculation and beyond the remit of 
this project to determine structural changes that occur from native to fully process 
collagen. If indeed the compressed sections have a higher ratio of cross-links compared 
to the underlying tissue, cellular penetration by proteolytic activity will indeed be 
impaired in these regions. Cellular migration into the matrix is an important factor in 
communication within and between multiple cell populations (SMC and EC) (Ziegler 
andNerem, 1994).
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The effect o f these structural deviations with respect to graft performance has not been 
fully evaluated, other than a qualitative visual analysis that had shown that cells, 
particularly HUVEC, appear to have a propensity for the compressed or non-fibrous 
regions. Importantly with regard to cell adhesion, the lumenal surface of blood vessels 
is lined by type IV collagen, a non-fibril forming two-dimensional basement membrane. 
Implications of attempting to seed EC onto type I collagen (fibrous), in contrast to 
native type IV basement membrane may account for (in concert with cytotoxic 
compounds) some of the difficulties observed in cell adhesion and proliferation with 
this cell type. The significance of the basement membrane and internal elastic lamina 
with reference to cell adhesion is discussed further in Chapter 5.
In this chapter a porcine derived dermal collagen has been assessed to determine its 
potential use as a small diameter graft. Conclusions drawn from this chapter show that 
this biomaterial is not a suitable biomaterial for applications in vascular tissue 
engineering where cellular ingrowth is a fundamental requirement. However after 
extensive washing and possible modification to the matrix structure (such as NaOH 
treatments) the material may prove adequate. This section of work has shown that 
although this material maybe used to generate a tissue engineered artery it is not ideal. 
In seeking an alternative matrix material for small diameter vascular graft several 
options were considered, including the alternative of full synthetic materials. Based on 
the current literature supporting natural materials for their mechanical characteristics 
(Schmidt and Baier, 2000) and our background in biological materials, a native 
muscular artery was chosen, specifically, the porcine carotid artery. This particular 
artery was chosen to serve as a model, representing approximate dimensions for arterial 
replacement, although it is envisaged that other arteries (possibly veins) would serve 
equally as well, in addition availability and ease of extraction promoted this choice.
The next chapter in this thesis describes the development an acellular matrix utilizing 
porcine carotid arteries as a starting material and the progressive removal of non- 
structural components of the ECM. The matrix is stabilised to host degradation by a 
non-cytotoxic cross-linking step which also known to reduce immunological response to 
implanted foreign materials.
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CHAPTER FOUR: DEVELOPMENT OF A SCAFFOLD 
FOR T IS S U E  ENGINEERING BLOOD V E S S E L S  USING 
PO R CIN E CAROTID ARTERY
4 .1  In t r o d u c t io n
The objective of the tissue engineering approach is to utilise a prosthetic material/matrix 
onto which the patients own cells are seeded or when technology allows, 
immunologically inert cells such as stem or genetically modified cells. Once seeded the 
combination of matrix and cells are cultured in a purpose built bioreactor that emulates 
physiological conditions, both mechanically and chemically, to produce an 
immunologically inert bioprosthetic graft with patency rates equal to or better than 
current autologous arterial transplantation methodologies.
In addition to the general characteristics detailed in Chapter 1.1, the ideal vascular 
prosthesis requires further properties that may give a tissue engineered graft increased 
patency over traditional synthetic materials.
Immunologically inert 
Chemically inert (non-toxic)
Resistance to infection and calcification 
Durability i.e. ability to withstand haemodynamic stresses  
Mechanical characteristics emulating native arteries 
Able to be remodelled by the patient
ECM components that regulate cell phenotype, growth and proliferation 
High efficiency of cell seeding
Positive handling characteristics i.e. suturability and simplicity of handling 
Post implantation healing as self tissue
Patency rates equal to or better than autologous artery (>90% at 5 years)
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There are currently no (bio) prostheses that encompass this ‘ideal’ list of graft 
characteristics. The choice of primary material in the development of a prosthesis is of 
particular importance. The matrix material must provide structural, mechanical and 
appropriate chemical stimuli that may ultimately produce a compliant prosthetic graft. 
Blood vessels of the vascular system, like other organs of the body have evolved to 
provide the body with a specific service/function, where, amongst other things, blood is 
transported efficiently to all cells of the body. The efficiency of natural vessels function 
is due in large to the physical characteristics of the extracellular matrix (ECM) where 
not only chemical stimuli is received by cells but by the manifestation of the physical 
characteristics when haemodynamic stresses are applied. Synthetic, biosynthetic or 
biological prosthetic graft research has aimed to replicate the natural vessel.
This section of work aimed to develop a material that can be shown to embody the 
requirements (above) by modifying, for generic use, the material whose biomechanics 
are second to none - biological vessels.
4.1.1 B io log ically  derived  ECM for vascular  grafting
Clinical usage of non-living grafts has predominantly used either human umbilical vein 
or cryo-preserved vessels such as the saphenous vein. A variety of pre-treatments (such 
as fixation with glutaraldehyde), have been applied to these vessels to improve both 
their biocompatibility and mechanical strength under arterial pressures.
Results from prepared biological tissue, in particular human umbilical vein (HUV) 
stabilised with glutaraldehyde cross-linking for arterial (or venous) grafting have had 
mixed results, in some cases a lack of stability has shown the graft to be aneurysmal, 
with an incidence of 33% beginning at three years and increasing with time (Karkow et 
al., 1986). Early graft degeneration and aneurysm formation have also been reported, 
(Hasson et al., 1986; Nevelsteen et al., 1988). Other data suggests this particular graft 
does in fact out perform polytetrafluoroethylene (PTFE), with patency rates 2.1 times 
higher (Eickhoff et al., 1987). Dardik et al (1982), who first described the formation of 
aneurysms in HUV grafts has since remarked that due to the poor rates of PTFE patency 
the HUV is an “acceptable alternative to the absent or deficient autologous vein”.
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Further describing the half-life patency of the HUV graft (popliteal, tibial and peroneal 
bypass) being 6.5, 2.3 and 1.7 years respectively, with overall infection rates of 4.3% 
(Dardik et al., 1988). In addition reduced infection rates have been shown by Koskas et 
al (1996), where human cadaver arteries (n=6), stored for >1 month in a preservation 
media at 4°C prior to implantation in a dog model were not infected after a 
Staphylococcus aureus challenge, whereas 4 out of the 6 ePTFE grafts were infected 
(Koskas et al., 1996). Although the mechanism for reduced infection is unclear, the 
biological model has, in this example, is clearly superior to the synthetic model. Further 
evidence by Johnson et al (2000) has again shown the potential suitability of biological 
grafts over synthetic alternatives, particularly PTFE, where five year cumulative 
assisted primary patency rates of 80% for saphenous vein (SV), 56% HUV, 33% PTFE 
and in cases of critical ischemia 68% SV, 52% HUV, 37% PTFE (Johnson and Lee, 
2000). It must be noted the site of graft placement, in terms of flow and vessel diameter 
largely determines the grafts ‘expected’ patency irrespective of the grafting material. 
Larger diameter grafts (e.g. femoral artery) generally achieve higher rates of patency 
compared to smaller diameter vessels (e.g. popliteal artery), although this is also 
dependent on the stage of vascular disease, age and sex of the patient.
The general mechanism through which prosthetic grafts fail at any point can be summed 
up as initial thrombosis, progressive intimal hyperplasia and degradation leading to graft 
dilation and aneurysm. Bioprosthetics achieve high initial patency but tend to fail due 
to progressive graft dilation (Courtman et al., 2000). Traditionally the basis for treating 
biological tissues has been to reduce or prevent chronic immune rejection by the patient 
and to stabilise the tissue to host proteolytic degradation. Cross-linking or tanning of 
prostheses, particularly prosthetic heart valves with the use of glutaraldehyde has 
concentrated on prevention of chronic immune rejection, mechanical stability and 
infection resistance. Other agents such as formaldehyde or low concentrations of 
glutaraldehyde have resulted in either mechanical graft failure or bacterial/fungal 
contamination (Schoen and Levy, 1999). Host cells are prevented from migrating into 
the matrix, by secretion of proteolytic remodelling enzymes by the barrier of ‘stabilised’ 
ECM proteins. Previous attempts to prepare biological tissue for arterial (or venous) 
grafting proved aneurysmal due to lack of stability, or being thrombogenic as a result of 
a ‘naked’ basement membrane (inherently thrombogenic) being exposed to host blood 
and its constituents (Hasson et al., 1986; Karkow et al., 1986; Nevelsteen et al., 1988;
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Niklason et al., 1999). Recently the role of cross-linking tissue has been questioned, 
Courtman et al (2000), using a unique acellular matrix glutaraldehyde, polyglycidyl- 
ether and carbodiimide where used to cross-link the matrix material. It was found that 
although the matrix was stabilised to cellular infiltration, by either an exclusion barrier 
or cytotoxic residues in the tissue; compared to the untreated acellular matrix there was 
an increase in humoral immune response. The importance of extracting cells, cell 
debris and other non-structural proteins from the starting material may indeed play a 
more important role in an immune response than tissue stabilisation through cross- 
linking. Where immunological and structural resistance, provided by cross-linking, is in 
fact the inhibition of immune cell penetration into the matrix and prevention of matrix 
degradation (Courtman et al., 2000).
The importance of local environmental conditions on cell growth, proliferation and 
phenotypic expression have been well documented, for example, (Birukov et al., 1995; 
Kim et al., 1999; Nerem et al., 1993; Olivier et al., 1999; Osol, 1995; Zilla et al., 1994). 
Mechanical properties are widely acknowledged as crucial to graft performance, 
allowing replication of natural arterial elasticity and compliance. Without doubt a 
natural biological blood vessel with matched compliance, offers the closest mechanical 
characteristics to an autologous vessel. Using experiences gathered with biological 
materials for tissue engineering purposes in Chapter 3 and published data in (Smith et 
al., 2000), an acellular porcine tubular matrix has been developed for use as small 
diameter vascular prostheses. Arterial tissue was chosen, over venous tissue due to the 
mechanical properties inherent with the artery, where the artery has a considerably 
strengthened medial layer (compared to veins), to accommodated arterial pressures. In 
addition it has been speculated that the mechanical properties associated with the artery 
wall to give explanation to improved patency associated with autologous arterial 
revascularisation compared to venous tissue.
The prosthesis is expected to have reduced immunogenicity and resistance to calcium 
deposition which, following implantation is aimed to extend the current rates of patency 
of biosynthetic grafts. Our investigations have focused on the development of this 
acellular tubular matrix derived from carotid arteries extracted from 6-8 month old 
Great White pigs. The matrix is initially stabilised though a solvent lipid extraction 
process, followed by an enzymatic digestion to reduce any potential immunogenic
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epitopes. Finally the matrix is preconditioned and cross-linked with the non-toxic 
photo-active dye, methylene green (Mechanic, 1994), further stabilising the tissue and 
minimising host rejection by concealing immunogenic epitopes (Moore et al., 1994).
4.1.2 Preparation  of biological tissue
As discussed above, processing native tissue to remove cells, cell debris in concert with 
crosslinking the tissue; aims to reduce the implants immune reactivity and stabilise the 
tissue to rapid host degradation. Methods including: chemical, enzymatic and 
mechanical treatments have been explored by others with the aim to produce an 
acellular matrix. Unlike a majority of other methods that rely exclusively on, for 
example SDS treatments to remove the matrix lipid content, the process developed in 
this thesis uses a combination of methods to remove both cellular materials and non­
matrix proteins/carbohydrates.
The literature describes a variety of methodologies used to intentionally remove lipids 
and host cells/cell components from tissue, either singularly or in concert with other 
treatments. These include: osmotic shock, solvent extraction, ionic and non-ionic 
detergents, acid treatments and enzymatic digestion with DNase, RNase, lipase and 
proteases, see Table 4.01.
These methodologies were assessed based on effectiveness of component removal, 
structural change of the matrix pre- and post-extraction and the retention of the vessel’s 
mechanical attributes, then used as a guide for the development of the biomaterial 
outlined in this chapter. The methods described in table 4.01 are a representative 
selection of treatments including: enzyme, ionic and non-ionic detergents, acids, 
alkaline and solvent-based systems. Although they have been segregated into these 
categories many are a combination of more than one type of treatment.
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Table 4.01 : Preparation of biological tissue: a methodology overview
METHOD PROCEDURE EXAMPLES
Osmotic shock 0.5 M sucrose (stepl), 4M NaCl (step 2) (Mechanic, 1994)1 M NaCl (Probst et al., 1997)
Acid
0.1% peracetic acid. Complete cell removal, no 
data given on matrix structure, though both 
dehydrated and hydrated forms support HMEC 
adhesion
(Badylak et al., 1999)
4% desoxycholate (bile acid) (Probst et al., 1997)
Alkaline DMSO (6%) plus Na+, K+ and Ca++ solutions at pH > 13 (Goissis et al., 2000)
Detergents 1% Triton X-100
(Courtman, et al 1994) 
(Tamura et al., 1999)
1% SDS plus 0.2% Glutaraldehyde (Bodnar et al., 1986)
Enzymes
Acetone (multiple washes) followed by trypsin 
(multiple exposures) (Oliver and Grant, 1985)
0.1% trypsin with 0.02% EDTA in PBS (Teebken et al., 2000)
1% Triton X100 + 0.02% EDTA. RNase + 
DNase (Bader et al., 1998)
Solvents
Ethanol
(Goissis et al., 2000) 
(Malone et al., 1984) 
(Vyavahare et al., 1997)
Butanol (Reid and Rojkind, 1987)See Section 4.3.2
Acetone (Oliver and Grant, 1985)
Xylene See Section 4.3.2
O s m o t ic  s h o c k
Several authors have reported the use of osmotic shock, with either hypo or hypertonic 
solutions to rupture cells thus releasing cellular material into free solution for removal. 
The method described by Mechanic (1994) has made no direct attempt to remove cells 
prior to dye mediated photo-oxidation other than the use o f high osmolarity solutions 
(0.5M C12H22O11 and 4M NaCl) as part o f the preconditioning and cross-linking steps. 
The effectiveness o f this method to completely remove cell lipid is perhaps limited, 
though there is no evidence o f DNA at the end o f the treatment, see Section 4.3.6 
(Mechanic, 1994).
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A c id  a n d  A l k a l in e
Badylak et al (1999) have published extensively on a matrix material derived from the 
porcine jejunum or the small intestinal submucosa (SIS) as it is commonly referred to. 
In this method the superficial layers of the tunicia mucosa are removed leaving a 
material approximately 80-100 pm thick. The SIS is said to be essentially cell prior to 
any treatments to remove cells/cell debris. A treatment of 0.1% peracetic acid followed 
by rinsing in PBS removes residual cells and cell components. The study showed that 
cells (human dermal microvascular endothelial cells) adhered to the hydrated matrix 
over a twenty-minute incubation period in greater densities than the dehydrated form, 
tissue culture plastic, collagen types I and IV, fibronectin and laminin (Badylak et al., 
1999). As our previous studies have shown, initial adhesion is a very different issue 
than long-term growth and proliferation where residual cytotoxic compounds may leach 
from the matrix material (Smith et al., 2000). However the treatment described by 
Badylak et al (1998), in a comparatively thin material is unlikely to retain processing 
compounds if washed appropriately and has been shown to provide a suitable support 
for extended cell culture (Badylak et al., 1998). This methodology to remove cells and 
cell debris, although suitable for thin near acellular materials, was deemed inappropriate 
due to differences in the thickness of the two tissue types. Peracetic acid (0.1% (v/v)) 
has not only been shown as an effective method to disrupt cellular material but an 
effective treatment to sterilise matrix materials prior to use, Badylak, S. (1999) 
Department of Biomedical Engineering, Purdue University, personal communication.
Probst et al (1997), developed a matrix material derived from a heterograft rat bladder, 
the ‘bladder acellular matrix graft’ (BAMG). The treatment or preparation protocol 
combines osmotic shock with enzyme and acid process steps. The matrix is washed 
repeatedly with 0.1% NaN3 (sodium azide), followed by a 1M solution of NaCl, 
presumably to disrupt any remaining whole cells by osmotic shock and precipitate 
DNA. The final treatment was with a solution of 4% desoxycholate, a bile acid, plus 
0.1% NaN3 . The results from an implantation study of 34 rats (a mortality of >32%), 
the matrix by 10 days had developed a new mucosal lining and by 4 weeks all
components of the bladder wall were complete. By 12 weeks the BAMG was
histologically similar to the host bladder tissue (Probst et al., 1997). More recent
studies with the BAMG as an acellular matrix in a dog model have also shown
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promising results with the implanted BAMG at 7 months showing near complete 
regeneration, the group is currently applying for approval for a human study (Probst et 
al., 2000).
Goissis et al (2000), employed a method with strong alkalines, where tissue is firstly 
‘preserved’ in a 70% EtOH solution, not part of the said ‘devitalisation process’ as a 
step prior to ‘cell removal’. Tissue preservation in a 70% ethanol solution will, in 
addition to preserving the tissue, solubilise a high percentage of lipids. The 
‘devitalisation process’ consists of a 6% DMSO solution containing alkaline salts Na+, 
K+ and the alkaline earth metal Ca** in the form of chlorides or sulphates, at a pH 
greater than 13. This was followed by a neutralisation step of 3% boric acid and pH 
correction in PBS. Concluding that both collagen and elastin fibres were ‘highly 
preserved’ although the removal of cells and cell debris is dependent on tissue type and 
diameter (Goissis et al., 2000).
D e t e r g e n t s
The predominant method, or treatment regime described in the literature to decellularise 
tissue has been incubation with detergents such as /-octyl-phenoxypolyethoxyethanol 
(Triton-XlOO) or sodium dodecyl sulphate (SDS) to solubilise lipids. Cell components 
such as DNA, RNA, non-structural protein and carbohydrates are released into the 
extracellular matrix to be subsequently digested enzymatically or removed by a series of 
washes. For example, Bader et al (1998), used a combination of Triton X-100 with 
DNase and RNase in PBS to decellularise porcine aortic valves, reporting that the 
structure was ‘largely’ cell free across the valve leaflet, with a general loosening or 
widening of the interfibrillar spaces within the collagen and elastic fibres. The matrix 
was washed several times in PBS prior to seeding EC onto the surface of the acellular 
structure. EC were found to form a monolayer over the surface of the construct, which 
were maintained for a three-day culture period. The process described, although not 
removing all cell remnants appears largely successful in as much as confirming the 
viability of seeded EC and maintaining the gross structure of the matrix (Bader et al., 
1998). Also reporting success, Tamura et al (1999), have shown that a 48 hour 
treatment of porcine carotid arteries with 1% Triton X-100 had completely removed cell
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nuclei. By 18 weeks confluent EC were evident in a dog model (Tamura et al., 1999). 
Courtman et al (2000), have developed a four-step process that utilizes both ionic and 
non-ionic detergents to decellularise canine arteries. First step is with protease 
inhibitors to prevent matrix degradation, followed by a 1% Triton X-100 solution tris 
buffer to pH 8 (including protease inhibitors), followed by DNase and RNase 
treatments. A fourth step is incorporated with 1% SDS tris buffered at pH 9 (Courtman 
et al., 2000). Interestingly work by Wilson and Courtman et al (1994), had previously 
concluded that the final treatment with SDS had proved detrimental porcine aortic 
leaflets (Courtman et al., 1994), citing Bodnar et al (1986), where 1% SDS treatments 
resulted in “profound degenerative changes” (Bodnar et al., 1986).
Cartmell and Dunn (2000) compared the efficiency of three chemical treatments: A non­
ionic detergent Triton X-100, an organic solvent tri (n-butyl)phosphate (TnBP) and a 
ionic detergent SDS on rat tail tendon cellularity, structure, nativity and the subsequent 
alterations to the tissues mechanical properties. Results from the Triton X-100 
displayed a disrupted tendon structure with the treatment failing to remove cells at 
lower concentrations (Cartmell and Dunn, 2000). This again contrasts Courtman et al 
(1994) who found the bovine pericardium maintained its mechanical properties after a 
1% Triton X-100 treatment (Courtman et al., 1994). Treatments with 1% SDS for 24 
hours did not cause significant denaturation of the rat tail collagen and found of the 
three treatments (SDS, Triton X-100 and TnBP) to have better retention of the tissues 
mechanical and structural properties. Finally tissue exposure to TnBP over any period 
of time (independent of concentration) resulted in a significant reduction in cell density. 
1% TnBP for 48 hours removed cells with the least damage to the matrix (structurally or 
its mechanical properties).
E nzym e tr e a t m e n t s
In most cases enzymes have been used to degrade DNA and RNA with DNase and 
RNase with the intention of reducing the risk that these macromolecules maybe 
recognised as foreign. Teebken et al (2000), aimed to generate a biocompatible and 
mechanically stable porcine aortic (thoracic) graft with exclusive use of enzymes. 
Their method involved a trypsin digest (0.1% with 0.02% EDTA) for 24 hours, 
followed by incubation with DNase (0.2mg/ml), RNase (20 pg/ml) all at 37°C 5%
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CO2 (Teebken et al., 2000). These results displayed positive removal of DNA, 
examined by H & E and immunohistochemically with CD 31, and a-actin for cellular 
debris. The use trypsin, a serine protease, is directed to the proteolysis of non-matrix 
proteins in particular cell remnants after a lipid extraction with multiple washes in 
acetone. The matrix described in Chapter 3 of this thesis has been exposed to a multi- 
step process, where porcine dermal collagen is firstly exposed to multiple acetone 
washes followed by an extensive enzymatic digestion of non-matrix proteins with 
trypsin. The remaining matrix is said to retain less than 5% of the tissues original non- 
fibrous tissue proteins, glycoproteins and lipid. The material is then cross-linked with 
HMDI (Oliver and Grant, 1985). The result of acetone treatments, specific cross- 
linking with hexamethylene diisocyanate and its subsequent sterilisation with gamma 
radiation renders a material that becomes a permanent implant. The matrix becomes 
impenetrable to cells, other than physical migration into fibrous pores, as cells are 
unable to digest heavily cross-linked matrix proteins. The choice of enzyme in this 
application is important to selectively reduce structural protein degradation. Trypsin is 
only active against the peptide bonds in protein molecules that have carboxyl groups 
donated by arginine and lysine, therefore collagen whose structure maintains the basic 
formula (Glycine-X-Y)„ where X maybe any residue other than glycine and Y is 
typically hydroxyproline (Williams, 1998), is particularly resistant to trypsin digestion 
(Friess, 1998).
S o l v e n t s
Industrial processes have extensively used solvents to extract lipids from tissue, for 
example the separation of lipid from fish tissue. Many of these processes are concerned 
with the complete extraction of a variety of lipids not the resulting properties of the 
tissue itself. Solvents used in these processes have traditionally been methanol and 
chloroform, which are both considered toxic (Undeland et al., 1998). Similarly, Reid 
and Rojkind (1987) patented a method describing the isolation of a connective tissue 
biomatrix. The patent describes a methodology to isolate connective tissue fibres, 
including basement membrane components and components of the “ground substance”, 
providing improved adhesion and growth properties compared with the then current 
culture substrates. The two steps in this process relevant to this project are the DNase, 
RNase digestion and lipid extraction. The solvents used for lipid extraction is 100
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ml of distilled H2O and an equal volume of butanol/ether (40:60) is added and stirred 
approximately every 5 minutes for 0.5-1 hour at room temperature (Reid and Rojkind, 
1987). The process aims to remove lipid from dissolved collagen solutions (retained 
lipids and nucleic acids are not quantified) with no interest in the mechanical properties 
of the original tissue.
As discussed above in the detergents subsection, EtOH has been used during 
decellularisation procedures as a wash to remove remnants of detergents (Malone et al., 
1984) or preserve tissue (Malone et al., 1984) and (Goissis et al., 2000). Several 
researchers have investigated EtOH as an integral part of tissue processing as a method 
to reduce calcification of bioprosthetic heart valves. The hypothesis is that EtOH pre­
treatment, results in structural changes of tissue proteins and extraction of lipids that 
inhibits the deposition of calcium (Vyavahare et al., 1997). Reduced calcification as a 
consequence of ethanol treatment cannot be solely put down as the removal of lipid, 
where more extensive lipid extraction methods such as chloroform and methanol do not 
offer the same protection against calcification (Demer, 1997). Vyavahare et al (1997) 
have shown that a concentration of 40% EtOH did not remove cholesterol and 
phospholipids, whereas treatments 60% and greater were very effective. Treatments of 
60% EtOH extracted up to 98% cholesterol and 71% phospholipid whereas 80% EtOH 
extracted 99% cholesterol and 94% phospholipid. Using a sheep mitral valve 
replacement model with treated (EtOH concentrations 60 -  80%) porcine bioprosthetic 
heart valves calcification was almost completely inhibited (Vyavahare et al., 1997). 
Vyavahare et al (1998), have also shown that ethanol pre-treatment stabilise the material 
to collagenase digestion and reduces the total water content within the tissue, assessed 
with NMR (Vyavahare et al., 1998).
In a later study from the same group, Lee et al (1998) have used an 80% treatment of 
EtOH with aortic wall implants in rat subdermal implants and porcine valves implanted 
into the mitral position of a sheep model. Results with this treatment were less 
conclusive than previous studies, where calcification of the bioprostheses was reduced 
from 129.90 ± 7.24 pg/mg to 71.80 ± 8.45 pg/mg in the rat model. In the sheep model 
the reduction in calcification was less significant falling from 56.35 ± 6.14 pg/mg in 
control tissue to 28.02 ± 4.42 pg/mg in the treatment sample. In contrast to Vyavahare 
et al (1998) the water content was not found to differ significantly as a result of the
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ethanol treatments. The conclusion of this work stated that ethanol treatment of 
bioprosthetic heart valves had significantly reduced calcification from control samples 
but would require the addition of a further agent to completely inhibit tissue 
calcification (Lee et al., 1998). Shen et al (2001), studied pretreatments of bovine 
pericardium with combinations ethanol, ether and Tween 80, their results found the 
combination with ethanol and surfactant or ethanol, ether and surfactant were more 
effective at preventing calcification than treatments of surfactant alone (Shen et al., 
2001).
4.1.3 C r o ss-linking  biological tissues
The use of collagen based biomaterials for tissue regeneration necessitates a degree of 
tissue processing to stabilise the tissue (against both pre- and post-implantation 
degradation) and prevent a chronic immune reaction against matrix epitopes (in this 
case porcine) associated with the biomaterial, Schmidt and Baier (2000). Cross-linking 
biological tissues has been shown to prolong the materials structure and mechanical 
characteristics in vivo while reducing the potential immune load on the graft recipient, 
Khor (1997). Chapter 3 has introduced the topic of cross-linking where the porcine 
derived dermal collagen matrix which had been previously been cross-linked with 
hexamethylene diisocynate (HMDI) was used as a potential biomaterial for this project, 
as discussed in Chapter 3, Sections 3.1 and 3.4.
Cross-linking methodologies can be grouped into two major sections, chemical and 
physical methods. Of the chemical methods, glutaraldehyde has been the most 
frequently used preservative in bioprosthetic tissue. The stabilising effect is said to be a 
complex, degradation-resistant, Schiff base and pyridinium salt-derived cross-links 
between collagen molecules. Compared to formaldehyde, which forms less stable 
methylene-based protein cross-links, Schoen and Levy (1999). Issues concerning these 
and other chemical methods to cross-link tissue have been with cytotoxic residues 
remaining within the matrix material post processing, Khor (1997). Bioprosthetic 
implanted as heart valves for example are continually perfused in the recipient’s body. 
Whereby potential cytotoxic compounds are continually removed from the implant 
giving the impression of ‘minimal’ toxicity. This was clearly noted with the HMDI
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cross-linked dermal collagen matrix used in Chapter 3. In vivo analysis had shown the 
matrix to elicit a minimal immune response, Oliver and Grant, (1985), where the more 
sensitive in vitro analysis had shown seeded HUVEC and hVSMC to loose adhesion 
between 4 and 7 days of static culture, see Figures 3.11-14. Extensive washing of the 
matrix was shown to improve this situation see Chapter 3.4.3. A number of other 
chemical treatments have been analysed, that have aimed to reduce toxicity, improve 
retention of the tissues mechanical characteristics, with better stability and reduced 
calcification; including carbodiimides, azide and polyether oxide, (Khor 1997).
The primary benefit of physical methods, such as heating, freeze dying and irradiating is 
that no potentially cytotoxic compounds are introduced into the tissue. The method 
favoured in this thesis is that of dye-mediated photo-oxidation, where the tissue is 
incubated in a photoactive dye and irradiated to introduce intermolecular cross-links 
that stabilised the tissue against degradation. Modification of amino acid residues 
histidine, tryptophan, methionine and tyrosine can be oxidised in the presence of visible 
light and a photosensitiser such as methylene blue or green; and that the reaction does 
not cause the cleavage of the peptide bond, (Tomita et al., 1969). Weil et al (1965) had 
shown a reduced yield of histidine after 24 hours hydrolysis of insulin after irradiation 
in the presence of methylene blue. The mechanism of action is said to be complex and 
may vary from system to system, Oster et al (1959) proposed that the dye (D) is raised 
to a higher energy level by exposure to visible light where it forms a DO2 complex that 
can then react with the substrate, p-toluenediamine (in this case). Equations 1.1-3 have 
been abbreviated, where D represents the dye, D* the dye in an excited electronic state 
(after visible light activation) and S  the substrate.
D <=> D* (1.1)
D* + 0 2 o D 02 (1.2)
D 0 2 + S <=> D + S 0 2 (1.3)
Gerdes et al., (1997) state that the dominant initial step is the formation of singlet 
oxygen, followed by oxidation of the substrate. In another model N-benzoyl-L-histidine 
has been used as a model system to analyse the chemical nature of the His-His cross­
link^) that form during photo cross-linking of proteins. His-His covalent cross-link(s)
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were formed when samples where incubated in singlet oxygen producing 
photosensitiser and illuminated with visible light. The His-His cross-links form 
between the 62-carbon of one residue and the e2-nitrogen of the other residue mediated 
by the singlet oxygen pathway, Shen et al., (2000).
In terms of the photo oxidation of collagen fibrils, Ramshaw et al (1994) have shown 
that exposure of rat-tail collagen fibrils to methylene blue and visible light (or UV light) 
resulted in reduced yields of amino acids, particularly histidine after irradiation. 
Concluding that the reduced yields were the result of introduced intermolecular cross­
links in the tendon collagen. Further discussion of cross-linking by means of this 
method, applied to whole tissue is discussed in Section 4.3.3.
Although much of the later work has been conducted with methylene blue, methylene 
green has a similar mode of action, the difference being the addition of a NO2 group on 
methylene green which very slightly affects the wave length at which light is absorbed, 
the mechanism is energy transfer will however be the same, Price (2001), Department 
of Chemistry, University of Bath, UK, personal communication.
It is generally accepted that the more exogenous bonds introduce to the tissue the 
increased durability and resistance to host degradative mechanisms such as matrix 
remodelling enzymes. Iterated throughout this thesis is the importance of the extent of 
cross-linking within the tissue. If a biomaterial is designed to behave similar to a 
permanent implant a high degree of cross-linking is required. However if desired, the 
tissue has the ability to remodel then exposure to the chemical or physical methods are 
reduced. The concept of tissue engineering is to seed cells onto the matrix to guide cell 
growth and proliferation to generate a neo-organ; if the matrix is excessively cross- 
linked cell ingrowth is likely to be inhibited. A balance is therefore required between 
stability, whereby the matrix remains stable long enough for the patients cells to 
infiltrate and remodel the matrix before matrix degradation and failure under arterial 
pressure conditions.
In this thesis a general methodology modified from Mechanic (1994) using methylene 
green as a photoactive dye to cross-link processed porcine arterial tissue has been 
described.
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4.1.4 P r o c e s s  o v e r v ie w
Clearly a multitude o f different paths available to remove cells and cellular debris from 
tissue, the aim o f this chapter is to describe a methodology that removes cells and their 
components, fatty tissue and physically removes connective tissue, and many non- 
structural proteins within the ECM without destroying the gross structural integrity o f  
the native vessel. Due to reported problems associated with SDS and Triton X-100 
detergent on destabilising the matrix and benefits foreseeable with a solvent extraction 
process, organic solvents was the method o f choice to extract tissue lipid. With the goal 
to reduce, ideally eliminate the potential for in vivo calcium deposition and 
immunogenic components with solvent extraction, non-structural protein digestion and 
cross-linking will ideally produce a 'clean', immunologically inert biomaterial, with a 
structurally intact matrix, as tested: histologically, pressure testing and load extension 
analysis, in a condition ready to seed the desired cell type/s for tissue engineering 
applications. Briefly, the process developed in this thesis is a stepwise procedure that 
incorporates a variety o f mechanisms to extract cellular and non-cellular components 
from the matrix material, Figure 4.01.
V e s s e l  h a r v e s t
I
M e c h a n i c a l  p r o c e s s i n g
1
L i p i d  e x t r a c t i o n
i
P r o t e i n  d i g e s t i o n
1
C r o s s - l i n k i n g
i
W a s h i n g  a n d  S t e r i l i s a t i o n  
Figure 4.01: Main processing steps of the decellularisation process.
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4 .2  Ma teria ls  and Methods
4.2.1 Materials
Unless stated otherwise all reagents and material details including vendor and are shown 
in Chapter 2.
4.2.2 Exper im en ta l  methods
All solution volumes to tissue weights are in a ratio of 15 ml solution to lg  tissue unless 
stated otherwise. This ratio was established due to the size and form of the arterial 
sections. It was found that this ratio of solution to tissue weight ‘arbitrarily’ covered or 
immersed the tissue section/s being treated within 15 or 50 Falcon tubes.
4.2 .2 .1  M ec h a n ic a l  pr o c e s s in g
Carotid arteries were harvested from 6-8 month old Great White pigs slaughtered at a 
local abattoir. Warm ischemic time was no more than two hours from the time of tissue 
extraction to storage at 5°C and subsequent processing; see Section 2.1.2 for harvest 
details. Initial tissue processing tissue involved removal of loose connective tissue 
surrounding the vessel with forceps and scalpel. Arteries selected for experimental use 
measured 80-110 mm in length with lumen diameters from 2.5-6.5 mm. Vessels were 
then stored at -20°C until required.
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4.2 .2 .2  P r e l im in a r y  d e c e l l u l a r is a t io n
Ammonium hydroxide
Porcine carotid artery sections (0.5 ± O.lg) were exposed a 10% solution of ammonium 
hydroxide (v/v) in 15 ml Falcon tubes for 12 hours in a temperature controlled water 
bath at 20°C. Samples where removed from the NH4OH solution, rinsed twice (10 
minutes each) in dF^O (same volumes). Following wax imbedding, sections were cut 
to 5 pm, then dewaxed and stained with haematoxylin, refer Chapter 2.3.7 for protocols.
Ultrasound treatments
Porcine carotid artery sections (0.5 ± O.lg) were exposed to high frequency sound 
waves with a Grant ultrasonic water bath (Model XB5, BDH, Poole, UK). Samples 
were either placed directly in the water bath or within a 15 ml Falcon tube for 12 hours 
in a temperature controlled water bath at 20 °C. Samples where removed from the 
water bath, rinsed twice (10 minutes each) in distilled H2 O (same volumes). Following 
wax imbedding, sections were cut to 5 pm, dewaxed and stained with haematoxylin, 
refer Chapter 2.3.7 for histology protocols.
4.2.2.3 Lipid e x tra c t io n
Tissue sections were incubated in 2 x 75% ethanol treatments for 10 minutes followed 
by 1 x 24 hr treatment. Unless stated otherwise samples where then incubated in the 
described solvent for 1, 2, 3, 6 and 24 hours on a rocking/rolling plate at room 
temperature (13-15°C.). Glass capillary tubes (1.5 x 125 mm) were inserted into each 
vessel to prevent kinking, which may have reduced tissue exposure to the solvent. In all 
cases tissue sections were cut, weighed and incubated in solvent (xylene, n-butanol or 
ethanol), see Table 4.02 for solvent properties, with a 1:15 ratio tissue weight (g) to 
solvent volume (ml) at room temperature and placed in a Duran bottle on a 
rolling/rocking table for the experimental duration. Sections were removed at 
prescribed time points and prepared for TLC as described in Section 2.3.2.
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Table 4.02: Solvents used for lipid extraction and their properties, (Tennant, 2000).
Molecular formula C6H4 (CH3)2
Molecular m ass 106









4 .2 .2 .4  C r o s s -lin kin g  a r te r ia l  d er iv ed  m atr ix
The method used to cross-link the processed porcine carotid arteries was a modification 
of a method described by (Mechanic, 1994). The cross-linking process consisted of 
four main steps: 1. preconditioning tissue in lOOmM NaP04 with 0.5 M sucrose (682 
mOso) pH 7.6, for 24 hr. 2. A second preconditioning step where the tissue was again 
soaked for a 24 hour period in the cross-linking solution (lOOmM NaP04 with 4M NaCl 
plus 0.1% w/v methylene green, pH 7.4). 3. Cross-linking the tissue in a modified 2.5 L 
stainless steel tank with the same solution as step 2 for a period of 22 hours (see below). 
4. Rinsing to remove remnants of the processing steps entailed washing the tissue 
sections in sodium phosphate buffer (pH 7.4) on a rolling/rocking table until the 
samples were substantially free of the dye catalyst. This required a minimum of 10 
washes, no less than 2 hours each, over a 2 week period.
The cross-linking step required the design and manufacture of a reaction chamber that 
enabled multiple arteries to be process simultaneously, supplying an even exposure of 
light from the 300 watt halogen bulb and maintained at 0 ±1°C. The published method 
neither describes the type of bulbs used nor the energy output in terms of Lux, heat of 
spectrum, only that visible light provide the reaction energy. The method was described 
using 2 x 150 watt flood light bulbs 7-15 cm from the sample tissue. Due to the 
variation in tissue dimension from the pericardium (used in the Mechanic et al (1994) 
protocol) to blood vessels (this thesis) the light source was changed to a more 
appropriate designed halogen bulb that better suited the physical characteristics of the 
cross-linking equipment. A calibration was performed using a Gossen Luna ID light 
meter (Hedges and Wright, Swindon, UK) to ensure a similar light intensity was used 
between the floodlights (2 x 150 watt) and the 300 watt halogen.
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Distance of tissue from light source (mm)
Figure 4.02: A calibration graph comparing two 150 watt flood lights (+) to one 300 watt 
halogen lamp (□). Illustrating a comparable light intensity at approximately 150 mm from the 
tissue surface.
Figure 4.03 displays the apparatus used for the cross-linking procedure, utilizing using a 
high-energy light source and methylene green as the photo-catalyst. Each artery had a 1 
mm stainless steel rod inserted through its lumen and placed in a purpose built perspex 
holder that held up to 10 arteries in a parallel formation 8 mm apart. The pre-cooled 
(5°C) cross-linking solution was poured into the reaction vessel, covering the arteries by 
not more than 2.5 mm. The reaction chamber was placed in the cooling unit, 
maintained at ”4 °C and vigorously stirred throughout the process. When the cross- 
linking solution fell to 0°C, the 300 watt halogen light source, suspended 150 mm above 
the surface o f the solution, was turned on to irradiate the methylene green solution. 
During the cross-linking step 10 ml/min o f air was sparged through the reaction 
chamber. The reaction chamber equilibrated at 0 °C ± 0.5 °C as a result o f the heat 
generated by the light source (a requirement o f Mechanic et al 1994 protocol).
Light source Pump for heat exchangers
Air Hr
V e s s e l s
•Thermostat, with heater unit 
Control unit
Main tank heat exchanger
Anti freeze maintained 
at - 4.5 +/- 0.5°C
Figure 4.03: Cross-linking assembly
4 .2 .2 .5  P o s t  p r o c e s s  w a s h in g
Post cross-linking; the matrix was washed to remove components o f the cross-linking 
reaction (methylene green, sucrose, NaCl) and to further aid the extraction o f remaining 
cell debris. Processed arteries were washed in batches o f 10, with a combined weight 
approximately 14-18g, in 2L o f distilled H2O on a rocking rolling plate. A minimum of 
7 complete changes over a 7 day period were carried out or until the bulk methylene 
green had been removed from the tissue. Extended washes to remove crystal substances 
exposed by LT-SEM, see Figure 4.15 required a further 7 days (7 further equidistant 
changes o f H2O) eliminated these crystals from the matrix/arterial wall. Cross-linked 
matrix was cut in transverse section for LT-SEM analysis and prepared as in Section 
2.3.8.1.
4.2 .3  A n a ly tic a l  M etho ds
All analytical methods used in this chapter are described in chapter 2, Material and 
Methods, analytical methods Section 2.3.
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4.3 Results
Results from experiments to modify the native porcine carotid artery to give a 
functional matrix for tissue engineering purposes are described in this section. Figure
4.01 displays an overview of the theme followed to generate a stable acellular tissue, 
whereas this section details the incremental steps within each o f the main headings. In 
addition, a comparative analysis was conducted between the acellular matrix produced 
by the method described by Mechanic et al (1994), and the methodology employed in 
this study. Finally mechanical properties, such as burst pressure and stress-strain 
relationships were measured and compared to the native porcine artery.
Unless stated otherwise all images and observations taken o f the tissue or processing 
methods are representative o f the sections or samples studied. Figure 4.04, illustrates a 
transverse section o f unprocessed porcine carotid artery, displaying the major functional 
and histological components o f the arterial wall. Note the high density of VSMC 
throughout the media and EC lining the vessels basement membrane. This 
representative image is referred throughout this chapter as the native or unprocessed 
tissue to distinguished changes induced by vessel processing described in this chapter.
Figure 4.04: An H & E stained transverse section of control (untreated) arterial wall. Showing 
the lumen and convoluted intimal lining (A), medial layer (B), adventitial layer (C) and 
connective tissue joining the artery to other tissues (D). Cell nuclei are stained purple (E).
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4 .3 .1  M e c h a n ic a l  p r o c e s s in g  a n d  s t o r a g e
In order to minimize the immunological load on the patient (once tissue engineered 
product is implanted) as much nonessential porcine arterial component was removed as 
possible. As the connective tissue provides little or no strength to the artery, in terms of 
resistance to mechanical failure imposed by haemodynamic stresses, it was removed, 
leaving as few ‘foreign’ immunological components as possible.
Observations of the mechanically processed arteries ablumenal surface display the 
adventitial layer largely intact around the medial layer of the vessel wall, with the bulk 
of the connective collagen removed. In some instance the adventitial layer had been 
partially removed, this was due to difficulty discerning between the said layer and the 
surrounding loose connective tissue. Storage of the vessels prior to processing at -20°C 
to rupture cells was not tested independently as a specific step.
4.3.2 Re m o va l  o f  cell and  cell com ponents
Initial e x t r a c tio n  tr ia ls
Early investigations focused on methodologies to extract nonstructural components of 
the arterial wall, including cells and their components, in a ‘one-step’ process. Two 
different treatment methodologies utilising NH4OH and ultrasonic radiation were 
assessed. Figure 4.05 shows an H & E stained section of porcine carotid artery exposed 
to 10% solution of NH4OH at 20°C as described in 4.2.2.2. Collagen fibres are severely 
fragmented with large spaces appearing between the elastin and collagen ECM. Cell 
nuclei are observed throughout the tissue section. Porcine carotid arterial sections 
immersed in H2 O within separate tubes and exposed to ultrasound displayed no 
histological change in structure from control tissue over the experimental duration. 
Arterial sections immersed directly in the ultrasound water bath and exposed to 
ultrasonic sound waves displayed similar histology to NH4OH treated samples. 
Fragmentation of the ECM was evident within the ECM (A) while cell nuclei remain in 
the tissue (B) see Figure 4.06.
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Figure 4.05: NH4OH treatments of arterial tissue fragmented the ECM framework and failed to 
remove cell nuclei (A).
Figure 4.06: Arterial sections post exposure to ultrasound (directly in ultrasonic bath) for 10 
minutes. Note ECM fragmentation (A) and retention of cell nuclei (B).
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S o l v e n t  b a s e d  l ip id  e x t r a c t io n
Due to the negative outcome of both NH4OH and ultrasound treatments, a two step 
process was designed that used a lipid extraction step followed by proteolytic digestion 
to allow non-structural components to be removed. A variety of solvents were tested 
and evaluated in terms of lipid extraction and effect on the structure of the arterial ECM.
Xylene
Sections of artery (0.5 ± O.lg) washed in xylene on a rocking rolling table at room 
temperature (14-17°C) for 24 hours. A barrier of H2O formed around the tissue as a 
result of xylene hydrophobicity, see Table 4.02. This layer diminished by
approximately 75% (qualitative reduction from ~ 0.5 to < 0.1 mm) by 6 hours but 
remained present (-10% of original size) after 24 hours. The treatment was altered to 
include 25% and 75% EtOH dehydration steps prior to, and 75% and 25% EtOH 
rehydration steps after exposure to xylene, for 2 hours. The tissue dehydrated severely 
when exposed to xylene after the 75% EtOH dehydration step, forming a rigid structure 
that did not rehydrate, irrespective of the duration (up to 72 hours) of washing in H2O. 
The vessel did not regain any of its previous mechanical characteristics due to its 
compacted (dehydrated) state. The vessels (after EtOH-xylene-EtOH treatment) were 
exposed to trypsin (1 x) at room temperature (14-17°C) for 24 hours and maintained its 
bulk structure with the vessels lumen remaining open.
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Butanol
Tissue sections with a mean weight o f 0.314 ± 0.03 g were incubated in 100% butanol 
solution on a rocking/rolling plate at room temperature (15-18°C) as described in 
Section 4.2.3. Tissue was prepared for TLC as described in Section 2.3.2 and 4pl 
aliquots were run for each sample on silica gel 60 TLC plates as described in Section 
4.2.3. Detectable lipids display a banding pattern o f 5 spots on control samples. Over 
the experimental time course these bands faded as more lipid was extracted from the 
tissue. By the end o f the third wash (3 hours) a significant reduction in banding 
intensity is noted. By 6 hours only small molecular weight lipid is noted at the top of 
the chromatography plate, which was further reduced by 24 hours see Figure 4.07. 
After 24 hour rehydration, samples were rigid with the bulk mechanical severely 
compromised, typical o f tissue in a dehydrated state. Unlike EtOH-xylene-EtOH 
treatments, trypsin digestion o f the butanol treated samples resulted in complete tissue 
collapse after 3 hours in a lx  solution at 16 ± 1.5°C.
Control aaaaessasassssssgssasssaeassgwg^ a^sg^ aaaaesas 1hr 2hr 3hr
............
6hr 24hr
Figure 4.07: TLC plate displaying detected lipids (A) as vertical marks on the chromatogram. 
The butanol treatment has removed all detectable lipids by the 5th wash at 24 hours.
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Ethanol-Butanol-Ethanol
Tissue with mean weights o f 0.20 ± 0.03 g was prepared and run on silica gel 60 TLC 
plates as described in Section 4.2.3. Detectable lipids display a banding pattern of 5 
spots on control samples. Results show that ethanol dehydration treatments, prior to 
butanol, have removed the bulk o f the detectable lipid. Samples remained pliable after 
the ethanol dehydration step, only after exposure to butanol did the tissue become rigid 
and lose beneficial mechanical properties, see Figure 4.08. Digestion o f the treated 
tissue with trypsin showed, like the EtOH-xylene-EtOH treatments, samples had 
retained their structural integrity though the 24-hour digestion period.
2hrControl 3hr 6hr 24hr
Figure 4.08: EtOH-butanol extraction of tissue lipids. TLC plate showing an almost complete 
extraction of lipid by the end of step A (2 x 10 minute washes EtOH (25%), 1 wash overnight 
EtOH (75%)). The extent of any further lipid extraction by the butanol treatments (1, 2, 3, 6 and 
24 hours) past the initial dehydration steps is subjective with this methodology.
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Ethanol
Tissue sections with a mean weight o f 0.31 ± 0.012 g were incubated with 75% ethanol 
as described in Section 4.2.3. By 3 hours the ethanol treatments had removed the bulk 
of the detectable lipid, with no further lipid being extracted by 48 hours see Figure 4.09. 
On rehydration the tissue had returned (qualitatively) to a near ‘native’ state. Trypsin 
digestion post ethanol treatment showed, like the EtOH-xylene-EtOH treatments, the 
tissue had retained its bulk mechanical properties after the 24 hour digestion period. 
Two controls were tested 1. non-washed unprocessed tissue and 2. tissue washed in the 
same manner as experimental samples except in H2O for the full duration of the 
experiment, neither o f which showed a loss o f lipid content.
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Figure 4.09: TLC plate displaying detected lipids after tissue treatment with 75% ethanol. A 
chromatogram showing the progressive reduction in lipid content over a 48 hour period. At the 
3rd wash after 1 hour, the 75% ethanol treatment was unable to extract further detected lipid (A) 
at the top of the chromatogram remaining throughout the 48 hour treatment.
Treatment with EtOH resulted in a matrix material with reduced lipid content and 
retention o f its bulk mechanical properties, unlike previous treatments that had 
detrimental effects on tissue mechanical properties, see Figure 4.10. EtOH treatment 
(progressive washes for 24 h) was therefore used as the lipid extraction protocol.
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Figure 4.10: An H & E transverse section of the arterial wall post ethanol lipid extraction. The 
internal elastic lamina remains intact (A) along with cell nuclei (B).
P r o t e in  d ig e s t io n
Following treatment in EtOH for 24 h with washes in new solutions o f EtOH at the 
prescribed time points, as illustrated in Figure 4.09, the tissue incubated in a trypsin 
solution, see Section 2.3.3. Structural change in the tissue was qualitatively monitored 
(tissue elasticity and collagen/elastin histology) and for the presence o f cell nuclear 
material (histological analysis) over time, see table 4.03. These results were used to 
determine an optimal digestion period (48 hours) where a compromise was required that 
retained the tissues elastic nature whist removing cell nuclear debris.
Table 4.03: Qualitative observations of native artery after treatments with 1 x trypsin
Time Elasticity Cell nuclei Collagen / elastin
Unprocessed control Present & intact Normal & intact
Post EtOH treatment small reduction Present & intact slightly compressed
24 hr trypsin reduced from t=0h partial disruption i i
48 hr trypsin reduced from t=24h complete disruption "
72 hr trypsin reduced from t=48h none present partial fragmentation
96 hr trypsin tissue collapsed •• I
120 hr trypsin ii i i extensive fragmentation
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Trypsin activity over time showed the enzyme’s activity was stabilized when arterial 
sections were present comparative to trypsin alone. This is likely to result from a 
reduction in autolysis as the enzyme competes with an increasing quantity o f partially 
digested protein hydrolysed from the arterial section. Although trypsin activity declines 
over 120 h, the reduction in catalytic activity over the 48-hour incubation period is not 
significant to require changing the trypsin solution, see Figure 4.11. Controls were 1. 
enzyme solution heated to 75°C for 30 minutes to inactivate the enzyme and 2. buffer 





















Figure 4.11: Trypsin activity without arterial sections present (□) reduced 63% (120 hours) and 
38% (48 hours) from initial activity n = 3 ± 1 sd. Trypsin activity when the arterial substrate is 
present (o) reduced 41% (120 hours) and 10% (48 hours) respectively.
SDS PAGE analysis o f tissue digestion (post ethanol treatments) shows the progressive 
extraction o f matrix proteins, particularly small molecular weight proteins. By 24 hr the 
bulk o f proteins less than -75  kD have been removed, Figure 4.12. Staining the arterial 
derived matrix with van Gieson (specific for elastin) displayed retention o f the internal 
elastic lamina and components o f the basement membrane, see Figure 4.13.
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Figure 4.12: SDS-PAGE analysis of arterial protein after incubation to trypsin. Lanes: 1
molecular weight marker, 2. untreated raw tissue, 3. tissue post EtOH lipid extraction, 4. trypsin 
digestion 24 hr, 5. 48hr, 6. 72hr, 7. 96hr, 8. 120 hr, 9. Trypsin (10x).
10 |xm
Figure 4.13: Identification of matrix elastin content. Matrix post trypsin digestion (48 hours) with 
elastin stained dark purple (A). Note retention of the internal elastic lamella (B) and basement 
membrane (C). Vessel lumen (D). van Gieson (Specific elastin stain).
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Similarly, Figure 4.14, an H&E stained section o f processed tissue shows the presence 
of the internal elastic lamina stained as a dark band beneath the translucent basement 
membrane on the lumenal surface of the section. Importantly, cell nuclear material 
have been disrupted and is no longer visible by staining with H&E compared to control 
unprocessed tissue, see Figure 4.04.
10 fxm
Figure 4.14: H & E  stained matrix post trypsin digestion (48 hours), no nuclei are present within 
the arterial wall (A). The internal elastic membrane (B), basement membrane (C) have been 
retained. Vessel lumen (D).
Based on the results from the observable changes in matrix structure, cell nuclei 
disruption and SDS-PAGE analysis o f protein extraction, a 48 h digest was chosen as 
the preferred method to disrupt residual cell components (after solvent treatment) for 
clearing from the tissue.
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4 .3 .3  C r o s s -l in k in g
As discussed in Section 4.1.3 the distinctive amino acid composition of collagen is used 
as a diagnostic tool to determine Hyp (hydroxyproline) content (Vincent, 1982). By 
assaying the proteolytic degradation products (particularly Hyp) with RP-HPLC a 
comparison was made between untreated (less resistant to degradation) to cross-linked 
tissue (more resistant to degradation).
E nzym e d e g r a d a t io n  r e s u l t s
The results in table 4.04 show tissue samples from the cross-linked arteries were 
resistant to degradation in the 1 0 0 0  activity unit/ml pepsin solution for the duration of 
the enzyme treatment. The Hyp samples from the untreated (raw) arteries displayed 
moderate levels of degradation indicated by the free Hyp concentration and total peak 
area. Comparative to cross-linked samples (total peak area only) the control group 
displayed consistent concentrations/total peak areas. Cross-linked samples were not 
degraded sufficiently to yield a discrete Hyp peak with this concentration of enzyme. 
Evaluation of the total peak area indicates that the extent of tissue degradation is almost 
6  times (5.73) less than that of the cross-linked samples, although this is not 
representative of specific collagen (Hyp) degradation, rather the total amino acids in 
solution post-pepsin treatment.
Standard cross-linked samples were compared to untreated tissue post digestion with 
5000 activity unit/ml pepsin at 37.5°C for 16.5 hours. At this higher enzyme activity, 
the extent of the tissue degradation of the cross-linked tissue was sufficient to result in a 
measurable level of free hydroxyproline in solution. Free hydroxyproline per gram 
from the cross-linked tissue is less than a quarter (21.4%) of raw tissue samples. The 
total peak area per gram of tissue in the cross-linked samples was approximately a third 
(32.5%) of the value for the uncross-linked tissue; see Table 4.04.
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Table 4.04: Comparison of unprocessed and cross-linked tissue digested with 1000 and 5000 
activity units/ml pepsin for 20 hours at 37.5°C. Mean peak areas and total free Hyp in solution 
digested (n=6).
Free hydroxyproline pmol/g Total Peak Area (units)
1000 activity units/ml pepsin
Mean S.D. Mean S.D.
Unprocessed artery 16.54 2.08 1055000 6961
Cross-linked 0 0 184100 17990
5000 activity unit/ml pepsin
Unprocessed artery 31.51 1.19 2200000 21320
Cross-linked 6.74 1.01 714600 11430
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4 .3 .4  P o s t  p r o c e s s  w a s h i n g  t o  r e m o v e  d i s r u p t e d  c e l l u l a r  a n d
NONCELLULAR COMPONENTS OF THE ECM
As described in Section 4.2.2.5, the processed porcine arteries were washed in H2O to 
remove vessel components that had been disrupted through the processing steps. Over 
the 7 day duration o f vessel washing it was observed that the dye was progressively 
removed, until day four when no further dye was removed, the final 3 days having no 
effect on dye removal, with the vessel remained light blue in colour. Transverse 
sections o f the vessel wall with LT-SEM showed the presence o f crystalline substance/s 
imbedded throughout the vessels medial layer. No direct analysis was conducted to 
determine the nature o f the substance, however it was believed to be residual salt from 
the cross-linking step where vessels were incubated in 4M NaCl, see Figure 4.15, where 
crystals are clearly visible. Extending the washing process a further 7 days eliminated 
these crystals from the matrix/arterial wall.
Figure 4.15: Presence of crystals within the matrix wall post processing. LT-SEM, vessel wall 
in transverse section (cut immediately prior to viewing) of a fully processed and ‘washed’ matrix 
wall. Note the abundance of crystals (A) exposed at the cut edge of the collagen/elastin matrix 
(B), approximately 2-4pm in diameter.
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DNA EXTRACTION
In order to determine the effectiveness o f the washing steps at removing residual cell 
components, sections of matrix (post trypsin treatment, pre-cross-linked and not 
washed) were compared to sections o f matrix that had been washed for two weeks, as 
described in Section 4.2.2.5. These Figures (4.16a^ and 4.17a/b) show DNA as bright 
‘light-blue’ strands (A) against a darker blue background. Figures 4.16a and b shows 
the vessels lumenal surface, with Figures 4.17a and b the vessels ablumenal surface. 
Figures 4.16a and 4.17a represent the matrix pre-cross-linking with Figures 4.16b and 
4.16b displaying DNA remaining post cross-linking and washing steps. These images 
show the near complete removal o f DNA from both the lumenal and ablumenal 
surfaces.
50 jLim
Figure 4.16a: Lumenal surface pre cross-linking and Figure 4.16b: post cross-linking and 
washing, DNA is stained by DAPI (A).
Figure 4.17a: Ablumenal surface pre cross-linking and Figure 4.17b: post cross-linking and 
washing, DNA is stained by DAPI (A).
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4.3.5 LT-SEM ANALYSIS OF FULLY PROCESSED MATRIX/VESSEL SURFACES
To assess the presence o f other non-specific cell debris retained on the surfaces o f the 
matrix LT-SEM image was conducted. Fully processed and washed matrix displays a 
lumenal surface void o f EC or large cellular debris with the undulating basement 
membrane retained (lumenal surface), see Figure 4.18. Although the basement 
membrane remains largely intact, gaps or holes were noted in some areas. Figure 4.19 
shows a higher magnification of the lumenal surface, clearly showing gaps in the 
basement membrane. Like the lumenal surface there was no evidence o f intact porcine 
cells on the ablumenal surface, Figure 4.20. Figure 4.21, a higher magnification of the 
matrices ablumenal surface shows the presence o f particulate matter bound to the 
surface fibres. The compressed or matted appearance o f the ECM was believed to be an 
artefact o f LT-SEM sample preparation where surface H2O is blotted which compacts 
the free surface fibres, standard SEM (not low temperature) has been used in Figure 
7.08 to display o f the outer fibrous nature o f the matrix surface o f the matrix.
Figure 4.18: LT-SEM image of fully processed matrix displaying the lumenal surface
morphology. Showing the hills (A) and valleys (B) associated with undulating lumenal surface. 
Breaks in the basement membrane can be seen (C). Inset: van Gieson stained arterial 
transverse section showing the equivalent surface structures (A and B) with the matrix wall (D) 
and vessel lumen (E).
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Figure 4.19: Higher magnification of the processed grafts lumenal surface. Holes in the
basement membrane can be clearly seen (B) compared to continuous areas (A).
Figure 4.20: Low magnification LT-SEM image of the processed grafts ablumenal surface. 
Like Figure 4.27, the bulk of the matrix appears free of particulate matter. Note the compressed 
or matted appearance of the ECM fibres lying flat on the surface of the matrix.
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Figure 4.21: A higher magnification LT-SEM image of the processed grafts ablumenal surface. 
Particulate matter (A) remains amongst the matrix fibres (B). No intact or partially lysed cells 
are noted on the matrix surface.
4 .3 .6  C om parative  p r o c e s s  a n a l y sis
In order to determine the process described in this thesis was an improvement over the 
processes published by Mechanic (1994) a comparative analysis between the final 
processed matrix described in this thesis and that published by (Mechanic, 1994) was 
conducted. The two key steps in this process were the lipid extraction using the EtOH 
washing protocol and digesting the vessel in trypsin to remove non-structural proteins. 
Results from TLC chromatograms have shown additional lipid has been extracted by the 
process described in this thesis compared to the method described by Mechanic (1994) 
protocol, see Figure 4.22a. SDS-PAGE analysis o f ECM protein content is similar to 
the lipid analysis, where the total protein content is considerably reduced from both 




Figure 4.22a Figure 4.22b
Figure 4.22a: Sample A, using 0.5 M sucrose followed by 4 M NaCI and cross-linked as 
described in Section 4.2.3.1/2. Sample B, lipids remaining in the tissue after the completed 
treatment developed and described in this thesis. 4.22b: Total protein content in (C), the 
method in this thesis ,is considerably reduced from both, controls (A) and Mechanic’s process 
(B). Gel loading 10pl/well.
SDS-PAGE had shown a visual loss o f protein, Figure 4.22b. To determine if  the 
reduction in protein content was detectable in gram quantities, initial weights were 
recorded and compared to post processing tissue weights. Tissue sections (n = 12) with 
mean weights pre-treatment o f (Mechanic 3.15 ± 0.39 g and the matrix developed in this 
thesis 3.19 ± 0.03 g) were treated in accordance with each method. Figure 4.23 
illustrates the physical loss in tissue weight between the two processing methods 
expressed as a percentage weight loss, with mean values ±1 sd, Mechanic 2.01% and 
the matrix developed in this thesis 17.92%. The student’s t-test was used to determine 
significance between pre and post-treatments. No significant difference was found with 
the Mechanic process from start to finish weight, with a t-test value o f 0.327 resulting in 
a p > 0.05. Conversely the matrix developed in this thesis showed a significant loss in 
weight p < 0.01 with a t-test result o f 9.449. Critical values for p=0.05 (2.07) and 















Figure 4.23: Tissue weight loss :D  pre-treatment a n d |  post-treatment. Error bars indicate ± 
one standard deviation.
4.3.7 Mechanical  p r o p e r t ie s
Critical to the success o f this matrix is the ability to withstand applied haemodynamic 
stresses imposed by the human arterial system. Arterial pressure rarely exceeds 200 
mmHg, it was therefore important that the described material maintains integrity to a 
level exceeding this working load. A pressure test was conducted to determine the 
mean rupture point o f the fully processed matrix comparative to unprocessed tissue. In 
addition the mechanical strength, a stress strain analysis was conducted to compare the 
elastic properties between untreated and fully processed tissue.
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P r e s s u r e  t e s t  a n a l y s is
The t-test was used to determine any significance between untreated porcine carotid 
sections and cross-linked samples. No significant difference was found between the 
two sample sets with a t-test value o f 0.111 with 8 degrees o f freedom (n=10) and a 











Figure 4.24: Variation in burst pressure between untreated and cross-linked tissue. No 
significant difference was found p > 0.05. Error bars indicate ± one standard deviation.
LOAD-EXTENSION DATA - S t r e s s -s t r a in  CURVE
Stress strain analysis has shown a significant difference between untreated and cross- 
linked arterial segments. Untreated tissue segments display the characteristic biphasic 
relationship between matrix proteins, elastin and collagen. This is shown at the point 
where the graph becomes non-linear at approximately 90% strain from which the trend 
line curves upwards. Cross-linked tissue did not display the same biphasic relationship 
between the two main matrix proteins. Cross-linked tissue displayed increased variation 
around mean values, compared to untreated tissue, see Figure 4.25. The termination of 
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Figure 4.25: Stress-strain curve: Untreated tissue A (n = 18) and cross-linked □ (n= 38). Error 
bars indicate ± one standard deviation.
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M e a n  f a il u r e : s t r e s s  a n d  s t r a in
The ultimate tensile strength o f cross-linked tissue was higher than untreated tissue with 
results for the mean failure stress 631.89 ± 192.92 and 188.17 ± 86.21 (g/mm2) 
respectively. To determine any significance differences between untreated and cross- 
linked tissue the student T-test was used. Between the two data sets, failure stress 
(g/mm2), a T-test value o f 3.87 was calculated, with a critical value o f 2.66 (p = 0.01) 
and 53 degrees o f freedom. This confirms a significant increase in the failure stress 
point o f the cross-linked tissue over the untreated tissue at the 1% level. Conversely the 
percentage failure strain no significant difference was found, with a t-test value of 
0.001, where the mean failure strain (%) for untreated tissue was 85.06 ± 18.97% and 
103.5 ± 14.37%, Figure 4.26.
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Figure 4.26: A graph to show the variation mean failure stress (g/mm2) and the mean failure 




O v e r v ie w  o f  m a t r ix  p r e p a r a t io n
This section o f work has focused on the generation o f a matrix for vascular tissue 
engineering purposes, derived from porcine carotid arteries. In this section the 
discussion has been divided up into topic headings, in the order the work was carried 
out. Figure 4.27 details the stepwise process leading from collection o f the carotid 
artery from the abattoir through to the fully processed matrix.
V e s s e l  e x t r a c t i o n  
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Figure 4.27: A diagrammatic representation of the complete processing methodology used in 
this thesis.
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4 .4 .1  M e c h a n ic a l  p r o c e s s in g  a n d  s t o r a g e
The first step in the process was the actual harvesting of the arteries whereby arteries of 
an appropriate size and undamaged during the extraction process were selected. The 
selection criterion encompassed intact arteries measuring between 80-110 mm in length 
with lumen diameters from 3.5 - 6.5 mm (proximal) tapering to 2 - 3 mm (distal). 
Observable variation in the physical parameters of the porcine carotid between 
individual animals was marked, with many intact arteries falling outside the selection 
criteria. The selected arteries were then washed and trimmed to reduce the artery to its 
minimum effective components that will allow it to withstand applied haemodynamics 
stresses, whilst retaining its mechanical properties. As such the final implant will 
present to the recipient as few as possible ‘foreign’ immunological components. For 
this reason the loose connective tissue surrounding the exterior of the vessel was 
removed.
The stability in terms of haemodynamic tolerance that the adventitial layer provides to a 
muscular artery is minimal compared to the considerably larger (and retained in this 
process) medial layer (Nerem and Seliktar, 2001). A qualitative decision was made to 
retain this layer in order to preserve the tissues mechanical properties as much as 
possible throughout the processing steps. The extent of this ‘retention of mechanical 
properties’ by retaining (or not) the adventitial layer was speculative and specific tests 
to prove or disprove this were not carried out. It was assumed that retention of the 
adventitial layer would not be detrimental from a mechanical perspective as it was an 
integral part of the natural artery; it was therefore retained in the processing. The 
mechanical removal of loose connective tissue surrounding the unprocessed arteries 
proved to be a delicate and lengthy operation. Results have shown the adventitial layer 
to be largely intact around the medial layer of the vessel wall with the bulk of the 
connective tissue removed. Considerable care was required to excise the surrounding 
connective tissue, as there was no clear boundary between the arteries outer adventitial 
layer and the adjoining connective tissue. In some instances the adventitial layer had 
been completely removed with the medial layer exposed.
An issue favouring the removal of this outer layer would be a decrease in the distance 
between EC seeded on the lumenal surface and SMC seeded onto the outer or
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ablumenal surface. Effective communication at both the cellular and molecular level 
plays an important role in retention of the endothelium as a whole and the maintenance 
of cell phenotype (Nackman et al., 2000). The domain around which a single cell can 
effectively communicate with surrounding cells has been estimated to be -250 pm 
(Francis and Palsson, 1997). The thickness of the porcine carotid arterial wall ranges 
between -500-2000 pm, including the adventitial layer, (~ 50- 500 pm), see Figure 
4.04, by reducing this distance it is speculated that the culture time required to generate 
a biofunctional artery with cell populations within communicative distances, maybe 
decreased. Additionally the removal of the adventitial and associated connective tissue 
layers (retaining only the intimal and medial layers), would increase the efficiency of 
later processing steps by decreasing the thickness of the wall. These initial decisions 
were made without the benefit of hindsight, where the final experimentation conducted 
in this thesis has proven the matrix to be over cross-linked preventing cellular migration 
into the matrix. Based on these results it would be beneficial to completely remove the 
adventitial layer prior to lipid extraction.
Storage of the vessels at -20°C after the mechanical removal of connective tissue was 
chosen not only to preserve the vessels prior to completing the processing steps, but to 
rupture porcine cells by formation of ice crystals, releasing cellular components into the 
ECM aiding the later, more specific decellularisation processes. Damage to the ECM as 
a result of the freezing process, for example fractures within the collagen matrix were 
not observed. In support, (Hunt et al., 1994) have show that collagen fibres are resistant 
to fracturing at these temperatures. Vessels were maintained in storage no more than 4 
weeks prior to processing to reduce the potential of damage by freeze-drying.
4.4.2 R emoval of cells  and  cell com ponents
Initially procedures were investigated that could employ a one-step process to extract as 
much non-structural protein, lipid, including cellular components as possible without 
affecting the mechanical properties of the ECM. Advantages of a one-step process, if 
successful, would be favourable from both manufacturing and ultimately cost 
perspectives. Several methodologies were employed to extract these components, 
including; ammonium hydroxide and ultrasound followed by multiple H2 O washes to
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remove both residual chemical and disrupted components within the ECM. Preliminary 
tests, see Figure 4.05 (NH4 OH) and Figure 4.06 (ultrasonic irradiation) show despite 
severe fragmentation within the collagen/elastin matrix and the appearance of large 
spaces between the elastin and collagen frameworks, cell nuclei remain visible in 
histological sections. After these initial experiments a more rational approach was 
taken where two major components of whole tissue were specifically targeted for 
extraction, lipid and non-structural matrix protein.
The order in which treatments were carried out was based on improving the 
accessibility of the tissue to the following treatment, refer to Figure 4.27. In addition to 
a potential reduction in immunogenicity by component removal, connective tissue 
would inhibit diffusion of all treatments into the arterial wall. By firstly removing this 
outer layer of connective tissue all following treatments will have improved access to 
the inner medial layer and thus increase the effectiveness of each treatment. The lipid 
extraction step was aimed to remove cellular and tissue lipids, by dissolving the cell 
lipid membrane many cell proteins will be washed from the tissue and the following 
proteolytic treatment will be more effective, through better access to cellular proteins.
L ip id  e x t r a c t i o n
The second step of the process was extraction of the vessels lipid content a number of 
different solvents or combinations of solvents were initially tested to evaluate both lipid 
extraction and alterations to the vessels gross mechanical characteristics, these included 
xylene, butanol and ethanol. Progress towards extraction of the lipid content within the 
arterial vessel began with xylene, an extremely hydrophobic solvent requiring excessive 
agitation before the (observable) H2O boundary layer was reduced, not removed, see 
Table 4.02 for solvent properties. The treatment was modified to include ethanol 
dehydration and post treatment rehydration steps (25-75%). Tissue rehydration post 
xylene treatment failed to return the tissue to its former elastic state resulting in a rigid 
structure irrespective of the duration (up to 72 hours) of washing in H2O.
As part of the processing methodology for the type I dermal collagen matrix used in 
chapter 3, trypsin is used after the acetone treatments to digest non-matrix protein 
(Oliver and Grant, 1985). This published treatment utilizes a 2-6 week digest in
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trypsin, clearly either the matrix material is strongly resistant to degradation by the 
neutral protease trypsin, as discussed by (Friess, 1998) or acetone pretreatment has a 
stabilizing effect, either through modification of the structure of the collagen/elastin 
molecule or mass transfer of the enzyme is limited due to compaction of the matrix after 
dehydration. Oliver and Grant (1985) state that less than 5% of the original non-matrix 
protein and cell debris remains after processing. A reduction in matrix water content 
may act as a barrier to the enzyme entering the matrix thus preventing excessive matrix 
degradation.
LT-SEM images of this biomaterial Chapter 3.3.1 show a matrix void of all visible cell 
debris supporting the findings of Oliver et al (1985). In order to determine the effect, if 
any, the solvent extraction process was having on the matrix sections, treated tissue was 
immersed in a lx  trypsin solution for 24 hours and assessed in terms of gross visual and 
structural properties. Tissue sections exposed to xylene and EtOH-xylene-EtOH 
remained viable with each vessel lumen remaining open and appearing structurally 
sound. The only noticeable effect of the trypsin digestion was the outer extremities of 
the arterial wall began to loosen with strands of attached ECM floating freely. This 
result is likely to be due to excessive dehydration of the matrix preventing the enzyme 
entering the arterial wall with only the exterior of the matrix rehydrating. The resulting 
loss of mechanical properties was so severe that regardless of the efficacy of lipid 
extraction the process was not deemed favourable. In addition xylene is rated as a Class 
II toxic solvent by the American Food and Drug Agency, where extensive extraction 
procedures are required post treatment, which may become problematic for human 
implantation studies.
Assessment of butanol as a solvent extraction mechanism was based on improved 
solubility in H2O, see Table 4.02 for solvent properties. Increased solubility would 
negate the requirement for EtOH dehydration/rehydration steps, reducing processing 
steps and additional handling. Results from TLC trials display a near complete removal 
of detectable lipid by 24 hours, Figure 4.07. However the tissue, like xylene without the 
EtOH treatments, failed after 24 hours washing in H2O to rehydrate, remaining rigid 
with the bulk mechanical severely compromised. Unlike xylene or EtOH-xylene-EtOH 
treated tissue, the butanol treatment failed to provide any stability to the matrix, which 
was severely compromised by 24 hours exposure to trypsin. The vessel wall had
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collapsed with the lumen folding in on itself after 3 hours despite being excessively 
dehydrated. This result suggests another mechanism for matrix stability other than sole 
protection from reduced water content. Vyavahare et al (1998) have also shown that 
ethanol pretreatments stabilise biomaterial to enzymatic digestion. In this example the 
enzyme treatment was with collagenase, an enzyme that (unlike trypsin) specifically 
targets collagen. EtOH alone was shown by NMR studies to have reduced the total 
tissue water content (Vyavahare et al., 1998). It is hypothesised to be minimal by 
comparison to the more hydrophobic butanol treatments, thus unlikely to be the sole 
reason for tissue stability. It was concluded that excessive dehydration and the tissues 
subsequent failure to rehydrate, in concert with reduced stability to trypsin, necessitated 
further modification to the process.
To assess the effect on EtOH on tissue stability and rehydration in concert with butanol 
treatments, samples were dehydrated with EtOH treatments (25 and 75%), exposed to 
butanol and once again rehydrated in graded EtOH treatments. The chromatogram of 
this treatment regime, Figure 4.12, shows that by the end of the initial EtOH 
dehydration step the bulk of the detectable lipid has been extracted. It was also 
observed that the tissue remained (qualitatively) pliable up to the point of butanol 
treatments. After 24 hours exposure to trypsin the vessels, like the xylene treatments, 
had retained their bulk mechanical properties. Like xylene, exposure of the matrix to 
butanol compromised the mechanical properties of the tissue due to the inability of the 
matrix to rehydrate post treatment. Under these conditions butanol was rejected as a 
solvent for lipid extraction. A reduction of butanol concentration in concert with EtOH 
may have produced the desired results, however from a simplicity point, trials 
progressed with EtOH alone as a sole mechanism to extract lipid and stabilise tissue. 
As discussed in the introduction to this chapter EtOH also reduces tissue calcification 
which has been a major issue in replacement collagen heart valves, for example 
(Vyavahare et al., 1997) and (Lee et al., 1998). Demer et al (1997) with the use of 
more volatile extraction solvents (chloroform and methanol) have shown a minimal 
reduction in calcification compared to EtOH treatments (Demer, 1997). Thus lipid 
extraction alone is not the sole factor in the prevention of tissue calcification. The 
hypothesis put forward by Vyavahare et al (1997) is that EtOH pre-treatment, in 
addition to extraction of lipid, results in structural changes of tissue proteins that 
inhibits the deposition of calcium (Vyavahare et al., 1997). Further evidence that EtOH
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stabilises the ECM framework is shown by Pieper et al (1999) were l-ethyl-3-(3- 
dimethyl aminopropyl) carbodiimide (EDC) was used as a cross-linking agent. When 
the cross-linking reaction was conducted in the presence of ethanol matrix porosity was 
preserved. The reduction in structural change by comparison to controls was clearly 
demonstrated when EtOH was used as a pretreatment (Pieper et al., 1999). Figure 4.13, 
illustrates the progressive extraction of lipid from the tissue using EtOH washes (at each 
time point the EtOH solution is replaced). By 3 hours no further lipid is extracted (A) 
with a total tissue exposure of 48 hours in the treatment solution. Unlike any of the 
previous treatments the EtOH treated tissue rehydrates to its near native state, though a 
slight increase in rigidity was noted. As expected, exposure to trypsin over a 48 hour 
time course showed no obvious signs of degradation, at the macroscopic level.
Analysis of the solvents tested with the porcine vascular tissue has made it clear that a 
degree of compromise is required between the complete removal of tissue lipid and 
retention of the tissues mechanical properties. Aggressive solvents such as xylene and 
butanol extract more lipid than the EtOH treatments but their use results in a matrix 
with severely compromised mechanical properties through dehydration. As discussed 
the presence alone of lipid is not the sole cause of calcification, but the extraction 
solvent and its secondary effects on the matrix conformation play an important role, 
which is not fully understood. Butanol offers no protection or stabilising effect to 
matrix structural proteins to the trypsin digestion, used to extract non-structural proteins 
of the ECM. This again supports the premise that protection against ECM calcification 
is a multi-variable process that involves aspects of lipid content and the lipid extraction 
process, which further affects ECM stability against enzymatic degradation and 
structural change in denaturing conditions.
In this section of work the lipid content has been specifically targeted for removal by 
the application of a variety of solvents. Proteins associated with lipids, such as 
lipoproteins of the cell membrane removed in the washing, is secondary, though 
beneficial, to the aim of this step, which has been lipid extraction and retention of the 
vessels bulk physical/mechanical characteristics. Figure 4.10 a micrograph of the 
arterial wall post EtOH treatment, shows that cell nuclei have not been disrupted and are 
clearly present in the tissue, though slightly elongated, possible due to tissue 
dehydration.
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P r o t e o l y t i c  d e g r a d a t i o n  ECM p r o t e i n s
After the removal of tissue lipids the process aimed to remove as much of the non- 
structural ECM (including cellular) proteins. Tissues were exposed to a proteolytic 
(trypsin) digestion. The aim of this step was to remove, in the same fashion as lipid 
extraction process, potential immunogenic porcine epitopes that may elicit an immune 
response to the engineered graft on implantation. Reduction in ‘non-self recognition of 
an implanted device/prosthetic by an individual’s immune system is a positive step 
towards biocompatibility.
This section of work aimed to determine several factors: an effective enzyme digestion 
period to disrupt cell nuclei and remove non-matrix proteins; to assay the activity of 
trypsin over time determining its effective life-span in relation to the optimal tissue 
digestion period and to assess macro and microscopic changes in the arterial wall 
through the digestion period. In order to optimise this process it was necessary to 
determine parameters of the enzymes activity. Firstly, trypsin activity was monitored 
over time to establish the enzymes operational stability. Arterial specimens were 
exposed to proteolytic digestion and studied both histologically and for gross protein 
reduction. Collagen is inherently resistant to neutral proteases (Friess, 1998), none-the- 
less it was critical to establish an optimal digestion period. Excessive proteolysis will 
render the matrix susceptible to failure under haemodynamics stresses, whereas a 
reduced digestion period may not remove residual cell components and other non­
matrix materials. Analysis of trypsin activity over the experimental time course and 
temperature range had shown 10.6% reduction in activity over 48 hours, a reduction not 
seen as significant to warrant changing the enzyme solution over the digestion period.
Similar to the lipid extraction process, a compromise was necessary, in this case 
between a digestion period that removes significant amounts of ECM protein and a 
digestion period, if too long, that damages the structure of the collagen/elastin fibres. 
Table 4.03 summarizes qualitative data that assessed effects of extended trypsin 
digestion on the ECM in terms of its elasticity, fibre morphology and the presence, or 
not, of porcine cell nuclei. Based on these results a 48 hour digestion period was 
selected. At this time point porcine cell nuclei had been completely disrupted and were 
no longer visible as independent structures, see Figure 4.14. Morphologically the
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ECM fibres appear slightly compressed or flattened at 48 hours with a marginal 
reduction in tissue elasticity. Digestion past 48 hours resulted in a more noticeable 
reduction in elasticity with partial fragmentation of collagen/elastin fibres, however no 
cell nuclei were present nor any nuclear material assessed by haematoxylin staining. 
The mechanism for nuclear disruption is speculated to be the proteolytic digestion of the 
molecules e.g. histones, which maintain the coiled nature of non-proliferating DNA 
within cell nuclei. As cell membranes have been disrupted by the solvent treatment the 
uncoiled DNA molecules are dispersed through the ECM.
In terms of protein extraction, SDS-PAGE analysis of processed arterial sections after 
ethanol treatments, taken at 24 hour intervals during trypsin digestion showed a 
progressive extraction of tissue proteins, particularly small molecular weight proteins. 
All samples displayed a reduction in the smaller molecular weight protein (<-75 kD). 
The end of the first 24 hour digestion SDS PAGE gels showed a loss of protein bands 
between -25-40 kD, from all tissue up to the point of the trypsin treatment. From 48 
hours and on to 120 hours further loss in protein is qualitatively noted. The aim of this 
experiment was to observe the gross loss of protein not identify individual proteins. 
Further analysis of loss in tissue weight is discussed in Section 4.4.5.
Images such as Figure 4.04 display variation of the 'preliminary’ material developed in 
Chapter 4. Showing sections of the adventitial layer remain attached to the ablumenal 
surface of the matrix, further and more importantly from an EC adhesion perspective the 
basement membrane has in some places been digested away altogether and in other 
areas (the majority) the basement membrane appears intact. Figures 4.18, show the 
basement membrane attached to the internal elastic lamina whereas Figure 4.19 shows 
regions where the underlying collagen of the medial layer is clearly evident. Although 
the importance of this layer is debatable as a tissue engineering product, it is 
undoubtedly critical within living systems where it provides cellular cues, aids EC 
adhesion, acts as a filtration barrier and as a barrier to VSMC migration into the vessel 
lumen which may result in neointimal hyperplasia. The argument for its complete 
removal, along with all other non-structural proteins and carbohydrates is that as the 
product must be considered a foreign body, irrespective of attempts to reduce its 
immunoreactivity through extraction processes and cross-linking, an immune response 
to the material is to be expected. Even if this response is considered ‘minor’ blood
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vessels, particularly small diameter vessels are extremely sensitive to thrombosis, due 
largely to there immediate proximity to blood and cells of the thrombolytic cascade. 
The argument to retain this membrane and other adhesive components of the ECM 
became clearer as the project matured. Again this is a qualitative assessment, but it 
appeared that EC have a propensity to adhere to regions of the matrix where the 
basement membrane has been retained. Although under static conditions (the bulk of 
the work) this was less obvious; when flow conditions where applied EC appear to have 
a higher retention in regions that the membrane has been retained. Apart for the 
adhesive components the membrane offers as relatively smooth surface for EC to 
adhere. The more fibrous sections, where the membrane has been removed, do not offer 
EC a uniform support surface that allows the EC to resist shearing off under flow 
conditions. Although the concept of a tissue engineered graft is that the graft is ‘grown’ 
in vitro prior to implantation the time required for EC to lay down a new and complete 
membrane may prove too long as time is a critical facto in production criteria. In my 
view, the maintenance of the membrane is advantageous to the final product, providing 
a confluent endothelium can be produced prior to implantation thus allowing some time 
for remodelling and the patient autologous cells to mask foreign epitopes remaining 
within the porcine tissue.
Processing steps involve chemical, physical (or other) agents to alter/modify a material 
will be subjected to variation associated with mass transfer within biological tissue. In 
particular a prolonged enzymatic digestion, a degenerative process, results in damage to 
the vessel wall, whereas a reduced digestion period fails to remove all the desired 
cellular and non-structural components. With uniform materials an acceptable balance 
can be found, by contrast observations of porcine carotid arteries have shown that the 
vessels taper and can have in excess of 50% variation in wall thickness from one end to 
the other. This variation results in thinner tissue being excessively digested in order for 
the cell nuclei etc. to be visually removed from thicker regions of the arterial wall.
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4 .4 .3  C r o s s -lin k in g
The final step, whereby the matrix material was physically altered was matrix cross- 
linking or stabilising the matrix, whereby potentially immunogenic epitopes are masked 
and the tissue modified in such a manner that it is resistant to host proteolysis. The 
process used to cross-link the matrix in this thesis was a modification of the method 
published by (Mechanic, 1994). The process utilizes methylene green as a photo­
catalyst to cross-link amino acids forming covalent bonds between adjacent chains of 
the collagen macromolecule (Kuntz, 1964). This was followed by and extensive 
washing step to aid removal of ECM components, including cellular and noncellular 
components that had been disrupted in previous steps such that washing would remove 
them from the tissue. In addition, mechanical characteristics: pressure test, stress-strain 
analysis and tensile strength were compared to non-processed material to ensure the 
matrix would remain viable if exposed to arterial haemodynamics, see Section 4.3.6.
As a methodology to cross-link collagen, the approach used in this thesis with 
methylene green as a photo-catalyst has been very successful. Firstly the method is 
simple and once set-up is relatively inexpensive to treat large quantities of tissue, 
secondly, the design and system application effectively cross-links the arterial tissue. 
This directly supports others e.g. (Mechanic, 1994) demonstrating the resistance of 
treated materials to both pepsin and collagenase digestion and (Moore et al., 1994) 
using xenogenic pericardial tissue, demonstrate the retention of physical and 
biochemical durability of the tissue implant, an essential quality for heart valve 
replacement. Photo-oxidation is an alternative method to what could be called 
‘traditional’ methodologies, such as glutaraldehyde tanning, to stabilize and render non- 
immunogenic. The mechanism of cross-linking is not completely understood, however 
the literature indicates that amino acids such as methionine, tryptophan, histidine and 
tyrosine maybe oxidised by irradiation with visible light in the presence of a 
photosensitiser resulting in the formation of cross-links that stabilise the collagenous 
material to enzymatic degradation (Moore et al., 1994) and (Schmidt and Baier, 2000).
Cross-linking was assessed in terms of resistance to enzymatic degradation with RP- 
HPLC by comparing treated with untreated (control) tissue. Collagen polypeptides are
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distinctive in their repetitive sequences in which every third residue is glycine (Gly), (- 
Gly-X-Y-)n) with a prevalence of proline (Pro) in the Y position (Creighton, 1993). 
Many of the proline residues in the Y position are hydroxylated after incorporation into 
the peptide chain to form hydroxyproline (Hyp). This distinctive amino acid 
composition has been used as a diagnostic tool to determine Hyp content and thus 
estimating the collagen content of tissues (Vincent, 1982). When collagen is cross- 
linked, it becomes more resistant to degradation by proteolysis due to the formation of 
non-digestible cross-links. Thus by comparing the concentration of free Hyp in solution 
after digestion in an enzyme solution for samples of cross-linked and untreated tissue 
samples the extent of degradation can be determined. The assay used in this thesis has 
been based on a protocol developed by (Bank et al., 1996).
Initial assessment of collagen degradation by the enzyme pepsin utilised lower 
concentrations of the enzyme ( 1 - 1 0 0  activity units/ml over a variety of time courses). 
At these lower concentrations and time courses, the extent of collagen degradation even 
with untreated tissue was minimal with no free Hyp detected. Pepsin concentration was 
increased to 1000 and finally to 5000 activity units/ml, with measurable quantities of 
Hyp not being resolved against background noise until 5000 activity units/ml was used 
as the digestion concentration (16.5 hours at 37°C). This alone gave a strong indication 
that the process has an effect in terms of stability or resistance to pepsin degradation. 
RP-HPLC showed the cross-linked tissue to yield only 21% of Hyp compared to control 
or untreated samples. Similarly the total peak area of the cross-linked tissue was less 
than a third (32%) of untreated control tissue.
Evaluation of the total peak area (as above) was an alternate method of accessing tissue 
degradation. This value is related to the total amount of amino acids and other 
detectable degradation products from the collagen break down, not specifically Hyp. 
This was used to give an estimation of the overall extent of the tissue degradation where 
Hyp is not present or where the concentration cannot be measured. The total peak area 
of tissue in the cross-linked samples was approximately a third (32.5%) of the control 
tissue which corresponds well with the results obtained for the digestion at 1 0 0 0  
units/ml, of only 23.4% of the amount of free Hyp digested from the unprocessed 
tissues. These results also support those described by (Mechanic, 1994) where cross- 
linked tissue was as low as a third of the unprocessed material.
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After the trypsin digestion DNA from disrupted cell nuclei remains associated with the 
tissue, shown as light blue strands, Figures 4.16a and 4.17a, both the lumenal and 
ablumenal surfaces, respectively. Following cross-linking and subsequent washing of 
the matrix to remove residual components, DNA on the surface has been removed, 
Figures 4.16b and 4.17b. The exact mechanism of DNA clearance is not clear but is 
likely to be combination of the cross-linking steps, where tissue is immersed in 4M 
NaCl, precipitating DNA and washing steps that facilitate removal non-bound 
particulates. The effect matrix cross-linking on cells seeded onto the matrix and their 
behaviour once seeded is discussed in Chapter 5.
4.4.4  W ashing
Amongst the selection criteria when choosing the method of photo-catalysing cross­
links in collagen using methylene green was to use a method where residual compounds 
posed no cytotoxic effect. Although methylene green is considered non-toxic it was 
desirable to remove as much of the residual stain as possible after the cross-linking 
procedure. In the series of images (Figures 4.16a-b and 4.17a-b) removal of DNA is 
shown after the washing steps, this process removes (in addition to the precipitated 
DNA and residual cellular debris) the bulk of the methylene green dye from the tissue. 
A third requirement of the washing process is to remove residues of the cross-linking 
process itself, in particular a 4M NaCl is used to allow the cross-linking solution to be 
held at 0°C without freezing also acting to osmotically shock and thus rupture cells. In 
addition, the hostility of the salt environment helps retain sterility of the tissue. Figures 
4.21 an SEM of the ablumenal surface post initial washing shows the presence of 
unidentified debris and Figure 4.15 a SEM of a ‘sliced’ transverse section displaying 
salt crystals within the matrix. Section 4.2.2.5 details the washing protocol where tissue 
is exposed to multiple washes in distilled H2 O over a two week period. Clearly this 
protocol has not removed the undesirable processing debris from the tissue. This issue 
is discussed in Chapter 6  ‘Perfusion Bioreactor Studies’ where the preparation and 
preconditioning treatments of the matrix within the bioreactor perfusion system further 
enhances the removal of salt deposition and processing debris.
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4 .4 .5  C o m p a r a t iv e  m e t h o d o l o g y  a n a l y sis
In terms of the success of a product the ultimate test is with implantation studies, any 
improvements from one tissue treatment methodology to the next without these 
implantation studies can only be speculative, with the literature used to support directive 
studies to theoretical advancements to the current technology. This section of work was 
carried out determine any comparative improvement over the tissue preparation 
methodology described by Mechanic et al (1994) cross-linking with the photo-oxidative 
process described in section 4.1.3. The product development from Mechanic et al 
(1994) earlier work has undoubtedly been enhanced since the publication of the initial 
patent, unfortunately the details of this work are unavailable for commercial reasons. 
The current product developed by Sulzer Medica, Austin Texas, using ‘PhotoFix® 
Technology’ (the development of Mechanic et al (1994) work) has been granted FDA 
approval and CE authorisation for human implantation. Comparisons made here are in 
no way meant as a direct comparison of their current methodology, only as an 
interpretation of one method described from the earlier publication (Mechanic, 1994) 
see section, 4.2.2.4. These methodological changes made from Mechanic et al (1994) 
work in this thesis may or may not improve the current technology as discussed below.
Although the cross-linking method described and utilised in this thesis is based on the 
said publication, the process has been theoretically enhanced with the addition of 
specific extraction steps for the removal of lipid and non-structural protein. Figure 4.27 
displays an expanded flow chart of processing events, where the main differences 
between the two methodologies are the lipid and protein extraction steps, which are in 
addition to the Mechanic et al (1994) patent. As a means to gauge relative differences 
between the two different treatment regimes, tissue lipid content and protein content 
were assayed.
Not surprisingly a reduction in both assayed components (lipid and protein) can be seen 
between the Mechanic et al (1994) process and this method due to the addition of 
specific lipid and protein extraction steps. Figure 4.22a, a chromatogram shows a 
dramatic reduction in tissue lipid content, where the Mechanic et al (1994) process 
retains all detected lipid components of untreated tissue. As discussed in the 
introduction to this chapter the extraction of lipids from the matrix has an important
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potential benefit, particularly with the use of EtOH as the extraction mechanism, where 
potentially immunogenic epitopes associated with lipids and lipoproteins are extracted 
and the associated reduction in tissue calcification. EtOH treatment as a method to 
reduce tissue calcification has been well documented in the literature, for example, 
(Courtman et al., 1994; Demer, 1997; Lee et al., 1998; Shen et al., 2001; Vyavahare et 
al., 1997; Vyavahare et al., 1998)
Figure 4.22b, an SDS-PAGE analysis of the tissues gross protein content, shows a 
progressive decline in total detected protein from untreated tissue to the Mechanic et al 
(1994) process to the method described in this thesis. Although the Mechanic et al 
(1994) process does not include a specific protein extraction step, the reduction in 
protein can be largely attributed to cellular proteins released into the ECM when 
exposed to high molarity preconditioning solutions and subsequently removed during 
the washing process. The further reduction of detected protein can be ascribed to two 
mechanisms. Firstly the process of lipid extraction will free (into the ECM) proteins 
associated with cell membranes (lipoproteins) and secondly proteolysis, where there is 
an increased efficiency of amino acid and peptide extraction/diffusion from the matrix 
results due to the smaller molecular weights of the digestion products. Results of the 
SDS-PAGE analysis clearly show a reduction in detected protein. This result is iterated 
with the results displayed in Figure 4.23, tissue weight loss. This establishes a 
significant difference in the weight of the tissue pre and post treatment between the two 
methods. Tissue processed according to Mechanic et al (1994) has no significant 
reduction in tissue weight with approximately 2%. Conversely, and predictably, the 
developmental matrix showed a significant weight loss of almost 18% compared to 
control tissue.
When considering the removal of protein from the tissue, a fine balance must be 
achieved between over-digestion and under-digestion. The ideal matrix would retain all 
the appropriate mechanical characteristics that maintain cellular phenotype and non- 
structural proteins critical to allow rapid adhesion, proliferation and migration of seeded 
cells. An important issue with the use of biological materials is the fact that they are not 
uniform. Along with variation in vessel wall thickness and diameter, the vessels are 
tapered. This variation complicates processing, where the process must either be 
modified to account for the variation or the variation must be reduced by tightening the
169
selection criteria. Without this balance, materials will have dramatically differing 
mechanical properties and compositions. The selection criteria used in the section of 
work was deemed adequate for experimental use where arteries measured 80-110 mm in 
length with lumen diameters from 3.5 - 6.5 mm (proximal) tapering to 2 - 3 mm (distal). 
Within this selection group variation was found to be acceptable, however arteries with 
dimensions at the extreme end of the selection range displayed inconsistent results, for 
example the trypsin digest was found to be ineffective at disrupting cell nuclei when the 
arterial wall thickness exceeded approximately 2.5 mm (qualitative observations). As 
preliminary studies in the development of this material, variation has proved a useful 
tool, for example EC prefer (qualitative observations) to adhere to the compressed 
section of the matrix, see Chapter 3, which has a similar morphology to the arterial 
basement membrane compared to the loose fibrous sections. These observation have 
promoted the idea that in preference to extracting all non-structural protein, retaining 
the basement membrane may allow a more rapid development of the endothelium, 
critical for a tissue engineered vascular graft.
4.4.6 M echanical  properties
To reiterate the objective of tissue engineering a vascular graft, an acellular matrix is 
prepared onto which cells of a known lineage are seeded. The developed construct is 
then ‘grown’ within a bioreactor, mimicking the in vivo environment to generate a neo­
organ that will behave in a similar fashion to the disease free native organ it is to 
replace. The research discussed in this chapter describes the development of a 
biomaterial suitable for use as a biomatrix for tissue engineering applications. Each 
phase, from matrix development to tissue engineering vascular grafts, required 
independent analysis. During the transition from an acellular matrix to a cellular 
neovessel, cells will lay down their own matrix materials, increase the density of the 
vessel and alter the physiology of the material by specific protein expression, for 
example SMC expression of a-actin, a contractile protein. In line with these concepts, 
the fully developed neovessel is likely to have markedly differing mechanical properties 
to the acellular matrix and in the case of vessel mechanics would ideally be analysed at 
three time points: untreated controls, as an acellular matrix and finally as a neovessel. 
Assessment of the acellular materials mechanical properties prior to cell seeding was
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deemed important to establish whether or not the decellularisation processing steps had 
altered the matrix to such a degree that recovery of the critical mechanical attributes, 
such as burst strength, was impossible, if indeed the mechanics had changed. Two 
analytical techniques were used to assess the mechanical attributes of the processed 
material: burst pressure and load extension.
P r e s s u r e  t e st in g
Although not a specific mechanical property of a material, pressure testing is a common 
property of all cylindrical vessels. Measurement of the burst pressure is a fundamental 
pre-requisite for a tissue engineered vascular prosthesis due to the haemodynamic 
stresses a prosthetic device with encounter on implantation. A variety of methods have 
been used to determine the point at which a vessel may fail at a given pressure, 
including pressurising the vessel with gas, (Roeder et al., 1999), where the pressure 
testing was measured by injecting regulated high pressure nitrogen gas into the artery. 
Contradictory to previous testing by Roeder et al (1999) the approach taken with this 
project has aimed to increase accuracy and yield more informative results by using an 
incompressible fluid (H2O) to pressurize the system. Initialisation of fracture is a 
function of the force applied by the fluid, whereas propagation of fracture is a function 
of the energy of the load. Gas is compressible and will retain some of the energy during 
propagation of fracture, resulting in a higher observed burst pressure than the true value 
(Vincent, 1982). The use of H2 O enabled the system to behave in a more appropriate in 
vivo Tike’ manner and allowed accurate identification of leakage points within the 
artery. Design aspects are detailed in the Section 4.2.4.
Burst pressure values reported in this investigation (1987 & 2260 mmHg mean values) 
are among the few reported in the literature. Roeder et al (1999) reported an average 
burst pressure of 2069-4654 mmHg for small intestine submucosa (SIS) vascular grafts 
of 5.5mm internal diameter; and Hiles et al (1995) reported a burst pressure of 5800 
mmHg for remodelled 5mm internal diameter SIS grafts in the dog (Hiles et al., 1995). 
It is clear that these values far exceed average pressures of approximately 80-120 
mmHg. In contrast to the initial presumption that the mean values at pressure failure 
would indicate an increase in the ability of the cross-linked tissue to withstand pressure 
over the untreated controls, no significant difference was found between the two
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data sets with a p > 0.05, see Figure 4.2.5. The important take home message is that 
although the pressure testing control, untreated porcine carotid arteries is only 
comparative to the fully processed acellular matrices and no direct comparison to the 
human arterial system is made, it can be said that processing has not been detrimental to 
the mechanical capacity of the material. Furthermore any remodelling of the material 
during the growth phase of development is likely to increase this capacity.
Lo a d - e x t e n sio n  TESTS
Load-extension tests involve cutting the artery into ringlets or strips and pulling them 
apart until the section structure failed. As a single 10cm artery could be used for twenty 
5mm length ringlets a large amount of data is produced thus reducing the effect of 
variation, often associated with biological tissue. Although convenient for mechanical 
analysis, the samples do fail to maintain their correct in vivo geometry. But since the 
tests are for a comparative analysis (raw and cross-linked tissue), this type of 
mechanical testing has been deemed acceptable (Dobrin, 1978). Hiles et al (1995) cut 
annular in the form of 3-5mm width ringlets and strained them to rupture in the radial 
direction, in open air, measuring force with extension. Courtman et al (1995) cut 4mm 
wide ringlets from the vascular sample, then cut them across to form strips, which were 
then attached to brass grips and stretched, all contained in an aqueous solution, giving 
force-extension results. The solution allowed the tissue to equilibrate and simulated in 
vivo conditions to some extent. Although this approach resembled in vivo conditions 
more closely, a piece of equipment similar to that described by Hiles et al (1995) was 
not available for use. Hence ringlet stretching in open air was chosen for this 
investigation. The error associated with testing (open air) is constant from test to test 
and is considered negligible in this comparative study. Load-extension measurements 
show how a material will act under increasing tensile force. Increasing the tensile load 
on a sample of material causes it to stretch and eventually fracture. It is common to 
express the load in terms of stress, and the extension in terms of strain to standardised 
values (i.e. per unit dimension and percent increase) clarifying result comparisons.
A stress-strain relationship can be determined for the tissue. Tensile strength can be 
analysed, based on the stress and strain observed respectively at fracture (De Diego et 
al, 2000). The elastic behaviour can be quantified in terms of the elastic modulus,
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which is a qualitative measure of stiffness; the larger the value or steepness of the 
gradient, the stiffer the material (Riley, 1999). The elastic modulus is equal to the 
gradient of the stress-strain graph.
MEAN FAILURE: STRESS AND STRAIN
The load-extension results, Figure 4.2.6, show the ultimate tensile strength (stress at 
which fracture occurs) to be over three times higher for the cross-linked material 
compared to the untreated raw tissue, 632 g/mm2 to 188 g/mm2 respectively. Figure 
4.2.6, shows the raw material fails at 85%, and the cross-linked tissue to fail at 104%. It 
is most likely that cross-linking is responsible for the great increase in ultimate tensile 
strength. The cross-linking process induces the formation of interchain cross-links 
amongst proteins (Schmidt and Baier, 2000). Collagen is a fibrous protein possessing a 
helical structure with 3 protein chains wound round a central axis. Numerous interchain 
links stabilise the helix and are probably the source of its great mechanical stiffness. At 
large distensions much of the stiffness of arteries is attributable to collagen (Dobrin, 
1978). Clearly increased cross-linking of these protein chains is likely responsible for 
the observed increase in ultimate tensile strength. Statistically there is no significant 
difference between these two values given the associated error.
Schmidt and Baier (2000) have shown significant increases in the apparent tensile 
extensibility and concluded that the effect is likely associated with shrinkage during 
fixation (Schmidt and Baier, 2000). Not dissimilar to the treatment process here, their 
treatment process involves an initial step where the tissue is ‘fixed’ with ethanol for 
preservation. Ethanol molecules essentially replace the water molecules within the 
tissue and stabilise the hydrogen bonds within the tissue protein. This has the effect of 
denaturing the protein as it shifts from a tertiary structure to a secondary structure whilst 
preserving it (Leong, 2001). It is speculated that the above-mentioned shrinkage may 
compress the matrix fibres, which may increase strain values (% extension) as initial 
stress values are higher due to earlier load uptake of the ECM fibres. In relation to the 
above references the results obtained in these tests, which show no significant change in 
strain values, maybe due to ethanol being removed from the tissue during the remaining 
processing steps.
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E l a s t ic it y
The biphasic shape of the graph (Figure 4.2.5) is expected for arterial walls distended 
circumferentially (Dobrin, 1978). The linear region is associated with elastin content in 
the wall, and the upward curving region is associated with collagen content in the wall. 
At extensions associated with physiological conditions (80-120 mmHg), stretched 
elastic lamellae and stretched collagen in the medial layer take the load and provide 
much of the stiffness. Above physiological pressures it is the collagen-rich medial and 
adventitial layers that provide the stiffness, acting as a protective outer jacket for the 
artery. At low strains much of the stiffness of the material is contributed by the elastin 
content in the arterial wall, and at high strains this is contributed by the collagen 
(Dobrin, 1978). As demonstrated in the previous section, the tissue has been tested far 
above physiological stresses. At physiological to moderate distensions it is a 
combination of elastin fibres and collagen fibres in the media that bears the load 
(Dobrin, 1978). At physiological pressures collagen fibres are not orientated and 
normally not taut (Dobrin, 1978). The elastic behaviour of the unprocessed and cross- 
linked material is illustrated Figure 4.25. The graphs are both a curvilinear shape, with 
the unprocessed material displaying a distinct linear and non-linear region, less obvious 
in the treated material. The increase in stress associated with the cross-linked material 
indicates an increase in stiffness or a decrease in the materials elasticity. The 
importance of elasticity in compliance matching of arterial grafts is an important issue, 
the reduction in elasticity shown in Figure 4.25 of the cross-linked material is not a 
positive result. Although a complete analysis comparing specific protein content 
(collagen EH, IV and elastin) between untreated and processed tissue is jet to be carried 
out, it is hypothesised that the increase in stiffness not necessarily a function of reduced 
elastin content, rather shrinkage if the ECM proteins and intermolecular cross-links 
restricting the normal function of the matrix resulting in increased tensile strength. The 
cross-linking process induces the formation of interchain cross-links amongst proteins 
(Schmidt and Baier, 2000). Clearly increased cross-linking of these protein chains is 
likely responsible for the observed increase in ultimate tensile strength.
With the development of enhanced cross-linking agents and methodologies previous 
problems with mechanical failures and infection can be overcome. The high cost 
involved with biological graft production may in turn be reduced with improved
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process control. The mechanical characteristics of biological materials are seen as its 
main advantage. If the vessel can be processed in such a manner that when implanted, 
the body accepts the conduit as a partially damaged vessel, in need of repair, i.e. it is 
treated as a wound, compared to foreign material, graft patency rates will improve. This 
is one of the important factors for the increased patency rates associated with the use of 
autologous veins or arteries. Characteristic of this processed artery is the retention of 
the basement membrane and internal elastic lamina. It has been suggested the presence 
of the internal elastic lamina acts as physical barrier to prevent the migration of vascular 
smooth muscle cells into the vessels lumen, which would otherwise result in intimal 
hyperplasia (Sims, 1985). Additionally the internal elastic lamina has been postulated 
to have an important role in the prevention of atherogenesis by acting as a diffusion 
barrier across the arterial wall (Hampton, 1983).
As discussed, this section of work is the first step in the development of a tissue 
engineered vascular graft. With a biomaterial that in theory has satisfactory 
biocompatible properties, the following chapters describe the use of this material initial 
under static conditions (Chapter 5) to monitor in vitro cell compatibility in terms of 
potential cytotoxicity and the ability of hVSMC to migrate into the matrix under static 
culture conditions, Chapter 5 and dynamic perfusion culture in Chapter 6 .
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CHAPTER FIVE: STATIC CELL CULTURE ON A PORCINE 
DERIVED ARTERIAL MATRIX
5 .1  Introduction
The previous chapter has detailed the development of a material for theoretical use as a 
substrate for tissue engineering purposes. The objective is to seed human vascular 
smooth muscle cells (hVSMC) and endothelial cells (HUVEC) onto the matrix and 
culture in vitro until a suitable cell density is achieved to function as a small diameter 
vascular graft. The effectiveness of a biomaterial to confer a high seeding/adhesion 
density of human primary cell lineages and their subsequent growth and proliferation is 
mainly dependent on the form in which a biomaterial is initially presented to the cells.
The aims of this chapter are to first assess the porcine derived arterial matrix developed 
in Chapter 4 in terms of biocompatibility under static in vitro culture conditions and 
second to determine if ECM remodelling enzymes are expressed by seeded cells. If 
expressed, are the cells able to migrate into the matrix via the degradative mechanisms 
associated with enzymes such as matrix metalloproteases during matrix remodelling or 
is migration a passive process where cells move from one location to the next via pores 
in the matrix? Third, to observe enzyme expression patterns of selected remodelling 
enzymes and note any unique spatial arrangements that may occur during static culture 
over extended time courses.
5.1.1 Matr ix  rem odelling
As discussed in Chapters 3 and 4, cross-linking collagenous matrices serves several 
functions: first to reduce the immunogenicity of the material by masking ‘foreign’ 
epitopes, second to sterilize the tissue and third to provide some level of resistance to 
enzymatic degradation, that is, resistance to host proteolytic enzymes. Based on the 
current literature, in particular (Mechanic, 1994) and (Moore et al., 1994), and the 
results discussed in Chapter 4.3 with RP-HPLC, it is clear that the matrix material has 
been stabilised to proteolytic digestion. However the degree of cross-linking can be
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further and possibly more accurately assessed by cellular migration within the 
biomatrix. The two main methods of cell migration within tissues are: motility 
between matrix fibres, much the same as when cells migrate from tissue explants onto 
the surrounding plastic culture plate (Kirschenlohr et al., 1996) and more importantly 
migration through matrix fibres by the secretion of a barrage of proteolytic enzymes, 
such as MMP to digest matrix components, for example in cancer metastasis (Foda and 
Zucker, 2001) and VSMC migration after endothelium injury (Owens and Clowes, 
1999). An important aspect of this study is that cells are able to migrate into the matrix 
to repopulate and functionalise the tissue engineered vessel. The extent of cross-linking 
is an important issue where a fine balance is required between too little and excessive 
cross-linking. Synthetic polymers may degrade via two main mechanisms: 
immunological reactions mediated by cellular recognition of foreign bodies and the 
material’s subsequent tagging for removal and the biomaterial simply dissolving in host 
fluids. In vascular networks, in particular the arterial system, the degradation rate is 
critical. If degradation is too rapid, graft tissue may fail prior to host cells repopulation 
and subsequent ECM production to stabilise the graft. The consequences, if utilised for 
coronary bypass, are likely to be fatal. At the other end of the spectrum, if the tissue is 
heavily cross-linked, host cells or those seeded onto the matrix during bioreactor 
development will not be able to penetrate into the matrix to remodel and populate the 
matrix to physiological levels. VSMC will ideally migrate into the matrix from the 
ablumenal surface to a distance of approximately 250 pm, a theoretical maximum 
distance between which cells can effectively communicate (Francis and Palsson, 1997), 
whereby cell-cell communication between VSMC and the endothelium can take place 
ensuring a more in vivo like phenotype. At this point cells will ideally be prevented 
from migrating or proliferating into the lumen of the vessel as a result of endothelium- 
induced inhibition of SMC proliferation (Owens and Clowes, 1999). It is envisaged that 
this will allow remodelling of a pseudo-muscular wall to confer contraction, and thus 
vascular tone.
As part of the cellular response to migration signals, which include: wound healing, 
matrix remodelling, chemotatic, mechano-transduced and cell density, a variety of 
proteolytic enzymes capable of degrading the ECM are expressed and localised to the 
immediate periphery of the cell surface allowing cells to migrate through tissues 
(Murphy and Gavrilovic, 1999; Owens and Clowes, 1999).
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Proteases have been classified into four major classes: serine, aspartate cysteine, and 
metallo. Grouped according to the different manner each enzyme catalyses the 
hydrolysis of the covalent bonds, which cleave the protein substrate (Chapman et al., 
1997). The following overview of these enzymes with emphasis on metallo and 
cysteine proteases clarifies the importance of these enzyme families in remodelling the 
ECM, particularly the vascular ECM.
S er in e  P r o t e a s e s
Earlier studies of cell migration concentrated on the serine protease urokinase-type 
plasminogen activator (uPA) and the generation of plasmin involved in cell migration. 
uPA is involved in a proteolytic cascade where it cleaves (specifically) a single bond in 
an inactive protease ‘plasminogen’ to yield its active form plasmin. Plasminogen is 
abundant in the blood stream and at sites such as wound healing, tumours, inflammation 
and other sites of tissue remodelling where it is expressed locally (Alberts et al., 1994). 
Plasmin is less specific than u-PA and cleaves a variety of proteins including laminin, 
fibronectin, and fibrin (Murphy and Gavrilovic, 1999). This is presumably to allow 
cells to migrate into the damaged area or tissue to be remodelled though a variety of 
different ECM molecules to elicit matrix repair, or in the case of tumour cells to allow 
cell migration through basement membranes during metastatic activity. uPA has been 
shown to play a role in VSMC migration through the basement membrane following 
denudation of the endothelium to initiate intimal repair and that uPA activity is essential 
but not sufficient for tumour cell migration in matrigel (Murphy and Gavrilovic, 1999). 
A further example of a serine protease relevant to this study is trypsin. Trypsin is one 
of the many mammalian digestive enzymes secreted from the pancreas. Its activity is 
strictly controlled by a series of inactive proforms or zymogens to prevent premature 
activation of this potentially destructive enzyme (Creighton, 1993). In this case 
trypsinogen is selectively cleaved by enterokinase to form active trypsin. Applications 
of this enzyme in the development of biomaterials are discussed further in Chapter 4.
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M a t r ix  m e t a l l o p r o t e in a s e s
The group ‘metalloproteinases’ consist of the proteolytic enzymes where heavy metal 
co-factors in the enzymes active site, such as zinc confer catalytic activity. As the name 
suggests matrix metalloproteases (MMP) comprise a family of enzymes that hydrolyse 
various ECM components. A selection of mammalian MMP and their known in vitro 
substrates are shown in Table 5.01 (Shapiro, 1998). With direct reference to the two 
MMP analysed for this part of the project, MMP-2 and 9, have a diverse range of 
catalytic activity with regard to components of the ECM. Both enzymes effectively 
degrade elastin, a range of collagens and multiple components of the ECM basement 
membrane. The earlier view that MMP are utilised as “weapons of mass destruction of 
the ECM” has recently been described as too simplistic, (McCawley and Matrisian, 
2001). Many observations describing the increasing complexity of protease function 
within the matrix depict several mechanisms where cleavage of matrix components may 
directly affect cell function McCawley and Matrisian et al (2001). For example 
fibroblast growth factor (FGF) and transforming growth factor-p (TGF-P), which have a 
strong affinity for matrix components, are released into solution when ECM 
components such as the proteoglycan perlecan which binds FGF is cleaved by MMP- 
1/3, similarly when decorin by is cleaved by MMP-2, 3 or 7 to release TGF-p 
(McCawley and Matrisian, 2001). In addition, both MMP-2 and 9 have been reported 
to convert the proform of TGF-p into an active ligand, which has effects ranging from 
the regulation of cell differentiation to increasing or decreasing cellular sensitivity to 
other growth factors (Alberts et al., 1994).
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Table 5.01: An overview of selected MMP and their substrates. With reference to MMP-2 and 
9 (highlighted), substrates of particular relevance to the arterial wall, which are studied here, are 
bold text. Modified from Shapiro (1998)*.
MMP Interstitial collagens Basement Membranes Elastin
Collagenases
MMP-1 I, II, III, VII, X FN, LN, EN, PG
MMP-8 I, II, III, (VII, X?) FN, LN, EN, PG -
MMP-13 I, II, III, GL (VII, X?) FN, LN, EN, PG -
Gelatinases
MMP-2 GL, I, VII, X, XI Col IV/V, FN, LN, EN, PG ++
MMP-9 GL Col IVA/, FN, LN, EN, PG ++
Stromelysins
MMP-3 FN, LN, EN, PG +/-
MMP-10 - FN, LN, EN, PG +/-
Stromelysins-like
MMP-7 FN, LN, EN, PG +
MMP-12 - FN, LN, EN, PG, PS col IV ++
Furin-recognition sites 
MMP-11






FN, LN, EN, PG
* As noted by Shapiro (1998), this is an incomplete list, representing only selected substrates 
tested to date (tested in vitro not in vivo). En, entactin; FN, fibronectin; GL, gelatin; LN, laminin; 
PG, proteoglycan; PS col IV, pepsinized collagen IV
C y st e in e  P r o t e a s e s
Cathepsin L belongs to the class of cysteine proteases. Cysteine proteases are further 
partitioned subgrouped into two super families: those relating to interleukin lp  
converting enzymes and papain superfamily of which Cathepsin L is a member 
(Chapman et al., 1997). Cysteine proteases are known to be specifically located within 
cellular lysosomes, although their localisation to outside the cell has been described in 
pathological circumstances such as cancer, rheumatoid arthritis and apoptosis (Turk et 
al., 2000). Lysosomes, membrane-bound vacuolar organelles, form part of the 
intracellular digestive system, within which an array of hydrolytic enzymes digest both 
unwanted cellular protein and extracellular material via phagocytosis or endocytosis. 
The more extensive role of cysteine proteases has only recently come to light. The 
significant role that cysteine proteases have outside the lysosomes, even within the 
ECM as part of normal physiology is only beginning to be understood in detail.
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There are currently 11 human cathepsins characterised (B, H, L, S, C, K, O, F, V, X and 
W). Cathepsin L appears to be ubiquitous in vertebrates, its main role within the 
cellular lysosome system being for protein degradation. Cathepsin L has also been 
identified outside the cell in both pro- and mature forms. Typically expressed by 
macrophages, fibroblasts, osteoclasts and others, cathepsin L has been found to have a 
variety of specific functions for example: Degradation of basement membranes (pH 3.5- 
6 ), elastin (pH 5.5), fibronectin (pH 5.5) and collagens (pH 3.3-6). Although these are 
optimal pH ranges, reduced activity will occur at physiological levels (Turk et al., 2000) 
and (Kirschke and Barrett, 1998).
The physiological role of these enzymes in tissue modification/remodelling clearly 
predicts their potential significance during the development of tissue engineered 
prostheses. It was with this view that experiments were designed to analyse the 
relationship between the degree of cross-linking and the ability of cells to migrate into 
and through the processed matrix.
This chapter describes the analysis of the arterial derived matrix, whereby initial studies 
focused on biocompatibility and methods to improve the efficiency with which cells 
adhere to the biomaterial. After static culturing on the matrix, hVSMC where assessed 
for expression of a-actin and their ability to migrate into the matrix. This was followed 
by immunohistochemical analysis of specific matrix metalloproteinases (MMP-2 and 9) 
and cathepsin L by to determine firstly, expression and secondly the spatial arrangement 
of expression. Examples from two classes of proteolytic enzymes, MMP (MMP-2 and 
9) and Cathepsins (cathepsin L) have been assayed for their presence and general 
pattern of expression when hVSMC have been seeded onto this material. (Two 
conditions were studied, static culture (this chapter) and perfusion culture with hVSMC 
in Chapter 7). The rationale for choosing and limiting analysis to these three enzymes is 
discussed in Section 5.3.
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5 .2  Material and  Meth o d s
5.2.1 Materials
Unless stated otherwise all reagents and material details are described in Chapter 2.1.4. 
All culture media was changed from either DMEM (hVSMC) or M l99 (HUVEC) based 
media to those supplied by PromoCell, Heidelberg, Germany. These media have been 
detailed in Chapter 2.1.3. This was due to the new media having improved buffering 
capacity.
5.2.2 Exper im en ta l  methods
Cells and cell conditions remain as described in Chapter 2.1.1 and 2.2.2 respectively. 
Matrix preparation, from unprocessed porcine carotid arteries to the processed and 
cross-linked matrix was carried out as described in Chapter 4.2.2, with an overview of 
the process in Figure 4.27. Immunohistochemistry, fluorescent immunohistochemistry 
and histological analysis were conducted as described in Chapter 2.3.6.
Matrix  ster il isa tio n  p r o c e d u r e
Sterilization and depyrogenation was a modification based on a method supplied by Dr. 
S. Badylak, Purdue University, USA, (personal communication). 0.1 % peracetic acid 
(v/v) and 4% EtOH (v/v) in distilled H2O was prepared in a solution ratio of 20:1 
solvent (ml) to tissue weight (g) e.g. 5 g tissue required 100 ml sterilising solution, 
consisting of 100 pi peracetic acid, 4 ml EtOH and 96 ml H2 O. Matrix sections were 
immersed in the sterilising solution for a total of 2  hours on a rotator/shaker then rinsed 
in 1 L volumes of sterile PBS on the rotator/shaker until the pH was stable at 7.4, 
minimum 24 hours and 3 PBS changes.
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P r e c o n d it io n in g  t r e a t m e n t s  a n d  HUVEC s e e d in g  t o  t h e  l u m e n a l  s u r f a c e  o f
THE ARTERIAL DERIVED MATRIX
To enhance the cell seeding efficiency a number of media or salt solutions were tested 
to determine an optimal preconditioning treatment immediately prior to cell seeding. 
Solutions tested; PBS, low serum EC media, (PromoCell), Smooth muscle cell media, 
Low serum VSMC media, (PromoCell), DMEM, FCS and FCS in a 1:1 ratio with 
DMEM. Media is described in detail in Chapter 2.1.3.
The matrix was dissected into sections approximately 5x5 mm and immersed in the test 
solutions (above) at 37 °C, 5% CO2 for 48 hours prior to cell seeding. Immediately 
prior to cell seeding the pre-treatment solution was removed and HUVEC suspensions 
(1.8 x 104 cell/ml/well) were seeded to a final density of 90 cells/mm2 onto the lumenal 
surface of the arterial matrix. Cell densities were assessed at days 3 and 9. Non-seeded 
matrix maintained in low serum VSMC media served as control samples.
hVSMC s e e d in g  t o  t h e  a b lu m e n a l s u r f a c e  o f  t h e  a r t e r i a l  d e r iv e d  m a tr ix
Matrix sections approximately 5 x 5  mm of fully process matrix was used and 
preconditioned with low serum SMC media for 48 hours at 37 °C 5 % CO2 . hVSMC 
(PIV) were seeded to a final density of 6.7 x 104 cell/ml or 333 cells/mm2 on the tissue. 
Data was collected on days 3 and 7 for DAPI staining and day 21 for histological 
analysis. Wax embedded 5 pm sections were cut and stained as appropriate for the final 
analytical technique utilised, see Chapter 2.3.6 for histological method.
5.2.3 A n a l y t i c a l  m e th o d s
All analytical methods used in this chapter are described in Chapter 2, Material and 
Methods.
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5.3 R e s u l t s
All cell lineages were phenotypically assessed prior to seeding cultures on matrix 
sections. As described in Appendix A l, HUVEC were assessed for their characteristic 
cobble stone morphology and for specific antigens CD 31 and von Willebrand factor 
(Factor 8). Similarly hVSMC were assessed for the spindle shape and characteristic 
‘hill and valley’ formations and for the specific hVSMC antigen for a-actin, see 
Appendix A l .
5.3.1 L u m en a l s e e d in g  an d  s t a t i c  c u l t u r e  o f  HUVEC o n  p o r c in e  d e r iv e d
ARTERIAL MATRIX
Matrix biocompatibility was tested by seeding HUVEC at PHI onto the matrix at 1 x 105 
cells/ml. A qualitative assessment was conducted by comparing cell adhesion to the 
matrix used straight from rinsing (H2O) to matrix pretreated for 48 hours in low serum 
EC growth media. After 3 days culture on the pretreated matrix, HUVEC were 
confluent, compared with cells on the non-treated matrix that remained at low densities, 
Figure 5.01, cell nuclei are stained light blue.
Figure 5.01: HUVEC seeded and cultured for 3 days on the porcine derived arterial matrix 
sections. HUVEC seeded onto control samples (non-treated matrix direct from washing) (A) 
show a lower retention than matrix pretreated with low serum EC media (B). Light stained cell 
nuclei were detected with the florescent nuclear stain DAPI.
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T r e a t m e n t s  t o  e n h a n c e  HUVEC a d h e s io n  o n  l u m e n a l  s u r f a c e  o f  t h e  p o r c in e
DERIVED ARTERIAL MATRIX
From previous work (Smith et al., 2000) we have found that pre-treatment o f porcine 
derived type I collagen scaffolds lead to improved fibroblast adhesion/proliferation. To 
determine if  the same was correct for this matrix the scaffold was pretreated with a 
number o f media or salt solutions. Solutions included HBSS, EC media, SMC media, 
DMEM, FCS and a 1:1 ratio FCS and DMEM, as described in Section 5.2.2. F1UVEC 
were seeded at 90 cells/mm2 onto the lumenal surface o f fully processed tissue sections. 
Results were assessed on days 3 and 9 using the fluorescent DNA stain DAPI, see 
Figure 5.02. As described in Chapter 2.3.1.2, 5 counts were taken on each of 2 tissue 
sections, with results expressed as mean values ± 1 sd, n = 2. The results show FCS and 
FCS:DMEM (1:1) have the highest seeding and proliferative efficiency with 1082 % 
and 871 % increase (respectively) in cell density from initial seeding. It was found that 
there was no significant differences between PBS, EC media, SMC media and DMEM 




















Figure 5.02: Effect of matrix pre-treatment on HUVEC adhesion to fully processed, cross- 
linked porcine carotid arteries. Day 3 g  Day 9 g . The dotted line represents initial seeding 
density of 90 cells/mm2. Results are expressed as mean values ± 1 sd, n = 2.
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5.3.2 A b lu m e n a l  s e e d in g  a n d  s t a t i c  c u l t u r e  o f  hVSMC o n  p o r c in e  d e r iv e d
ARTERIAL MATRIX
Based on the results in Section 5.32 where matrix sections were preconditioned in low 
serum SMC media for 48 hours as described in Section 5.2.2. hVSMC (PHI) were 
seeded at 6.7 x 104 cell/ml (333 cells mm2) and results assessed on days 3 and 7 for 
DAPI analysis and 3 and 5 weeks for immunohistochemistry analysis. As described in 
Chapter 2.3.1.2, 5 counts were taken on each of 2 tissue sections. Results from seeding 
hVSMC onto the ablumenal surface and cultured under normal conditions yielded 
variable cell densities that were not necessarily representative of the true cell density. 
Assessment of cell number/density was difficult due to the 3-dimensional fibrous 
structure of the matrix, limited by minimal depth-of-field at high magnification of cells 
embedded within the matrix during counting procedures could not be assessed, see 
discussion for further details.
186
After 3 days static culture cells are clearly seen among the ablumenal fibres of the 
processed matrix 5.04. Cell morphology was difficult to assess due to fibrous and more 
3-dimentional nature o f the matrix fibres surrounding the medial layer o f the processed 
artery. This is compared with the near 2-dimentional viewing o f HUVEC on the 
undulating basement membrane o f the lumenal surface.
100 pm
Figure 5.04: hVSMC seeded onto the ablumenal surface of the porcine derived arterial matrix 
and assessed at three days. DAPI stained hVSMC can be seen, (like lumenal HUVEC, Figure 
5.02) as light blue ‘spots’ against a darker blue background.
Extended cultures o f hVSMC seeded onto the ablumenal surface at 333 cell/mm2 were 
assessed after static culture periods o f 3 and 5 weeks for a phenotypic marker o f SMC, 
a-actin. Figure 5.05 displaying the migration o f cells stained with haematoxylin into the 
matrix, with Figure 5.06 showing immunohistochemically localised a-actin from the 
same cultures. It was speculated that cells have migrated into the matrix via the cut 
edge not necessarily through the EMC fibres. In all sections studied it was noted that 
hVSMC which often proliferated to multiple cell layers on the cut edge o f the matrix 








Upper: ablumenal surface of 
the matrices adventitial layer
Matrices medial layer
Lower: lumenal surface 
(face down on culture plate)
Figure 5.05: Extended culture of hVSMC on porcine derived arterial matrix. hVSMC seeded 
onto the ablumenal surface and cultured for 5 weeks, sections stained with haematoxylin 
showing hVSMC encasing the matrix and migrated into the arterial wall via the cut section of the 
matrix
Either initial cell adhesion, higher proliferation rates or migratory cues appear to favour 
hVSMC density at the cut edge o f the matrix compared with either lumenal or 
ablumenal surfaces, see Figure 5.06. hVSMC were positive for expression o f a-actin, 
particularly the outer layer o f cells where cells were more than one cell layer deep. The 
matrix displays a non-quantified ability to maintain the phenotypic expression o f a -  
actin by the hVSMC at 5 weeks, which contrasts static cultures on plastic surfaces 





positive for a-actin 
(DAB)
25 jim
Lower lumenal surface 
(face down on culture plate)
Matrix cut edge
Matrix
Figure 5.06: a-actin expression by hVSMC on arterial derived matrix. A higher magnification 
of hVSMC on the cut edge of the medial layer of the matrix after 5 weeks having been 
immunohistochemically stained for a-actin (shown as brown colouration by DAB) around the 
haematoxylin counter stained cell nuclei. Note the image orientation is the same as figure 5.05 
gauged by the orientation of the collagen fibres.
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5.3.3 A s s e s s m e n t  o f  m a t r ix  p e n e t r a t io n  a n d  r e m o d e l l in g  b y  hVSMC
Figure 5.07 shows the matrices outer adventitial layer seeded with hVSMC after 5 
weeks in culture, stained by haematoxylin. Cells were interspersed throughout the 
adventitial layer, showing an observable predominance for the outer surface. This 
contrasts Figure 5.06 where cells have adhered directly to the medial layer. Figure 5.07 
shows the adventitial layer o f the matrix wall, which contrasts the medial layer shown in 
Figure 5.06. The adventitial layer, which is less structured than the medial layer 
provides a very different physical environment for cell adhesion and viability.
Figure 5.07: Culture of hVSMC on the ablumenal surface of the porcine derived arterial matrix. 
hVSMC were seeded at 333 cell/mm2 and cultured for 3 weeks under static culture conditions. 
hVSMC nuclei have stained dark purple (A) by haematoxylin, note the random dispersion of 
cells within the loose adventitial layer compared to Figure 5.06.
A range o f proteolytic enzymes: MMP-2, 9 and cathepsin L which are known to be 
involved in the mechanisms o f cell migration and matrix remodelling were assessed for 
expression at two time points; 3 and 5 weeks. This was to gain an initial understanding 
o f the expression pattern, if  any, o f these enzymes in static culture on the developed 
matrix. In this section all hVSMC were seeded onto the ablumenal surface at 333 
cell/mm and were assessed after static culture periods o f  3 and 5 weeks. Results
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are shown for each immunolabelled enzyme from each time point at 3 and 5 weeks. 
The first image for each time/enzyme set is the negative control tissue section. 
Negative controls used the same tissue sections as the immunolabelled sections, i.e. 
with hVSMC adhered, the immunofluorescent staining process was identical except the 
step where the primary antibody is incubated with the sample was omitted. This was to 
determine the extent of background and non-specific staining by the antibody and to 
ensure, with evidence from H & E section that the localised staining is the actual 
enzyme targeted. As the controls are only for the immunolabelling procedure, which 
was the same for each time point, only one time point is shown.
MMP-2 EXPRESSION BY HVSMC ON ARTERIAL DERIVED MATRIX
Figure 5.08 shows a control section (as described above) illustrating a strong 
background staining of the acellular medial layer. Little background or non-specific 
staining of the adventitial layer is noted where the hVSMC were known to reside. 
Sections stained for MMP-2 at 3 weeks clearly identify the presence of hVSMC adhered 
to and within the adventitial layer of the matrix, Figure 5.09 at three weeks. Cells 
expressing MMP-2 are sparsely populated with no distinct pattern other than randomly 
dispersed throughout the adventitial layer of the matrix. Figure 5.10 where hVSMC are 
present large multicellular aggregates present on the cut surface of the matrix, having 
been cultured for 5 weeks on the matrix show similar positive staining for MMP-2.
In this study, as previously in Section 5.32, the matrix was laid, lumenal surface down 
on the culture plate, with the hVSMC seeded directly onto the adventitial layer. As with 
all images in this section, the collagen fibres, which were parallel to the culture surface, 
can be used to orient the image, see Figure 5.08.
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Figure 5.08: Control section, hVSMC seeded for 3 weeks on processed matrix and stained for 
MMP-2. The upper, adventitial surface B and lower lumenal surface A, can be used to orientate 
the image. Note the strong background staining of the medial layer (acellular), with little 
background or non-specific staining of the SMC layer on and within the adventitial layer of the 
matrix (A).
500 fim
Figure 5.09: Matrix staining positive for MMP-2 after 3 weeks culture, the presence of cells 
corresponds with areas of immunolabelled enzyme within the adventitial layer of the matrix.
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Figure 5.10: Positive staining for MMP-2 after 5 weeks culture, the presence of cells
corresponds with areas of immunolabelled enzyme (A) within the large cellular aggregates 
present on the cut surface of the matrix.
MMP-9 EXPRESSION BY HVSMC ON ARTERIAL DERIVED MATRIX
Figure 5.11 shows a control section (as described above) illustrating strong background 
staining, similar to the MMP-2 analysis, o f the acellular medial layer. Little background 
or non-specific staining o f the adventitial layer is noted where the hVSMC were known 
to reside, see Figure 5.05. Sections stained specifically for MMP-9 at 3 weeks clearly 
identify the presence o f MMP-9 having been expressed by hVSMC adhered to and 
within the adventitial layer o f the matrix. The most intense staining (qualitative) o f  
MMP-9 was at three weeks appearing on the extreme outer surface o f the matrix, see 
Figure 5.12.
Figure 5.13 where hVSMC are present large multicellular aggregates present on the cut 
surface o f the matrix, having been cultured for 5 weeks under static culture conditions 
on the matrix showing a similar positive staining as MMP-2. The pattern o f MMP-9 
positive regions within the cell aggregates is the extreme ablumenal surface, at the 
matrix-cell interface as expected.
F ig u re  5.11: Control section, hVSMC seeded for 5 weeks on processed matrix and stained for 
MMP-9. Strong background staining of the medial layer (acellular), with little background or 
non-specific staining of the SMC layer (A).
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F igure 5.12: Positive staining for MMP-9 after 3 w eeks culture, the  p resen ce  of cells
corresponds with a re a s  of immunolabelled enzym e (A) in this c a se  a s  a  m onolayer on the 
surface of the adventitial layer.
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F ig u r e  5 .1 3 :  Positive staining for MMP-9 after 5 w eeks in culture, the  p resen ce  of cells 
co rresponds with a re a s  of immunolabelled enzym e (A) within the  large cellular ag g reg a tes  
p resen t on both the cut surface and a re a s  of the  adventitial layers of the  matrix
C a t h e p s i n  L e x p r e s s i o n  b y  hVSMC o n  a r t e r i a l  d e r i v e d  m a t r i x
Control sections o f hVSMC seeded and cultured under static conditions for 3 and 5 
weeks on processed matrix, like previous controls where incubated without the specific 
primary antibody to determine background or non-specific staining. Figure 5.14 shows 
a control section displaying minimal background or non-specific staining within the 
hVSMC layer (A). Like previous controls for MMP-2 and 9 the collagen and elastin 
ECM (where hVSMC may reside but in low densities, see Figure 5.05) has a strong 
non-specific background staining. Little background or non-specific staining o f the 
adventitial layer is noted where the hVSMC were known to reside, see Figure 5.05. 
Sections o f matrix stained specifically for cathepsin L after 3 weeks static culture with 
hVSMC do not display a distinct increase in staining where hVSMC are present, 
indicating minimal, if  any gene expression and subsequent processing o f this protein, 
see Figure 5.15. Conversely static cultures extended out to 5 weeks clearly identify the 
presence o f MMP-9 having been expressed by hVSMC that have adhered to and within 
the adventitial layer o f the matrix, see Figure 5.16. Like MMP-2 and 9 
immunolocalisation o f the gene product appears to be restricted to the adventitial layer 
o f the matrix. The strong background staining within the matrix made it impossible to 
determine whether or not cathepsin L was expressed by cells within the matrix.
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Figure 5.14: Control section of hVSMC seed ed  for 3 w eeks on p rocessed  matrix and stained 
for C athepsin  L. Strong background staining of the medial layer (acellular), with little 
background or non-specific staining of the SMC layer (A).
Figure 5.15: No definitive positive immunolocalisation for C athepsin  L after 3 w eeks of hVSMC 
static culture.
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Figure 5.16: Unlike SMC cultured for 3 w eeks and stained for C athepsin L, 5 w eek cultures 
have stained positive (A), with som e sections showing a strong p resence  of cathepsin  L in a 
circular pattern speculated  to be the periphery of cell structures (B).
5 .4  D is c u s s io n
The objective o f this chapter was to establish in vitro biocompatibility o f the porcine 
derived arterial matrix, enhance HUVEC and hVSMC adhesion to the lumenal and 
ablumenal surfaces (respectively) and establish if  seeded hVSMC were actively 
remodelling the matrix by analysing the expression o f selected proteolytic enzymes.
Cell seeding studies have demonstrated that the matrix confers cell adhesion, growth 
and proliferation under static conditions. Previous experience with cross-linked porcine 
dermal collagen (Smith et al., 2000) has shown direct seeding, without preconditioning 
can result in sub-optimal adhesion, initial growth and proliferation o f cells seeded onto 
the matrix surface. Similar observations were made with this developed matrix, when 
HUVEC were seeded directly onto the lumenal surface after rinsing with H2O, (see 
Figures 5.01a compared to low serum EC media preconditioned matrix, Figure 5.01b), 
displayed noticeably different cell adhesion/growth rates. In order to optimise the cell 
seeding efficiency a variety o f treatments were applied to the matrix. Duplicate studies 
of preconditioning treatments revealed that the use o f 100% FCS resulted in very low
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cell counts on day 3, it was speculated that this was due to cells being washed off the 
surface during slide preparation. The likely cause of this result was that as the more 
dense fractions of the FCS settled during the 48 hour pretreatment phase a relatively 
thick layer of protein covered the surface of the tissue section, this in turn prevented 
cells at day 3 from fully adhering to the matrix and subsequently being washed off 
during slide preparation. Cells cultured over 9 days have more time to penetrate the 
protein/FCS boundary layer to adhere to the matrix resulting in higher cell densities of 
adhered cells. As the ultimate goal is to be able to implant the prosthesis, a defined 
media with minimal FCS, ideally none, is preferable. This is due to the unknown 
components (particularly growth factors) within serum that acceptable for use for 
products presented for implantation in humans by the FDA. For this reason both the 
SMC media (2 % FCS) and EC media (2 % FCS) with increases of 721 % and 558 % 
respectively, were not initially used. DMEM displayed a higher adhesion at day 3 (134 
%) than HBSS (3.6 %), although the day 9 results are not significantly different with 
615 % and 600 % increases respectively. Based on these results the media specific to 
the cells to grown was used to pre-treat the matrix prior to seeding, offering a qualitative 
increase in cell adhesion over H2O washed matrix preparations.
An important aspect with the use of biologically derived matrices is that the matrix 
material is presented to the seeded cells as a physical environment that is likely to be 
preferable over synthetic or reconstituted collagen matrices. It was intuitive that if the 
environment (both physical and chemically) more closely resembles the origins of the 
cells seeded onto the matrix, that cell phenotype may be maintained resulting in 
potentially improved graft patency. Direct evidence is not available in the literature to 
support this speculation, however the application of mechanical forces on cell seeded 
matrices, which is discussed in Chapter 7.1, undoubtedly demonstrate a link between 
the cells physical environment and gene expression. The ideal biologically derived 
graft would be immunologically inert and would retain components (e.g. basement 
membrane) that would confer an improved environment for cell adhesion, growth and 
proliferation over other materials. Comparative studies are required to determine any 
significant effect. In addition the application of further foreign materials could 
unnecessarily complicate graft development and the patients immune response to the 
implanted material. For these reasons methodologies to enhance cell adhesion 
involving, for example, immobilising biologically active molecules to inhibit thrombin
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formation or platelet adhesion (Phaneuf et al., 1997), have not been employed.
Characteristic of these processed biological arteries has been the retention of the internal 
elastic lamina; see Figures 4.18, 4.19 and LT-SEM Figures 4.23 and 4.24 which include 
elements of the basement membrane, although this has not been empirically confirmed. 
Providing remnant immunogenic epitopes associated with the internal elastic lamina 
(from the digestion step) have been masked by the cross-linking step, in concert with 
endothelium development during the tissue culture prior to implantation, the retention of 
the basement membrane is perceived as positive aspects towards a successful graft 
material. Although it is recognized that a fine balance exists between over digesting the 
vessel resulting in poor mechanical performance and inadequate digestion period where 
potentially immunogenic protein remains within the vessel. It has been suggested the 
presence of the internal elastic lamina (EEL) acts as physical barrier preventing the 
migration of vascular smooth muscle cells into the vessels lumen resulting in intimal 
hyperplasia (Sims, 1985). In addition the IEL has been postulated to have an important 
role in the prevention of atherogenesis by acting as a diffusion barrier across the arterial 
wall (Hampton, 1983).
The effect of having the appropriate cell-specific surface for cell to adhere to can be 
compared with earlier studies with the type I dermal collagen used in Chapter 3. Initial 
cell seeding density for this dermal derived matrix (after extensive washing and soaking 
in SMC media) was approximately 600 cell/mm , after 30 days culture cell densities 
remained below seeding density at 400 cell/mm2. Modification of the same matrix with 
NaOH, where the same seeding density allowed cells to reach 400 cell/mm still took 20 
days in tissue culture. This arterial derived matrix, under the same culture conditions 
when cells were seeded at 90 cell/mm2 reached almost 900 cell/mm2 with the same pre­
treatment regime by day 9. This may in part be due to the retention of the basement 
membrane, where, for example perlecan, an important proteoglycan located in basement 
membranes and associated with cell attachment (Haralson and Hassell, 1995). As the 
porcine derived dermal collagen matrix has no basement membrane, this could account 
for the increased adhesion of HUVEC to the arterial derived matrix, where the basement 
membrane had been retained. Basement membranes are specialized extracellular 
matrices fundamental to a diverse range of biological processes, including: embryonic 
development, maintenance of tissue architecture during remodelling and the ultra
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filtration of blood. The basement membrane has been described as an amorphous sheet­
like structure positioned between a cell layer and a thick collagenous stroma, composed 
of several macromolecular constituents, including type IV collagen, laminin and 
entactin interacting to form a supramolecular structure anchored to the underlying 
stroma by collagen VII fibrils (Haralson and Hassell, 1995). In blood vessels the 
basement membrane lies between the extreme lumenal surface of the endothelium and 
the internal elastic lamina, see Figures 4.18, 4.19 and LT-SEM Figures 4.23 and 4.24. 
Chapter 6 , it is speculated that the specialised structure of the basement membrane 
offers improved anchorage to HUVEC under flow conditions. This effect was not noted 
in this section of work due, likely due to reduced stress on cells allowing them to adhere 
to non-optimal surfaces (i.e. matrix not pretreated) during static growth.
Adhesion of hVSMC to the matrix is less clear, although appears to follow a similar 
pattern where the surface to which these cell naturally reside offers a preferred 
environment for growth and proliferation. SMC appear to favour adhesion and growth 
on the cut surface (exposed medial layer) as apposed to the adventitial surface. The cut 
surface, see Figure 5.05 is the area of the matrix, the media, that VSMC normally 
populate, whereas the adventitial layer is predominantly populated with fibroblasts. 
Results show that the density of seeded hVSMC within the adventitial layer is much 
lower than where hVSMC have adhered (or migrated to) the medial layer. This occurs 
in two places, 1 . where the adventitial layer has been completely removed during tissue 
processing and 2. the cut edge exposes the medial layer as described earlier. It is 
hypothesised that the variation in cell density is a result o f the cell-specific signal being 
retained in the medial layer, compared to the adventitial layer that, under normal 
conditions is predominantly populated with a lower density of fibroblasts (Wheater et 
al., 1979). This is based on the premise that hVSMC require higher densities within the 
medial layer of the arterial wall in order to perform the function of contraction 
conferring vaso-control of the arterial wall. This contrasts the lower density of 
fibroblasts, which sparsely populate the outer adventitial layer which have no physical 
role in contraction of the arterial wall (Sunthareswaran, 1998).
This chapter has explored the ability of the arterial derived matrix to support cell 
adhesion, growth and proliferation. Further to adhesion, growth and proliferation of 
HUVEC and hVSMC seeded onto the matrix the expression of matrix remodelling
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enzymes: matrix metalloproteinase 2 (MMP-2), matrix metalloproteinase 9 (MMP-9), 
Cathepsin L and general histology has been studied with the objective to determine if 
cells are migrating into the matrix, if they are expressing typical proteolytic enzymes 
and what type of barrier, if any, the cross-linked matrix offers to cells expressing these 
proteins. These and other enzymes serve as a barrage of proteolytic activity that under 
normal conditions readily allow cells to migrate through elastin and collagen fibres, to 
effectively remodel tissue as part of the natural course of growth and wound healing 
(Shapiro, 1998). The ability of transplanted cells to digest and migrate into the 
engineered tissue is of critical importance to confer high densities that may ultimately 
allow the construct to behave as native artery.
The rationale for choosing and limiting analysis to these three enzymes was based on 
several issues. MMP expression and function in the ECM plays a critical role in both 
physiological and pathological settings. In vivo remodelling of the vascular system is in 
a state of constant flux, where variations in blood pressure, heart rate and general health 
all contribute to this remodelling process. Inappropriate activity of these potentially 
damaging enzymes has received much attention in recent years due to their involvement 
in diseases such as rheumatoid arthritis and the progression of tumour cells during 
metastasis, have been shown to be mediated by members of the MMP family 
(McCawley and Matrisian, 2001). The requirement for general representatives of a 
wide variety of different protease groups was necessary. The activity of these enzymes 
is directly linked to cell migration with MMP-2 and 9 intimately linked in tumour cell 
metastasis and the turnover of arterial basement membranes (Foda and Zucker, 2001). 
Further, up regulation of MMP-2 and 9 is associated directly with abdominal aortic 
aneurysms (Crowther et al., 2000) and the reduction in scleroprotein content during 
plaque calcification (and its destabilisation) of the coronary arteries (Kieffer et al., 
2001). It is therefore expected that if expression occurs, providing the material is not 
presented as an impenetrable barrier, cells will migrate to a greater or lesser degree 
within the arterial wall. Also, between the gelatinases, MMP-2 and 9 a wide range of 
substrates are available within the vascular ECM that may present differing expression 
patterns.
In this study it was found that MMP-2 and 9 where expressed at both time points (3 and 
5 weeks). Confirmation of expression shows that cells are ‘attempting’ to modify the
201
matrix in some manner. Due to the limited nature of this study one can only speculate 
as to the intended nature of this expression, ECM remodelling, migration or both. It is 
with some certainty that the assumption can be made that the cross-linked matrix forms 
an impenetrable barrier at the medial layer to cellular migration, where close knit and 
non-degradable (due to extensive cross-linking) collagen fibres reside. It is noted in 
Figure 5.05 that migration does occur into the matrix, this is believed to be from the cut 
edge of the matrix only. As the collagen fibres lie in concentric layers around the 
matrix, cutting perpendicular to the fibres allows hVSMC direct access into the matrix 
without having to rely on matrix degrading enzymes to degrade collagen or elastin 
fibres. Cells adhered to the medial layer, via the adventitial surface do not appear to 
have migrated into the outer medial layer and remain as cell layers or dispersed within 
the adventitial matrix, Figure 5.07. The prevention of cell migration into heavily cross- 
linked biological tissue is supported by evidence with the matrix used in Chapter 3, 
where Smith et al (2001) unpublished data, noted human primary fibroblasts failed to 
penetrate into matrix after 5 weeks in culture. It is possible that cells are not receiving 
the correct cues to initiate migration, however the expression and subsequent immuno- 
localisation of specific matrix degrading enzyme to cells, clearly indicate cells are 
intending to migrate but are prevented in doing so.
The surfaces that hVSMC have adhered to (adventitial and/or directly onto the medial 
layer) show a variation in cell proliferation and spatial arrangements, as discussed 
earlier. Cells within the adventitial layer are sparsely populated, Figure 5.06 which 
directly contrasts cells adhered on or near to the medial layer, Figure 5.05 that are 
densely packed in multiple cell layers. In both of these regions cells display MMP-2 
and 9 immunolocalisation. The pattern of immuno-localisation was expected to be 
intense staining at the base of the cell layers immediately adjacent to the collagen 
barrier that would indicate the cellular intention to migrate or remodel the adjacent 
matrix. It was interesting to observe that 5 week cultures where cells are densely 
packed the localisation of both MMP-2 and MMP-9 was around cells on the outer most 
layer, that is the layer not adjacent to the matrix, see Figures 5.11 and 5.15. An 
explanation for this is speculative in that cells adjacent to the matrix have been in close 
association with the impenetrable ECM for the longest period, it is possible that by the 
first time point these cells have completed ECM expression and remodelling, whereas 
cells in the outer layers are still in the process. It is also possible that it is an artefact of
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specimen preparation, however controls eradicate this possibility.
The selection of the cysteine protease cathepsin L was based on several factors; firstly 
and primarily as an integral part of the cellular degradations system, this enzyme along 
with other lysosomal enzymes maybe highly expressed due to large amounts of protein 
fragments from the matrix processing steps, in particular trypsinisation remaining in the 
ECM. Secondly as a secreted protease, compared to other cathepsins, the function of 
cathepsin L outside the cell membrane is not fully understood. As discussed in the 
introduction, procathepsin L or cathepsin L it has been noted that a wide range of cells 
express this gene and export the gene product to the ECM. The functions of this 
proteolytic enzyme range from degradation of basement membranes, elastin, fibronectin 
and collagens to the activation of urokinase-type plasminogen activator (uPA) involved 
in the proteolytic cascade that generates plasmin which is implicated in the processes 
cell migration, (Kirschke and Barrett, 1998) and (Alberts et al., 1994).
Results from this series of experiments, done in concert with the MMP work, have 
shown, firstly that cathepsin L did not appear to be expressed in 3 week cultures 
whereas the enzyme was immuno-localised in 5 week cultures. In 5 week cultures 
cathepsin L was not localised where cells were present in monolayers, nor where cells 
were densely packed in cell layers, the enzyme was localised in clusters within the 
adventitial section of the ECM, Figure 5.19. In this image, a circular arrangement of the 
localised enzyme is associated with what appears to be the cell membrane, this supports 
the hypothesis that cells focus proteolytic activity at the cell surface to degrade ECM 
components presented as barriers to migration or as a mechanism of cell detachment 
(Murphy and Gavrilovic, 1999). This was however only one tissue section of many and 
was atypical, a majority of expressed enzyme was seen as smaller amorphous zones that 
are possibly associated with the lysosomal activity which cathepsin L is mainly 
associated.
Initial studies of the porcine derived arterial matrix, in terms of cell compatibility, have 
shown that like the porcine derived dermal collagen matrix used in Chapter 3, 
preconditioning is an important prerequisite to seeding primary human cells. Studies 
designed to determine an appropriate pretreatment have illustrated that different 
solutions provide (not surprisingly) a range of environments, some more compatible
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than others for cell growth on this matrix under these conditions. The resulting choice, 
DMEM was found to be substantially better than distilled H2O. Evidence in this chapter 
has shown that this matrix is superior to the dermal collagen used in chapter 3 as a 
material for adhesion, growth and proliferation of HUVEC on the lumenal surface under 
static conditions. Results from hVSMC culture on the ablumenal surface are more 
difficult to interpret due to technical issues with the method used to determine cell 
density, though it appears to offer a stable environment that is conducive to cell 
maintenance with no evidence of the matrix cytotoxicity displayed with the former 
matrix. Immuno-localisation of MMP and cathepsin L proteases has clearly shown the 
expression of these enzymes. The primary aim of this study was see if these enzymes 
were being expressed and if so, are cells capable of migrating into the matrix given the 
‘machinery’ is present. Evidence from immuno-localisation of MMP-2 and 9 and 
Cathepsin L suggests that under static culture condition hVSMC are unable to penetrate 
into the medial layer of the processed matrix.
Results have shown that the porcine vascular matrix retains a large degree of it native 
biomechanics (Chapter 4) and in vitro biocompatibility properties. The growth 
inhibition displayed by the dermal collagen used in Chapter 3 (cross-linked with HMDI) 
is not noted with this specifically designed and developed biomaterial. Under static 
conditions both HUVEC and hVSMC have been shown to maintain adhesion over 
extended culture periods and express enzymes involved in the processes of matrix 
remodelling. It is clear that these results support continued studies using this matrix to 
further develop a tissue engineered small diameter vascular graft.
The following section of work, Chapter 6 , describes the progressive development of a 
dynamic perfusion system. The system incorporates bioreactors that maintain the 
porcine derived arterial matrix in sterile containment whilst allowing the application of 
dynamic forces that mimic in vivo conditions. Chapter 7 progresses this work further by 
seeding human primary cell lineages onto the matrix, within the bioreactors to ‘grow’ 
the graft under defined conditions.
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C H A PT E R  SIX: DEVELOPMENT O F A VASCULAR 
PER FU SIO N  CULTURE SYSTEM
6 .1  In t r o d u c t io n
Typically, static cell culture within tissue engineered matrices is limited by reduced 
mass transfer of key components, for example O2 , metabolic by-products, growth 
factors, glucose etc. The limit with which these components can effectively diffuse into 
and out of a matrix to provide the adhered cell populations with an environment 
conducive to cell growth and proliferation is approximately 100 pm (Vanjak- 
Novakovic, 2002). A methodology to reduce these mass transfer limitations is with the 
use of bioreactors. The second design parameter is that the bioreactor needs to deliver 
to the matrix an environment that mimics the environment that the developing matrix is 
to replace. With specific regard to this project, the bioreactor has been designed to 
deliver media (that emulates the human bodies blood) through the matrix lumen media 
in a pulsatile fashion (that emulates the pressure and flow of blood delivered through the 
vasculature by the heart).
The design and calculation of the bioreactor and its support infrastructure has taken into 
consideration two important criteria, first the emulation of physiological conditions in a 
system that allows for the continuous modification of flow parameters, much the same 
as the heart under normal operating conditions where pulse, flow and pressure are in a 
state of dynamic flux delivering blood throughout the circulatory system. Second, the 
system must be compact and functional in its use in both sterile and non-sterile 
environments. Importantly, concessions have been made that have sacrificed the 
principle aim, to emulate physiological conditions, in order to develop a system that that 
is both useable and is capable of delivering the desired results. These concessions will 
be discussed in this chapter along with the developmental process where a three-part 
system including a functional bioreactor and process flow and support infrastructure has 
been created. As an overview to the three primary components of the vascular 
perfusion system a brief description of each component and its primary function is 
given.
205
As part of the closed circuit pumping system the bioreactor, which contains the matrix, 
is the focal point of the system. Connected to the pumping circuit via lumenal and 
ablumenal flow connectors the reactor receives the pulsed flow generated by the 
peristaltic pump and delivers it to the matrix with minimal disruption to the prescribed 
flow regime. The reactor, using the principles of convective flow, aims to deliver 
uniform transmatrix pressure differentials that allow for uniformity of matrix processing 
and the delivery of nutrients/gases to the cellular populations to confer optimal cell 
growth and proliferation. The flow circuit and pump contained within it comprises a 
pumping unit where pulsatile media flow, pressure, and the pulsatile wave form are 
developed, the characteristics of which emulate in vivo physiological conditions. Media 
is delivered to the bioreactor by the flow circuit, a recirculatory system allowing for 
multiple passes of media. Coupled to the flow circuit are a number of devices, ports 
that allow for the efficient running and monitoring of the system, the support 
infrastructure. The media within the system was maintained within set parameters. A 
multitude of different components (discussed in this chapter) provide an environment 
conducive to long-term mammalian, specifically, primary human cell culture. These 
include: temperature control, CO2 and O2 gas regulation, nutrient maintenance, pH 
control and pulsatile pressure wave analysis, via a specifically designed computer 
program. The system has also been designed to allow transfer of the whole system into 
and out of sterile containment for process manipulation, sample analysis and media 
exchange etc.
The objectives of this chapter have been the development of a pulsatile perfusion 
system that mimics human small arterial blood flow and retains the ability to modulate 
pressure in both lumenal and ablumenal volumes. The reactor and support 
infrastructure must transfer to the matrix a physiological-like environment, which is 
conducive to long-term culture of human primary cell cultures.
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6 .1 .1  T h e  e f f e c t  o f  m e c h a n ic a l  f o r c e s
The important of mechanical forces applied to a tissue engineered graft cannot be 
understated. The physical environment in which a cell persists has a profound effect on 
cellular behaviour. Why are these effects so important? Cells persist in a state of 
constant flux, molecular attachment to the matrix, cell-cell adhesion and diffusible 
molecules or ligands modulate the cellular phenotype. Furthermore mechanical forces 
contribute directly as the matrix surrounding the cells expands, contracts or blood shear 
forces act on the cell surface. These shear forces act by stressing a variety of different 
molecules attached to the cell membrane that transmit via cell signalling cascades or 
directly through actin filaments or other transmembrane proteins connecting to the cells 
interior organelles, (Davies 2002).
Over the last 30-40 years cell culture technology has profoundly affected the cell 
biologist ability to culture specialised cells in the laboratory, however this has usually 
been at the expense of using undefined media, for example when supplementing with 
foetal calf serum, the addition of multiple growth factors, or both. The use of such 
media, from a FDA perspective, is undesirable due in large to our lack of knowledge of 
the specific action of undefined serum components. Even with the use of these complex 
medias, terminally differentiated primary human cells progressively loose their specific 
phenotype after prolonged maintenance in static tissue culture. The use of tissue 
engineering principles, such as the application of mechanical forces to maintain cellular 
phenotype for extended periods in vitro prior to implantation is an important aspect of 
this approach.
In this section an overview complementing the review on tissue engineering 
applications in chapter 1, outlining the forces acting on EC and VSMC biology that 
critically modulate cell function. This includes mechanical forces, gas concentrations, 
waste and nutrient gradient. It is therefore necessary to emulate as closely as possible 
the conditions the graft will be placed in, in order to precondition the living graft to its 
intended environment.
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R e s p o n s e s  E n d o t h e l ia l  C e l l s  t o  M e c h a n ic a l  s t r e s s e s
The heart provides the driving force for blood flow; where the systolic contraction of 
the ventricles ejects blood into the circulatory system; see Table 6.01 for pressure wave 
velocities. When contraction is complete the heart relaxes, ‘diastole’, and some back 
flow is evident in the aorta and blood vessel elasticity acts to store blood volume during 
systole allowing forward flow to continue as the heart cycles back to diastole. The 
pressure wave is generated as blood is ejected from the heart and is dependent on stroke 
volume, heart rate, blood volume, peripheral resistance and elasticity of the arterial wall.
Table 6.01: Arterial p re ssu re  w ave velocities (Milnor, 1989).
Artery W ave Velocity (cm /s)





Pulse pressure is determined by the difference between systolic and diastolic pressures, 
where the mean arterial pressure is averaged over time. As a larger portion of time is 
spent in diastole than systole, the mean average arterial pressure is not merely taken as 
the midpoint between systolic and diastolic pressures. Approximate mean arterial 
pressure is calculated by adding one third of the pulse pressure to the diastolic pressure. 
(Sunthareswaran, 1998). At rest, the normal blood pressure for a healthy adult male is 
120/80 mmHg. Variations in blood pressure are caused by factors including age, sleep, 
exercise, anger, stress, sexual excitement, pregnancy, respiration, physiological and 
pathological processes. The three main flow regimes in systemic and pulmonary 
circulation are turbulent, laminar and single-file flow. Systemic and pulmonary blood 
flow is predominately laminar. Turbulent flow occurs in the heart ventricles, as blood 
passes through the valves, and as blood immediately leaves the heart via the pulmonary 
artery and aorta, as well as in abnormally narrowed regions e.g. arteriosclerosis. Blood 
flow through capillaries is defined, as is single-file due to the single file manner in 
which red blood cells travel through the capillary (Sunthareswaran, 1998).
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The endothelium was once thought of a simple passive nonthrombogenic barrier but is 
now recognised as a dynamic participant in the active physiology of the vasculature by 
controlling vascular tone and haemostasis (Sumpio, 1993) and (Nerem et al., 1993). 
Haemodynamic forces acting on the endothelium include: tensile stress, acting along the 
vessel wall due to circumferential deformations, hydrostatic pressure stress (cyclic 
strain) and shear stress acting along the length of the vessel due to blood flow (Sumpio, 
1993). All of which are generated by the pulsatile action of the cardiac cycle and the 
resulting blood flow through the arterial system. The action of these forces on the 
endothelium results in a host of different responses ranging from morphological 
changes to secretion of bioactive compounds. At a morphological level the application 
of fields of force on a confluent layer of endothelial cells results in an elongation of the 
cells to align tangential to the flow field. In an earlier study Ives, et al (1986) had 
shown HUVEC, which under static growth conditions form a cobble stone pattern, 
when exposed to cyclic stress, the cells align in the direction of stretch (Ives et al., 
1986). Thoumine et al (1995) exposed confluent bovine aortic endothelial cells 
(BAEC) to a range of conditions that included exposure to laminar steady shear stress of 
30 dynes/cm2 for 24 hours. Similar to Ives et al (1985) the BAEC elongated in the 
direction of flow between 12 and 24 hours after the commencement of the flow regime. 
Not surprisingly a direct relationship was noted between the cytoskeletal proteins (f- 
actin, vimentin, and vinculin) with this change in morphology. Interestingly they had 
shown that four other conditions also produced elongation of cells, including: altering 
Ca concentrations, culture on collagen gels, adhered c.f. floating monolayers and 
culturing cells on patterned surfaces (Thoumine et al., 1995). A change in morphology 
is therefore not necessarily a result of one condition alone, but a process in which cells 
adapt to each unique environment, unless with direct chemical intervention, such as 
altering Ca concentrations, to alter a variety of different cell mechanisms such as the 
concentration of intracellular second messengers.
The effects on endothelium physiology are reported extensively in he literature and have 
not been reviewed; rather it is suffice to say that forces (as mentioned above) acting on 
EC biology critically modulate cell function (Davies 2002). It is therefore necessary to 
emulate as closely as possible the conditions the graft will be placed in, in order to 
precondition the living graft to its intended environment. For example a decrease in cell 
proliferation as shear stress increases and the lack of any stress may induce apoptosis in
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vascular endothelial cells, where a basal level of apoptosis occurs in normal static 
culture conditions of 0.5-3% (Kaiser et al., 1997). In addition there is a strong influence 
on secretion of active molecules, in some cases up regulated others down regulated and 
others show no change at all (Nerem et al., 1998). Importantly, the application of a 
specific shear regime determines a specific result or change in cell behaviour. For 
example pulsed compared to steady flow produces different patterns of gene expression, 
Nerem et al (1998) have shown HUVEC expression of VCAM-1, an adhesion molecule 
altered differentially between culture conditions from static to steady and pulsed flow 
(Nerem et al., 1998).
R e s p o n s e s  o f  V a s c u l a r  S mooth  Mu sc l e  C ells t o  M ech anical  s t r e s s e s
Vascular smooth muscle cells are a critical component of the vasculature residing in the 
medial layer of the vessel wall and as such are directly exposed to mechanically 
dynamic environment (Kim et al., 1999). If environmental cues are lost, for example 
when explanted vascular tissue is cultured statically in a laboratory, cells, particularly 
specialised primary human cells such as hVSMC, revert back to a more simplistic or 
less specialised phenotype. Like the endothelium, smooth muscle cells provide a 
specific function to a vessel wall, not least to confer the ability of vessel contraction, 
thus providing control over peripheral blood flow. The loss of the in vivo phenotype is 
often associated with an increase in proliferation and a loss their specialised expression. 
In the case of hVSMC they loose the ability to contract, which confers vasomotor action 
to the arterial wall and as such do not behave in vitro as they do in vivo (Jones, 1996). 
This loss of contractile ability can be identified immunohisto/cytologically by localising 
the protein a-actin, as part of this contractile machinery, within the cell cytoplasm. The 
anti-human smooth muscle actin antibody binds to the a  smooth muscle isoform of 
actin. This technique has been used in this thesis to identify and confirm the different 
cellular phenotypes cultivated in this thesis, see Appendix A l.
It has been widely shown that the application of mechanical forces akin to the cells 
native in vivo environment prolong their specific phenotypic expression in in vitro 
culture, and certainly affects or modulates a gene expression. PDGF is a potent 
mitogenic stimulus to VSMC proliferation and is likely to mediate the response of 
VSMC to cyclic strain, Ma et al (1999) demonstrated the expression of platelet-
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derived growth factor-B (PDGF-B) and its receptor PDGF p (PDGF p) on the cell 
surface in response to exposure to cyclic strain (Ma et al., 1999). Birukov et al (1995) 
have clearly shown the application of cyclic stress on VSMC selectively induces 
expression of the phenotypic marker h-caldesmon, whereas omission of the stress 
reduces expression (Birukov et al., 1995). Interestingly Kim et al (1999) showed that 
rat cells cultured on fibronectin or vitronectin responded to mechanical stimulation 
(Flexercell unit) by an increase in proliferation, however the same cells cultured on 
laminin or collagen exposed to the same conditions did not when cultured in serum free 
media, when changed to serum-containing media proliferation was induced. This was 
explained by the adsorption of fibronectin and vitronectin from the 1 0 % serum- 
containing media onto the surface the cells were cultured on. Similarly Kim et al (1999) 
cited an increase in elastin and collagen synthesis on fibronectin-coated bonded PGA 
scaffolds but not on type I collagen sponges when cells were cultured in serum-free 
media, again when cultured in 1 0  % serum media and exposed to cyclic strain cell on 
the collagen sponge produced increased levels of elastin. In both cases western blot 
analysis had shown that fibronectin had been adsorbed to the matrix, concluding the 
adsorbed proteins were responsible for the positive response of SMC when exposed to 
cyclic strain. Costa et al (1991) also reported an increase of elastin synthesis by bovine 
aortic SMC when subjected to repetitive cyclic strain (Costa et al., 1991).
Mechanical strain of this nature can be seen as an indirect force applied to the arterial 
wall as a consequence of cardiovascular output. Intimal hyperplasia and medial 
thickening is a critical factor, particularly in vein grafts, where VSMC migrate and 
proliferate into the vessel lumen effectively restricting blood flow. The significant 
histological changes undergone in this process have been reported to be a response to 
mechanical stimuli and has been shown that when blood flow or velocity has been 
reduced the occurrence of intimal hyperplasia increases (Sumpio, 1993).
The importance of blood flow characteristics and vessel wall structure/mechanics are 
not to be underestimated in the development of a tissue engineered vascular graft. The 
cells that populate blood vessels (endothelial, smooth muscle and fibroblasts) maintain a 
specific phenotype largely due to the direct effect of chemical and physical factors in 
the local environment e.g. matrix structure, mechanical properties and the fluid flow 
regime. Structural and dynamic effects on cell populations in vivo are an important
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factor in the prevention of graft thrombosis, the main cause of small diameter graft 
failure. For this reason this project aims to progressively develop in vivo fluid and 
mechanical characteristics that aims to improve the patency of small diameter vascular 
grafts.
6.1.2 B io r e a c t o r s
The previous section describes why the mechanical environment is critically important 
in maintaining cellular phenotype, this section describes the design and application of a 
pulsed perfusion flow circuit using a unique bioreactor to apply or direct the appropriate 
mechanical stimuli to the cultured graft. The importance of these forces in maintaining 
function of a prosthesis are seen as a critical preconditioning step that allows the cellular 
component to interact and in theory improve performance prior to implantation. In 
addition the application of convective flow will generate uniform transmatrix pressures, 
see Figure 6.01, that will allow cells to migrate into the matrix without subjecting them 
to the same nutrient and gas diffusion limitations of cells in static culture. Due to the 
relative infancy of the subject area, literature describing the development of vascular 
bioreactors is limited with little in the way of standardised design (L'Heureux et al., 
1998; Nerem and Seliktar, 2001; Niklason et al., 1999; Niklason et al., 2001; Seifalian 
et al., 1999; Smith et al., 2000; Surowiec et al., 2000; Teebken et al., 2000; Werkmeister 
et al., 1995; Zilla et al., 1994). With few exceptions the descriptions of vascular 
bioreactors have tended to either overly simplistic or appear to have avoided accurate 
description of the reactor due presumably to intellectual property issues. For this reason 
a unique system has been developed that draws on design features from a variety of 
different perfusion culture systems, see Figure 6.01.
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D e s ig n  O b j e c t iv e s :
Control chemical environment; e.g. C 02, P 02, nutrients, pH
Control physical environment; e.g. pulsed flow rate and frequency, and pressure
Maintenance of sterility
Accessibility; e.g. removal and addition of culture/growth components
Material compatibility; e.g. cell-media exposure to all components within the system
Maintenance of long-term cell culture
Reproducibility of ‘standardised’ reactor design
Reproducibility of ‘standardised’ culture conditions
Ability to monitor system: e.g. construct progression
Simplicity in design and implementation
Ablumenal 
nutrient flow
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Figure 6.01: An illustration of perfusion conditions and construction theory: ► Indicates cell
migration into vessel, media perfusion and transmembrane differential pressure, —> -  indicates 
nutrient flow indicated.
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A major challenge in reactor design is the analysis of the tissue engineered construct 
within the reactor. Current technology requires off-line analysis, where the construct is 
harvested for each sample. Several analytic methodologies can be employed to 
detennine the progress the construct during the culture phase of development, however 
many of these are indirect approaches that are dependent on the metabolic activity of the 
cells being cultured. Current methods employed to analyse cellular metabolic activity 
from media samples include: glucose consumption, lactate production and concentration 
of O2 and CO2 . These methods are likely to perform well with cell lines such as 3T3 
fibroblasts where cell growth and proliferation are relatively uniform within a defined 
environment. Where the challenge lies is with the use of autologous or patient specific 
primary human cells. The process of isolating specific cell lineages from a patient 
further complicates this issue, however the important point is that each patients cells 
behave differently. Parameters such as age, cell source, patients general health and the 
potential diseased nature of some cell isolations results in a huge variation in metabolic 
activity which makes in-line construct monitoring vital. The clinical use of tissue 
engineered vascular constructs by its very nature requires rapid expansion of a very 
limited number of isolated cells and growth of the product in vitro. Due to this 
limitation there may only be one construct generated, off-line analysis is therefore not 
an ideal option.
As discussed above, initial aims and concepts for reactor development are very similar 
for different tissue engineering applications; the main functional differences are due 
specific organs requirements. The imposed requirements are to reproduce the in vivo 
mechanical environment in vitro, in addition to reducing problematic mass transfer 
issues by developing uniform trans matrix pressures. For example, it would be illogical 
to expose a skin equivalent to the same fluid shear forces as the endothelium of a tissue 
engineered vascular graft and expect a positive outcome. The following sections 
describe the progressive development of a three-component bioreactor system that 
delivers to the tissue engineering matrix and seeded cells, an in vivo like environment.
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6 .2  Ma teria ls  and Meth o d s
6.2.1 Materials
As in previous chapters all reagents and material details including vendor are shown in 
Chapter 2 unless stated otherwise. Materials noted in this section are primarily from the 
final design other materials are described in the text, see Table 6.02. Materials from 
earlier developmental bioreactors are omitted as they are too numerous to mention and 
irrelevant to the final system used.
Table 6.02: Materials
Materials Cat. No. Supplier
Silicon tubing 4.8 mm ID, 7.0 mm OD 326/0512/18 BDH, Poole, UK
PharMed tubing 4.8 mm ID, 7.0 mm OD 275/1145/24 BDH, Poole, UK
Clamps 221/0140/01 BDH, Poole, UK
Watson Marlow Peristaltic pumps 503U Jencons, London, UK
Watson Marlow Peristaltic pump 504U Jencons, London, UK
Glass (all sizes) borosilicate glass 275/0080 BDH, Poole, UK
Media containment vesse ls (1) 215/0150/12 BDH, Poole, UK
Media containment vessel (2) 215/0150/11 BDH, Poole, UK
Plastic tubing connectors (straight) 275/0284/01 BDH, Poole, UK
Plastic tubing connectors (Y shaped) 275/0287/01 BDH, Poole, UK
Stainless steel tubing 4.8 mm ID, 6.0 mm OD SS/0048.006 BDH, Bath, UK
Duran bottles (100 ml -2 L) 215/0150/15 BDH, Poole, UK
6.2.2 Me t h o d s
Figure 6.02 shows the Watson Marlow pump calibration carried out to ensure accurate 
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Figure 6.02: Watson Marlow 505U pump calibration for 3.2 -o- and 4.8 mm -X- ID peristaltic 
tubing.
Further methodologies used to design and build the reactor system were based on a 
pragmatic approach to component design and assembly, as such are not described here.
All analytical methods are described in Chapter 2.
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6 .3  R e su lts
6 .3 .1  R e a c t o r  d e v e l o p m e n t
The design of the perfusion culture system has been a progressive development with 
incremental modifications to achieve a satisfactory result. Initial design concepts 
reflected the list of design aims in section 6.1. In this section the developmental process 
has been condensed to major design or concept changes rather than individual 
modifications. Preliminary reactor designs, which included reactors capable of 
containing multiple matrices, have not been included for reasons of space in this report. 
An overview of the main reactor design changes are tabulated in Table 6.03 and 
described in further detail in the following text.
Table 6.03: Overview of main bioreactor design and modifications. With reference to
‘complexity1 as a design issue/problem, was found during handling and general use of the 
reactor to maintain sterility.
Reactor Design concept Problem Design solution
Mark 1A Initial design PTFE/glass Leakage Alter seals
Mark 1B ( i Leakage Change to a taper seal
Mark 1C M Leakage Compress taper
Mark 1D (1 Leakage/complex Alter fundamental design
Mark 2 All glass with multiple tapered 
Quickfit style connections
Too complex Reduce complexity
Mark 3 
Mark 4
Similar to Mark 2 but with 
reduced connections 
Final and current design
Still too complex Remove tapered fittings, use only 
glass treaded attachments
Mark 1A
The first fully functional reactor (Mark la) was constructed from PTFE (extruded) rod 
65 mm in diameter, RS Components, Corby, UK, and glass tube. PTFE was used due to 
its ability to withstand long-term exposure to saline solutions and super heated steam, 
with a maximum service temperature of 260°C the PTFE could withstand autoclaving 
without deforming or degrading and was capable of being machined to the precision 
dimensions, Figure 6.03.
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End E levation Side E levation (end cap)
End cap assem bly
3.76 mm 
2.26 mm *  
'3.77 mm4«>|
2.26 mm16.56 mm
15.81 mm G lass adapter rod
18.82 mm
B iosynthetic conduit
2 degree taper to suit glass taper
tension and seal assem bly
Os
SO
V ariab le length  glass con n ecting  tube
Figure 6.03: Technical specification of Mark 1A reactor.
Interchangeable lengths o f glass tube (the reactors main body) connected the machined 
PTFE copolymer end caps. The end caps were machined to allow fitment o f Viton ‘O’ 
rings (2 per end cap), Barnwell, Warley, UK, to seal the glass main body once 
assembled, see Figure 6.03. The design allowed for the central glass body to be 
interchangeable to accommodate arteries with large variations in length, while the 
lumenal adapters maybe adjusted to fine tune for length and to tension (laterally) the 
inserted matrix. Processed porcine derived matrix was fitted between glass adapter 
rods (6 mm OD, 3 mm ID) drawn out to a hollow point and blunted to create a ridge to 
which the artery/matrix could be secured with the use o f plastic zip ties, Sigma, Poole, 
Figure 6.04. Under trial conditions (37°C 5 % CO2 with pulsed flow rates o f 80 
bpm/140 ml/min, used throughout testing) the reactor leaked between the PTFE end 
caps and the ablumenal glass body, resulting in unacceptable media loss and possible 
system infection. It was initially thought the non-uniform circumference of the glass 
tubing resulted media leakage.
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Figure 6.04: A. Mark 1A reactors of differing lengths (B), showing both lumenal and ablumenal 
inlets and outlets with glass connectors for connection to the simulated tan coloured matrix.
Mark 1b
The Mark IB reactor had the PTFE end caps redesigned with 1 ‘O’ ring and a Tip-seaT 
BDH, Bath, UK, to improve the seal to the glass main body as the Tip-seaT has a higher 
tolerance to variation in the glass main body, see Figure 6.05. Like the Mark 1A reactor 
these seals were inadequate and the reactor leaked under operating conditions (as 
above).
Figure 6.05: Mark 1 reactor PTFE end caps showing the two different sealing methods
between Mark 1A (2 Viton ‘O’ rings) and Mark 1B reactors (1 Viton ‘O ’ ring and 1 lip-seal).
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Mark 1c:
A further modification to prevent leakage between the PTFE end caps and the glass 
main body, a 2° female taper was machined into the PTFE end caps and the parallel 
glass main body was replaced with tapered ground glass male fittings at each end of the 
glass body, (Quickfit style) to suit the female taper within the PTFE end caps, see 
Figure 6.06A. Like reactors Mark la  and lb this modification failed to prevent leakage. 
It was found that the PTFE end caps became loose after the transition from ambient to 
operating temperatures.
Mark Id :
In a bid to hold the PTFE end caps secure to the glass body a series of adjustable springs 
were added to pull these components together. It was at this point that it was observed 
that the two different materials (glass and PTFE) have differing thermal expansion 
properties where the glass would expand approximately 0.25 mm less than the PTFE 
end caps during the transition from ambient temperature to 37°C in the incubator, see 
Figure 6.06B. However the springs pulled the PTFE end caps together which prevented 
leakage.
Figure 6.06. Mark 1c (A) reactor showing the tapered male ground glass, which fits the 
equivalent female taper machined into the PTFE end cap. Mark 1d (B), the first leak-proof 
reactor, showing the attached springs that ‘pulled’ the two PTFE end caps together preventing 
leakage due to differing thermal expansion properties.
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Mark 2:
To eliminate differing thermal expansion properties of two materials the first ‘all glass’ 
reactor was designed. The lumenal glass diameter measured (OD) 25 mm (ID) 20 mm. 
This design (not shown) used a variety of Quickfit adapters to allow attachment of 
ablumenal glass housing (male ends) to fit the reduced size of the female tapered luer 
holders, however the operation of this design proved to complicated for continued use.
Mark 3:
Due to the complexity (and expense) of the Mark 2 reactor the Mark 3 was developed. 
This reactor consisted of a central glass body with female tapered ground glass 
couplings to which the lumenal adapters fitted. This reactor had a reduced diameter 
main body from (OD) 25 mm (ID) 20 mm to (OD) 18 mm (ID) 14 mm, with a length of 
170 mm, reducing the ablumenal volume from 53.41 cm3 to 26.12 cm3, see Figure 6.07. 
This decrease in surface area ratio of the glass ablumenal void from 10.68 cm2 to 7.48 
cm2 to the matrix, increasing the potential for cells seeded into the ablumenal void to 
adhere to the matrix at higher densities. In addition to the potential of increasing 
seeding efficiency, the reduced ablumenal volume reduces the total media content of the 
system, thus reducing costs.
Figure 6.07: Mark 3 reactor showing the central glass body with female tapered ground glass 
couplings to which the lumenal male adapters connected directly, thus eliminating the need for 
either PTFE or numerous glass adapters (Mark 5) to fit the inlet/outlet manifolds.
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Mark 4: Final Design and Specification
The mark 4 reactor was again constructed with glass, with the main body reduced in 
diameter to (OD) 10 mm (ID) 8  mm x 180 mm long. This further reduced the 
ablumenal volume from the mark 3 reactor of 26.2 cm to 9.1 cm . This design was 
later altered to an overall length of 2 0 0  mm to suit longer arteries increasing the 
ablumenal volume to 10.1 cm3. To further reduce complexity and cost and simplify use 
the male tapered manifolds at either end of the reactor were eliminated and replaced by 
a quick-fit 10/4 threaded tube with complementary screw cap couplings (BDH, UK) to 
attach to the reactors main body and the luer-type adaptors that connected to the 
artery/matrix.
The transition to this model saw the replacement of the glass to stainless steel luer-type 
adaptors to connect the matrix (within the bioreactor) to the tubing of the flow circuit. 
The rationale for changing from the glass to the stainless steel luer-type adaptors 
(London Surgical, UK) was for several design considerations. Firstly retention of the 
artery to the glass under flow conditions proved problematic due to the smooth surface 
(even when buffed) vessels tended to disconnect under pressure. The addition of 
flattened or bulbous end solved the disconnection problem, however flow dynamics 
were compromised. Using the equation for velocity:
where V = velocity, Q = flow rate and A = cross-sectional area flow rates within the 
normal range (-140 ml/m) with arterial diameters of 3 mm ID were calculated with a 
velocity of 0.33 m/s. The reduction from 3 mm ID to 1.2 ± 0.3 mm as the glass was 
moulded increased media velocity to 2.09 m/s under the test conditions (rt 16 ± 2°C 
with pulsed flow rates of 80 bpm/140 ml/min). At this magnitude (over 6 x) of velocity 
increase was found to strip cells off the matrix surface even at flow rates as low as 50 
ml/min (results not shown). With the aim of reduced ablumenal media volume the glass 
was replaced with the stainless steel adaptors as a thin wall thickness was desirable to 
allow fitment into the vessel and reactor housing ( 8  mm ID).
2 2 2
To ensure flow into the reactor was within the laminar flow range the Reynolds number 
(Nrc) was calculated using the test conditions above, which are at the high end of the 
flow regime for initial system testing (Best and Taylor, 1991).
_ P u d  
JM Re  ------------  ( 6 . 2 )
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where d = vessel diameter, u = velocity, p = density and p = viscosity. It is generally 
accepted that as the calculated Reynolds number increases over 2300, there is a 
transition from laminar to turbulent flow. Fluid viscosity (p) is assumed to be the same 
as water at 20 °C. The Reynolds numbers for the three conditions set out above where: 
1. artery mean diameter 3 mm, 2. modified glass and 3. stainless steel, where N rc = 987, 
6270 and 801 respectively. A further advantage of using stainless steel was to reduce 
the wall thickness of the luer-type adapter, where the glass adapter had an end thickness 
ranging from 1-2 mm whereas the stainless steel was 0.3 mm. This reduction reduces 
the potential for flow disruption where the adapter is connected to the vessel, as such 
further justifies the modification to the stainless steel tube with 3.3 mm ID, 4.1 mm OD.
To enhance the fluid dynamics of the reactor a modified lumenal inlet was designed that 
provided improved flow into the bioreactor that ensured fully developed flow entered 
the reactor, thus improving flow by minimising disruption within the flow field. To 
confer fully developed laminar flow into the bioreactor the equation for ‘entry port flow 
conditioning’ was used, (Perry and Green, 1998).
Lent/D  =  0.370 exp(-0.148Re)+0.0550 Re  +  0.260  (6.3)
Where D = diameter, Re = Reynolds number (801) and Lent is the flow conditioning 
entry port length required to ensure 99% of fully developed flow into the reactor.
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With the use o f stainless steel luer adapters with a 3.3 mm ID, under the test flow 
conditions described above, the right side o f equation 6.3 equals 44.32, combined with 
the left side o f the equation equals an entry length o f 146.3 mm. The fmal design length 
of the lumen entry length was 250 mm to allow for variation in flow conditions. By 
contrast if the original glass inlet adapters had been retained where flow was turbulent 
with a Re o f 6270, equation (6.4) is used:
Len/D  =  (6.4)
The inlet length calculated (under the same conditions) would be 41.2 mm to achieve 
similar developed flow (99 %) (Perry and Green, 1998). The outlet port is only long 
enough to allow a degree o f adjustability or tensioning o f the artery once connected, no 
consideration was given to down stream fluid dynamics, an illustration o f reactor 4 is 







Figure 6.08: An illustration of the Mark 4 bioreactor displaying inlet and outlet ports of the 
reactors main body.
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6 .3 .2  P r o c e s s  f l o w  d e v e l o p m e n t
The final process flow system was designed to operate in concert with the bioreactor to 
deliver media to the cellular population/s within the matrix under pulsatile flow 
conditions, see Figure 6.09. Although earlier systems were considerably more complex 
in design, where a variety of parameters such as pH and temperature were monitored 
real time (data not shown), due to the cost of media, the relatively high flow rates that 
necessitates media recycling and ease with which complete media changes could be 
made, media was completely (100 %) replaced every 3 days which negated the 
requirement for real time analysis. The consequence was that much of the system 
support apparatus was not required, for example continuous pH monitoring, where the 
media was buffered and shown to maintain physiological pH over extended periods, see 
Figure 6.14. Factors influencing media pH in this system include: media type, media 
volume, flow rate, gas environment and the process flow design that exposes media to 
the surrounding gas environment. Parameters and media analysis under flow conditions 
are given in section 6.3.3.
Initial designs used 1-litre fermentation vessels for bulk media containment. This vessel 
was later reduced in size to 500 ml, with the media return passing through an inverted 
sparge, situated at the top of the media vessel for gas exchange purposes. Originally 
this was to increase gas exchange within the returning media in a sterile atmosphere. 
Due to pH issues this was later replaced with a 100 ml Duran bottle with a modified lid 
to have 4 ports: 1. Media pick up port 2 and 3 were connected to 0.2 pm filters, which 
were open for atmospheric gas exchange (5 % CO2 + air) the final port on the media 
storage vessel was the return for recycled media. Media was drawn and pulsed by a 
Watson Marlow 503U peristaltic pump, from the media storage vessel through a one 
way check valve to prevent back flow, into a compliance chamber, designed to reduced 
system noise or vibration caused by the roller action of the peristaltic pump head. The 
flow was then directed to the lumenal inlet port on the bioreactor, see Figure 6.09. At 
this point the flow was split into the ablumenal and lumenal inlets. Immediately prior to 
the ablumenal inlet a progressive clamp controlled the flow rate into the ablumenal of 
the reactor at a flow rate of approximately 0.5 ml/minute. The only changes to this 
basic design was the inclusion of a second reactor. Initial testing attempted to run 
reactors in a parallel configuration to reduce complexity and handling issues with
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‘plumbing’. Variation in matrix dimensions resulted in inconsistent pressure drops 
between lumenal inlet and outlets, resulting in differential flow rates between each 
reactor system. As the media was recirculating all later models utilising multiple 












Figure 6.09: Schematic of the final process flow circuit, illustrating a single reactor. This design 
was retained when using dual reactors that were run in series. The compliance chamber serves 
to reduce system ‘noise’, thus improving the flow regime.
System tubing as above in Figure 6.09, consisted o f silicone tubing 4.8 mm ID, 8 mm 
OD, with the exception of PharMed medical grade peristaltic tubing around the pump 
head due its increased resistance to compression failure. This section o f PharMed was 
progressively moved around the pump head to prevent failure after prolonged exposure 
(up to 5 weeks) to the compressive nature o f the pump head rollers.
Total system volume was calculated by adding all discrete sections together. From table 
6.04 the total media volume for a dual reactor system (in series) are listed with the 
addition of a second reactor (10 cm3), giving a total volume o f 200 cm3 (200 ml media). 
The total volume for a single reactor system is 183 cm3. This compares with the earlier 
the Mark 1 reactor system volume o f 237 cm3 with a single reactor.
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Table  6.04: Component media volumes for perfusion system
Component Media volumes (cm-3)
System 63.4 cm3
Each Bioreactor 10 cm3
Additional tubing for second reactor 7.2 cm3
Compliance chamber 10 cm3
Media reservoir 100 cm3
P u ls e  P r e s s u r e  W a v e  A s s e s s m e n t , D e v e l o p m e n t
The current method to develop a pressure wave analogous to in vivo blood flow has 
been based on the reproduction of images from the literature, Figure 6.10 (Beme and 
Levy, 1992). The progressive development o f an accurate representation o f in vivo 











Figure 6.10: Arterial pressure curves recorded from several sites in an anaesthetised dog, 
modified from (Berne and Levy, 1992). A, peak systolic pressure, B, dicrotic notch (caused by 
the closure of the aortic valve) and C, minimum diastolic pressure.
Figure 6.11 shows progress made towards replication o f the peripheral arterial pressure 
wave form. Initial testing o f the pulsatile flow system was conducted using 4.8 mm ID 
silicon tubing at pulse rates of 80 beats (40 rpm) per minute, which resulted in a flow 
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Figure 6.11: A, Illustrates the basic pulsatile pressure wave characteristics of the Watson- 
Marlow 503U peristaltic pump when integrated into the flow system. B, The addition of a 
compliance chamber alters both the waveform and removes much of the system noise. C, To 
prevent back flow a one way check valve (cracking pressure of 0.33 p.s.i.) was integrated into 
the flow system immediately after the peristaltic pump. Pressure readings (Y axis) in mmHg 
with real time capture shown above each image.
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In vivo, reverse blood flow occurs only in the aorta due to the elastic recoil of the 
arterial wall, this event closes the heart valves prior to the next pulsed ejection of blood; 
the peripheral vasculature has no such back flow. Prior to the final process flow circuit 
shown in Figure 6.09, reverse flow occurred through out the flow circuit, resulting from 
the roller mechanism of the peristaltic pump. To prevent back flow a one-way check 
valve was inserted into the system after the pumps outlet. In addition to preventing 
back flow, the one-way check valve almost completely removed system noise; compare 
Figure 6.11 A, B and C.
F inal  p r o c e s s  f l o w  w it h  in t e g r a t e d  r e a c t o r / s
Perfusion culture described in this thesis was carried out using an apparatus similar to 
the process flow represented in Figure 6.12. Unlike the in model in Figure 6.12, 
multiple reactors were always set up in series and lumenal and ablumenal flow was not 
a separate pumped circuit. The model shown in Figure 6.12 shows 2 Mark 4 reactors 
set-up in parallel with the lumenal flow pumped separately from the ablumenal circuit. 
As discussed in Future Work, when the system is used to coculture EC and hVSMC, 























Figure 6.12: Representation o f the systems final operating design.
6.3.3 Media analysis and stabilisation
Static cultures on the developed biomaterial had shown that incubating the matrix in 
media prior to seeding cells provided a significant improvement in cell adhesion and 
subsequent growth compared to matrix samples with no pre-treatment, Chapter 5.3.1. 
Initial trials used DMEM due to the high cost of specific low serum media’s and 
minimal gain shown in cell density by the other pretreatment methods. Preconditioning 
the matrix within the bioreactor with DMEM resulted in a rapid increase in media pH, 
according to the media manufactures this was due to oxidation of media components, 
see Figure 6.13. This result was not characterised. DMEM as the basic component of 







0 24 48 72
Time (hr)
Figure 6.13: Variation in media pH: perfusion compared to static cultures. (-0-) DMEM
oxidation under pulsed flow (standard conditions for testing), resulting in a dramatic increase in 
pH comparative to (-x-) the same media in static culture conditions.
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In order to control the pH and reduce the extent of oxidation several modifications were 
made to the apparatus to reduce gas exchange, these included: removal of the inverted 
sparge to allow media to enter the return vessel smoothly reducing mixing effects and 
reduction in the volume size of the bulk media vessel. Due to these results a variety of 
HEPES buffered media was analysed but failed to maintain media pH at acceptable 
levels (data not shown). Of these media PromoCell Media (specific for each cell type) 
was used as a preconditioning treatment due to its improved buffering capacity. 
Analysis was conducted over a test period of 7 days at 37°C and 5% CO2 (standard test 
conditions). For each analytical test the same three conditions were evaluated: 1 pulsed 
perfusion system with no cells and 200 ml HUVEC media recirculating at 80 bpm, 150 
ml/minute, 2 T-75 culture flask with 10 ml HUVEC media (no cells) and 3, T-75 culture 
flask with 10 ml HUVEC media (confluent with HUVEC). Analytical parameters 
tested were gas composition (PCO2 and PO2), HCO3 ', and pH variations and compared 
to arterial measurements (Homick, 2002) and glucose (Coster et al., 2000).
Theoretical cell density within the bioreactor was estimated to be considerably less than 
the 3 xlO6 cells typically found in a confluent T75 static culture flask, in concert with 
experimental evidence illustrating pH (Figure 6.14) and glucose (Figure 6.15) and at 
these cell densities has little effect on media quality. Given that the ratio of media to 
cells in perfusion system is 20X that in static culture (and replaced at the same rate), it 
was assumed the influence of cells within the system has little effect on media life span, 
given their low density to media ratio.
Figure 6.14 displays results of media pH analysis conducted over a 7 day time course. 
The PromoCell media (EC) clearly shows improved pH buffering over DMEM shown 
in Figure 6.13. Although the pH in all these tests are below the physiological range, 
(pH 7.4 ± 0.2), the pH remains within the range indicated in the literature supplied by 
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Figure 6.14: Comparative change in pH between static and perfusion systems. pH analysis -o- 
reactor (no cells), -x- T-75 flask (no cells) and -A- T-75 flask (confluent HUVEC cells). In both 
systems pH falls, with the perfusion system maintaining pH closer to the physiological 
conditions (pH 7.4 ± 0.2) over the extended time course.
Glucose consumption was monitored over time using the same three conditions 
evaluated previously, see Figure 6.15. In vivo blood glucose levels vary considerably 
depending on the dietary status of the individual, a range between 3.8 and 6.7 mmol/L is 
considered within the acceptable physiological range (Coster et al., 2000). HUVEC 
media contains 5 mmol/L or 0.005 mmol/ml glucose, it was calculated that 10 ml media 
contains 0.05mmol and the 200 ml in the perfusion system 1 mmol. Data estimates that 
3 xlO6 cells in this population of HUVEC utilises approximately 0.0022 mmol/ml 
glucose in 24 hours. Therefore the total glucose in the perfusion system (200 ml = 1 
mmol glucose) would theoretically maintain 3 xlO6 cells in excess of 40 days, glucose is 
not therefore a limiting factor in this system.
PCO2 analysis shows that only the T75 flask with HUVEC maintains a PCO2 close to 
the in vivo environment over the first 4 days, after which PCO2 levels increase above 
physiological conditions, see Figure 6.16. Although the level of Levels of PCO2 are 
higher (~5 mmHg from 48 hours) in the perfusion system than the T-75 flask, a closer 
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Figure 6.15: Comparative change in glucose concentration between static and perfusion 
systems. Glucose concentration: -o- reactor (no cells), -x- T-75 flask (no cells) and -A- T-75 
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Figure 6.16: Comparative change in PC02 between static and perfusion systems . PC 02 
analysis: -o- reactor (no cells), -x- T-75 flask (no cells) and -A- T-75 flask (confluent HUVEC 
cells). The PC 02 is highest in the T75 culture flask with confluent HUVEC, consistently 4-6 
mmHg higher than PC 02 in the perfusion system and 7-10 mmHg in the T75 without cells. In 
vivo arterial PC 02 is approximately 40 mmHg.
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Figure 6.17 shows PO2 under the same conditions as described above. Surprisingly the 
results show increased PO2 in the T75 with confluent HUVEC over a T75 flask allowed 
to equilibrate within the incubator. PO2 within the perfusion circuit is similar to the PO2 
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Figure 6.17: Comparative change in P 02 between static and perfusion systems. P 0 2: -o- 
reactor (no cells), -x- T-75 flask (no cells) and -A- T-75 flask (confluent HUVEC cells). Levels of 
P 02 are considerably higher than arterial P 0 2, which approximates 98 mmHg. The perfusion 
system is consistently higher (-65 mmHg) than the T-75 flask (120 mmHg at 24 hours). 
Reduction in P 0 2 within the perfusion system to closer resemble the in vivo environment 
remains an objective.
Bicarbonate concentrations in both perfusion (11.1 ± 0.78 mEq/L) and static cultures 
(6.44 ± 0.28 mEq/L media alone and 11.88 ± 0.59 mEq/L with HUVEC) are lower than 
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Figure 6.18: Comparative change in HC03' between static and perfusion systems. HC03' 
(bicarbonate) concentration: -o- reactor (no cells), -x- T-75 flask (no cells) and -A- T-75 flask 
(confluent HUVEC cells). Both perfusion and static cultures (with and without cells) are lower 
than in vivo serum bicarbonate concentrations of approximately 24 mEq/L.
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6 .4  D isc u ssio n
R e a c t o r  D e v e l o pm e n t
In order for the system to function as proposed, the parameters of a normal healthy 
individual have been used as a base line, such that blood pressure and flow rates are 
akin to normal physiology. These conditions were determined as flow rates up to 150 
ml/min, pulse rates up to 80 bpm and pressure approximating 120/80 mmHg. The 
validity of this base line if  a prosthetic is to be implanted into a section with non-normal 
flow begs the question; should the flow regime for individual graft be determined by the 
haemodynamics of the patient receiving the graft? As a baseline for the development of 
this system, the parameters serve as intended to test the perfusion system for everything 
from leaks to media oxidation. It is intended that perfusion cultures (Chapter 7), 
particularly EC cultures will be exposed to a progressive flow regime to allow the 
seeded cells time to develop in vivo-like adhesion sufficient to withstand shear stresses 
associated with arterial blood flow.
The design and application of this perfusion system has been an incremental 
development where concept and ideas were modified to realise a functional reactor 
system. A variety of different systems have been described in the literature varying 
substantially on this design. Of the systems described, the fundamental difference with 
this system is the ability to control and monitor both ablumenal and lumenal pressure, 
making possible uniform transmembrane pressure differentials, either lumenal to 
ablumenal or visa versa. Minimising the ablumenal volume improves efficiency both in 
media and adhesion dynamics by allowing the system to operate as a completely sealed 
unit. Niklason et al (1999) have detailed a bioreactor used in perfusion culture of small 
diameter arteries seeding bovine SMC and EC onto a biodegradable PGA scaffold. The 
significant difference between the reactor described by Niklason et al (1999) reactor, 
where pulsed flow is controlled through the reactors lumen by a bellows-style pump, is 
a considerably larger reactor ablumenal compared to the reactor developed in this thesis. 
Designed like a box with a hinged lid, the reactors lumenal inlets/outlets are midway up 
the walls of the box, the lid designed to allow gas exchange is secured to the top. The 
potential advantages of this system would include: improved access to the matrix
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ablumenal surface for either analysis or cell seeding and reduced shear stresses. Prior to 
EC seeding in the system used by Niklason et al (1999), the shell-side surface of the 
matrix (seeded with SMC) is immersed in a tank media that is changed at regular 
intervals. Media does not perfuse through the tube-side circuit until EC have been 
seeded to the lumenal surface. PBS is used as the lumenal perfusate until EC seeding 
(Niklason et al., 1999). The advantages of the Niklason et al (1999) system are 
reduced media usage, reduced oxygenation of media resulting in a more stable pH over 
long-term cultures and easier access to the ablumenal surface of the reactor. Improved 
access for cell seeding is an important issue, with this system SMC can be seeded 
directly onto the PGA scaffold in high concentrations dramatically improving adhesion 
efficiency. Although not currently seen as an important issue, seeding a uniform cell 
layer using this method onto the matrix may prove problematic. With human 
autologous cells in limited supply other methods may require visitation.
Another system design recently published by Hoerstrup et al (2001), typifies 
presentation of the system and reactor design. Other than an illustration of the systems 
process flow, and naming the pumping circuit as a ‘pulse duplicator’, no other 
information is published. The experimental design seeds ovine cells onto a PGA 
scaffold, and applies pulsed flow (progressively) up to 750 ml/min (Hoerstrup et al., 
2001). It is difficult to comment accurately with the information published, but several 
potential design flaws are apparent. Firstly the system uses as many as 4 vessels in a 
parallel array. No mention is made of pressure drop between and across the 4 reactors. 
Unless resistance is applied to the downstream side of the reactors and monitored, flow 
rates may vary widely from the published description. In a worst case, the bulk flow 
will take the path of least resistance, increased pressure drop, which may shear all EC 
off the lumenal surface of the one graft, whereas the remaining three are exposed to 
considerably less shear stress and display an intact endothelium. Similarly the 
illustration shows no evidence of an extended lumenal inlet to allow flow to develop. 
Given the maximum flow rates result in a Nrc in the turbulent flow range of 3190, the 
inlet adapter, using equation 6.3, would need to be 200 mm to allow flow to fully 
develop. Given that the illustration is not likely scaled, using the graft dimension of 40 
mm, the inlet is not more than 50 mm. Either the system illustration is wholly 
inaccurate, equation 6.3 from (Perry and Green, 1998) is not applicable under these 
conditions or the adhesion of ovine EC is remarkable to yield a confluent endothelium.
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The important benefit of controlling ablumenal and lumenal pressure is to provide an 
environment within the matrix wall that is conducive to cell growth and proliferation. 
As illustrated in previous chapters the matrix is acellular, prior to removing the porcine 
cell population the arterial wall is densely paced with VSMC, that depending on the 
thickness of the arterial wall maybe in close association with smaller arteries or vasa 
vasorum that are intercalated through the medial, though predominantly adventitial 
layers. Once the porous acellular matrix has been placed within the bioreactor and 
pulsed flow applied, fresh media needs to permeate through the matrix wall to allow 
seeded cells that may migrate into the matrix wall to thrive. Potential limitations in 
mass transfer of key components such as O2 , metabolic by-products, growth factors, 
glucose etc can be reduced by convective flow applied by increasing or decreasing the 
pressure gradient across the matrix wall. Without these pressure gradients cell in 
growth is limited to approximately 100 pm (Vanjak-Novakovic, 2002). Additionally 
these pressure gradients may increase the effective distance with which cell-cell 
communication is possible, which has been theorised at approximately 250 pm, at least 
in the direction of the pressure gradient (Francis and Palsson, 1997).
An enclosed ablumenal can be advantageous in several respects. Firstly, as discussed 
above pressure can be applied and modulated to attain desired gradients across the 
matrix wall, secondly SMC can be seeded directly into the shell-side void an under 
specific circumstances this can have an improved seeding distribution over the entire 
surface of the graft. Briefly this method involves the coating the bioreactors inner shell- 
side surface with poly-HEME (Sigma, Poole, UK) to prevent cells adhering to the glass 
surface and rotating the bioreactor around its axis allowing the cells in suspension to 
‘fall’ onto the matrix material thus increasing the percentage cell adhesion to the matrix 
compared with the glass wall of the reactor, in addition to producing a more uniform 
cell layer. Secondly environmental factors such as, trans-matrix pressure and the 
associated delivery of nutrients and gases can be more precisely controlled and 
monitored.
Like the bioreactor, the perfusion support system was a series of progressive 
modifications designed to deliver to the matrix, within the bioreactor, a suitable in vivo- 
like environment. Once the initial bioreactor and process flow system where 
operational it was possible to adjust components of the system to achieve the desired
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result. The system component that required considerable adjustment was the media 
reservoir, many of the assumptions first made were proven inaccurate, for example gas 
tensions. The first media reservoir had a 1L capacity where returning media was forced 
through a sparger at the top of the vessel. As a result of increased exposure to oxygen 
the media oxidised rapidly becoming alkaline, see Figure 6.13. Subsequent vessels 
where reduced in size (1L, 500 ml, 250 ml and finally 100 ml capacities) and returning 
media was directed to reduce oxygenation. Like other environmental factors, the 
control over O2 levels is particularly important, Lee et al (2001) have shown that 
elevated levels of O2 reduces VSMC proliferation. Previous work of this group had 
shown that at the artery-prosthesis anastomosis resulted in significant arterial wall 
hypoxia, which returns to control conditions after 42 days. In this study it was shown 
that the first 7 days post implantation of a prosthetic graft were the most hypoxic which 
correlated with significant VSMC proliferation. However the mechanism for reduced 
proliferation is unclear with the authors acknowledging that both low and high O2  
tension results in oxidative stress, shown to cause VSMC apoptosis, interestingly they 
indicate a possible antioxidant effect from supranormal O2 levels, although no clear 
argument is presented (Lee et al., 2001).
Under static culturing conditions and in accordance with PromoCell’s culturing 
protocols, media for both hVSMC and HUVEC was replaced every 2-3 days. As a base 
unit to ensure media volumes would be adequate for cell viability under pulsed flow 
conditions, the static culture of HUVEC in T-75 culture plates was used. Confluent 
cultures of HUVEC in T-75 culture flasks have densities approximating 3 xlO6 cells or 
4000 cells/mm , maintained in 10 ml of media replaced every 2-3 days. The surface 
area of the matrix, assuming it is smooth is 10.37 cm and 16.65 cm ID and OD 
respectively, with a T-75 culture flask having 75 cm2. Contact inhibition of these cells 
will prevent, particularly during initial adhesion, higher than confluent densities 
adhering. Under ideal conditions and 100% adhesion of the available surface area, the 
total number of cells able to adhere to both the lumenal (4.15 xlO5 cells) the ablumenal 
(6 . 6 6  x 105 cells) surfaces would total 1.08 xlO6 of the total 3 x 106 cells seeded. This 
approximates to 36 % of the initial cell number. As 3 xlO6 cells (cells in a confluent T- 
75 flask) are maintained in 10 ml media (every 2-3 days), the reactor initially supports 
only ~36 % of this number in concert with substantially increased media (183.38 ml) it 
was assumed media components would be in excess for similar culture durations. Initial
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tests were run for 5-7 days before changing media (data not shown), however due to 
degradation of growth factors in the media this time frame was reduced to 2-3 days. It 
was concluded that media would not be a limiting factor under these conditions. Other 
factors such as growth factor degradation at 37°C, media oxidation, volume and flow 
rate play a more significant role in stabilising the media over the duration of the 3 day 
exchange cycle. The extended duration of this set of experiments (7 days) past the three 
day media changing schedule was to gather data in the event the bulk media would be 
retained and supplements such as growth factor added rather than replacing total media. 
The advantage of this method would be the ability to analyse metabolites within the 
media over a longer time frame.
The extended duration of the media testing (7 days) past the three day media changing 
schedule, was to gather data in the event the bulk media would be retained and 
supplements such as growth factors would be added rather than replacing total media. 
The advantage of this method would be the ability to analyse metabolites within the 
media over a longer time frame thus assessing cell growth or metabolism. The results 
after these modifications and using the PromoCell HUVEC media, the pH in both the 
perfusion system and the control T-75 flask falls with the perfusion system maintaining 
pH closer to the physiological conditions (pH 7.4 ± 0.2) over the extended time course. 
O2 tension (225 falling to 185 mmHg over 48 hours) was still above normal arterial 
conditions of ~98 mmHg. Reduction of the PO2 within the perfusion system to closer 
resemble the in vivo environment remains an objective. Levels of PCO2 are higher (33 
± 4.89 mmHg) in the perfusion system than the T-75 flask, (29.89 ± 2.89 mmHg) a 
closer resemblance of the in vivo environment where arterial PCO2 is approximately 40 
mmHg. The current system design allows for simple adjustment of several parameters, 
for example avenues to reduce PO2 , 1. Removing one, or both, of the 0 . 2  pm filters 
situated at the top of the media vessel, 2. Replacing silicone tubing for non-permeable 
tubing or 3. Redesigning the media return outlet to be below the surface of the bulk 
media. Any adjustment will require complete revaluation of the media conditions as 
change in PO2 will affect PCCV and media pH.
The overall aim of this section of work was the development of a pulsed perfusion 
system to allow adhesion, growth and proliferation of vascular cell lineages under in 
vitro conditions that emulate the in vivo physiological environment. As described
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on the first page of this chapter, objectives were divided into three categories: 1. The 
perfusion system to generate appropriate mechanical forces and transmit them to the 
bioreactor while simultaneously allowing sampling and media changes. 2. The design 
and development of a bioreactor that allows for the seeding of specific cell lineages to 
both the lumenal and ablumenal surfaces. Once seeded the mechanical forces generated 
by the perfusion system must be transferred to the matrix and 3. Design a support 
infrastructure to allow long-term culture of human primary cell cultures. Although 
these objectives are complex and multifactorial the system presented in this thesis has 
accomplished all the major tasks presented to the level of a working prototype. The 
perfusion system generates pulsed flow with waveforms and pressures similar to in vivo 
haemodynamics where pressure, frequency and flow can be modulated to suit the 
researchers specific requirements. Like the perfusion system, the bioreactor has been 
modified progressively as new challenges have occurred during development. The 
underling theme was to keep moving parts and complexity to a minimum, where a 
single researcher must be able to assemble the reactor, insert the matrix, inoculate 
primary human cell cultures and transfer the entire apparatus to the appropriate gas 
environment, whilst maintaining strict sterile conditions.
Although several properties of this system require further adjustment, e.g. gas tensions, 
to more accurately emulate the in vivo haemodynamic environment, the prerequisites 
have been met with this working reactor system. The next chapter in this thesis, 
Chapter 7, utilises the perfusion bioreactor system described in this chapter to apply 
conditions mimicking physiological parameters to the porcine derived vascular matrix 
upon which hVSMC and HUVEC have been seeded and cultured.
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CHAPTER SEVEN: PERFUSION BIOREACTOR STUDIES 
OF HUMAN VASCULAR CELLS CULTURED ON PORCINE 
DERIVED VASCULAR MATRICES
7 .1  Introduction
The arterial derived porcine matrix was first tested in Chapter 6 , where sections were 
assessed for biocompatibility under traditional static culture conditions using two 
primary human cell lines. The conclusions drawn indicated that although the material is 
biocompatible with primary human cells (HUVEC and VSMC) the matrix required 
media pre-treatment to achieve efficient seeding densities. After treatment, seeded 
HUVEC attained confluence rapidly. hVSMC were more difficult to assess numerically 
due to the 3 dimensional structure of the ablumenal surface. Sections of the matrix had 
shown hVSMC had adhered and expressed distinctive matrix remodelling enzymes, 
MMP-2, MMP-9 and Cathepsin L. Cells appeared unable to migrate fully into the 
tissue after 5 weeks in static culture when assessed by the same matrix remodelling 
enzymes. Following results in Chapter 5 and the prototype reactor designed and 
developed in Chapter 6 , a number of objectives were ascertained to progress toward a 
tissue engineered vascular conduit with the use of the reactor based perfusion culture 
system. The initial objective was to develop static cell seeding protocols for both 
lumenal and ablumenal surfaces of the matrix, ideally within the reactor system, then to 
optimise HUVEC seeding conditions and cell retention under preliminary flow 
conditions and allow cells to reach equilibrium within the perfusion bioreactor over 
extended time courses. Once the culture conditions had been evaluated, expand on the 
static studies to determine differences between Tike’ cell populations cultured under the 
two different regimes (static verses perfusion cultures). Similarly, optimise seeding 
methodologies for hVSMC onto the ablumenal surface via the ablumenal port 
inoculation, and finally culture under pulsed perfusion conditions that mimic the in vivo 
environment to assess matrix remodelling enzyme activity and contrast with static 
cultures. As outlined above the aims of this part of the project were to assess the 
biomatrix and seeded cell populations under a variety of mechanical conditions such as 
fluid and mechanical shear stresses. The spatial arrangement of the same matrix 
remodelling enzymes as in chapter 5 (static cultures) was assessed
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immunocytochemically and histochemically paying particular attention to differences in 
the cell migration profile within the matrix under both static and pulsed flow cultures.
HUVEC and hVSMC have previously been cultured under static conditions on the 
porcine derived vascular matrix, results from static cultures, Chapter 5, have shown 
HUVEC adhere to and were maintained on the matrix. hVSMC adhesion and growth 
on the ablumenal surface under static culture conditions, Chapter 5, has shown the 
inability of primary hVSMC to migrate into the medial layer of the matrix. It was 
shown that in the presence of specific matrix degrading enzymes (MMP-2 and 9 and 
cathepsin L), hVSMC were unable to migrate directly into the medial section of the 
matrix wall from the ablumenal surface. This chapter describes and discusses the use of 
the novel bioreactor described in Chapter 6  to apply physical and chemical conditions 
that mimic the in vivo environment to seeded HUVEC on the lumenal and hVSMC on 
the ablumenal surfaces. The first section of this chapter describes HUVEC seeding 
conditions that are specific to the perfusion culture system and determined the ability of 
cells to maintain adhesion to the lumenal surface when exposed to arterial-like 
haemodynamic flow. The second section of work describes hVSMC seeding to the 
ablumenal surface within the perfusion culture system. Followed by assessment of cell 
adhesion and migration using the same matrix degrading enzymes (MMP-2 and 9 and 
cathepsin L). These results were then compared and contrasted to the results from static 
cultures conducted in chapter 5 to assess differences in hVSMC migration behaviour 
when cells are cultured with the perfusion bioreactor. It must be note that a direct 
comparison between static and perfusion results is limited as the two experiments were 
not conducted in parallel and different batches of cells (from different individuals) were 
used.
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7 .2  Ma teria ls  and  Metho d s
7.2.1 Ma ter ia ls
Unless stated otherwise all reagents and material details including vendor and purity are 
shown in chapter 2 .1 .
7.2.2 Expe r im en ta l  methods
All hVSMC and HUVEC where cultured using materials described in Chapter 2.1.3 and 
cultured using methodologies described in Chapter 2.2.2. Matrix preparation, from 
unprocessed porcine carotid arteries to the fully processed, cross-linked and washed 
matrix was carried out in accordance to the protocol described in Chapter 4.3.5.
7.2.2.1 R e a c to r  s e t u p
Mark 4 reactors were used in all cultures and set up in a similar fashion to Figure 6.12. 
All tubing throughout the process flow other than around the peristaltic pump head was 
4.80 mm I.D. 8.00 mm O.D silicone, as described in Chapter 6.2.1. Tubing around the 
pump head was 4.8 mm I. D. 8  mm O. D. PharMed, peristaltic pump tubing, MERCK, 
Poole, UK. Two reactors where set up in series, as described in 6.3.2 with two fully 
processed arteries, see Section 1.2.23. Matrix within both reactors (number one closest 
to the pump head) measured, 100 mm long with the inlet or proximal I.D. being ~6.5 
mm O.D. ~5 mm and the ~3 mm I.D. and -4.5 mm O.D. at the distal end. Inserting the 
matrix into the bioreactor is detailed in Section 1.2.23.
1 .2 2 .2  R e a c to r  and M a tr ix  Assem bly
Due to the variety of different reactor versions only the final (Mark 4) design is 
described. All materials with the exception of the matrix material were first rinsed in
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distilled H2O and autoclaved (standard conditions: 121°C 15 minutes) prior to 
assembly. The reactor is laid out within a sterile class II safety cabinet with all reactor 
or components in contact with internal surfaces resting on sterile surfaces. The matrix 
material was selected and briefly inspected to ensure no gross fractures or leaks were 
apparent and any loose ends trimmed. A 300 mm long x 3mm OD sharpened spike was 
inserted into distal end of the lumenal outlet until the tapered end was just proud of the 
proximal end. This was used to draw the narrow end of the tapered matrix over the 
outlet adapter. Using the ligation devise, two rubber rings clamped the matrix to the 
adapter. The spike was then removed ensuring the matrix was not overly stressed. The 
wider end of the tapered matrix was then selected and the lumenal inlet inserted. The 
same process was applied to the proximal end of the matrix to connect it to the inlet 
adapter. Once the matrix was firmly attached to the inlet and outlet adapters the outlet 
adapter was lowered into the body of the glass reactor body. A silicon seal was placed 
over the adapter with the locking cap securing and sealing the adapter to the reactor. 
The same procedure was followed to secure the opposite end. The assembled reactor 
was then connected to the process flow circuit with silicon tubing. Section 1.2.23-1, 
describes the method used to precondition and seed cells into the bioreactor.
7 .2 .2 .3  Matrix  p r e p a r a t io n
Once the processed arteries had been inserted into the bioreactor and all ports connected 
to the perfusion system, the matrix was sterilized and depyrogenated based on a method 
supplied by Dr. S. Badylak, Purdue University, USA, (personal communication). A 0.1 
% peracetic acid (v/v) and 4% EtOH (v/v) in distilled H2O was prepared in a solution 
ratio of 20:1 solvent (ml) to tissue weight (g) e.g. 5 g tissue required 100 ml sterilising 
solution, consisting of 100 pi peracetic acid, 4 ml EtOH and 96 ml H2O. The solution 
was perfused through the system for 3 hours at 50 bpm, 37°C, 5% CO2 to ensure 
sterility within the system. PSB was then flushed through the system at 50 bpm, 37°C, 
5% CO2 in batch lots of 150 ml until pH was stabilized to 7.4. The matrices were then 
preconditioned for 48 hours with 150 ml SMC specific media, (PromoCell, Heidelberg, 
Germany), perfused through the system at 2 0  bpm, at 37°C, 5% CO2 .
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7.2.2A S e e d i n g  c e l l  s u s p e n s i o n s  o n t o  t h e  l u m e n a l  s u r f a c e  o f  t h e  m a t r ix
Prior to cell seeding, all preconditioning media was pumped back to the media reservoir 
and discarded. Seeding HUVEC was carried out by inoculating the lumenal void 
(including the inlet and outlet leur adapters) by attaching a 1 0  ml plastic pipette 
containing known volume and density of cells to the inlet leur and pumping cell into the 
lumenal void. For all HUVEC experiments the ablumenal void was clamped off to 
prevent disrupting flow within the lumen. Media in both the lumenal and ablumenal 
flow circuits was replaced every 48 hours with fresh media.
7 .2 .2 .5  S e e d i n g  H U V E C
Method 1: Using the same seeding methodology as described in section 7.2.2.4, cell 
suspensions were injected into the matrix lumen via the inlet leur adapter and allowed to 
adhere for three hours before rotating the reactor body 180 degrees and leaving for a 
further 24 hours. A progressive flow regime was then applied, where the flow rate was 
increased from 0 bpm to 5 bpm (0-8.25 ml/min) for the first day post seeding, days 2 
through to 3 the rate was increased from 5 bpm to 10 bpm (8.25-16.5 ml/min), then 
increased progressively by 20 bpm (33 ml/min), except day 7 at 10 bpm, each 48 hour 
period until 80 bpm (165.5 ml/min) was reached. Media was 100% changed every 48 
hours.
Method 2: The same inoculation and application of flow was followed as method 1, 
differing only immediately post inoculation where the reactor body was rotated 1 2 0  
degrees, each for 3 hours, where at the final rotation the progressive flow regime was 
followed (as above in Method 1). Media was 100% changed every 48 hours.
Method 3: The same inoculation and rotation procedure was followed as method 2. 
Prior to the application of the graduated flow regime the reactor (and seeded cells) were 
cultured under minimal flow conditions, 1 bpm (1.65 ml/min) for two weeks prior to 
applying the same flow regime (as above in Method 1). Media was 100% changed 
every 48 hours.
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7.2.2.6 S e e d i n g  hVSMC
Method A: Seeding hVSMC was carried out in a similar fashion to HUVEC except 
cell suspensions were injected directly into the ablumenal void. Using a 25 ml pipette, 
cell suspensions were injected into the inlet port of number one reactor. As the two 
reactors were in series the cell suspension was pumped in until both reactor ablumenal 
voids were full of the cell suspension. All ablumenal inlets and outlets were then 
clamped to prevent the cell suspension flooding into the return media flow. Post 
inoculation the reactor body was rotated 120 degrees, each for 3 hours to allow cells to 
adhere, where 3 hours after the final rotation a flow rate of 80 bpm (165.5 ml/min) was 
applied through the lumen. In all hVSMC monoculture experiments the ablumenal void 
was clamped off to prevent disrupting flow within the lumen. Media in the ablumenal 
void was refreshed every 24 hours by diverting flow from the lumenal flow at 
approximately 1.65 ml/min or 1 bpm. Every 48 hours media discarded and 100% 
replaced with fresh media.
Method B: Each fully processed matrix was pretreated in 45 ml SMC media on a 
rock/rolling table at 37°C for 48 hours. In preparation for cell seeding the 
preconditioning media was evacuated and 2  matrices were placed in the well of a 6 -well 
culture plate forming concentric rings to completely cover the surface of the culture 
plate. Cells were divided into 2 equal densities and seeded at 3 hour intervals onto the 
matrices surface (rotating the matrix 180° between seeding). Cell suspensions were in 
minimal media to enhance adhesion to the matrix surface. After two weeks in static 
culture (maintained using standard feeding methodologies) seeded matrices were 
transferred to the reactor system under sterile conditions. A flow rate of 80 bpm. (165.5 
ml/min) was applied through the lumen and maintained as above in ‘method 1 ’.
Method C: Essentially the same as method 2 with the exception of placing whole cell 
‘sheets’ onto the matrix ablumenal surface. hVSMC cultures were bulked up in the 
normal fashion until cells were confluent for three weeks within T-75 culture flasks. A 
cell scraper was used to remove large sections of cells from the plastic in sheet form. 
These sheets of cells were transferred onto the matrix material and cultured in minimal 
media for one week prior to insertion into the bioreactor system. A flow rate of 80 bpm.
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(165.5 ml/min) was applied through the lumen and maintained as above in ‘method 1*.
7 .2 .2.7 HUVEC AND HVSMC CULTURE WITHIN THE BIOREACTOR
All monocultures used the appropriate media, as described in chapter 2.1.3.1-2 
Complete media changes were made every 48 hours by removing the reactor system 
from the incubator, draining the old media from the system using a separate peristaltic 
pump (5 rpm). Fresh, prewarmed media at 37°C (200 cm3 for dual reactors and 185 cm3 
for single reactor systems) was progressively added to the media reservoir and pumped 
around the system ensuring all bubbles had been removed before sealing and replacing 
the unit in the 800 L capacity incubator (Cat. 394-049 Millennium XL, Jencons, 
Bedfordshire, UK) at 37°C 5% C 02.
7.2.3 A nalytical  methods
All analytical methods used in this chapter including fixing cells for DAPI staining and 
subsequent counting are described in Chapter 2.3, Analytical Methods.
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7.3 R esults
7.3.1 L u m e n  c u l t u r e s  o f  HUVEC o n  t h e  a r t e r i a l  d e r i v e d  m a t r i x
Results from the earlier tests, which did not use the compliance chamber, show minimal 
retention o f HUVEC by the end of the flow regime (detailed in section 7.2.2.4), see 
Figure 7.01. The addition o f a compliance chamber to smooth out the vibration in the 
pulsed flow further increased cell retention over the experimental time course. In both 
of these initial methods cells were seeded directly into the lumen, later methods that 
were shown to improved cell adhesion/retention, seeding methods 1-3 are detailed in 
Section 7.2.2. Figure 7.01 shows the remaining cells after application o f the progressive 
flow regime where the pulse flow was applied without the compliance chamber to 
reduce high frequencies vibrations. Like Figure 7.01, Figure 7.02 (DAPI stained cell 
nuclei) and Figure 7.03 (SEM image) illustrate increased cell density on the matrix 
surface using application o f method 3 for seeding HUVEC. Although the viability of 
these cells was not directly assessed, SEM images show cells o f normal morphology 
compared to apoptotic o f lysing cells
Figure 7.01: HUVEC adhered to the lumenal surface of matrix after trial flow conditions.
HUVEC were seeded at 4 x105 cells ml (6 ml) directly into the matrix lumen with no rotation 
during initial adhesion and no compliance chamber to reduce high frequencies vibrations. Cells 
remaining on the lumenal surface after flow (A) are shown stained with the nuclear stain DAPI. 
The undulating surface is noted with protruding sections (B) and recessed sections (C).
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Figure 7.02: Improved HUVEC adhesion after modifying seeding conditions. D.A.P.I. stained 
HUVEC nuclei seeded at 4 x105 cells ml directly into the matrix lumen using HUVEC seeding 
method 3. A clear visual increase in cell density is noted over Figure 7.01.
Figure 7.03: Improved HUVEC adhesion after modifying seeding conditions, surface analysis 
with LT-SEM showing matrix and HUVEC morphology seeded at 4 x105 cells/ml directly into the 
matrix lumen using seeding method 3. Cells remaining on the lumenal surface (A) are shown, 
with sections of the matrix void of cells (B). The undulating surface of the matrix can be seen 
with protruding sections (into the lumen) (C) and recessed sections (D).
Figure 7.04 illustrates progression towards a confluent endothelium, were cell densities 
would approach 600 cells/mm2 (based on cell dimensions o f  20 x 30 pm) after a total 














Figure 7.04: Quantitative analysis of improved HUVEC adhesion with variation in system and 
seeding methodologies. Displays increased cell densities after a total of 10 days culture (each) 
using different seeding methodologies and reactor/system design.
Earlier results with DAPI stained HUVEC nuclei (Figure 7.01) clearly show the 
presence o f  cells on the matrix material after cells had been exposed to pulse flow 
conditions for a total culture time o f 10 days. Non-seeded control matrix was negative 
for DAPI staining. SEM images o f the same matrix material were more difficult to 
interpret. Figures 7.05 displays a much higher degree o f  intimal convolutions compared 
to Figure 7.06, which intern shows higher convolutions than Figure 7.07, where 
HUVEC had been seeded using method 3 and exposure to pulsed flow conditions as 
described in section 7.2.2 for a total o f 10 days.
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Figure 7.05: A SEM showing matrix and HUVEC morphology seeded at 4 x105 cell/ml and 
cultured for a total of 10 days using seeding method 3. This image displays a deeply 
convoluted lumenal surface with HUVEC adhered (A). Gaps between cells are shown (B).
Figure 7.06: A SEM showing matrix and HUVEC morphology seeded at 3.5 x105 cells/ml and 
cultured for a total of 10 days after seeding using method 3. This image shows a reduction of 
surface convolutions compared to Figure 7.05. Smooth surface of HUVEC cells are shown (A), 
with areas void of cells (B).
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Figure 7.07: A SEM showing matrix and HUVEC morphology seeded at 4.5 x105 cells ml and 
cultured for a total of 10 days using seeding method 3. This image shows a near flat surface 
compared to Figures 7.05 and 7.06. Smooth surface of HUVEC cells are shown (A), with gaps 
between cells or areas void of cells (B).
7.3.2 A b lu m en a l  hVSMC cu ltu r es  on th e  a r te r ia l  d e r iv e d  m atrix
In this section o f work, results from hVSMC seeding methodologies and adhesion were 
qualitatively assessed. hVSMC phenotype was confirmed by immunolocalisation o f a- 
actin (see Appendix A2) and analysis o f cell migration and expression patterns o f  
MMP-2 and 9 and cathepsin L was conducted. Attempts to seed hVSMC onto the 
matrix using method A., see section 7.2.2.6, via the ablumenal port, into the ablumenal 
void proved unsuccessful. Histological analysis displayed very few cells adhered to the 
matrix. It was postulated that the loose fibrous nature o f the matrices ablumenal surface 
was unfavourable as an environment for cell adhesion, particularly when submerged in 
media. The second seeding method, method B, was designed to allow hVSMC to be 
seeded onto the matrix prior to inserting the matrix into the reactor assembly. With this 
method a total culture time o f 5 weeks consisting o f 2 weeks static and three weeks 
under pulsed flow conditions as described in section 1 2 2 .6 .  Figure 7.08 shows a 
section o f matrix viewed by SEM after the total o f 5 weeks culture, few cells appear 
viable. Although cell adhesion improved (qualitative histology), cell density remained 
comparatively low. The final method used was to seed or attach cell sheets onto the 
matrix (method C, see Section 7.2.2.6), this was used as an attempt to bind-up the
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loose outer layer (adventitial) o f fibrous collagens to improve cell adhesion. Figure 
7.09 displays an SEM image o f hVSMC taken from confluent cultures in T-75 plastic 
culture dishes, removed by cell scraping and laid upon the matrices ablumenal surface. 
Cells were cultured for two weeks in static culture to allow cells to adhere then three 
weeks under pulsed flow conditions.
Figure 7.08: SEM of the ablumenal surface displaying loose ECM fibres (A) of the adventitial 
layer with remnants of cells (B) interlaced between the fibres after 5 weeks culture.
100pm
Figure 7.09: SEM image of hVSMC upon the ablumenal surface of the matrix after 5 weeks 
pulsed flow culturing. Note two distinct areas, (A) confluent hVSMC (B) cell free matrix. Cells 
appear to be migrating from the cell sheet (C) to the acellular region. Evidence of cell debris is 
also noted among the loose fibres of the matrix (D).
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P h e n o ty p ic  e x p re s s io n  o f  o i-a c tin  by hVSMC s e e d e d  o n to  th e  a r t e r i a l
DERIVED MATIX
Extended cultures o f hVSMC seeded onto the ablumenal surface as described in Section 
7.2.2. A total o f approximately 5x105 cells were seeded under static conditions (see 
Section 1 2 2 .6 )  and cultured for two weeks prior to insertion into the reactor assembly 
and a further 3 weeks culture under pulsed flow. Figure 7.10 shows hVSMC migration 
within the adventitial layer o f the matrix by counterstaining with haematoxylin. No 
evidence was found o f cells migrating past the adventitial/medial boundary. Figure 7.10 
also shows immunohistochemically labelled hVSMC for a-actin from the same 
cultures. Cell adhesion appears to favour the outer most surface o f the adventitial layer 
with a reduced number o f cells present within the adventitial layer and none observable 
within the medial layer.
Ablumenal surface a-actin positive cells
Cells migrating 
into the adventitial 
layer of the matrix
Adventitial/medial 
boundary .
Multiple haematoxylin stained cells
Figure 7.10: hVSMC were seeded at a total of 5 x105 cells under static conditions for two 
weeks onto the ablumenal surface and a further 3 weeks within the bioreactor being exposed to 
mechanical stresses, a-actin expression was confirmed by the presence of brown stained 
(DAB) hVSMC above. Sections were counter stained with haematoxylin to identify the location 
of all cells within the matrix.
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7.3.3. A s s e s s m e n t  o f  m a t r i x  p e n e t r a t i o n  b y  hVSMC
As discussed previously, a range o f proteolytic enzymes: MMP-2, 9 and Cathepsin L 
known to be involved in the mechanisms o f  cell migration and matrix remodelling were 
assessed for expression at 5 weeks to attain an initial understanding o f the expression 
pattern, if  any, o f these enzymes when exposed to mechanical stresses imposed by 
pulsed flow conditions transmitted through the arterial wall. Figure 7.11 is shown to 
provide reference to other images in this chapter to further appreciate that the adventitial 
layer is less structured than the medial layer and provides a different environment for 
cell viability.
Figure 7.11: Cross-section of hVSMC adhesion to the adventitial surface of the matrix.
Seeded at 5 x105 cell mm under static conditions for two weeks onto the ablumenal surface and 
a further 3 weeks within the bioreactor being exposed to mechanical stresses. hVSMC are 
stained dark purple (A,B) by haematoxylin, note the layers of cells on the matrix surface (A) and 
the random dispersion of cells within the loose adventitial layer (B).
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Similar to Chapter 5, a range of proteolytic enzymes: MMP-2, 9 and cathepsin L which 
are known to be involved in the mechanisms of cell migration and matrix remodelling 
were assessed for expression at 5 weeks. The earlier time point at 3 weeks used in 
Chapter 5 was omitted to give cells cultures an extended time frame to extend the 
opportunity for cellular migration. In this section all hVSMC were seeded or wrapped 
onto the ablumenal surface at as cell sheets and cultured using the method described in 
Section 7.2.2.6 , seeding method C. The exact cell density is unknown as the normal 
counting method was not applicable. It was estimated to be approximately 600 
cells/mm . Like the static cultures the negative controls used the same tissue sections as 
the immunolabelled sections, for example sections with hVSMC adhered were 
processed using the immunofluorescent staining protocol described in Chapter 2.3.3.6/7. 
The method was identical except the step where the primary antibody is incubated with 
the sample was omitted. This was to determine the extent of background and non­
specific staining by the antibody and to ensure, with evidence from H & E sections that 
the localised staining is the actual enzyme targeted. As with all results in this section, 
the first image for each time point/enzyme is the negative control with the following 
image displaying the section incubated with the primary antibody.
MMP-2 EXPRESSION BY HVSMC CULTURED UNDER PERFUSION CONDITIONS ON THE 
PORCINE DERIVED ARTERIAL MATRIX
Figure 7.12 shows control sections of hVSMC seeded and cultured for 5 weeks on 
processed matrix show little background staining in the areas where hVSMC were know 
to reside, see Figure 7.11. Similar to static cultures the medial layer of the matrix stains 
non-specifically for the MMP-2 antibody in the same control sections. Figure 7.13 
shows no distinct immunolocalisation of MMP-2, after 5 weeks perfusion culture was 
evident.
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Figure 7.12: Control section of hVSMC seeded and cultured for 5 weeks on processed matrix 
and stained for MMP-2. Note minimal background staining of the medial layer (acellular), with 
little background or non-specific staining of the adventitial layer where the hVSMC reside.
Figure 7.13: Matrix and cell populations staining negative for MMP-2 after 5 weeks culture.
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MMP-9 EXPRESSION BY HVSMC CULTURED UNDER PERFUSION CONDITIONS ON THE 
PORCINE DERIVED ARTERIAL MATRIX
Figure 7.14 shows control sections o f hVSMC seeded and cultured for 5 weeks on 
processed matrix show little background staining in the areas where hVSMC were know 
to reside, see Figure 7.11. Unlike previous controls these sections had minimal non­
specific staining o f the medial layer. Figure 7.15 clearly displays the positive 
immunolocalisation o f MMP-9 in the outer adventitial layer o f the matrix.
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F ig u r e  7 .1 4 :  Control, no background or non-specific staining of MMP-9 in the SMC layer (A).
F ig u r e  7.15: Positive immunolocalisation for MMP-9 after 5 weeks in perfusion culture (A).
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A s s e s s m e n t  o f  C a t h e p s in  L e x p r e s s io n  b y  hV S M C  c u l t u r e d  u n d e r  p e r f u s io n
CONDITIONS ON THE PORCINE DERIVED ARTERIAL MATRIX
Control sections o f hVSMC seeded and cultured under perfusion conditions for 5 weeks 
on processed matrix, like previous controls where incubated without the specific 
primary antibody to determine background or non-specific staining. Figure 7.16 shows 
a control section displaying minimal background or non-specific staining within the 
hVSMC layer (A). Like previous controls for MMP-2 and 9, the collagen and elastin 
ECM (where hVSMC may reside but in low densities, see Figure 7.11) has a strong 
non-specific background staining. Little background or non-specific staining o f the 
adventitial layer is noted where the hVSMC were known to reside, see Figure 7.11.
Perfusion cultures at the 5 week time point clearly show the presence o f MMP-9 having 
been expressed by hVSMC within the adventitial layer o f the matrix, see Figure 7.17. 
Like MMP-2 and 9 immunolocalisation o f the gene product appears to be restricted to 
the adventitial layer o f the matrix, where hVSMC reside, in this section with reduced 
background staining o f the medial layer no distinct staining is evident in the medial or 
intimal layers. This data supports H & E stained sections, see Figure 7.11.
F ig u r e  7 .1 6 :  Control section of hVSMC seeded and cultured for 5  weeks on processed matrix 
and stained for Cathepsin L. Strong background staining of the medial layer (acellular), with 
little background or non-specific staining of the SMC layer (A).
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Figure 7.17: Sections stained for C athepsin L after 5 w eeks perfusion culture have stained 
strongly positive (A).
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7 .4  D isc u ssio n
A vascular replacement graft that could be removed from its sterile packaging, 
immediately used while providing optimal biocompatibility would be the simplest and 
most cost effective option for vascular replacements. While manufactures of synthetic 
replacements work towards this goal, methodologies to enhance existing and prototype 
prostheses are actively researched. The advantage of autologous endothelial cell 
seeding is to enhance graft patency by exposing the only known 1 0 0 % 
nonthrombogenic surface. To provide a graft with viable autologous cells to a patient in 
the operating theatre adds new levels of complexity to production, where cells must 
firstly be isolated from patient tissue (until immunologically inert cells are available for 
use) then grown rapidly in vitro prior to seeding onto the matrix and culturing under in 
vivo ‘like’ conditions. Once the graft has been seeded and surgically implanted, 
problems remain during reperfusion where the endothelial cell lining maybe stripped 
from the matrix wall. This is seen as one of the advantages of the tissue engineering 
approach where the application of a progressive flow regime (in vitro) to seeded and 
cultured EC allows acclimatization and adaptation time and facilitates endurance against 
the rigors of pulsed flow.
In order to seed cells onto a matrix, they must be first sourced. In this thesis human 
primary cells were chosen over immortalized human cell lines as they offer a 
phenotype/genotype closer to the patient cells. The main advantage with immortalized 
cell lines is consistency. These include consistently high proliferation rates and 
consistent phenotypic expression compared to primary cell cultures extracted from 
multiple human donors. This consistency allows experimental conditions to be 
optimised, but does not take genotypic or phenotypic variation between patients into 
account. Isolation of adult vascular endothelial cells in densities high enough for graft 
seeding are not only technically more difficult but may have a negative impact on the 
patient, such as removal of ‘nonessentiaT vessels e.g. saphenous vein. Although this 
method is successful in isolation of EC, the question must be asked if the vessel may be 
better served as the prosthesis. In addition, these vessels may have been used 
previously in other reconstructive surgery. Other sources of EC include: micro vascular 
endothelial cells harvested from microvessels (arterioles, capillaries and venules) found 
in adipose tissue (Williams et al., 1994) and extraction of EC progenitor cells from
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circulating blood. The choice of SMC to seed onto the ablumenal surface was 
simplified by the ready availability of adult saphenous vein from which hVSMC were 
isolated. Although slow to culture, appropriate densities were achievable for seeding 
purposes within 4-6 weeks of explanting tissue. In addition, variability between cell 
cultures adds validity to results as they are seen to more closely replicate the perceived 
surgical application with multiple patients and autologous cells.
Ideally, only autologous cells should be used in the final phases of graft development to 
ensure methodologies are repeatable with the more sensitive, adult cells. This is in 
reference to neonatal EC as the hVSMC are adult derived. A balance between the use 
of rapidly growing immortalized cell lines and the difficult to source and cultivate 
autologous cells from potentially diseased patients is required for research purposes. 
Much of the current research in Tissue Engineering have used non-autologous cells, 
such as HUVEC, such as bovine derived (Niklason et al., 1999; Niklason et al., 2001; 
Patel et al., 1988) murine derived (Kim et al., 1999) and human cell lines (Fernandez et 
al., 2001). These cell lineages are comparatively easier to grow and maintain in culture, 
unlike the fore mentioned adult human primary cells. The validity of experiments 
conducted with cells of this origin has been questioned. Justification for the use of these 
cells is that they offer a considerable advantage over human cell lines (immortal) in that 
they represent a more appropriate phenotype, but still have the advantage of the rapid 
replication associated with neonatal cells or non-human cell lineages.
Numerous techniques have been used to seed EC into the lumenal surface of prosthetic 
devices. As described be Schmidt et al (1999) these methodologies can be divided into 
three main categories: 1. Gravitational 2. Hydrostatic, application of either external 
vacuum or internal pressure and 3. Electrostatic. Methods 1 and 2 have had reduced 
success due to the time required for cells to flatten and fully adhere to the surface prior 
to implantation. Delays of this nature during an operative procedure prior to closure are 
far from ideal. Application of electrostatic charges to improve EC adhesion was first 
applied by Bowlin and Rittgers (1997) and late described and applied by Schmidt and 
Bowlin (1999), electrostatic seeding, utilises the properties of ePTFE whereby the 
surface polarity is temporarily changed to a positive charge which attracts and speeds up 
a more mature HUVEC adhesion (Bowlin and Rittgers, 1997) and (Schmidt and 
Bowlin, 1999). The approach taken with tissue engineering, with the application of
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flow would increase the time taken for graft maturation, the benefits in specific cases 
where time is less critical are clearly obvious. It is accepted that this is a serious 
limitation of the Tissue Engineering methodology.
7.4.1 Lum en  C ultures
The vascular graft bioreactor and support systems described in this thesis was designed 
to allow direct seeding or inoculating cells through the shell or lumenal inlet ports, 
using the gravitational method of seeding. An advantage of this method was a reduction 
in handling compared with seeding cells onto the matrix prior to assembling the reactor, 
which reduces the likelihood of bacterial or fungal infection. Furthermore, multiple 
reactors could be seeded in a single step, again minimising potential contamination. 
Seeding the lumen with HUVEC displayed a progressive improvement in cell retention 
after application of pulsed flow conditions. Initial trials where HUVEC were injected 
into the reactor without rotation of the reactor (to allow cells to adhere over the surface), 
in concert with the lack of a compliance chamber to smooth out high frequency 
vibrations in the flow, resulted in poor cell retention. All normal mammalian cells in 
tissue culture are contact inhibited, where upon contact with other cells (higher 
densities) remain in G1 prior to the restriction or ‘start* point of the mitotic cell cycle, 
(Alberts et al., 1994). Amongst other reasons, contact inhibition is part of the body’s 
self-defence mechanism against excessive or uncontrolled proliferation. EC, which 
grow as a monolayer, do not as a rule form 3-dimensional structures. As soon as an EC 
contacts other EC, proliferation ceases thus preventing layers of cells forming. 
Although SMC are contact inhibited they are not as strongly inhibited by cell-cell 
contact EC. SMC, to a degree begin to form 3-dimensional structures. This can be seen 
in the Appendix A2 with the formation of ‘hills and valleys’ characteristic of the VSMC 
phenotype. Earlier seeding methods where large numbers of cells were seeded directly 
into the lumen failed in part due to contact inhibition. As the cell suspension settles or 
gravitates to the bottom of the matrix, only those cells in immediate contact with the 
substrata (matrix) will begin the adhesion process. The remaining cells are loosely 
stacked and unable to adhere. With the application of flow through the lumen these 
cells are likely to be washed out of the system. The result illustrated in Figure 7.01 
show that the only cells remaining on the matrix are those on the lower surface where
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cells had initially adhered as the reactor was not rotated during seeding. The addition of 
a compliance chamber and reactor rotation during the seeding process (methods 1 and 2 , 
see section 7.2.2.) significantly improved cell retention. As seen in figures 7.02, 7.03 
and 7.05-07 the density of cells adhering to the matrix approach densities of a complete 
endothelium. Qualitative analysis showed that on average these cultures have densities 
a little over 1 . 6  times less than that of flat surface and potentially much less than a 
native convoluted endothelium. Estimation of the size of a HUVEC in culture is 
approximately 25 x 40 pm (1000 p m ) giving a density of approximately 1000
9  9cells/mm , compared to 634 ± 158 cells/mm of these cultures. Cross-linking 
collagenous matrices alters the structure of the natural matrix. This may be the basis for 
the differences between the theoretical and the observed cell densities per unit area.
The method described in chapter 4 was aimed at minimising structural change whist 
removing immunogenic epitopes. As reviewed by Schoen and Levy (1999) some of the 
potential changes a matrix may incur are: cross-linking proteins, locking structures in 
one phase of the cardiac cycle, loss of collagen ‘waviness’, loosening of collagen 
bundles, loss of the amorphous acellular matrix and loss of compliance (Schoen and 
Levy, 1999). As discussed in chapter 4 this matrix has under gone most of these 
structural changes to a greater or lesser degree. In this section of work a far greater 
degree of SEM surface analysis was conducted above initial studies that obtained 
representative images of the matrix lumenal surface. Although the initial assessment 
that the basement membrane remained essentially intact after processing is correct, what 
became apparent was variation in the lumenal surfaces structural morphology after cells 
were seeded onto the matrix and flow conditions applied. The lumenal surface of the 
matrix is predominantly convoluted (qualitatively) see Figure 7.07, however as shown 
in images 7.06 and 7.05 this varies from convoluted to wavy and a flat morphology in 
some areas. Areas where there is a loss of the convoluted structure of the ECM fibres 
are likely to strongly affect the mechanical and fluid handling properties of the matrix, 
as physical forces are transmitted during the pulse flow regime. Further research is 
required to quantify this effect if indeed it has a negative impact on graft patency.
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7 .4 .2  A b l u m e n a l  C u l t u r e s
Like lumenal seeding, it was envisaged that the ablumenal inoculation protocol would 
prove successful, however, the use of this particular matrix seeding and subsequent 
adhesion proved problematic. As the matrix material was suspended within the 
ablumenal cavity, the percentage cell adhesion to the matrix material was considerably 
lower than if cells were seeded directly onto the matrix. When cells v/ere seeded into 
the ablumenal void those not directly above the matrix would gravitate to the bottom of 
the reactor, resulting in only a small section of the matrix being seeded. To improve the 
seeding efficiency a number of methods were assessed, including: variation in seeding 
densities and periodic rotation of the reactor/s about their longitudinal axes. 
Histological and SEM analysis of the ‘seeded’ matrices after 7 day culturing had shown 
that these methods failed to improve cell adhesion onto the matrix, and few cells had 
adhered to the matrix, (see Figure 7.09). This initial experiment was designed to 
evaluate seeding efficiency of cells seeded directly into the ablumenal void with a 
preconditioned artery present, without any material, such as Poly-HEME present on the 
reactor wall to prevent cell adhesion. Poly-HEME or poly (2-hydroxethylmethacrylate) 
has been used widely as a coating to prevent cell adhesion. Folkman and Moscona 
(1978) used poly-HEME to observe the relationship between cell shape, DNA synthesis 
and growth in cells by coating plastic culture plates with varying thickness of poly- 
HEME (Folkman and Moscona, 1978). Although coating the inside of the glass reactor 
with poly-HEME and rotating the reactor to improve adhesion was considered, it was 
found that the main issue with seeding cells onto the ablumenal surface was not 
limitations with initial adhesion. As mentioned above, densities as high as 4 x 106 cells 
were injected into the ablumenal to literally flood the matrix with cells. After 
histological and SEM analysis little differences were noted other than an increase in cell 
debris among the adventitial fibres on the ablumenal surface. Assessment of these 
results indicated a need for a fundamental change in seeding methodology. It was 
predicted that the problem was not one of biocompatibility with the matrix surface as 
static cultures had shown positive cell adhesion, growth and proliferation, but the way 
in which the surface was presented to the cells in free suspension. When supported in 
the reactor, collagen fibres on the matrices ablumenal surface literally ‘float’ in the 
media within the ablumenal void. Thus, the surface is not stable or static enough for
267
cells to adhere. In order to improve this each matrix was seeded outside the reactor in 
tissue culture plates, as described in section 7.2.2. Although an improvement was 
noted, the fibres were still essentially in free solution and each time the media was 
changed (every 48 hours) these fibres were disrupted. The use of method three for 
ablumenal seeding was designed to bind up the loose fibres by seeding down not cell 
suspensions, but sheets of cells wrapped around the matrix. The method, described in 
section 7.2.2 was not fully optimised but results show that the cell sheets adhered well 
to the matrix and layers of viable layers are present. Figure 7.10 shows an SEM image 
of the cell layer bordering an acellular region of the matrix. The positive result is clear 
compared to cell seeded as a suspension either into or in static culture, as illustrated in 
Figure 7.09. Histological analysis of 5 pm haematoxylin stained sections show, like 
static cultures presented in Chapter 5, that some areas of the matrix displayed a capacity 
to maintain the phenotypic expression of a-actin, contrasting static cultures where 
expression is lost over time, see Figures 7.11-2. Figures 7.11 and 7.12 typify the 
migration pattern of hVSMC cultured under these conditions. Cells remain as a sheet of 
multiple cell layers on the extremity of the ablumenal surface, displaying some 
migration into and up to the adventitial-medial boundary.
The ultimate purpose of seeding hVSMC onto the ablumenal side of the matrix is to 
fully populate the medial layer of the matrix with functional SMC. Static cultures have 
shown the inability of hVSMC to migrate through the matrix, while samples grown 
under pulsed flow conditions follow a similar pattern. Analysis of a representative 
group of matrix remodelling enzymes was conducted to determine if cells were 
expressing the matrix-degrading enzymes whether they were migrating.
An inherent lack of chemical or physical signals ‘instructing’ cell/s to migrate would 
result in cells remaining in a similar region (other than proliferative expansion) to where 
they were seeded. One would expect that if the cellular machinery is activated to 
express these enzymes then a stimulation to migrate would be provided to the cells. It 
can therefore be speculated, that if  the cells are unable to penetrate the adventitial- 
medial boundary it is because they are unable to break down the bonds holding the 
ECM components, together which prevents migration. Static cultures have shown that 
hVSMC seeded or adhered to the cut surface of the matrix migrate along (not through) 
the matrix fibres into the vessels medial layer. hVSMC seeded onto the surface of the
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matrix were unable to migrate, via degradative mechanisms associated with the 
presence of the above mentioned matrix remodelling enzymes. By the very nature of 
cross-linking and the methods used to determine cross-linking efficiency to stabilize 
proteins against enzymatic degradation, it is not surprising that cellular migration across 
ECM is not observed. Methods to test the effectiveness of cross-linking have used 
collagenase or pepsin to degrade the ECM and either colorimetric or RP-HPLC to 
quantify soluble by-products such as hydroxyproline. Studies in Chapter 4 have shown 
this matrix has a three-fold increase in resistance to pepsin digestion over non-cross- 
linked samples.
Similar to the static cultures of chapter 5, several enzymes involved in matrix 
remodelling were immunologically detected to determine their expression and potential 
effectiveness at degrading the cross-linked matrix. Chapter 5 concluded that under 
static culturing conditions MMP-2 and 9 were expressed at both 3 and 5 week time 
frames, with Cathepsin L only being expressed at 5 weeks. Under pulsed flow 
conditions, expression of MMP-2 was not evident at 5 weeks while both MMP-9 and 
Cathepsin L were strongly expressed. The main role of Cathepsin L is within the 
cellular lysosome system for protein degradation. As discussed in chapter 5 the 
understanding of cathepsin L with regard to its role outside cellular lysosomes is not 
fully understood. Kirschke et al (1998) and Turk et al (2000) support the evidence 
found here that cathepsin L is expressed both intercellular and extracellularly (Turk et 
al., 2000) and (Kirschke and Barrett, 1998). The difference here is that firstly hVSMC 
are expressing the enzyme and secondly expression is in a “foreign” environment. 
Cathepsin L has a variety of functions outside the cell including: degradation of 
basement membranes, elastin, fibronectin and collagens all of which are present in these 
cultures. Optimal pH ranges between pH 3 and 6 , indicative of the acidic lysosomal 
environment cathepsins are normally associated. This may mean reduced extracellular 
activity unless; acidic microenvironments exist, the enzyme is post-translationally 
modified to increase its activity outside the cell. Conversely the reduced extracellular 
activity/active life span is part of the control mechanism for these potentially dangerous 
enzymes when outside the protective walls of the lysosome. It is difficult to determine 
if expression is increased between static and flow cultures due to differences in density, 
however these preliminary results indicate some factor has induced a higher expression, 
with physical forces acting on the cells being a likely cause. It is clear that there is
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differences in expression patterns between the static and pulsed flow cultures. It is 
difficult however to draw firm conclusions from the data due to differences in seeding 
methodology and the density.
It was hypothesized that the application of pulsed flow would provide the mechanical 
signals required for hVSMC to express a barrage of proteolytic activity, and to allow 
cells to effectively migrate through the matrix. Either the stimulation to migrate was 
ineffective or the matrix is extensively cross-linked whereby seeded hVSMC are unable 
to migrate into the medial section. Analysis of MMP-2, 9 and cathepsin L has shown 
the enzymes are expressed indicating an attempt to remodel the matrix, but neither 
activity nor concentrations are quantifiable. Based on hVSMC normal proliferative rate 
in static culture it was expected cell densities would be considerably higher than a layer 
of cells 2-3 deep over the adventitial surface after 5 weeks culture. Glucose, pH and gas 
analysis show that the culture parameters are not limiting and range from static 
conditions to physiological in vivo conditions. The most likely conclusion that can be 
drawn from the inability of cells to migrate into the medial layer is that the tissue is over 
cross-linked. It is important to note that both static and pulsed flow cultures of hVSMC 
were conducted as mono-cultures, that is hVSMC were the only cell type present. In 
normal vascular physiology the two main cell types present are hVSMC and EC and 
communication between is a requirement to normal function. It is possible that co- 
culturing hVSMC with HUVEC in the reactor system may provide the EC with a 
stronger chemical signal that would induce the expression of other proteolytic enzymes, 
such as MMP-1,8 and 13 (specific collagenases) not analysed in this study. Further 
studies are required to determine which of these hypotheses are correct.
The aim of this section of work was to develop an understanding of the comparative 
differences between the results gathered in Chapter 5, which assessed the developed 
matrix in terms of biocompatibility under simple static in vitro conditions and results in 
this chapter, application of mechanical forces such as fluid and mechanical shear 
stresses to the matrix and cell populations.
Seeding HUVEC into the lumen of the matrix and exposing them to a prescribed flow 
regime has shown a progressive increase in cell adhesion as the system was modified. 
Final densities remain below that of a confluent endothelium. Continued system
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development is likely to improve this issue. hVSMC adhesion to the ablumenal surface 
follows a similar prescription to HUVEC seeding, where progressive system and 
protocol development has shown that a continuous layer of cells on the ablumenal 
surface is possible. Unfortunately, it was not possible to seed cells directly into the 
ablumenal void and achieve high adhesion efficiencies due to the fibrous nature of the 
matrices ablumenal surface.
Given the range of ECM components capable of being degraded by the two matrix 
metalloproteinases and cathepsin L chosen for this study, see Figure 5.01, it is not 
surprising that these enzymes are indeed being expressed. The lack of MMP-2 maybe 
explained as a temporal expression whereby signals for its transcription are blocked by 
feed back signals. It can be concluded that the altered structure, by means of exposure 
to the numerous processing steps, particularly cross-linking of the matrix prevents cell 
migration into the medial layer. This is a critical aspect of this project and further study 
is required to determine if reduced exposure to the cross-linking step may allow cell to 
migrate freely through the matrix. A high level of matrix cross-linking confers 
resistance to enzymatic degradation and increased biocompatibility prevents cells from 
migrating freely into the matrix. Conversely reduced cross-linking results in a matrix 
that is susceptible to degradation in vivo and is more likely to be recognised as ‘foreign’ 
when implanted. It is essential that a balance between stability, biocompatibility and 
allowance for cell migration be met if the aim remains to fully populate the medial layer 
with VSMC.
The likely consequences of reduced migration into the medial layer and thus out of 
effective communicative range of the endothelium is reduced control of both VSMC 
and EC growth and proliferation. Co-cultures within the bioreactor system will be an 
important aspect of future studies to determine the effectiveness of this processed matrix 
in allowing cellular migration and matrix remodelling, resulting in a physiologically 
competent graft suitable for vascular reconstructive surgery.
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CHAPTER EIGHT: CONCLUSIONS AND FUTURE W ORK
8 .1  C o n c l u s io n s
Progress towards a tissue engineered small diameter vascular graft began with the use of 
porcine derived dermal collagen as a matrix material; supplied in sheet form, see 
Chapter 3. Results have shown that this matrix (after extensive washing to remove 
residual cross-linking chemicals) supports primary human cell adhesion growth and 
proliferation. Preparation of the matrix by means of incubation in cell culture media has 
been shown to improve cell-matrix biocompatibility, as does treatment by modification 
of the ECM proteins with chemical treatments, such as NaOH, see Chapter 3.3.3. 
However the material was not found to be an ideal matrix material for the development 
of a tissue engineered vascular graft. By comparison to a native artery, the sheets of 
collagen would require fashioning into a tube, creating a longitudinal ridge (0.75 mm) 
within the matrix lumen that is likely to detrimentally affect flow dynamics and thus EC 
adhesion. In addition, further handling of the material increases the potential for graft 
infection. Both experimental and cited literature have shown that cross-linked matrices 
are resistant to host degradation, an attribute desired in bioartificial heart valves where 
degradation may result in failure. The object of the tissue engineering approach is to 
allow the graft to remodel using the matrix as a platform to guide cellular growth and 
development into a functional shape/organ. For remodelling to occur cells must be able 
to digest matrix components, freeing the way for cells to migrate into the matrix, thus 
populating the full thickness of the graft. This is a one of the design objectives to 
ultimately confer vascular tone by attaining a high density of VSMC throughout the 
medial layer of the matrix. Extended cultures on the dermal collagen matrix have 
shown the inability of human primary fibroblasts to migrate into the tissue suggesting, 
like other chemically cross-linked matrices, that excessive stabilisation was the reason 
for this effect.
In seeking an alternative matrix material for use as a small diameter vascular graft, 
several options were considered, including the alternative of full synthetic materials. As 
biological materials can offer superior mechanical properties compared to synthetic
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matrices the potential for maintaining the in vivo cell phenotype is increases. This is 
due to a closer replication of a more natural in Wvo-like environment. Further, previous 
experimental knowledge working with biological biomaterials contributed to the 
selection of porcine carotid arteries as a starting material for matrix preparation.
After treatments the porcine derived arterial matrix described in Chapter 4 has a reduced 
lipid and protein content compared to unprocessed tissue, with the bulk of the cellular 
components removed. The effect of cross-linking the matrix has increased its 
mechanical strength in terms of burst pressure and ultimate failure (stress/strain), whilst 
retaining a similar structure and ECM morphology to the native artery. The processing 
methodology preserves the bulk of the basement membrane and internal elastic lamina, 
central to maintaining the matrices mechanical and cell adhesion properties. The 
internal elastic lamina has also been suggested to act as physical barrier to prevent the 
migration of hVSMC into the vessels lumen, which would otherwise result in intimal 
hyperplasia. The effect cross-linking and ethanol treatment has on the matrix with 
regard to immunogenicity and resistance to calcification are theoretical and based on 
literature cited within the chapter, further studies are required to ascertain the 
effectiveness of these and other combined treatments.
An assessment of the processed porcine matrix described in Chapter 4, in terms of 
compatibility with primary human cell lineages (HUVEC and hVSMC), was conducted 
under static culture conditions in Chapter 5. Unlike the dermal collagen matrix used in 
Chapter 3, HUVEC remained adhered to the matrix after 9 days static culture when used 
directly from the final processing step. Initial compatibility tests concluded that pre­
treatment of the matrix after processing and washing in H2O was essential to attain 
efficient adhesion of HUVEC under static conditions. Under static conditions DMEM 
basal media was chosen due to its low cost and that it provided no significant advantage 
over the substantially more expensive cell specific medias. Due to the restrictive depth- 
of-field of the analytical technique used and the 3-dimensional structure of the matrix, 
no conclusions could be drawn from ablumenal seeding of hVSMC, other than cells had 
adhered and were maintained up to 5 weeks in culture, as assessed by H&E, DAPI 
staining. Extended culture of hVSMC on the arterial derived matrix appears to offer a 
stable environment conducive to cell maintenance with no evidence of the matrix 
cytotoxicity displayed with the former porcine derived dermal matrix.
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Immuno-localisation of MMP-2 and 9 and cathepsin L proteases within the matrix 
clearly identifies expression of these matrix remodelling enzymes by hVSMC under 
static culture conditions. Based on the inability of hVSMC to migrate into the matrix 
medial layer other than by the cut edge of the matrix, it was concluded that the 
adventitial/medial boundary acts as a physical barrier to cell migration. The mechanism 
preventing cell penetration was not clear; as no chemical or mechanical stimuli was 
applied, it is possible there was no driving force for migration, however cell migration 
via the matrix cut edge does imply that the necessary stimuli was provided. As shown 
in Chapter 4.3.3 the matrix is stabilised against pepsin digestion as a result of the cross- 
linking process. This would indicate, in concert with extended cultures of hVSMC, that 
once cells have migrated through the adventitial layer up to the medial boundary they 
were unable to migrate further into the matrix as the dense fibrillar medial ECM poses 
as a barrier to migration as direct result of cross-linking the matrix. When a matrix is 
not cross-linked cells from surrounding tissue are able to migrate fully into a similar 
matrix (Clarke et al., 2000).
In Chapter 6  a perfusion bioreactor was designed and implemented in concert with a 
pulsed flow system that aimed to deliver to the matrix, sealed within the bioreactor, 
conditions that simulated the in vivo peripheral arterial environment. The first aim was 
to generate appropriate mechanical forces and transmit them to the bioreactor while 
simultaneously allowing sampling and media changes. Secondly the bioreactor was 
required to allow direct cell seeding into both the lumenal and ablumenal cavities, with 
the support infrastructure allowing long-term, sterile culture of human primary cell 
cultures.
These objectives were complex and compromises were required to achieve certain 
goals. For example system design, with regard to on-line monitoring, was limited to 
ensure the unit was useable and transportable to a sterile facility for routine cell culture 
maintenance. As a conclusion to this section, all of the major tasks to develop a 
workable reactor and support infrastructure have succeeded. The perfusion system 
generates a user defined pulsed flow with waveforms and pressures similar to in vivo 
haemodynamics. Similarly the Mark 4 bioreactor allows for the delivery of nutrients 
and extraction of by-products, including gasses. Although not quantified, the reactor by
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design is likely to deliver uniform transmembrane/matrix pressures that have allowed 
hVSMC to remain viable within the matrix wall, inside the 100 pm cell in-growth limit, 
whilst shown to maintain strict sterile conditions.
The aim of Chapter 7 was to develop an understanding of the comparative differences 
between the results gathered in Chapter 5, which assessed the porcine derived arterial 
matrix in terms of biocompatibility under static in vitro conditions, and results from 
perfusion bioreactor studies in this chapter, where mechanical forces such as fluid and 
mechanical shear stresses were applied to the matrix and cell populations. Seeding of 
HUVEC into the lumen of the matrix and exposing them to prescribed flow regimes has 
shown a progressive increase in cell adhesion as the system was modified. Final 
densities remain below that of a confluent endothelium. Continued system development 
is likely to improve this issue. hVSMC adhesion to the ablumenal surface follows a 
similar pattern to HUVEC seeding, where progressive system and protocol 
developments have shown that a continuous layer of cells on the ablumenal surface is 
possible. Unfortunately, it was not possible to seed cells directly into the ablumenal 
void and achieve high adhesion efficiencies due to the fibrous nature of the matrices 
ablumenal surface. The final method of hVSMC seeding (method C) to the ablumenal 
surface applied cell sheets and a period of static culture to allow cells to adhere. This 
methodology was successful in stabilising the free fibrous nature of the matrices outer 
ablumenal surface by allowing hVSMC to adhere to the matrix. Either extended 
cultures or reduced cross-linking may allow cells to migrate further into the matrix.
Studies in Chapter 5 and 7 have shown a range of matrix degrading enzymes are 
expressed by hVSMC under both static and perfusions culture conditions. Both MMP-9 
and cathepsin L displayed the same expression pattern under both static and perfusion 
culture, where there is a qualitative increase in expression in the perfusion cultures after 
5 weeks culture. MMP-2 was strongly expressed in 3 and 5 week static cultures but was 
not localised in 5 week perfusion cultures. In terms of cell expression patterns, little can 
be concluded from the observed data, other than there appears to be a temporal change 
in expression (MMP-2 / 9). Given further resources, a more restrictive study over 
defined time points would help elucidate this variation. In addition to these and other 
results, it was concluded that the altered structure of the matrix prevents cell migration 
into the medial layer. This is a critical point with the project and further study is
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required to determine the steps required to allow cells to migrate freely through the 
matrix. Again, it must be noted that the ability for cells to freely migrate means that the 
matrix is susceptible to degradation in vivo. It is essential that a balance between 
stability, biocompatibility and allowance for cell migration be met if  the aim remains to 
fully populate the medial layer with VSMC.
8 .2  F u t u r e  w o r k
Future work has been subdivided into 3 sections each outlining a research objective by 
identifying issues that may lead to a more complete understanding of why small 
diameter grafts fail, followed by experimental methodologies to further develop the 
process of tissue engineering to overcome these problematic issues.
8.2.1 B io m a tr ix  unifo rm ity
Any developed tissue engineered product must meet strict parameters in order to be 
issued licence for human implantation. One of those requirements is that the product 
must be uniform with limited variation between each individual product. Inherent in 
biological systems is the fact that they are non-uniform. This issue became obvious 
during the extraction process at the abattoir, although all animals were of the same age 
and breed, variation in carotid arteries usable length (range -50-130 mm) vessel wall 
thickness (range -  0.8-2.5 mm) and taper over the usable length (range 9.5- 4 mm OD) 
added to compound the issue. As discussed in Chapter 4, the first step in the process 
was to narrow the potential range of variation by the initial selection process at the 
abattoir. Although the arteries selected for processing were within a given dimension 
range the observed variation at the macroscopic level is indicative of the variation that is 
likely to occur at the microscopic and molecular level.
The problem of uniformity or lack of it is yet to be resolved; if  a methodology is to be 
pursued further these issues must be addressed and logical steps taken to ensure product 
homogeny.
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A list is shown below that pinpoints process steps requiring modification in order to 
produce a more uniform product.
Tighten initial v e sse l selection criteria
Adventitial ECM to b e  rem oved  using a  dissection m icroscope: to red u ce  d am ag e  to the  medial 
layer and  p roduce  a  m ore uniform excision of surrounding connective tissu e  layer, 
identification of arterial flaws such  a s  d ise a se  and to aid th e  v esse l selection  to  reducing 
variation
Cross-linking carried  ou t within the  reacto r system  using a  m otorized revolving system  to confer 
360° rotation and  uniform cross-linking of v esse l su rface
O ptim ise cross-linking duration to e n su re  th e  balance betw een  red u ced  im m unogenicity and  cell 
migration and  estab lish  light penetration into tissue, i.e. is th e  tis su e  m ore heavily cross-linked 
on the  v e sse ls  su rface  than  the  lum en?
S eed ing  both EC and  hVSMC to b e  carried out within th e  revolving reactor, w here  cells a re  
p reven ted  adhering  to th e  g la ss  reac to rs ablum enal and  a d h e re  uniformly on the  appropriate 
su rface , e .g . EC lum en and  hVSMC the  ablum enal surface.
O ptim ise flow conditioning for EC retention
Although far from a complete list of modifications to the system/process design, if  these 
things are carried out a more uniform product is likely to result. It is unlikely that a 
‘one-fit-system process’ will solve the problem due to tissue variation irrespective of the 
initial selection process, unless the processing method is changed from the system 
described herein.
8.2.2 D evelo pm en t  of a  variable  pulse  flow  model
Changes in cellular phenotype and chemical responses as a result of physiological 
stresses, such as pressure, pulse and shear conditions have received considerable 
attention in the last two decades. Most if not all studies have focused on phenotypic 
changes to cells under a predefined flow protocol (often linear) that encompasses an 
initial flow regime to prepare cells for a primary flow rate that approximates a single 
physiological flow condition. It has become clear that in order to replicate a true in vivo 
cellular phenotype in an in vitro model, the application of a variety of growth factors 
alone is not enough. The mechanical or physical conditions cells are exposed to is
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critical in the maintenance of the in vivo phenotype.
In this series of studies, it is proposed to developed a physiological flow regime that 
fluctuates as a normal (or diseased) heart, altering pulse rate and associated pressure 
changes in concert with modulation of peripheral vascular tone. A number of questions 
require answering. Is any change in cell phenotype or gene expression noted when 
comparing the proposed dynamic perfusion system to non-pulsed or a single pulsed 
flow regimes? Is any variation noted in cell densities, particularly SMC? For example 
VSMC density is an important aspect of tissue engineered vascular prostheses to confer 
vascular tone and allow the matrix to remodel ECM components giving the ability to 
withstand arterial pressures. Particularly important is the expression of matrix 
components, such as collagen and elastin, essential if the matrix is degraded over time. 
Studies required to answer these questions would include modelling heart and vascular 
haemodynamics, where pulse, flow and pressure data (over time) from a number of 
appropriate adults is collected and used to define a programme that models real time 
vascular haemodynamics. Development of a pulsed flow system to mimic ‘real time’ 
vascular haemodynamics, where the pump and reactor systems will allow fully 
developed flow conditions and be computer monitored and controlled throughout all 
stages, from cell seeding to flow modulation. The choice of matrix material will be 
fundamental as results and performance vary considerably from one material to another. 
Finally all these studies would need to be integrated to produce a generic methodology 
for perfusion cultures that incorporates the dynamic flow system with the perfusion 
bioreactors conferring reproducibility, with design strategies for scaling up the process.
Key steps include the development of a pump, pump-head that can produce 
physiological pulse pressures waves at prescribed frequencies that models normal and 
diseased vascular systems. A computer programme designed to incorporate data from 
the modelling of physiological conditions that can control pump output and frequency. 
Added to this, bioreactor design, development and integration to realise the desired 
pressure and pulse wave conditions prescribed from physiological modelling. This brief 
overview is obviously not one project but a series of studies that can be used in concert 
to develop a model system for continued research. These projects are not limited to 
vascular studies but can be integrated into all areas of tissue engineering.
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8 .2 .3  D e v e l o p m e n t  o f  a  s e c o n d  g e n e r a t io n  m a t r ix
This thesis has described the use of established tissue engineering and biochemical 
principles to progress our knowledge towards a biocompatible nonthrombogenic small 
diameter vascular graft. It is now possible to critically assess the initial findings and 
fully optimise the graft preparing it for in vivo modelling. To achieve this, an 
assessment of cell adhesion, growth, proliferation and the maintenance of cell specific 
phenotype would be required. In combination with aspects from Sections 8.21 and 
8 .2 2 , the product may be optimised to allow the matrix to be fully remodelled 
conferring full functionality, where the graft is capable of regulating vascular tone and 
maintaining the integrity of the endothelial layer. With respect to the prototype porcine 
vascular graft a ‘second generation’ graft would be developed to generate a unique 
product that would preferentially use autologous cells.
The experimental programme would consist of 4 major section of work. The first stage 
would entail optimisation of the solvent and enzyme extraction steps leading to not only 
complete removal of undesirable non-structural ECM components but to an efficient 
process in preparation for a potential scaling up for industrial application. The second 
section of work, once process optimisation is complete would be characterised with 
reference to:
Histological appearance and structural analysis
Maintenance of cellular phenotypes
Strength and elasticity in relationship to cell density
Cell proliferation rates, both EC (time to achieve confluence) and hVSMC with 
relevance to intimal hyperplasia.
Once the graft has been fully characterised in terms of content (protein, lipid, 
carbohydrates etc), the ablumenal and lumenal surfaces would need to be assessed 
under perfusion conditions to allow efficient adhesion, growth and proliferation of 
cocultured primary EC and VSMC. A reduction in graft lead time (reduction in the 
time required for the culture phases of the tissue engineered graft) is crucial if this 
technology can be employed in situations where patients require urgent treatment.
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The perfusion culture system would ideally be fine-tuned to match more closely arterial 
pulse, pressure and optimisation of PO2 , PCO2 , pH and other in vivo biochemical 
parameters, with the degree of cross-linking optimised to allow cell migration whilst 
maintaining biocompatibility. Once characterisation is complete, the final step is to test 
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A 1 : D eterm inatio n  o f  endoth elial  c el l  p h e n o t y p e
In this section the primary human cell lineages used in this thesis are characterised and 
confirmed as HUVEC and VSMC by immunocytochemistry and visual analysis of cell 
morphology. HUVEC were confirmed by their characteristic ‘cobble stone’ 
morphology when confluent and staining antigens for both von Willebrand factor 
(vWF) and CD31 surface markers. Human VSMC were characterised morphologically 
by ‘hill and valley’ formations, characteristic of this cell type confirmed by staining for 
a-actin. Chapter 2.3.3.5 describes the protocols for immunocytochemical staining 
procedures.
Eukaryotic cell behaviour is critically dependent on a cells terminal or differentiated 
state, therefore determination of cell phenotype, or terminally differentiated state, was 
an essential requisite to ensure the intended cell type was indeed the specific phenotype 
used experimentally. The aim of this section was to firstly determine specific cell 
lineages by immunocytochemical staining methods, then to characterise
EC lining the lumenal surface of arteries as described in chapter one, provide a number 
of distinct and important roles that allow a blood vessel to function normally. HUVEC 
as the name implies were isolated from neonatal umbilical cords, using the now 
standard technique described by (Jaffe, 1973) to enzymatically remove the endothelium, 
which is subsequently cultured as described in 2.2.2. Figure A.01 displays EC in 
normal culture conditions using phase-contrast microscopy. Cell morphology when 
cultured on plastic shows the characteristic cobble stone morphology (Bicknell, 1996).
Immunocytochemical phenotype characterisation was carried out with two separate 
monoclonal mouse antibodies, anti-human Von Willebrand Factor (vWF) and anti­
human endothelial cell, CD31. The antibody to vWF binds to a family of vWF 
multimeric plasma glycoproteins with molecular weight ranging from 40,000 to 20 
million and is expressed in both EC and megakaryocytes to facilitate platelet adhesion 
to the underlying vascular wall. The vWF glycoprotein links the platelet membrane
290
receptors to the subendothelium and serves as the plasma carrier for Factor VIII, in 
addition the vWF glycoprotein stabilizes the molecule Factor VIII. (DAKO, 2000). EC 
stained positive for vWF show spherical Weibel-Palade bodies (A) adjacent to the cell 
plasma membrane figure A.02.
The second EC identifier was the platelet/endothelial adhesion molecule (PECAM-1) or 
CD31 belongs to the immunoglobulin superfamily with adhesive properties. It is a 
single chain type 1 transmembrane glycoprotein with a molecular mass o f 130 kD. 
CD31 is strongly expressed by all endothelial cells and more weakly on several types o f  
leucocytes. Functionally CD31 is an adhesion molecule with both homophilic and 
heterophilic binding. The homotypic binding involves interaction as an important step 
in leucocyte transendothelial migration (diapedesis) and passage through the 
extracellular matrix. The heterotypic ligands have been reported to include integrin 
avp3 and glycosaminoglycans. Figure A.03 shows clearly the EC stained positive for 
CD31 cell surface antigen.
Figure A.01: HUVEC displaying ‘cobblestone’ morphology
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Figure A.02: HUVEC positively staining for vWF
Figure A.03: Showing the CD31 surface marker (A) outlining the cell periphery
A2: D eterm ination  o f  sm o o th  m u sc le  c ell  p h e n o t y p e s
Human vascular smooth muscles (hVSMC) were derived from several sources, 
including: adult human saphenous vein, umbilical cord artery and vein. Cell isolation 
methods are described up in Chapter 2.2.1.1. Most cell lineages have been cultured 
using explanted tissue. The exception being hVSMC isolated from umbilical cords by 
exposure to a second collagenase treatment after EC have been extracted, refer to
Chapter 2.2.1.1 for protocols. Umbilical artery SMC initially isolated by enzyme 
extraction were shown to proliferate readily in contrast to other studies using human 
aortic SMC, found high levels o f TGF-(3 a potent inhibitor o f SMC proliferation 
(Kirschenlohr et al., 1996). Possible differences in cell phenotype and resulting gene 
expression due to cell source may explain these differences. Later experiments used 
hVSMC isolated using the explant method, this was primarily due to using a standard 
protocol for a range o f tissue types that were in some cases unsuitable to use the enzyme 
extraction method. In addition, although umbilical arterial SMC proliferated readily 
when isolated enzymatically, higher cell densities were achieved by the explant method.
Like the endothelium, smooth muscle cells provide a specific function to a vessel wall, 
not least to confer the ability o f vessel contraction, thus providing control over 
peripheral blood flow. Isolation of immunocytochemically proven hVSMC is therefore 
important to confirm the cell lineage and resulting patterns o f adhesion, growth and 
proliferation. Figure A.04 shows umbilical vein hVSMC in normal culture conditions, 
displaying characteristic ‘hill and valley’ formations indicative o f this cell type.
Figure A.04: hVSMC displaying the characteristic ‘hill and valley’ formation
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Figures A.05 and A.06 having been immunohistochemically stained for a-actin with 
Vector-RTU kits using the DAB substrate kit for peroxidase yielding a brown stain. 
Monoclonal mouse -  anti-human smooth muscle actin: clone 1A4 code No. M0851 lot 
028 from DAKO, UK. was used to bind the a-actin epitopes. The anti-human smooth 
muscle actin antibody binds to the a  smooth muscle isoform of actin and does not cross 
react with; P- and y- cytoplasm actin, striated muscle or myocardial fibroblasts. The 
antibody reacts with smooth muscle cells, my epithelial cells and parricides o f vessels 
and different parenchyma’s without exception (DAKO, 2000).
Figure A.05: Neonatal umbilical cord arterial derived hVSMC stained positive for a-actin.
_
Figure A.06: Adult saphenous vein hVSMC stained positive for a-actin
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A3: SDS-PAGE m eth o d
Glass plates (two with raised spacers, two without) were set out and the plastic seals 
were inserted. The plain glass plates were then laid on top and clamped together. The 
combs were then added and tested for leaks by filling with distilled water. The 
resolving and stacking gels were then made up (see below) minus the final 7.5 pi (each 
gel) of TEMED as this reagent sets the gel. The TEMED was added to the final 
solutions immediately prior to pupating the gel solution between the glass plates, this 
was to prevent the gel setting prematurely.
Table A.01: Resolving gel








18 g in  100 ml HzO pH 8.8 









The resolving gel was then pipetted between the plates to a level just below the combs,
ensuring that no air bubbles where trapped within the gel itself. The gel was then
covered with a thin layer of CLH2O saturated with butanol to produce a straight edge
across the gel. The gel was then left for 15-20 minutes to set.
Table A.02: Stacking gel
Materials 4 % Stacking gel (2 gels) Concentration Volume
Distilled Water 4.98 ml
Acrylamide (40%) 0.66 ml
Tris/base 12 g in 100 ml dd H20 pH 6.8 0.84 ml
SDS; Sodium Dodecylsulfate (Lauryl Sulphate) 20 % w/v 33.4 ul
AMPS (Ammonium persulphate) 10 % w/v 66 ul
TEMED (N.N.N'.N'-Tetramethylethylenediamine) 8 ul
When the resolving gel had set, the unpolymerised surface gel in saturated butanol was 
poured off and washed with ddThO. The combs were then replaced and the stacking gel 
was pipetted on top of the resolving gel. As with the resolving gel the TEMED was 
added last to the stacking gel solution to prevent premature setting. The gel was then 
left to set for 15-20 minutes.
Table A.03: Running buffer
Materials running buffer (1000 ml) Concentration Volume
Tris/base 25 mM 3.06 g
Glycine 190 mM 14.4 g
SDS 0.001 % 1 9
Made up to a total volume of 1000 ml total 1 L
The gel tank was set up with enough running buffer to cover the base of the tank, which 
was then tipped to one side to expel any bubbles that may have become trapped during 
the filling process. When the gels had set the clamps, combs and spacers were removed 
and the plates where then placed in the tank with the shaped plates facing inwards. 
Importantly, the tank must contain two gels to run correctly (even if only one is 
required). The plates were held in place by inserting supports with the ledged section 
upper most. The running buffer was then poured into the reservoir between the two sets 
of plates until full. The lid was fitted and the tank connected to the power supply. The 
tank was run (100V, 2-3 minutes) without the samples loaded to allow the gels to settle.
Table A.04: Loading buffer
Materials loading buffer (stock soln.) Concentration Volume
2-Mercaptoethanol 100 mM 77.125 mg
SDS; Sodium Dodecylsulfate (Lauryl Sulphate) 2% 100 mg
Glycerol (ACS Reagent) 20% 1 ml
Trizma Hydrochloride 50 mM 5 ml
Bromophenol blue 0.10% 50 ul
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A 4: A nalytical t e c h n iq u e s
M e c h a n ic a l  t e s t in g  c a l c u l a t io n
This section details the approach used to convert the raw load-extension data into stress- 
strain data. The equations developed, as well as the margins o f error, were used in 
computations for stress and strain. The chart recorder produced graphical raw data as 
typified in Figure A.07. The distance along the x-axis is representative o f time. Since 
the rate o f extension is constant this is effectively the distance the ringlet is pulled apart:
X d ist apart — [ ^ext /  Vchart ] * ^ d is t  chart (4 * 1 )
Where X d is t apart is the distance the ringlet is pulled apart (mm); rext is the rate of 
extension (5 mm/min); v Chart is the chart drive speed (50 mm/min); and X d is t chart is the 
distance measured on the chart graph x-axis (Hiles, Badylak et al. 1995). Therefore 10 
mm on the chart recorder represented an extension o f 1mm.
Distance (mm)
Figure A.07: A stylised stress-strain curve produced by the chart recorder in the load-extension 
tests.
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Zero extension was taken to be the point where the load just began to rise above zero 
grams (Hiles et al, 1995). Prior to this the load did not increase with extension due to 
slack of the ringlet around the fittings. Due to the gradual increase in load the point of 
initial strain was difficult to determine, an approximation would be within 2  ± 0 . 2  mm 
of initial stain. It is assumed that the rate of extension and chart drive speed, of the 
Instron rig, have negligible error.
I n it ia l  le n g t h  c a l c u l a t io n
The ringlet can be thought of as a single strip as represented in Figure A.08. The length 
of this strip is thus the circumference of the ringlet, however the arterial ringlet is not a 
thin walled vessel. To be thin walled the ratio of the wall thickness to inner radius 
would have to be less than 0 .1 , whereas 1 0 0  % of the samples had a ratio of greater than 
0.19 (mean of 0.51). The best approximation for the circumference was based on an 
average of the internal and external diameters (Riley et al, 1999). Hence:
Yinitial =  71 [ 0 . 5  ( d i  -h d0)] (4.2)
Where Yjnitiai is the initial strip length (mm); dj is the internal diameter (mm); and d0 is 
the external diameter (mm). Measurements of the internal diameter and wall thickness 
were accurate to +/- 0.2mm. In equation 4.2 this gives the error in Yjnitiai of:
Yinitial, error =  7t [ 0 . 5  (0 .2 +  0.2)] =  +/- 0 .6m m  (4.3)
B i s e c t
/
\
F igure  A.08: Pictorial representation of a tissue ringlet in the form of a strip after bisection. 
Note that the thin side of the strip is a trapezium shape, representative of the difference in 
internal and external diameters of the ringlet.
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E x t e n s io n  c a l c u l a t io n
By geometrical analysis it can be seen that the actual extension is twice the distance the 
ringlet has been pulled apart, assuming that the curved region at either end remains the 
same shape (and same length), see Figure A.09. This is assumption is reasonable as the 
tissue stretched into constant shape around the curved metal hooks. Hence:
• ^ e x t e n s i o n  —  2 .  X j j s t  a p a r t  (4.4)
Where X extension is the actual extension (mm); and X d is t apart is the distance the ringlet is 
pulled apart (mm), from equation 4.1.
F igure A.09: Side-on view of the ringlet during extension by two hooks on the Instron™ 1122 
rig. Note that the distance the ringlet has been pulled apart is X d js t a p a r t-
It is assumed tissue thickness does not change during extension, only when the ultimate 
tensile strength is reached, that a ductile specimen will begin to thin or neck down 
(Riley, 1999). As expected it was observed that thickness was only seen to change 
significantly once fracture had initiated at which point the test was ended. The error 
involved for the actual extension is hence twice that of the distance the ringlet has been 
pulled apart:
^ e x t e n s i o n ,  e r r o r  —  2 X 0.2 — d“/- 0.4mm (4.5)
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S t r a in  c a l c u l a t io n
Strain (s) has been defined as the extension over the initial length as a percentage 
(Dobrin, 1978). Using equations 4.2 and 4.4:
£  =  [ ^extension /  Y initial ] . 100%  (4 .6 )
The % error in the strain was calculated as the sum of the % errors of the initial length 
and the extension, from equations 4.3 and 4.5. hence:
terror ( [ X extension, error /  -^extension ] [ Yjnitiai, error / Yjnitiai ] )  • 100 /o (4 .7 )
It must be noted that as X e x ten sio n  increases over the test period, the margin of error 
decreases as expected.
S t r e s s  c a l c u l a t i o n  
Stress (a) has been defined as
CT = F / A (4 .8 )
Where F is the force exerted by the extended tissue and A is the area over which that 
force is exerted (Dobrin, 1978). Stress has units of pressure and the force component 
can be expressed as grams, as opposed to the traditional unit of force, the Newton. 
Throughout the tests it is assumed that the degree of error in the load is negligible, as 
the rig used is of a professional standard, and compared to the degree of error in the area 
component of the stress calculations, was insignificant.
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The force is circumferential throughout these tests, and the area over which the force is 
exerted is the cross-sectional, annular region of the wall, depicted in Figure A.08. This 
area is:
A =  W  . t  (4 .9)
Where A is the area over which the force is exerted; w is the width of the ringlet (5mm); 
and t is the wall thickness (mm). As before, the change in this cross-sectional area is 
considered negligible throughout the test. The accuracy of measurements for both the 
width and wall thickness of each matrix ringlet, were ± 0.2mm. For the wall thickness 
this also accounts for the variation in thickness both in the circumferential direction and 
the longitudinal direction, where an average value was approximated for individual 
samples.
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